<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230002783</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>52</s160></s100><s200><s210>1</s210><s211>12248</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>is a nucleotide sequence of event MON 87411</s223></s220><s220><s221>misc_feature</s221><s222>(1)..(500)</s222><s223>represents the genomic DNA flanking the left      border of the TDNA</s223></s220><s220><s221>misc_feature</s221><s222>(501)..(11748)</s222><s223>represents the TDNA</s223></s220><s220><s221>promoter</s221><s222>(2948)..(3559)</s222><s223>represents the reverse complement sequence of      an enhanced CaMV 35S promoter</s223></s220><s220><s221>promoter</s221><s222>(2948)..(4534)</s222><s223>represents a divergent promoter region that      promotes bidirectional transcription</s223></s220><s220><s221>promoter</s221><s222>(3586)..(4534)</s222><s223>represents a Corn PIIG promoter</s223></s220><s220><s221>misc_feature</s221><s222>(11749)..(12248)</s222><s223>represents the genomic DNA flanking the right      border of the TDNA</s223></s220></s200><s400> 1ccctagcgtt gggcccaact agtcagtctg ccttccctcc cagtcgctga cctccttggt     60ccacttgtca gctttcgcgc tcagatctaa tctcaactgt cgatctgtga tcgggtggcc    120gagatcaccc gatgcccgtt cgtttgcaaa agttgttaaa agaccctctg tttcttagaa    180aataacctac attcatgttt cttgcgatta ggcccctggt ttcttgtaga gaagcccctt    240gctttatttt aatcacaaaa ataaatctaa tttagtgttt tgaattctaa aacttgtgaa    300tttcatatct tttgcatatg aactctaaat tgggtggttt aaattgcaaa atgatcataa    360tattattctc tatctgttta aattataata tttcactgtc tacatgtatg tattttatga    420ctagacaata ggttcattta aagtgatgga ttatttatta aaaggaaaat aaaaaggcaa    480aacactaatg aatagttaag tggcttcatg tccgggaaat ctacatggat cagcaatgag    540tatgatggtc aatatggaga aaaagaaaga gtaattacca attttttttc aattcaaaaa    600tgtagatgtc cgcagcgtta ttataaaatg aaagtacatt ttgataaaac gacaaattac    660gatccgtcgt atttataggc gaaagcaata aacaaattat tctaattcgg aaatctttat    720ttcgacgtgt ctacattcac gtccaaatgg gggcttagat gagaaacttc acgatcgatg    780cggccaccac tcgaggtcga ggtaccgttg tcaatcaatt ggcaagtcat aaaatgcatt    840aaaaaatatt ttcatactca actacaaatc catgagtata actataatta taaagcaatg    900attagaatct gacaaggatt ctggaaaatt acataaagga aagttcataa atgtctaaaa    960cacaagagga catacttgta ttcagtaaca tttgcagctt ttctaggtct gaaaatatat   1020ttgttgccta gtgaataagc ataatggtac aactacaagt gttttactcc tcatattaac   1080ttcggtcatt agaggccacg atttgacaca tttttactca aaacaaaatg tttgcatatc   1140tcttataatt tcaaattcaa cacacaacaa ataagagaaa aaacaaataa tattaatttg   1200agaatgaaca aaaggaccat atcattcatt aactcttctc catccatttc catttcacag   1260ttcgatagcg aaaaccgaat aaaaaacaca gtaaattaca agcacaacaa atggtacaag   1320aaaaacagtt ttcccaatgc cataatactc aaactcagta ggattctggt gtgtgcgcaa   1380tgaaactgat gcattgaact tgacgaacgt tgtcgaaacc gatgatacga acgaaagcta   1440ggcctcagcg agtaccgctg gcgatctaat ccatgatatc gtgaacatca tctacattca   1500aattcttatg agctttctta agggcatctg cagcattttt catagaatct aatacagcag   1560tatttgtgct agctccttcg agggcttccc tctgcatttc aatagttgta agggttccat   1620ctatttgtag ttgggtcttt tccaatcgtt tcttcttttt gagggcttgg agtgcaactc   1680ttttattttt cgacgcattt ttctttgcgc tcctgcaggc ggccgcgtgg atgaggagtt   1740aatcggtcgt gtgagagtag tgatcgagtg gatgtcgtcg agagtgatga gtgttgatgt   1800tgttagtgat atgtggtaga aggtatcgtg ataaagcgtt aacgcgatcg cagtacttgc   1860aaagaaaaat gcgtcgaaaa ataaaagagt tgcactccaa gccctcaaaa agaagaaacg   1920attggaaaag acccaactac aaatagatgg aacccttaca actattgaaa tgcagaggga   1980agccctcgaa ggagctagca caaatactgc tgtattagat tctatgaaaa atgctgcaga   2040tgcccttaag aaagctcata agaatttgaa tgtagatgat gttcacgata tcatggatgg   2100tatcgcacag cgactgctga gggacgtcga gctcccgctt ggtatctgca ttacaatgaa   2160atgagcaaag actatgtgag taacactggt caacactagg gagaaggcat cgagcaagat   2220acgtatgtaa agagaagcaa tatagtgtca gttggtagat actagatacc atcaggaggt   2280aaggagagca acaaaaagga aactctttat ttttaaattt tgttacaaca aacaagcaga   2340tcaatgcatc aaaatactgt cagtacttat ttcttcagac aacaatattt aaaacaagtg   2400catctgatct tgacttatgg tcacaataaa ggagcagaga taaacatcaa aatttcgtca   2460tttatattta ttccttcagg cgttaacaat ttaacagcac acaaacaaaa acagaatagg   2520aatatctaat tttggcaaat aataagctct gcagacgaac aaattattat agtatcgcct   2580ataatatgaa tccctatact attgacccat gtagtatgaa gcctgtgcct aaattaacag   2640caaacttctg aatccaagtg ccctataaca ccaacatgtg cttaaataaa taccgctaag   2700caccaaatta cacatttctc gtattgctgt gtaggttcta tcttcgtttc gtactaccat   2760gtccctatat tttgctgcta caaaggacgg caagtaatca gcacaggcag aacacgattt   2820cagagtgtaa ttctagatcc agctaaacca ctctcagcaa tcaccacaca agagagcatt   2880cagagaaacg tggcagtaac aaaggcagag ggcggagtga gcgcgtaccg aagacggttc   2940agcgtgtcct ctccaaatga aatgaacttc cttatataga ggaagggtct tgcgaaggat   3000agtgggattg tgcgtcatcc cttacgtcag tggagatatc acatcaatcc acttgctttg   3060aagacgtggt tggaacgtct tctttttcca cgatgctcct cgtgggtggg ggtccatctt   3120tgggaccact gtcggcagag gcatcttcaa cgatggcctt tcctttatcg caatgatggc   3180atttgtagga gccaccttcc ttttccacta tcttcacaat aaagtgacag atagctgggc   3240aatggaatcc gaggaggttt ccggatatta ccctttgttg aaaagtctca atcggaccat   3300cacatcaatc cacttgcttt gaagacgtgg ttggaacgtc ttctttttcc acgatgctcc   3360tcgtgggtgg gggtccatct ttgggaccac tgtcggcaga ggcatcttca acgatggcct   3420ttcctttatc gcaatgatgg catttgtagg agccaccttc cttttccact atcttcacaa   3480taaagtgaca gatagctggg caatggaatc cgaggaggtt tccggatatt accctttgtt   3540gaaaagtctc aatcggacct gcagcctgca ggctagcggc gcgccacaaa tcacaggcca   3600tgaaccctac tcatgcttcg atttgtccaa cacacactta ccaaaactca aatcatgtcc   3660ttgacagtca ctcgggactc ataacatggg tacgtatcga ctatgtcaac tatatgtgtt   3720ctcatcagat tatagattgg cctagtacgt agtgatattt ccactagcac tgtggttatg   3780gctgtacctg atagtgatat cagcaccggg tcatggctct actaccaggt agtgagagtg   3840acctttatac tgtcagactg taactaagga tttccaatca ctgttcggat cctaggctta   3900gaattaagta aaactctatc actataggct gcagcacact cggtatatat tgatgggcca   3960acagaaattg tgcgtactat gcgcgatgta aaatggacat aaaccctacc catatacaat   4020gcaataactt ttgtccggtc tgggccaccg gttagcagag gtcctgattt cggtggtagt   4080ggtagcttga tctggtcgtc gtatcgtaga gggatatata aaatcatgtc acttttgaag   4140ggagcgctca cagaaataat aggtattcgc gggagccgcc cccgcagaac acaaaataag   4200gcgagcacgc acacgcatca gtttcgataa aataataata gcgccagctg atcggaacaa   4260ttccagctag cactaatgta tttctgcatt gatctgttta tacaacatgc tacctcgttg   4320agtgattttg acatgatttg tcaacttgct ccgatcctat atctcgatcg atctccacat   4380gacgatggtt gttgtcctgt atcccatgac aaccaggcaa cgctcaaagc acacatgcgt   4440tgccgattac ccgtgcatgc cgccaagcac gaaagcacct ccctccacac cgtccatcag   4500ctataaaaac catgccaagc accctgtgaa aagccccggg aaccatcttc cacacactca   4560agccacacta ttggagaaca cacagggaca acacaccata agatccaagg gaggcctccg   4620ccgccgccgg taaccacccc gcccctctcc tctttctttc tccgtttttt tttccgtctc   4680ggtctcgatc tttggccttg gtagtttggg tgggcgagag gcggcttcgt gcgcgcccag   4740atcggtgcgc gggaggggcg ggatctcgcg gctggggctc tcgccggcgt ggatccggcc   4800cggatctcgc ggggaatggg gctctcggat gtagatctgc gatccgccgt tgttggggga   4860gatgatgggg ggtttaaaat ttccgccgtg ctaaacaaga tcaggaagag gggaaaaggg   4920cactatggtt tatattttta tatatttctg ctgcttcgtc aggcttagat gtgctagatc   4980tttctttctt ctttttgtgg gtagaatttg aatccctcag cattgttcat cggtagtttt   5040tcttttcatg atttgtgaca aatgcagcct cgtgcggagc ttttttgtag gtagaagtga   5100tcaaccatgg ccaaccccaa caatcgctcc gagcacgaca cgatcaaggt cacccccaac   5160tccgagctcc agaccaacca caaccagtac ccgctggccg acaaccccaa ctccaccctg   5220gaagagctga actacaagga gttcctgcgc atgaccgagg actcctccac ggaggtcctg   5280gacaactcca ccgtcaagga cgccgtcggg accggcatct ccgtcgttgg gcagatcctg   5340ggcgtcgttg gcgtcccctt cgcaggtgct ctcacctcct tctaccagtc cttcctgaac   5400accatctggc cctccgacgc cgacccctgg aaggccttca tggcccaagt cgaagtcctg   5460atcgacaaga agatcgagga gtacgccaag tccaaggccc tggccgagct gcaaggcctg   5520caaaacaact tcgaggacta cgtcaacgcg ctgaactcct ggaagaagac gcctctgtcc   5580ctgcgctcca agcgctccca ggaccgcatc cgcgagctgt tctcccaggc cgagtcccac   5640ttccgcaact ccatgccgtc cttcgccgtc tccaagttcg aggtcctgtt cctgcccacc   5700tacgcccagg ctgccaacac ccacctcctg ttgctgaagg acgcccaggt cttcggcgag   5760gaatggggct actcctcgga ggacgtcgcc gagttctacc gtcgccagct gaagctgacc   5820caacagtaca ccgaccactg cgtcaactgg tacaacgtcg gcctgaacgg cctgaggggc   5880tccacctacg acgcatgggt caagttcaac cgcttccgca gggagatgac cctgaccgtc   5940ctggacctga tcgtcctgtt ccccttctac gacatccgcc tgtactccaa gggcgtcaag   6000accgagctga cccgcgacat cttcacggac cccatcttcc tgctcacgac cctccagaag   6060tacggtccca ccttcctgtc catcgagaac tccatccgca agccccacct gttcgactac   6120ctccagggca tcgagttcca cacgcgcctg aggccaggct acttcggcaa ggactccttc   6180aactactggt ccggcaacta cgtcgagacc aggccctcca tcggctcctc gaagacgatc   6240acctcccctt tctacggcga caagtccacc gagcccgtcc agaagctgtc cttcgacggc   6300cagaaggtct accgcaccat cgccaacacc gacgtcgcgg cttggccgaa cggcaaggtc   6360tacctgggcg tcacgaaggt cgacttctcc cagtacgatg accagaagaa cgagacctcc   6420acccagacct acgactccaa gcgcaacaat ggccacgtct ccgcccagga ctccatcgac   6480cagctgccgc ctgagaccac tgacgagccc ctggagaagg cctactccca ccagctgaac   6540tacgcggagt gcttcctgat gcaagaccgc aggggcacca tccccttctt cacctggacc   6600caccgctccg tcgacttctt caacaccatc gacgccgaga agatcaccca gctgcccgtg   6660gtcaaggcct acgccctgtc ctcgggtgcc tccatcattg agggtccagg cttcaccggt   6720ggcaacctgc tgttcctgaa ggagtcctcg aactccatcg ccaagttcaa ggtcaccctg   6780aactccgctg ccttgctgca acgctaccgc gtccgcatcc gctacgcctc caccacgaac   6840ctgcgcctgt tcgtccagaa ctccaacaat gacttcctgg tcatctacat caacaagacc   6900atgaacaagg acgatgacct gacctaccag accttcgacc tcgccaccac gaactccaac   6960atgggcttct cgggcgacaa gaatgaactg atcattggtg ctgagtcctt cgtctccaac   7020gagaagatct acatcgacaa gatcgagttc atccccgtcc agctgtgata ggaactctga   7080ttgaattctg catgcgtttg gacgtatgct cattcaggtt ggagccaatt tggttgatgt   7140gtgtgcgagt tcttgcgagt ctgatgagac atctctgtat tgtgtttctt tccccagtgt   7200tttctgtact tgtgtaatcg gctaatcgcc aacagattcg gcgatgaata aatgagaaat   7260aaattgttct gattttgagt gcaaaaaaaa aggaattaga tctgtgtgtg ttttttggat   7320cccattttcg acaagcttgc ctcgagacaa caacatgctt ctcatcaaca tggagggaag   7380agggagggag aaagtgtcgc ctggtcacct ccattgtcac actagccact ggccagctct   7440cccacaccac caatgccagg ggcgagcttt agcacagcca ccgcttcacc tccaccaccg   7500cactacccta gcttcgccca acagccaccg tcaacgcctc ctctccgtca acataagaga   7560gagagagaag aggagagtag ccatgtgggg aggaggaata gtacatgggg cctaccgttt   7620ggcaagttat tttgggttgc caagttaggc caataagggg agggatttgg ccatccggtt   7680ggaaaggtta ttggggtagt atctttttac tagaattgtc aaaaaaaaat agtttgagag   7740ccatttggag aggatgttgc ctgttagagg tgctcttagg acatcaaatt ccataaaaac   7800atcagaaaaa ttctctcgat gaagatttat aaccactaaa actgccctca attcgaaggg   7860agttcaaaac aattaaaatc atgttcgaat tgagtttcaa tttcacttta acccctttga   7920aatctcaatg gtaaaacatc aacccgtcag gtagcatggt tctttttatt cctttcaaaa   7980agagttaatt acaaacagaa tcaaaactaa cagttaggcc caaggcccat ccgagcaaac   8040aatagatcat gggccaggcc tgccaccacc ctccccctcc tggctcccgc tcttgaattt   8100caaaatccaa aaatatcggc acgactggcc gccgacggag cgggcggaaa atgacggaac   8160aacccctcga attctacccc aactacgccc accaacccac acgccactga caatccggtc   8220ccacccttgt gggcccacct acaagcgaga cgtcagtcgc tcgcagcaac cagtgggccc   8280acctcccagt gagcggcggg tagatctgga ctcttaccca cccacactaa acaaaacggc   8340atgaatattt tgcactaaaa ccctcagaaa aattccgata ttccaaacca gtacagttcc   8400tgaccgttgg aggagccaaa gtggagcgga gtgtaaaatt gggaaactta atcgaggggg   8460ttaaacgcaa aaacgccgag gcgcctcccg ctctatagaa aggggaggag tgggaggtgg   8520aaaccctacc acaccgcaga gaaaggcgtc ttcgtactcg cctctctccg cgccctcctc   8580cgccgccgct cgccgccgtt cgtctccgcc gccaccggct agccatccag gtaaaacaaa   8640caaaaacgga tctgatgctt ccattcctcc gtttctcgta gtagcgcgct tcgatctgtg   8700ggtggatctg ggtgatcctg gggtgtggtt cgttctgttt gatagatctg tcggtggatc   8760tggccttctg tggttgtcga tgtccggatc tgcgttttga tcagtggtag ttcgtggatc   8820tggcgaaatg ttttggatct ggcagtgaga cgctaagaat cgggaaatga tgcaatatta   8880ggggggtttc ggatggggat ccactgaatt agtctgtctc cctgctgata atctgttcct   8940ttttggtaga tctggttagt gtatgtttgt ttcggataga tctgatcaat gcttgtttgt   9000tttttcaaat tttctaccta ggttgtatag gaatggcatg cggatctggt tggattgcca   9060tgatccgtgc tgaaatgccc ctttggttga tggatcttga tattttactg ctgttcacct   9120agatttgtac tcccgtttat acttaatttg ttgcttatta tgaatagatc tgtaacttag   9180gcacatgtat ggacggagta tgtggatctg tagtatgtac attgctgcga gctaagaact   9240atttcagagc aagcacagaa aaaaatattt agacagattg ggcaactatt tgatggtctt   9300tggtatcatg ctttgtagtg ctcgtttctg cgtagtaatc ttttgatctg atctgaagat   9360aggtgctatt atattcttaa aggtcattag aacgctatct gaaaggctgt attatgtgga   9420ttggttcacc tgtgactccc tgttcgtctt gtcttgataa atcctgtgat aaaaaaaatt   9480cttaaggcgt aatttgttga aatcttgttt tgtcctatgc agcctgatcc atggcgcaag   9540ttagcagaat ctgcaatggt gtgcagaacc catctcttat ctccaatctc tcgaaatcca   9600gtcaacgcaa atctccctta tcggtttctc tgaagacgca gcagcatcca cgagcttatc   9660cgatttcgtc gtcgtgggga ttgaagaaga gtgggatgac gttaattggc tctgagcttc   9720gtcctcttaa ggtcatgtct tctgtttcca cggcgtgcat gcttcacggt gcaagcagcc   9780ggcccgcaac cgcccgcaaa tcctctggcc tttccggaac cgtccgcatt cccggcgaca   9840agtcgatctc ccaccggtcc ttcatgttcg gcggtctcgc gagcggtgaa acgcgcatca   9900ccggccttct ggaaggcgag gacgtcatca atacgggcaa ggccatgcag gcgatgggcg   9960cccgcatccg taaggaaggc gacacctgga tcatcgatgg cgtcggcaat ggcggcctcc  10020tggcgcctga ggcgccgctc gatttcggca atgccgccac gggctgccgc ctgacgatgg  10080gcctcgtcgg ggtctacgat ttcgacagca ccttcatcgg cgacgcctcg ctcacaaagc  10140gcccgatggg ccgcgtgttg aacccgctgc gcgaaatggg cgtgcaggtg aaatcggaag  10200acggtgaccg tcttcccgtt accttgcgcg ggccgaagac gccgacgccg atcacctacc  10260gcgtgccgat ggcctccgca caggtgaagt ccgccgtgct gctcgccggc ctcaacacgc  10320ccggcatcac gacggtcatc gagccgatca tgacgcgcga tcatacggaa aagatgctgc  10380agggctttgg cgccaacctt accgtcgaga cggatgcgga cggcgtgcgc accatccgcc  10440tggaaggccg cggcaagctc accggccaag tcatcgacgt gccgggcgac ccgtcctcga  10500cggccttccc gctggttgcg gccctgcttg ttccgggctc cgacgtcacc atcctcaacg  10560tgctgatgaa ccccacccgc accggcctca tcctgacgct gcaggaaatg ggcgccgaca  10620tcgaagtcat caacccgcgc cttgccggcg gcgaagacgt ggcggacctg cgcgttcgct  10680cctccacgct gaagggcgtc acggtgccgg aagaccgcgc gccttcgatg atcgacgaat  10740atccgattct cgctgtcgcc gccgccttcg cggaaggggc gaccgtgatg aacggtctgg  10800aagaactccg cgtcaaggaa agcgaccgcc tctcggccgt cgccaatggc ctcaagctca  10860atggcgtgga ttgcgatgag ggcgagacgt cgctcgtcgt gcgtggccgc cctgacggca  10920aggggctcgg caacgcctcg ggcgccgccg tcgccaccca tctcgatcac cgcatcgcca  10980tgagcttcct cgtcatgggc ctcgtgtcgg aaaaccctgt cacggtggac gatgccacga  11040tgatcgccac gagcttcccg gagttcatgg acctgatggc cgggctgggc gcgaagatcg  11100aactctccga tacgaaggct gcctgatgag ctccagggtt cttgcctggt gccttggcaa  11160tgcttgatta ctgctgctat cctatgatct gtccgtgtgg gcttctatct atcagtttgt  11220gtgtctggtt ttgaaaaaca tttgcttttc gattatgtag ggtttgcttg tagctttcgc  11280tgctgtgacc tgtgttgttt atgtgaacct tctttgtggc atctttaata tccaagttcg  11340tggtttgtcg taaaacgaag cctctacttc gtaaagttgt gtctatagca ttgaaatcgt  11400ttttttgctc gagaataatt gtgaccttta gttggcgtga aactagtttt ggatatctga  11460ttctctggtt cgcaatcttg agatcgtcgc tgcttaggtg agctaagtga tgttcctaag  11520taaatgctcc tcaccagaat acgtagctgt gtgaaaagag aacgcgtgaa tacgtagctg  11580tgtaaagatt gtgtcccaag taaacctcag tgatttttgt ttggattttt aatttagaaa  11640cattcgactg ggagcggcta gagccacacc caagttccta actatgataa agttgctctg  11700taacagaaaa caccatctag agcggccgcg tttaaactat cagtgtttag agaatcacaa  11760acctctagat gtattaatct accctagaac tagttcactt ttgtgtgcat acttttctat  11820tgaactggtg ttcactttgt tgcatatgtt ttgtgtactg tttatttgtc attgcccaaa  11880tgtgtttaat gagtgattgc tttgcgtaga caacgagcag ttcaaggttt ccgagtgtgt  11940tgcaaaagac ttccctgagc agcaacctgg tgaaggtaag tgtcctctga cccattatgt  12000catatttact ttataattat atccttaaca atatgattaa agattaacac caaattatat  12060acatacatat gttaaaattt taaatgtcaa ataattcaga tgtttagaat gcatccctaa  12120gacggccagt gcaggctcgt acgatgcata cgaaaaccta tccctagtgt tcgcttcgaa  12180ttaatgccga cagtttaaac tactgcatct gcaatctata gagacaaaaa cactatgaaa  12240atagtaga                                                           12248</s400><s200><s210>2</s210><s211>763</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>is a nucleotide sequence of event MON 87411</s223></s220><s220><s221>misc_feature</s221><s222>(1)..(500)</s222><s223>represents the genomic DNA flanking the left      border of the TDNA</s223></s220><s220><s221>misc_feature</s221><s222>(501)..(763)</s222><s223>left border remnant</s223></s220></s200><s400> 2ccctagcgtt gggcccaact agtcagtctg ccttccctcc cagtcgctga cctccttggt     60ccacttgtca gctttcgcgc tcagatctaa tctcaactgt cgatctgtga tcgggtggcc    120gagatcaccc gatgcccgtt cgtttgcaaa agttgttaaa agaccctctg tttcttagaa    180aataacctac attcatgttt cttgcgatta ggcccctggt ttcttgtaga gaagcccctt    240gctttatttt aatcacaaaa ataaatctaa tttagtgttt tgaattctaa aacttgtgaa    300tttcatatct tttgcatatg aactctaaat tgggtggttt aaattgcaaa atgatcataa    360tattattctc tatctgttta aattataata tttcactgtc tacatgtatg tattttatga    420ctagacaata ggttcattta aagtgatgga ttatttatta aaaggaaaat aaaaaggcaa    480aacactaatg aatagttaag tggcttcatg tccgggaaat ctacatggat cagcaatgag    540tatgatggtc aatatggaga aaaagaaaga gtaattacca attttttttc aattcaaaaa    600tgtagatgtc cgcagcgtta ttataaaatg aaagtacatt ttgataaaac gacaaattac    660gatccgtcgt atttataggc gaaagcaata aacaaattat tctaattcgg aaatctttat    720ttcgacgtgt ctacattcac gtccaaatgg gggcttagat gag                      763</s400><s200><s210>3</s210><s211>515</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>is a nucleotide sequence of event MON 87411</s223></s220><s220><s221>misc_feature</s221><s222>(1)..(15)</s222><s223>right border remnant</s223></s220><s220><s221>misc_feature</s221><s222>(16)..(515)</s222><s223>represents the genomic DNA flanking the right      border of the TDNA</s223></s220></s200><s400> 3aaactatcag tgtttagaga atcacaaacc tctagatgta ttaatctacc ctagaactag     60ttcacttttg tgtgcatact tttctattga actggtgttc actttgttgc atatgttttg    120tgtactgttt atttgtcatt gcccaaatgt gtttaatgag tgattgcttt gcgtagacaa    180cgagcagttc aaggtttccg agtgtgttgc aaaagacttc cctgagcagc aacctggtga    240aggtaagtgt cctctgaccc attatgtcat atttacttta taattatatc cttaacaata    300tgattaaaga ttaacaccaa attatataca tacatatgtt aaaattttaa atgtcaaata    360attcagatgt ttagaatgca tccctaagac ggccagtgca ggctcgtacg atgcatacga    420aaacctatcc ctagtgttcg cttcgaatta atgccgacag tttaaactac tgcatctgca    480atctatagag acaaaaacac tatgaaaata gtaga                               515</s400><s200><s210>4</s210><s211>11248</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>is a nucleotide sequence of Event MON 87411,      and represents the TDNA of event MON 87411</s223></s220><s220><s221>misc_feature</s221><s222>(1)..(263)</s222><s223>left border remnant</s223></s220><s220><s221>promoter</s221><s222>(2086)..(4034)</s222><s223>Corn PIIG promoter</s223></s220><s220><s221>promoter</s221><s222>(2448)..(3059)</s222><s223>represents the reverse complement sequence of      an enhanced CaMV 35S promoter</s223></s220><s220><s221>promoter</s221><s222>(2448)..(4034)</s222><s223>represents a divergent promoter region that      promotes bidirectional transcription</s223></s220><s220><s221>misc_feature</s221><s222>(11233)..(11248)</s222><s223>right border remnant</s223></s220></s200><s400> 4tggcttcatg tccgggaaat ctacatggat cagcaatgag tatgatggtc aatatggaga     60aaaagaaaga gtaattacca attttttttc aattcaaaaa tgtagatgtc cgcagcgtta    120ttataaaatg aaagtacatt ttgataaaac gacaaattac gatccgtcgt atttataggc    180gaaagcaata aacaaattat tctaattcgg aaatctttat ttcgacgtgt ctacattcac    240gtccaaatgg gggcttagat gagaaacttc acgatcgatg cggccaccac tcgaggtcga    300ggtaccgttg tcaatcaatt ggcaagtcat aaaatgcatt aaaaaatatt ttcatactca    360actacaaatc catgagtata actataatta taaagcaatg attagaatct gacaaggatt    420ctggaaaatt acataaagga aagttcataa atgtctaaaa cacaagagga catacttgta    480ttcagtaaca tttgcagctt ttctaggtct gaaaatatat ttgttgccta gtgaataagc    540ataatggtac aactacaagt gttttactcc tcatattaac ttcggtcatt agaggccacg    600atttgacaca tttttactca aaacaaaatg tttgcatatc tcttataatt tcaaattcaa    660cacacaacaa ataagagaaa aaacaaataa tattaatttg agaatgaaca aaaggaccat    720atcattcatt aactcttctc catccatttc catttcacag ttcgatagcg aaaaccgaat    780aaaaaacaca gtaaattaca agcacaacaa atggtacaag aaaaacagtt ttcccaatgc    840cataatactc aaactcagta ggattctggt gtgtgcgcaa tgaaactgat gcattgaact    900tgacgaacgt tgtcgaaacc gatgatacga acgaaagcta ggcctcagcg agtaccgctg    960gcgatctaat ccatgatatc gtgaacatca tctacattca aattcttatg agctttctta   1020agggcatctg cagcattttt catagaatct aatacagcag tatttgtgct agctccttcg   1080agggcttccc tctgcatttc aatagttgta agggttccat ctatttgtag ttgggtcttt   1140tccaatcgtt tcttcttttt gagggcttgg agtgcaactc ttttattttt cgacgcattt   1200ttctttgcgc tcctgcaggc ggccgcgtgg atgaggagtt aatcggtcgt gtgagagtag   1260tgatcgagtg gatgtcgtcg agagtgatga gtgttgatgt tgttagtgat atgtggtaga   1320aggtatcgtg ataaagcgtt aacgcgatcg cagtacttgc aaagaaaaat gcgtcgaaaa   1380ataaaagagt tgcactccaa gccctcaaaa agaagaaacg attggaaaag acccaactac   1440aaatagatgg aacccttaca actattgaaa tgcagaggga agccctcgaa ggagctagca   1500caaatactgc tgtattagat tctatgaaaa atgctgcaga tgcccttaag aaagctcata   1560agaatttgaa tgtagatgat gttcacgata tcatggatgg tatcgcacag cgactgctga   1620gggacgtcga gctcccgctt ggtatctgca ttacaatgaa atgagcaaag actatgtgag   1680taacactggt caacactagg gagaaggcat cgagcaagat acgtatgtaa agagaagcaa   1740tatagtgtca gttggtagat actagatacc atcaggaggt aaggagagca acaaaaagga   1800aactctttat ttttaaattt tgttacaaca aacaagcaga tcaatgcatc aaaatactgt   1860cagtacttat ttcttcagac aacaatattt aaaacaagtg catctgatct tgacttatgg   1920tcacaataaa ggagcagaga taaacatcaa aatttcgtca tttatattta ttccttcagg   1980cgttaacaat ttaacagcac acaaacaaaa acagaatagg aatatctaat tttggcaaat   2040aataagctct gcagacgaac aaattattat agtatcgcct ataatatgaa tccctatact   2100attgacccat gtagtatgaa gcctgtgcct aaattaacag caaacttctg aatccaagtg   2160ccctataaca ccaacatgtg cttaaataaa taccgctaag caccaaatta cacatttctc   2220gtattgctgt gtaggttcta tcttcgtttc gtactaccat gtccctatat tttgctgcta   2280caaaggacgg caagtaatca gcacaggcag aacacgattt cagagtgtaa ttctagatcc   2340agctaaacca ctctcagcaa tcaccacaca agagagcatt cagagaaacg tggcagtaac   2400aaaggcagag ggcggagtga gcgcgtaccg aagacggttc agcgtgtcct ctccaaatga   2460aatgaacttc cttatataga ggaagggtct tgcgaaggat agtgggattg tgcgtcatcc   2520cttacgtcag tggagatatc acatcaatcc acttgctttg aagacgtggt tggaacgtct   2580tctttttcca cgatgctcct cgtgggtggg ggtccatctt tgggaccact gtcggcagag   2640gcatcttcaa cgatggcctt tcctttatcg caatgatggc atttgtagga gccaccttcc   2700ttttccacta tcttcacaat aaagtgacag atagctgggc aatggaatcc gaggaggttt   2760ccggatatta ccctttgttg aaaagtctca atcggaccat cacatcaatc cacttgcttt   2820gaagacgtgg ttggaacgtc ttctttttcc acgatgctcc tcgtgggtgg gggtccatct   2880ttgggaccac tgtcggcaga ggcatcttca acgatggcct ttcctttatc gcaatgatgg   2940catttgtagg agccaccttc cttttccact atcttcacaa taaagtgaca gatagctggg   3000caatggaatc cgaggaggtt tccggatatt accctttgtt gaaaagtctc aatcggacct   3060gcagcctgca ggctagcggc gcgccacaaa tcacaggcca tgaaccctac tcatgcttcg   3120atttgtccaa cacacactta ccaaaactca aatcatgtcc ttgacagtca ctcgggactc   3180ataacatggg tacgtatcga ctatgtcaac tatatgtgtt ctcatcagat tatagattgg   3240cctagtacgt agtgatattt ccactagcac tgtggttatg gctgtacctg atagtgatat   3300cagcaccggg tcatggctct actaccaggt agtgagagtg acctttatac tgtcagactg   3360taactaagga tttccaatca ctgttcggat cctaggctta gaattaagta aaactctatc   3420actataggct gcagcacact cggtatatat tgatgggcca acagaaattg tgcgtactat   3480gcgcgatgta aaatggacat aaaccctacc catatacaat gcaataactt ttgtccggtc   3540tgggccaccg gttagcagag gtcctgattt cggtggtagt ggtagcttga tctggtcgtc   3600gtatcgtaga gggatatata aaatcatgtc acttttgaag ggagcgctca cagaaataat   3660aggtattcgc gggagccgcc cccgcagaac acaaaataag gcgagcacgc acacgcatca   3720gtttcgataa aataataata gcgccagctg atcggaacaa ttccagctag cactaatgta   3780tttctgcatt gatctgttta tacaacatgc tacctcgttg agtgattttg acatgatttg   3840tcaacttgct ccgatcctat atctcgatcg atctccacat gacgatggtt gttgtcctgt   3900atcccatgac aaccaggcaa cgctcaaagc acacatgcgt tgccgattac ccgtgcatgc   3960cgccaagcac gaaagcacct ccctccacac cgtccatcag ctataaaaac catgccaagc   4020accctgtgaa aagccccggg aaccatcttc cacacactca agccacacta ttggagaaca   4080cacagggaca acacaccata agatccaagg gaggcctccg ccgccgccgg taaccacccc   4140gcccctctcc tctttctttc tccgtttttt tttccgtctc ggtctcgatc tttggccttg   4200gtagtttggg tgggcgagag gcggcttcgt gcgcgcccag atcggtgcgc gggaggggcg   4260ggatctcgcg gctggggctc tcgccggcgt ggatccggcc cggatctcgc ggggaatggg   4320gctctcggat gtagatctgc gatccgccgt tgttggggga gatgatgggg ggtttaaaat   4380ttccgccgtg ctaaacaaga tcaggaagag gggaaaaggg cactatggtt tatattttta   4440tatatttctg ctgcttcgtc aggcttagat gtgctagatc tttctttctt ctttttgtgg   4500gtagaatttg aatccctcag cattgttcat cggtagtttt tcttttcatg atttgtgaca   4560aatgcagcct cgtgcggagc ttttttgtag gtagaagtga tcaaccatgg ccaaccccaa   4620caatcgctcc gagcacgaca cgatcaaggt cacccccaac tccgagctcc agaccaacca   4680caaccagtac ccgctggccg acaaccccaa ctccaccctg gaagagctga actacaagga   4740gttcctgcgc atgaccgagg actcctccac ggaggtcctg gacaactcca ccgtcaagga   4800cgccgtcggg accggcatct ccgtcgttgg gcagatcctg ggcgtcgttg gcgtcccctt   4860cgcaggtgct ctcacctcct tctaccagtc cttcctgaac accatctggc cctccgacgc   4920cgacccctgg aaggccttca tggcccaagt cgaagtcctg atcgacaaga agatcgagga   4980gtacgccaag tccaaggccc tggccgagct gcaaggcctg caaaacaact tcgaggacta   5040cgtcaacgcg ctgaactcct ggaagaagac gcctctgtcc ctgcgctcca agcgctccca   5100ggaccgcatc cgcgagctgt tctcccaggc cgagtcccac ttccgcaact ccatgccgtc   5160cttcgccgtc tccaagttcg aggtcctgtt cctgcccacc tacgcccagg ctgccaacac   5220ccacctcctg ttgctgaagg acgcccaggt cttcggcgag gaatggggct actcctcgga   5280ggacgtcgcc gagttctacc gtcgccagct gaagctgacc caacagtaca ccgaccactg   5340cgtcaactgg tacaacgtcg gcctgaacgg cctgaggggc tccacctacg acgcatgggt   5400caagttcaac cgcttccgca gggagatgac cctgaccgtc ctggacctga tcgtcctgtt   5460ccccttctac gacatccgcc tgtactccaa gggcgtcaag accgagctga cccgcgacat   5520cttcacggac cccatcttcc tgctcacgac cctccagaag tacggtccca ccttcctgtc   5580catcgagaac tccatccgca agccccacct gttcgactac ctccagggca tcgagttcca   5640cacgcgcctg aggccaggct acttcggcaa ggactccttc aactactggt ccggcaacta   5700cgtcgagacc aggccctcca tcggctcctc gaagacgatc acctcccctt tctacggcga   5760caagtccacc gagcccgtcc agaagctgtc cttcgacggc cagaaggtct accgcaccat   5820cgccaacacc gacgtcgcgg cttggccgaa cggcaaggtc tacctgggcg tcacgaaggt   5880cgacttctcc cagtacgatg accagaagaa cgagacctcc acccagacct acgactccaa   5940gcgcaacaat ggccacgtct ccgcccagga ctccatcgac cagctgccgc ctgagaccac   6000tgacgagccc ctggagaagg cctactccca ccagctgaac tacgcggagt gcttcctgat   6060gcaagaccgc aggggcacca tccccttctt cacctggacc caccgctccg tcgacttctt   6120caacaccatc gacgccgaga agatcaccca gctgcccgtg gtcaaggcct acgccctgtc   6180ctcgggtgcc tccatcattg agggtccagg cttcaccggt ggcaacctgc tgttcctgaa   6240ggagtcctcg aactccatcg ccaagttcaa ggtcaccctg aactccgctg ccttgctgca   6300acgctaccgc gtccgcatcc gctacgcctc caccacgaac ctgcgcctgt tcgtccagaa   6360ctccaacaat gacttcctgg tcatctacat caacaagacc atgaacaagg acgatgacct   6420gacctaccag accttcgacc tcgccaccac gaactccaac atgggcttct cgggcgacaa   6480gaatgaactg atcattggtg ctgagtcctt cgtctccaac gagaagatct acatcgacaa   6540gatcgagttc atccccgtcc agctgtgata ggaactctga ttgaattctg catgcgtttg   6600gacgtatgct cattcaggtt ggagccaatt tggttgatgt gtgtgcgagt tcttgcgagt   6660ctgatgagac atctctgtat tgtgtttctt tccccagtgt tttctgtact tgtgtaatcg   6720gctaatcgcc aacagattcg gcgatgaata aatgagaaat aaattgttct gattttgagt   6780gcaaaaaaaa aggaattaga tctgtgtgtg ttttttggat cccattttcg acaagcttgc   6840ctcgagacaa caacatgctt ctcatcaaca tggagggaag agggagggag aaagtgtcgc   6900ctggtcacct ccattgtcac actagccact ggccagctct cccacaccac caatgccagg   6960ggcgagcttt agcacagcca ccgcttcacc tccaccaccg cactacccta gcttcgccca   7020acagccaccg tcaacgcctc ctctccgtca acataagaga gagagagaag aggagagtag   7080ccatgtgggg aggaggaata gtacatgggg cctaccgttt ggcaagttat tttgggttgc   7140caagttaggc caataagggg agggatttgg ccatccggtt ggaaaggtta ttggggtagt   7200atctttttac tagaattgtc aaaaaaaaat agtttgagag ccatttggag aggatgttgc   7260ctgttagagg tgctcttagg acatcaaatt ccataaaaac atcagaaaaa ttctctcgat   7320gaagatttat aaccactaaa actgccctca attcgaaggg agttcaaaac aattaaaatc   7380atgttcgaat tgagtttcaa tttcacttta acccctttga aatctcaatg gtaaaacatc   7440aacccgtcag gtagcatggt tctttttatt cctttcaaaa agagttaatt acaaacagaa   7500tcaaaactaa cagttaggcc caaggcccat ccgagcaaac aatagatcat gggccaggcc   7560tgccaccacc ctccccctcc tggctcccgc tcttgaattt caaaatccaa aaatatcggc   7620acgactggcc gccgacggag cgggcggaaa atgacggaac aacccctcga attctacccc   7680aactacgccc accaacccac acgccactga caatccggtc ccacccttgt gggcccacct   7740acaagcgaga cgtcagtcgc tcgcagcaac cagtgggccc acctcccagt gagcggcggg   7800tagatctgga ctcttaccca cccacactaa acaaaacggc atgaatattt tgcactaaaa   7860ccctcagaaa aattccgata ttccaaacca gtacagttcc tgaccgttgg aggagccaaa   7920gtggagcgga gtgtaaaatt gggaaactta atcgaggggg ttaaacgcaa aaacgccgag   7980gcgcctcccg ctctatagaa aggggaggag tgggaggtgg aaaccctacc acaccgcaga   8040gaaaggcgtc ttcgtactcg cctctctccg cgccctcctc cgccgccgct cgccgccgtt   8100cgtctccgcc gccaccggct agccatccag gtaaaacaaa caaaaacgga tctgatgctt   8160ccattcctcc gtttctcgta gtagcgcgct tcgatctgtg ggtggatctg ggtgatcctg   8220gggtgtggtt cgttctgttt gatagatctg tcggtggatc tggccttctg tggttgtcga   8280tgtccggatc tgcgttttga tcagtggtag ttcgtggatc tggcgaaatg ttttggatct   8340ggcagtgaga cgctaagaat cgggaaatga tgcaatatta ggggggtttc ggatggggat   8400ccactgaatt agtctgtctc cctgctgata atctgttcct ttttggtaga tctggttagt   8460gtatgtttgt ttcggataga tctgatcaat gcttgtttgt tttttcaaat tttctaccta   8520ggttgtatag gaatggcatg cggatctggt tggattgcca tgatccgtgc tgaaatgccc   8580ctttggttga tggatcttga tattttactg ctgttcacct agatttgtac tcccgtttat   8640acttaatttg ttgcttatta tgaatagatc tgtaacttag gcacatgtat ggacggagta   8700tgtggatctg tagtatgtac attgctgcga gctaagaact atttcagagc aagcacagaa   8760aaaaatattt agacagattg ggcaactatt tgatggtctt tggtatcatg ctttgtagtg   8820ctcgtttctg cgtagtaatc ttttgatctg atctgaagat aggtgctatt atattcttaa   8880aggtcattag aacgctatct gaaaggctgt attatgtgga ttggttcacc tgtgactccc   8940tgttcgtctt gtcttgataa atcctgtgat aaaaaaaatt cttaaggcgt aatttgttga   9000aatcttgttt tgtcctatgc agcctgatcc atggcgcaag ttagcagaat ctgcaatggt   9060gtgcagaacc catctcttat ctccaatctc tcgaaatcca gtcaacgcaa atctccctta   9120tcggtttctc tgaagacgca gcagcatcca cgagcttatc cgatttcgtc gtcgtgggga   9180ttgaagaaga gtgggatgac gttaattggc tctgagcttc gtcctcttaa ggtcatgtct   9240tctgtttcca cggcgtgcat gcttcacggt gcaagcagcc ggcccgcaac cgcccgcaaa   9300tcctctggcc tttccggaac cgtccgcatt cccggcgaca agtcgatctc ccaccggtcc   9360ttcatgttcg gcggtctcgc gagcggtgaa acgcgcatca ccggccttct ggaaggcgag   9420gacgtcatca atacgggcaa ggccatgcag gcgatgggcg cccgcatccg taaggaaggc   9480gacacctgga tcatcgatgg cgtcggcaat ggcggcctcc tggcgcctga ggcgccgctc   9540gatttcggca atgccgccac gggctgccgc ctgacgatgg gcctcgtcgg ggtctacgat   9600ttcgacagca ccttcatcgg cgacgcctcg ctcacaaagc gcccgatggg ccgcgtgttg   9660aacccgctgc gcgaaatggg cgtgcaggtg aaatcggaag acggtgaccg tcttcccgtt   9720accttgcgcg ggccgaagac gccgacgccg atcacctacc gcgtgccgat ggcctccgca   9780caggtgaagt ccgccgtgct gctcgccggc ctcaacacgc ccggcatcac gacggtcatc   9840gagccgatca tgacgcgcga tcatacggaa aagatgctgc agggctttgg cgccaacctt   9900accgtcgaga cggatgcgga cggcgtgcgc accatccgcc tggaaggccg cggcaagctc   9960accggccaag tcatcgacgt gccgggcgac ccgtcctcga cggccttccc gctggttgcg  10020gccctgcttg ttccgggctc cgacgtcacc atcctcaacg tgctgatgaa ccccacccgc  10080accggcctca tcctgacgct gcaggaaatg ggcgccgaca tcgaagtcat caacccgcgc  10140cttgccggcg gcgaagacgt ggcggacctg cgcgttcgct cctccacgct gaagggcgtc  10200acggtgccgg aagaccgcgc gccttcgatg atcgacgaat atccgattct cgctgtcgcc  10260gccgccttcg cggaaggggc gaccgtgatg aacggtctgg aagaactccg cgtcaaggaa  10320agcgaccgcc tctcggccgt cgccaatggc ctcaagctca atggcgtgga ttgcgatgag  10380ggcgagacgt cgctcgtcgt gcgtggccgc cctgacggca aggggctcgg caacgcctcg  10440ggcgccgccg tcgccaccca tctcgatcac cgcatcgcca tgagcttcct cgtcatgggc  10500ctcgtgtcgg aaaaccctgt cacggtggac gatgccacga tgatcgccac gagcttcccg  10560gagttcatgg acctgatggc cgggctgggc gcgaagatcg aactctccga tacgaaggct  10620gcctgatgag ctccagggtt cttgcctggt gccttggcaa tgcttgatta ctgctgctat  10680cctatgatct gtccgtgtgg gcttctatct atcagtttgt gtgtctggtt ttgaaaaaca  10740tttgcttttc gattatgtag ggtttgcttg tagctttcgc tgctgtgacc tgtgttgttt  10800atgtgaacct tctttgtggc atctttaata tccaagttcg tggtttgtcg taaaacgaag  10860cctctacttc gtaaagttgt gtctatagca ttgaaatcgt ttttttgctc gagaataatt  10920gtgaccttta gttggcgtga aactagtttt ggatatctga ttctctggtt cgcaatcttg  10980agatcgtcgc tgcttaggtg agctaagtga tgttcctaag taaatgctcc tcaccagaat  11040acgtagctgt gtgaaaagag aacgcgtgaa tacgtagctg tgtaaagatt gtgtcccaag  11100taaacctcag tgatttttgt ttggattttt aatttagaaa cattcgactg ggagcggcta  11160gagccacacc caagttccta actatgataa agttgctctg taacagaaaa caccatctag  11220agcggccgcg tttaaactat cagtgttt                                     11248</s400><s200><s210>5</s210><s211>313</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>is a nucleotide sequence of event MON 87411</s223></s220><s220><s221>misc_feature</s221><s222>(1)..(50)</s222><s223>represents the genomic DNA flanking the left      border of the TDNA</s223></s220><s220><s221>misc_feature</s221><s222>(51)..(313)</s222><s223>left border remnant</s223></s220></s200><s400> 5ttatttatta aaaggaaaat aaaaaggcaa aacactaatg aatagttaag tggcttcatg     60tccgggaaat ctacatggat cagcaatgag tatgatggtc aatatggaga aaaagaaaga    120gtaattacca attttttttc aattcaaaaa tgtagatgtc cgcagcgtta ttataaaatg    180aaagtacatt ttgataaaac gacaaattac gatccgtcgt atttataggc gaaagcaata    240aacaaattat tctaattcgg aaatctttat ttcgacgtgt ctacattcac gtccaaatgg    300gggcttagat gag                                                       313</s400><s200><s210>6</s210><s211>373</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>is a nucleotide sequence of event MON 87411</s223></s220><s220><s221>misc_feature</s221><s222>(1)..(110)</s222><s223>represents the genomic DNA flanking the left      border of the TDNA</s223></s220><s220><s221>misc_feature</s221><s222>(111)..(373)</s222><s223>left border remnant</s223></s220></s200><s400> 6tttcactgtc tacatgtatg tattttatga ctagacaata ggttcattta aagtgatgga     60ttatttatta aaaggaaaat aaaaaggcaa aacactaatg aatagttaag tggcttcatg    120tccgggaaat ctacatggat cagcaatgag tatgatggtc aatatggaga aaaagaaaga    180gtaattacca attttttttc aattcaaaaa tgtagatgtc cgcagcgtta ttataaaatg    240aaagtacatt ttgataaaac gacaaattac gatccgtcgt atttataggc gaaagcaata    300aacaaattat tctaattcgg aaatctttat ttcgacgtgt ctacattcac gtccaaatgg    360gggcttagat gag                                                       373</s400><s200><s210>7</s210><s211>408</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>is a nucleotide sequence of event MON 87411</s223></s220><s220><s221>misc_feature</s221><s222>(1)..(145)</s222><s223>represents the genomic DNA flanking the left      border of the TDNA</s223></s220><s220><s221>misc_feature</s221><s222>(146)..(408)</s222><s223>left border remnant</s223></s220></s200><s400> 7cataatatta ttctctatct gtttaaatta taatatttca ctgtctacat gtatgtattt     60tatgactaga caataggttc atttaaagtg atggattatt tattaaaagg aaaataaaaa    120ggcaaaacac taatgaatag ttaagtggct tcatgtccgg gaaatctaca tggatcagca    180atgagtatga tggtcaatat ggagaaaaag aaagagtaat taccaatttt ttttcaattc    240aaaaatgtag atgtccgcag cgttattata aaatgaaagt acattttgat aaaacgacaa    300attacgatcc gtcgtattta taggcgaaag caataaacaa attattctaa ttcggaaatc    360tttatttcga cgtgtctaca ttcacgtcca aatgggggct tagatgag                 408</s400><s200><s210>8</s210><s211>117</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>is a nucleotide sequence of event MON 87411</s223></s220><s220><s221>misc_feature</s221><s222>(69)..(83)</s222><s223>right border remnant</s223></s220><s220><s221>misc_feature</s221><s222>(84)..(117)</s222><s223>represents the genomic DNA flanking the right      border of the TDNA</s223></s220></s200><s400> 8acacccaagt tcctaactat gataaagttg ctctgtaaca gaaaacacca tctagagcgg     60ccgcgtttaa actatcagtg tttagagaat cacaaacctc tagatgtatt aatctac       117</s400><s200><s210>9</s210><s211>173</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>is a nucleotide sequence of event MON 87411</s223></s220><s220><s221>misc_feature</s221><s222>(69)..(83)</s222><s223>right border remnant</s223></s220><s220><s221>misc_feature</s221><s222>(84)..(173)</s222><s223>represents the genomic DNA flanking the right      border of the TDNA</s223></s220></s200><s400> 9acacccaagt tcctaactat gataaagttg ctctgtaaca gaaaacacca tctagagcgg     60ccgcgtttaa actatcagtg tttagagaat cacaaacctc tagatgtatt aatctaccct    120agaactagtt cacttttgtg tgcatacttt tctattgaac tggtgttcac ttt           173</s400><s200><s210>10</s210><s211>338</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>is a nucleotide sequence of event MON 87411</s223></s220><s220><s221>misc_feature</s221><s222>(69)..(83)</s222><s223>right border remnant</s223></s220><s220><s221>misc_feature</s221><s222>(84)..(338)</s222><s223>represents the genomic DNA flanking the right      border of the TDNA</s223></s220></s200><s400> 10acacccaagt tcctaactat gataaagttg ctctgtaaca gaaaacacca tctagagcgg     60ccgcgtttaa actatcagtg tttagagaat cacaaacctc tagatgtatt aatctaccct    120agaactagtt cacttttgtg tgcatacttt tctattgaac tggtgttcac tttgttgcat    180atgttttgtg tactgtttat ttgtcattgc ccaaatgtgt ttaatgagtg attgctttgc    240gtagacaacg agcagttcaa ggtttccgag tgtgttgcaa aagacttccc tgagcagcaa    300cctggtgaag gtaagtgtcc tctgacccat tatgtcat                            338</s400><s200><s210>11</s210><s211>663</s211><s212>DNA</s212><s213>Diabrotica virgifera virgifera</s213><s220><s221>misc_feature</s221><s222>(1)..(660)</s222><s223>Dv_Snf7o ORF encoding a putative ESCRT-III      complex subunit from Diabrotica virgifera</s223></s220></s200><s400> 11atgagctttt ttggaaaatt gttcgggggg aaaaaggaag agatagcccc tagtcctggg     60gaggctattc aaaaactcag agagactgaa gaaatgttaa taaaaaaaca ggatttttta    120gaaaagaaga tagaagaatt taccatggta gcaaagaaaa atgcgtcgaa aaataaaaga    180gttgcactcc aagccctcaa aaagaagaaa cgattggaaa agacccaact acaaatagat    240ggaaccctta caactattga aatgcagagg gaagccctcg aaggagctag cacaaatact    300gctgtattag attctatgaa aaatgctgca gatgccctta agaaagctca taagaatttg    360aatgtagatg atgttcacga tatcatggat gacatagccg aacaacacga catagccaac    420gaaatcacaa acgctattag caatcctgtc ggattcaccg acgatctgga tgacgatgaa    480ttagaaaaag aattagaaga gctcgaacaa gaaggattgg aagaagacct gctccaagtg    540ccaggtccaa ctcaactgcc ggctgtgcct gctgatgcag ttgctactaa accaatcaaa    600ccagcagcta aaaaagttga agatgatgac gatatgaaag aattggaagc ctgggcctcg    660taa                                                                  663</s400><s200><s210>12</s210><s211>2753</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>is a nucleotide sequence representing the      antisense strand of an inverted repeat RNA expression cassette</s223></s220><s220><s221>3&#x2032;UTR</s221><s222>(1)..(633)</s222><s223>Ps.RbcS2-E9 3&#x2032; UTR antisense strand</s223></s220><s220><s221>misc_feature</s221><s222>(663)..(902)</s222><s223>inverted repeat Dv_Snf7o arm</s223></s220><s220><s221>misc_feature</s221><s222>(903)..(1052)</s222><s223>inverted repeat loop</s223></s220><s220><s221>misc_feature</s221><s222>(1053)..(1292)</s222><s223>inverted repeat Dv_Snf7o arm</s223></s220><s220><s221>Intron</s221><s222>(1329)..(2132)</s222><s223>Corn DnaK intron antisense strand</s223></s220><s220><s221>misc_feature</s221><s222>(2133)..(2141)</s222><s223>CaMV 35S leader antisense strand</s223></s220><s220><s221>promoter</s221><s222>(2142)..(2753)</s222><s223>represents the reverse complement sequence of      an enhanced CaMV 35S promoter</s223></s220></s200><s400> 12gttgtcaatc aattggcaag tcataaaatg cattaaaaaa tattttcata ctcaactaca     60aatccatgag tataactata attataaagc aatgattaga atctgacaag gattctggaa    120aattacataa aggaaagttc ataaatgtct aaaacacaag aggacatact tgtattcagt    180aacatttgca gcttttctag gtctgaaaat atatttgttg cctagtgaat aagcataatg    240gtacaactac aagtgtttta ctcctcatat taacttcggt cattagaggc cacgatttga    300cacattttta ctcaaaacaa aatgtttgca tatctcttat aatttcaaat tcaacacaca    360acaaataaga gaaaaaacaa ataatattaa tttgagaatg aacaaaagga ccatatcatt    420cattaactct tctccatcca tttccatttc acagttcgat agcgaaaacc gaataaaaaa    480cacagtaaat tacaagcaca acaaatggta caagaaaaac agttttccca atgccataat    540actcaaactc agtaggattc tggtgtgtgc gcaatgaaac tgatgcattg aacttgacga    600acgttgtcga aaccgatgat acgaacgaaa gctaggcctc agcgagtacc gctggcgatc    660taatccatga tatcgtgaac atcatctaca ttcaaattct tatgagcttt cttaagggca    720tctgcagcat ttttcataga atctaataca gcagtatttg tgctagctcc ttcgagggct    780tccctctgca tttcaatagt tgtaagggtt ccatctattt gtagttgggt cttttccaat    840cgtttcttct ttttgagggc ttggagtgca actcttttat ttttcgacgc atttttcttt    900gcgctcctgc aggcggccgc gtggatgagg agttaatcgg tcgtgtgaga gtagtgatcg    960agtggatgtc gtcgagagtg atgagtgttg atgttgttag tgatatgtgg tagaaggtat   1020cgtgataaag cgttaacgcg atcgcagtac ttgcaaagaa aaatgcgtcg aaaaataaaa   1080gagttgcact ccaagccctc aaaaagaaga aacgattgga aaagacccaa ctacaaatag   1140atggaaccct tacaactatt gaaatgcaga gggaagccct cgaaggagct agcacaaata   1200ctgctgtatt agattctatg aaaaatgctg cagatgccct taagaaagct cataagaatt   1260tgaatgtaga tgatgttcac gatatcatgg atggtatcgc acagcgactg ctgagggacg   1320tcgagctccc gcttggtatc tgcattacaa tgaaatgagc aaagactatg tgagtaacac   1380tggtcaacac tagggagaag gcatcgagca agatacgtat gtaaagagaa gcaatatagt   1440gtcagttggt agatactaga taccatcagg aggtaaggag agcaacaaaa aggaaactct   1500ttatttttaa attttgttac aacaaacaag cagatcaatg catcaaaata ctgtcagtac   1560ttatttcttc agacaacaat atttaaaaca agtgcatctg atcttgactt atggtcacaa   1620taaaggagca gagataaaca tcaaaatttc gtcatttata tttattcctt caggcgttaa   1680caatttaaca gcacacaaac aaaaacagaa taggaatatc taattttggc aaataataag   1740ctctgcagac gaacaaatta ttatagtatc gcctataata tgaatcccta tactattgac   1800ccatgtagta tgaagcctgt gcctaaatta acagcaaact tctgaatcca agtgccctat   1860aacaccaaca tgtgcttaaa taaataccgc taagcaccaa attacacatt tctcgtattg   1920ctgtgtaggt tctatcttcg tttcgtacta ccatgtccct atattttgct gctacaaagg   1980acggcaagta atcagcacag gcagaacacg atttcagagt gtaattctag atccagctaa   2040accactctca gcaatcacca cacaagagag cattcagaga aacgtggcag taacaaaggc   2100agagggcgga gtgagcgcgt accgaagacg gttcagcgtg tcctctccaa atgaaatgaa   2160cttccttata tagaggaagg gtcttgcgaa ggatagtggg attgtgcgtc atcccttacg   2220tcagtggaga tatcacatca atccacttgc tttgaagacg tggttggaac gtcttctttt   2280tccacgatgc tcctcgtggg tgggggtcca tctttgggac cactgtcggc agaggcatct   2340tcaacgatgg cctttccttt atcgcaatga tggcatttgt aggagccacc ttccttttcc   2400actatcttca caataaagtg acagatagct gggcaatgga atccgaggag gtttccggat   2460attacccttt gttgaaaagt ctcaatcgga ccatcacatc aatccacttg ctttgaagac   2520gtggttggaa cgtcttcttt ttccacgatg ctcctcgtgg gtgggggtcc atctttggga   2580ccactgtcgg cagaggcatc ttcaacgatg gcctttcctt tatcgcaatg atggcatttg   2640taggagccac cttccttttc cactatcttc acaataaagt gacagatagc tgggcaatgg   2700aatccgagga ggtttccgga tattaccctt tgttgaaaag tctcaatcgg acc          2753</s400><s200><s210>13</s210><s211>240</s211><s212>RNA</s212><s213>Artificial Sequence</s213><s220><s223>is a ribonucleotide sequence representing the      Dv_Snf7o RNA inverted repeat</s223></s220></s200><s400> 13gcaaagaaaa augcgucgaa aaauaaaaga guugcacucc aagcccucaa aaagaagaaa     60cgauuggaaa agacccaacu acaaauagau ggaacccuua caacuauuga aaugcagagg    120gaagcccucg aaggagcuag cacaaauacu gcuguauuag auucuaugaa aaaugcugca    180gaugcccuua agaaagcuca uaagaauuug aauguagaug auguucacga uaucauggau    240</s400><s200><s210>14</s210><s211>3712</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>is a nucleotide sequence representing the sense      strand of a DNA expression cassette that includes a recombinant      gene engineered to encode and express a Cry3Bb protein</s223></s220><s220><s221>promoter</s221><s222>(1)..(949)</s222><s223>Corn PIIG promoter</s223></s220><s220><s221>misc_feature</s221><s222>(956)..(1016)</s222><s223>Wheat Lhcb1 leader sense strand</s223></s220><s220><s221>Intron</s221><s222>(1033)..(1512)</s222><s223>Rice Act1 intron sense strand</s223></s220><s220><s221>CDS</s221><s222>(1522)..(3483)</s222><s223>cry3B2 ORF sense strand</s223></s220><s220><s221>3&#x2032;UTR</s221><s222>(3503)..(3712)</s222><s223>Wheat Hsp17 3&#x2032; UTR sense strand</s223></s220></s200><s400> 14acaaatcaca ggccatgaac cctactcatg cttcgatttg tccaacacac acttaccaaa     60actcaaatca tgtccttgac agtcactcgg gactcataac atgggtacgt atcgactatg    120tcaactatat gtgttctcat cagattatag attggcctag tacgtagtga tatttccact    180agcactgtgg ttatggctgt acctgatagt gatatcagca ccgggtcatg gctctactac    240caggtagtga gagtgacctt tatactgtca gactgtaact aaggatttcc aatcactgtt    300cggatcctag gcttagaatt aagtaaaact ctatcactat aggctgcagc acactcggta    360tatattgatg ggccaacaga aattgtgcgt actatgcgcg atgtaaaatg gacataaacc    420ctacccatat acaatgcaat aacttttgtc cggtctgggc caccggttag cagaggtcct    480gatttcggtg gtagtggtag cttgatctgg tcgtcgtatc gtagagggat atataaaatc    540atgtcacttt tgaagggagc gctcacagaa ataataggta ttcgcgggag ccgcccccgc    600agaacacaaa ataaggcgag cacgcacacg catcagtttc gataaaataa taatagcgcc    660agctgatcgg aacaattcca gctagcacta atgtatttct gcattgatct gtttatacaa    720catgctacct cgttgagtga ttttgacatg atttgtcaac ttgctccgat cctatatctc    780gatcgatctc cacatgacga tggttgttgt cctgtatccc atgacaacca ggcaacgctc    840aaagcacaca tgcgttgccg attacccgtg catgccgcca agcacgaaag cacctccctc    900cacaccgtcc atcagctata aaaaccatgc caagcaccct gtgaaaagcc ccgggaacca    960tcttccacac actcaagcca cactattgga gaacacacag ggacaacaca ccataagatc   1020caagggaggc ctccgccgcc gccggtaacc accccgcccc tctcctcttt ctttctccgt   1080ttttttttcc gtctcggtct cgatctttgg ccttggtagt ttgggtgggc gagaggcggc   1140ttcgtgcgcg cccagatcgg tgcgcgggag gggcgggatc tcgcggctgg ggctctcgcc   1200ggcgtggatc cggcccggat ctcgcgggga atggggctct cggatgtaga tctgcgatcc   1260gccgttgttg ggggagatga tggggggttt aaaatttccg ccgtgctaaa caagatcagg   1320aagaggggaa aagggcacta tggtttatat ttttatatat ttctgctgct tcgtcaggct   1380tagatgtgct agatctttct ttcttctttt tgtgggtaga atttgaatcc ctcagcattg   1440ttcatcggta gtttttcttt tcatgatttg tgacaaatgc agcctcgtgc ggagcttttt   1500tgtaggtaga agtgatcaac c atg gcc aac ccc aac aat cgc tcc gag cac     1551                        Met Ala Asn Pro Asn Asn Arg Ser Glu His                        1               5                   10gac acg atc aag gtc acc ccc aac tcc gag ctc cag acc aac cac aac     1599Asp Thr Ile Lys Val Thr Pro Asn Ser Glu Leu Gln Thr Asn His Asn                15                  20                  25cag tac ccg ctg gcc gac aac ccc aac tcc acc ctg gaa gag ctg aac     1647Gln Tyr Pro Leu Ala Asp Asn Pro Asn Ser Thr Leu Glu Glu Leu Asn            30                  35                  40tac aag gag ttc ctg cgc atg acc gag gac tcc tcc acg gag gtc ctg     1695Tyr Lys Glu Phe Leu Arg Met Thr Glu Asp Ser Ser Thr Glu Val Leu        45                  50                  55gac aac tcc acc gtc aag gac gcc gtc ggg acc ggc atc tcc gtc gtt     1743Asp Asn Ser Thr Val Lys Asp Ala Val Gly Thr Gly Ile Ser Val Val    60                  65                  70ggg cag atc ctg ggc gtc gtt ggc gtc ccc ttc gca ggt gct ctc acc     1791Gly Gln Ile Leu Gly Val Val Gly Val Pro Phe Ala Gly Ala Leu Thr75                  80                  85                  90tcc ttc tac cag tcc ttc ctg aac acc atc tgg ccc tcc gac gcc gac     1839Ser Phe Tyr Gln Ser Phe Leu Asn Thr Ile Trp Pro Ser Asp Ala Asp                95                  100                 105ccc tgg aag gcc ttc atg gcc caa gtc gaa gtc ctg atc gac aag aag     1887Pro Trp Lys Ala Phe Met Ala Gln Val Glu Val Leu Ile Asp Lys Lys            110                 115                 120atc gag gag tac gcc aag tcc aag gcc ctg gcc gag ctg caa ggc ctg     1935Ile Glu Glu Tyr Ala Lys Ser Lys Ala Leu Ala Glu Leu Gln Gly Leu        125                 130                 135caa aac aac ttc gag gac tac gtc aac gcg ctg aac tcc tgg aag aag     1983Gln Asn Asn Phe Glu Asp Tyr Val Asn Ala Leu Asn Ser Trp Lys Lys    140                 145                 150acg cct ctg tcc ctg cgc tcc aag cgc tcc cag gac cgc atc cgc gag     2031Thr Pro Leu Ser Leu Arg Ser Lys Arg Ser Gln Asp Arg Ile Arg Glu155                 160                 165                 170ctg ttc tcc cag gcc gag tcc cac ttc cgc aac tcc atg ccg tcc ttc     2079Leu Phe Ser Gln Ala Glu Ser His Phe Arg Asn Ser Met Pro Ser Phe                175                 180                 185gcc gtc tcc aag ttc gag gtc ctg ttc ctg ccc acc tac gcc cag gct     2127Ala Val Ser Lys Phe Glu Val Leu Phe Leu Pro Thr Tyr Ala Gln Ala            190                 195                 200gcc aac acc cac ctc ctg ttg ctg aag gac gcc cag gtc ttc ggc gag     2175Ala Asn Thr His Leu Leu Leu Leu Lys Asp Ala Gln Val Phe Gly Glu        205                 210                 215gaa tgg ggc tac tcc tcg gag gac gtc gcc gag ttc tac cgt cgc cag     2223Glu Trp Gly Tyr Ser Ser Glu Asp Val Ala Glu Phe Tyr Arg Arg Gln    220                 225                 230ctg aag ctg acc caa cag tac acc gac cac tgc gtc aac tgg tac aac     2271Leu Lys Leu Thr Gln Gln Tyr Thr Asp His Cys Val Asn Trp Tyr Asn235                 240                 245                 250gtc ggc ctg aac ggc ctg agg ggc tcc acc tac gac gca tgg gtc aag     2319Val Gly Leu Asn Gly Leu Arg Gly Ser Thr Tyr Asp Ala Trp Val Lys                255                 260                 265ttc aac cgc ttc cgc agg gag atg acc ctg acc gtc ctg gac ctg atc     2367Phe Asn Arg Phe Arg Arg Glu Met Thr Leu Thr Val Leu Asp Leu Ile            270                 275                 280gtc ctg ttc ccc ttc tac gac atc cgc ctg tac tcc aag ggc gtc aag     2415Val Leu Phe Pro Phe Tyr Asp Ile Arg Leu Tyr Ser Lys Gly Val Lys        285                 290                 295acc gag ctg acc cgc gac atc ttc acg gac ccc atc ttc ctg ctc acg     2463Thr Glu Leu Thr Arg Asp Ile Phe Thr Asp Pro Ile Phe Leu Leu Thr    300                 305                 310acc ctc cag aag tac ggt ccc acc ttc ctg tcc atc gag aac tcc atc     2511Thr Leu Gln Lys Tyr Gly Pro Thr Phe Leu Ser Ile Glu Asn Ser Ile315                 320                 325                 330cgc aag ccc cac ctg ttc gac tac ctc cag ggc atc gag ttc cac acg     2559Arg Lys Pro His Leu Phe Asp Tyr Leu Gln Gly Ile Glu Phe His Thr                335                 340                 345cgc ctg agg cca ggc tac ttc ggc aag gac tcc ttc aac tac tgg tcc     2607Arg Leu Arg Pro Gly Tyr Phe Gly Lys Asp Ser Phe Asn Tyr Trp Ser            350                 355                 360ggc aac tac gtc gag acc agg ccc tcc atc ggc tcc tcg aag acg atc     2655Gly Asn Tyr Val Glu Thr Arg Pro Ser Ile Gly Ser Ser Lys Thr Ile        365                 370                 375acc tcc cct ttc tac ggc gac aag tcc acc gag ccc gtc cag aag ctg     2703Thr Ser Pro Phe Tyr Gly Asp Lys Ser Thr Glu Pro Val Gln Lys Leu    380                 385                 390tcc ttc gac ggc cag aag gtc tac cgc acc atc gcc aac acc gac gtc     2751Ser Phe Asp Gly Gln Lys Val Tyr Arg Thr Ile Ala Asn Thr Asp Val395                 400                 405                 410gcg gct tgg ccg aac ggc aag gtc tac ctg ggc gtc acg aag gtc gac     2799Ala Ala Trp Pro Asn Gly Lys Val Tyr Leu Gly Val Thr Lys Val Asp                415                 420                 425ttc tcc cag tac gat gac cag aag aac gag acc tcc acc cag acc tac     2847Phe Ser Gln Tyr Asp Asp Gln Lys Asn Glu Thr Ser Thr Gln Thr Tyr            430                 435                 440gac tcc aag cgc aac aat ggc cac gtc tcc gcc cag gac tcc atc gac     2895Asp Ser Lys Arg Asn Asn Gly His Val Ser Ala Gln Asp Ser Ile Asp        445                 450                 455cag ctg ccg cct gag acc act gac gag ccc ctg gag aag gcc tac tcc     2943Gln Leu Pro Pro Glu Thr Thr Asp Glu Pro Leu Glu Lys Ala Tyr Ser    460                 465                 470cac cag ctg aac tac gcg gag tgc ttc ctg atg caa gac cgc agg ggc     2991His Gln Leu Asn Tyr Ala Glu Cys Phe Leu Met Gln Asp Arg Arg Gly475                 480                 485                 490acc atc ccc ttc ttc acc tgg acc cac cgc tcc gtc gac ttc ttc aac     3039Thr Ile Pro Phe Phe Thr Trp Thr His Arg Ser Val Asp Phe Phe Asn                495                 500                 505acc atc gac gcc gag aag atc acc cag ctg ccc gtg gtc aag gcc tac     3087Thr Ile Asp Ala Glu Lys Ile Thr Gln Leu Pro Val Val Lys Ala Tyr            510                 515                 520gcc ctg tcc tcg ggt gcc tcc atc att gag ggt cca ggc ttc acc ggt     3135Ala Leu Ser Ser Gly Ala Ser Ile Ile Glu Gly Pro Gly Phe Thr Gly        525                 530                 535ggc aac ctg ctg ttc ctg aag gag tcc tcg aac tcc atc gcc aag ttc     3183Gly Asn Leu Leu Phe Leu Lys Glu Ser Ser Asn Ser Ile Ala Lys Phe    540                 545                 550aag gtc acc ctg aac tcc gct gcc ttg ctg caa cgc tac cgc gtc cgc     3231Lys Val Thr Leu Asn Ser Ala Ala Leu Leu Gln Arg Tyr Arg Val Arg555                 560                 565                 570atc cgc tac gcc tcc acc acg aac ctg cgc ctg ttc gtc cag aac tcc     3279Ile Arg Tyr Ala Ser Thr Thr Asn Leu Arg Leu Phe Val Gln Asn Ser                575                 580                 585aac aat gac ttc ctg gtc atc tac atc aac aag acc atg aac aag gac     3327Asn Asn Asp Phe Leu Val Ile Tyr Ile Asn Lys Thr Met Asn Lys Asp            590                 595                 600gat gac ctg acc tac cag acc ttc gac ctc gcc acc acg aac tcc aac     3375Asp Asp Leu Thr Tyr Gln Thr Phe Asp Leu Ala Thr Thr Asn Ser Asn        605                 610                 615atg ggc ttc tcg ggc gac aag aat gaa ctg atc att ggt gct gag tcc     3423Met Gly Phe Ser Gly Asp Lys Asn Glu Leu Ile Ile Gly Ala Glu Ser    620                 625                 630ttc gtc tcc aac gag aag atc tac atc gac aag atc gag ttc atc ccc     3471Phe Val Ser Asn Glu Lys Ile Tyr Ile Asp Lys Ile Glu Phe Ile Pro635                 640                 645                 650gtc cag ctg tga taggaactct gattgaattc tgcatgcgtt tggacgtatg         3523Val Gln Leuctcattcagg ttggagccaa tttggttgat gtgtgtgcga gttcttgcga gtctgatgag   3583acatctctgt attgtgtttc tttccccagt gttttctgta cttgtgtaat cggctaatcg   3643ccaacagatt cggcgatgaa taaatgagaa ataaattgtt ctgattttga gtgcaaaaaa   3703aaaggaatt                                                           3712</s400><s200><s210>15</s210><s211>653</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic Construct</s223></s220></s200><s400> 15Met Ala Asn Pro Asn Asn Arg Ser Glu His Asp Thr Ile Lys Val Thr1               5                   10                  15Pro Asn Ser Glu Leu Gln Thr Asn His Asn Gln Tyr Pro Leu Ala Asp            20                  25                  30Asn Pro Asn Ser Thr Leu Glu Glu Leu Asn Tyr Lys Glu Phe Leu Arg        35                  40                  45Met Thr Glu Asp Ser Ser Thr Glu Val Leu Asp Asn Ser Thr Val Lys    50                  55                  60Asp Ala Val Gly Thr Gly Ile Ser Val Val Gly Gln Ile Leu Gly Val65                  70                  75                  80Val Gly Val Pro Phe Ala Gly Ala Leu Thr Ser Phe Tyr Gln Ser Phe                85                  90                  95Leu Asn Thr Ile Trp Pro Ser Asp Ala Asp Pro Trp Lys Ala Phe Met            100                 105                 110Ala Gln Val Glu Val Leu Ile Asp Lys Lys Ile Glu Glu Tyr Ala Lys        115                 120                 125Ser Lys Ala Leu Ala Glu Leu Gln Gly Leu Gln Asn Asn Phe Glu Asp    130                 135                 140Tyr Val Asn Ala Leu Asn Ser Trp Lys Lys Thr Pro Leu Ser Leu Arg145                 150                 155                 160Ser Lys Arg Ser Gln Asp Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu                165                 170                 175Ser His Phe Arg Asn Ser Met Pro Ser Phe Ala Val Ser Lys Phe Glu            180                 185                 190Val Leu Phe Leu Pro Thr Tyr Ala Gln Ala Ala Asn Thr His Leu Leu        195                 200                 205Leu Leu Lys Asp Ala Gln Val Phe Gly Glu Glu Trp Gly Tyr Ser Ser    210                 215                 220Glu Asp Val Ala Glu Phe Tyr Arg Arg Gln Leu Lys Leu Thr Gln Gln225                 230                 235                 240Tyr Thr Asp His Cys Val Asn Trp Tyr Asn Val Gly Leu Asn Gly Leu                245                 250                 255Arg Gly Ser Thr Tyr Asp Ala Trp Val Lys Phe Asn Arg Phe Arg Arg            260                 265                 270Glu Met Thr Leu Thr Val Leu Asp Leu Ile Val Leu Phe Pro Phe Tyr        275                 280                 285Asp Ile Arg Leu Tyr Ser Lys Gly Val Lys Thr Glu Leu Thr Arg Asp    290                 295                 300Ile Phe Thr Asp Pro Ile Phe Leu Leu Thr Thr Leu Gln Lys Tyr Gly305                 310                 315                 320Pro Thr Phe Leu Ser Ile Glu Asn Ser Ile Arg Lys Pro His Leu Phe                325                 330                 335Asp Tyr Leu Gln Gly Ile Glu Phe His Thr Arg Leu Arg Pro Gly Tyr            340                 345                 350Phe Gly Lys Asp Ser Phe Asn Tyr Trp Ser Gly Asn Tyr Val Glu Thr        355                 360                 365Arg Pro Ser Ile Gly Ser Ser Lys Thr Ile Thr Ser Pro Phe Tyr Gly    370                 375                 380Asp Lys Ser Thr Glu Pro Val Gln Lys Leu Ser Phe Asp Gly Gln Lys385                 390                 395                 400Val Tyr Arg Thr Ile Ala Asn Thr Asp Val Ala Ala Trp Pro Asn Gly                405                 410                 415Lys Val Tyr Leu Gly Val Thr Lys Val Asp Phe Ser Gln Tyr Asp Asp            420                 425                 430Gln Lys Asn Glu Thr Ser Thr Gln Thr Tyr Asp Ser Lys Arg Asn Asn        435                 440                 445Gly His Val Ser Ala Gln Asp Ser Ile Asp Gln Leu Pro Pro Glu Thr    450                 455                 460Thr Asp Glu Pro Leu Glu Lys Ala Tyr Ser His Gln Leu Asn Tyr Ala465                 470                 475                 480Glu Cys Phe Leu Met Gln Asp Arg Arg Gly Thr Ile Pro Phe Phe Thr                485                 490                 495Trp Thr His Arg Ser Val Asp Phe Phe Asn Thr Ile Asp Ala Glu Lys            500                 505                 510Ile Thr Gln Leu Pro Val Val Lys Ala Tyr Ala Leu Ser Ser Gly Ala        515                 520                 525Ser Ile Ile Glu Gly Pro Gly Phe Thr Gly Gly Asn Leu Leu Phe Leu    530                 535                 540Lys Glu Ser Ser Asn Ser Ile Ala Lys Phe Lys Val Thr Leu Asn Ser545                 550                 555                 560Ala Ala Leu Leu Gln Arg Tyr Arg Val Arg Ile Arg Tyr Ala Ser Thr                565                 570                 575Thr Asn Leu Arg Leu Phe Val Gln Asn Ser Asn Asn Asp Phe Leu Val            580                 585                 590Ile Tyr Ile Asn Lys Thr Met Asn Lys Asp Asp Asp Leu Thr Tyr Gln        595                 600                 605Thr Phe Asp Leu Ala Thr Thr Asn Ser Asn Met Gly Phe Ser Gly Asp    610                 615                 620Lys Asn Glu Leu Ile Ile Gly Ala Glu Ser Phe Val Ser Asn Glu Lys625                 630                 635                 640Ile Tyr Ile Asp Lys Ile Glu Phe Ile Pro Val Gln Leu                645                 650</s400><s200><s210>16</s210><s211>4370</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>is a nucleotide sequence representing the sense      strand of a DNA expression cassette that includes a recombinant      gene engineered to encode and express a 5-enolpyruvylshikimate-3-      phosphate synthase (EPSPS) protein</s223></s220></s200><s400> 16gacaacaaca tgcttctcat caacatggag ggaagaggga gggagaaagt gtcgcctggt     60cacctccatt gtcacactag ccactggcca gctctcccac accaccaatg ccaggggcga    120gctttagcac agccaccgct tcacctccac caccgcacta ccctagcttc gcccaacagc    180caccgtcaac gcctcctctc cgtcaacata agagagagag agaagaggag agtagccatg    240tggggaggag gaatagtaca tggggcctac cgtttggcaa gttattttgg gttgccaagt    300taggccaata aggggaggga tttggccatc cggttggaaa ggttattggg gtagtatctt    360tttactagaa ttgtcaaaaa aaaatagttt gagagccatt tggagaggat gttgcctgtt    420agaggtgctc ttaggacatc aaattccata aaaacatcag aaaaattctc tcgatgaaga    480tttataacca ctaaaactgc cctcaattcg aagggagttc aaaacaatta aaatcatgtt    540cgaattgagt ttcaatttca ctttaacccc tttgaaatct caatggtaaa acatcaaccc    600gtcaggtagc atggttcttt ttattccttt caaaaagagt taattacaaa cagaatcaaa    660actaacagtt aggcccaagg cccatccgag caaacaatag atcatgggcc aggcctgcca    720ccaccctccc cctcctggct cccgctcttg aatttcaaaa tccaaaaata tcggcacgac    780tggccgccga cggagcgggc ggaaaatgac ggaacaaccc ctcgaattct accccaacta    840cgcccaccaa cccacacgcc actgacaatc cggtcccacc cttgtgggcc cacctacaag    900cgagacgtca gtcgctcgca gcaaccagtg ggcccacctc ccagtgagcg gcgggtagat    960ctggactctt acccacccac actaaacaaa acggcatgaa tattttgcac taaaaccctc   1020agaaaaattc cgatattcca aaccagtaca gttcctgacc gttggaggag ccaaagtgga   1080gcggagtgta aaattgggaa acttaatcga gggggttaaa cgcaaaaacg ccgaggcgcc   1140tcccgctcta tagaaagggg aggagtggga ggtggaaacc ctaccacacc gcagagaaag   1200gcgtcttcgt actcgcctct ctccgcgccc tcctccgccg ccgctcgccg ccgttcgtct   1260ccgccgccac cggctagcca tccaggtaaa acaaacaaaa acggatctga tgcttccatt   1320cctccgtttc tcgtagtagc gcgcttcgat ctgtgggtgg atctgggtga tcctggggtg   1380tggttcgttc tgtttgatag atctgtcggt ggatctggcc ttctgtggtt gtcgatgtcc   1440ggatctgcgt tttgatcagt ggtagttcgt ggatctggcg aaatgttttg gatctggcag   1500tgagacgcta agaatcggga aatgatgcaa tattaggggg gtttcggatg gggatccact   1560gaattagtct gtctccctgc tgataatctg ttcctttttg gtagatctgg ttagtgtatg   1620tttgtttcgg atagatctga tcaatgcttg tttgtttttt caaattttct acctaggttg   1680tataggaatg gcatgcggat ctggttggat tgccatgatc cgtgctgaaa tgcccctttg   1740gttgatggat cttgatattt tactgctgtt cacctagatt tgtactcccg tttatactta   1800atttgttgct tattatgaat agatctgtaa cttaggcaca tgtatggacg gagtatgtgg   1860atctgtagta tgtacattgc tgcgagctaa gaactatttc agagcaagca cagaaaaaaa   1920tatttagaca gattgggcaa ctatttgatg gtctttggta tcatgctttg tagtgctcgt   1980ttctgcgtag taatcttttg atctgatctg aagataggtg ctattatatt cttaaaggtc   2040attagaacgc tatctgaaag gctgtattat gtggattggt tcacctgtga ctccctgttc   2100gtcttgtctt gataaatcct gtgataaaaa aaattcttaa ggcgtaattt gttgaaatct   2160tgttttgtcc tatgcagcct gatccatggc gcaagttagc agaatctgca atggtgtgca   2220gaacccatct cttatctcca atctctcgaa atccagtcaa cgcaaatctc ccttatcggt   2280ttctctgaag acgcagcagc atccacgagc ttatccgatt tcgtcgtcgt ggggattgaa   2340gaagagtggg atgacgttaa ttggctctga gcttcgtcct cttaaggtca tgtcttctgt   2400ttccacggcg tgcatgcttc acggtgcaag cagccggccc gcaaccgccc gcaaatcctc   2460tggcctttcc ggaaccgtcc gcattcccgg cgacaagtcg atctcccacc ggtccttcat   2520gttcggcggt ctcgcgagcg gtgaaacgcg catcaccggc cttctggaag gcgaggacgt   2580catcaatacg ggcaaggcca tgcaggcgat gggcgcccgc atccgtaagg aaggcgacac   2640ctggatcatc gatggcgtcg gcaatggcgg cctcctggcg cctgaggcgc cgctcgattt   2700cggcaatgcc gccacgggct gccgcctgac gatgggcctc gtcggggtct acgatttcga   2760cagcaccttc atcggcgacg cctcgctcac aaagcgcccg atgggccgcg tgttgaaccc   2820gctgcgcgaa atgggcgtgc aggtgaaatc ggaagacggt gaccgtcttc ccgttacctt   2880gcgcgggccg aagacgccga cgccgatcac ctaccgcgtg ccgatggcct ccgcacaggt   2940gaagtccgcc gtgctgctcg ccggcctcaa cacgcccggc atcacgacgg tcatcgagcc   3000gatcatgacg cgcgatcata cggaaaagat gctgcagggc tttggcgcca accttaccgt   3060cgagacggat gcggacggcg tgcgcaccat ccgcctggaa ggccgcggca agctcaccgg   3120ccaagtcatc gacgtgccgg gcgacccgtc ctcgacggcc ttcccgctgg ttgcggccct   3180gcttgttccg ggctccgacg tcaccatcct caacgtgctg atgaacccca cccgcaccgg   3240cctcatcctg acgctgcagg aaatgggcgc cgacatcgaa gtcatcaacc cgcgccttgc   3300cggcggcgaa gacgtggcgg acctgcgcgt tcgctcctcc acgctgaagg gcgtcacggt   3360gccggaagac cgcgcgcctt cgatgatcga cgaatatccg attctcgctg tcgccgccgc   3420cttcgcggaa ggggcgaccg tgatgaacgg tctggaagaa ctccgcgtca aggaaagcga   3480ccgcctctcg gccgtcgcca atggcctcaa gctcaatggc gtggattgcg atgagggcga   3540gacgtcgctc gtcgtgcgtg gccgccctga cggcaagggg ctcggcaacg cctcgggcgc   3600cgccgtcgcc acccatctcg atcaccgcat cgccatgagc ttcctcgtca tgggcctcgt   3660gtcggaaaac cctgtcacgg tggacgatgc cacgatgatc gccacgagct tcccggagtt   3720catggacctg atggccgggc tgggcgcgaa gatcgaactc tccgatacga aggctgcctg   3780atgagctcca gggttcttgc ctggtgcctt ggcaatgctt gattactgct gctatcctat   3840gatctgtccg tgtgggcttc tatctatcag tttgtgtgtc tggttttgaa aaacatttgc   3900ttttcgatta tgtagggttt gcttgtagct ttcgctgctg tgacctgtgt tgtttatgtg   3960aaccttcttt gtggcatctt taatatccaa gttcgtggtt tgtcgtaaaa cgaagcctct   4020acttcgtaaa gttgtgtcta tagcattgaa atcgtttttt tgctcgagaa taattgtgac   4080ctttagttgg cgtgaaacta gttttggata tctgattctc tggttcgcaa tcttgagatc   4140gtcgctgctt aggtgagcta agtgatgttc ctaagtaaat gctcctcacc agaatacgta   4200gctgtgtgaa aagagaacgc gtgaatacgt agctgtgtaa agattgtgtc ccaagtaaac   4260ctcagtgatt tttgtttgga tttttaattt agaaacattc gactgggagc ggctagagcc   4320acacccaagt tcctaactat gataaagttg ctctgtaaca gaaaacacca              4370</s400><s200><s210>17</s210><s211>531</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>is an amino acid sequence translation of      nucleotide positions 2186 through 3781 of SEQ ID NO 16</s223></s220><s220><s221>misc_feature</s221><s222>(1)..(76)</s222><s223>chloroplast transit peptide (CTP) from      Arabidopsis thaliana (thale cress)</s223></s220><s220><s221>misc_feature</s221><s222>(77)..(531)</s222><s223>5-enolpyruvylshikimate-3-phosphate synthase      gene (EPSPS) from Agrobacterium sp strain CP4</s223></s220></s200><s400> 17Met Ala Gln Val Ser Arg Ile Cys Asn Gly Val Gln Asn Pro Ser Leu1               5                   10                  15Ile Ser Asn Leu Ser Lys Ser Ser Gln Arg Lys Ser Pro Leu Ser Val            20                  25                  30Ser Leu Lys Thr Gln Gln His Pro Arg Ala Tyr Pro Ile Ser Ser Ser        35                  40                  45Trp Gly Leu Lys Lys Ser Gly Met Thr Leu Ile Gly Ser Glu Leu Arg    50                  55                  60Pro Leu Lys Val Met Ser Ser Val Ser Thr Ala Cys Met Leu His Gly65                  70                  75                  80Ala Ser Ser Arg Pro Ala Thr Ala Arg Lys Ser Ser Gly Leu Ser Gly                85                  90                  95Thr Val Arg Ile Pro Gly Asp Lys Ser Ile Ser His Arg Ser Phe Met            100                 105                 110Phe Gly Gly Leu Ala Ser Gly Glu Thr Arg Ile Thr Gly Leu Leu Glu        115                 120                 125Gly Glu Asp Val Ile Asn Thr Gly Lys Ala Met Gln Ala Met Gly Ala    130                 135                 140Arg Ile Arg Lys Glu Gly Asp Thr Trp Ile Ile Asp Gly Val Gly Asn145                 150                 155                 160Gly Gly Leu Leu Ala Pro Glu Ala Pro Leu Asp Phe Gly Asn Ala Ala                165                 170                 175Thr Gly Cys Arg Leu Thr Met Gly Leu Val Gly Val Tyr Asp Phe Asp            180                 185                 190Ser Thr Phe Ile Gly Asp Ala Ser Leu Thr Lys Arg Pro Met Gly Arg        195                 200                 205Val Leu Asn Pro Leu Arg Glu Met Gly Val Gln Val Lys Ser Glu Asp    210                 215                 220Gly Asp Arg Leu Pro Val Thr Leu Arg Gly Pro Lys Thr Pro Thr Pro225                 230                 235                 240Ile Thr Tyr Arg Val Pro Met Ala Ser Ala Gln Val Lys Ser Ala Val                245                 250                 255Leu Leu Ala Gly Leu Asn Thr Pro Gly Ile Thr Thr Val Ile Glu Pro            260                 265                 270Ile Met Thr Arg Asp His Thr Glu Lys Met Leu Gln Gly Phe Gly Ala        275                 280                 285Asn Leu Thr Val Glu Thr Asp Ala Asp Gly Val Arg Thr Ile Arg Leu    290                 295                 300Glu Gly Arg Gly Lys Leu Thr Gly Gln Val Ile Asp Val Pro Gly Asp305                 310                 315                 320Pro Ser Ser Thr Ala Phe Pro Leu Val Ala Ala Leu Leu Val Pro Gly                325                 330                 335Ser Asp Val Thr Ile Leu Asn Val Leu Met Asn Pro Thr Arg Thr Gly            340                 345                 350Leu Ile Leu Thr Leu Gln Glu Met Gly Ala Asp Ile Glu Val Ile Asn        355                 360                 365Pro Arg Leu Ala Gly Gly Glu Asp Val Ala Asp Leu Arg Val Arg Ser    370                 375                 380Ser Thr Leu Lys Gly Val Thr Val Pro Glu Asp Arg Ala Pro Ser Met385                 390                 395                 400Ile Asp Glu Tyr Pro Ile Leu Ala Val Ala Ala Ala Phe Ala Glu Gly                405                 410                 415Ala Thr Val Met Asn Gly Leu Glu Glu Leu Arg Val Lys Glu Ser Asp            420                 425                 430Arg Leu Ser Ala Val Ala Asn Gly Leu Lys Leu Asn Gly Val Asp Cys        435                 440                 445Asp Glu Gly Glu Thr Ser Leu Val Val Arg Gly Arg Pro Asp Gly Lys    450                 455                 460Gly Leu Gly Asn Ala Ser Gly Ala Ala Val Ala Thr His Leu Asp His465                 470                 475                 480Arg Ile Ala Met Ser Phe Leu Val Met Gly Leu Val Ser Glu Asn Pro                485                 490                 495Val Thr Val Asp Asp Ala Thr Met Ile Ala Thr Ser Phe Pro Glu Phe            500                 505                 510Met Asp Leu Met Ala Gly Leu Gly Ala Lys Ile Glu Leu Ser Asp Thr        515                 520                 525Lys Ala Ala    530</s400><s200><s210>18</s210><s211>29</s211><s212>DNA</s212><s213>artificial sequence</s213><s220><s223>is a nucleotide sequence of a synthetic      oligonucleotide, and is referred to as SQ27011</s223></s220></s200><s400> 18aaggaaaata aaaaggcaaa acactaatg                                       29</s400><s200><s210>19</s210><s211>14</s211><s212>DNA</s212><s213>artificial sequence</s213><s220><s223>is a nucleotide sequence of a synthetic      oligonucleotide, and is referred to as PB3552</s223></s220></s200><s400> 19ccggacatga agcc                                                       14</s400><s200><s210>20</s210><s211>26</s211><s212>DNA</s212><s213>artificial sequence</s213><s220><s223>is a nucleotide sequence of a synthetic      oligonucleotide, and is referred to as SQ9085</s223></s220></s200><s400> 20actcattgct gatccatgta gatttc                                          26</s400><s200><s210>21</s210><s211>80</s211><s212>DNA</s212><s213>artificial sequence</s213><s220><s223>is a nucleotide sequence of Event MON 87411      corresponding to positions 462 through 541 of SEQ ID NO 1</s223></s220></s200><s400> 21aaggaaaata aaaaggcaaa acactaatga atagttaagt ggcttcatgt ccgggaaatc     60tacatggatc agcaatgagt                                                 80</s400><s200><s210>22</s210><s211>19</s211><s212>DNA</s212><s213>artificial sequence</s213><s220><s223>is a nucleotide sequence of a synthetic      oligonucleotide referred to as SQ27066</s223></s220></s200><s400> 22acaccatcta gagcggccg                                                  19</s400><s200><s210>23</s210><s211>25</s211><s212>DNA</s212><s213>artificial sequence</s213><s220><s223>is a nucleotide sequence of a synthetic      oligonucleotide referred to as PB11300</s223></s220></s200><s400> 23tttaaactat cagtgtttag agaat                                           25</s400><s200><s210>24</s210><s211>29</s211><s212>DNA</s212><s213>artificial sequence</s213><s220><s223>is a nucleotide sequence of a synthetic      oligonucleotide referred to as SQ26977</s223></s220></s200><s400> 24gggtagatta atacatctag aggtttgtg                                       29</s400><s200><s210>25</s210><s211>75</s211><s212>DNA</s212><s213>artificial sequence</s213><s220><s223>is a nucleotide sequence of Event MON 87411      corresponding to positions 11710 through 11784 of SEQ ID NO 1</s223></s220></s200><s400> 25acaccatcta gagcggccgc gtttaaacta tcagtgttta gagaatcaca aacctctaga     60tgtattaatc taccc                                                      75</s400><s200><s210>26</s210><s211>11743</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>DNA construct 417</s223></s220><s220><s221>promoter</s221><s222>(2627)..(3238)</s222><s223>represents the reverse complement sequence of      an enhanced CaMV 35S promoter</s223></s220><s220><s221>promoter</s221><s222>(2627)..(4213)</s222><s223>represents a divergent promoter region that      promotes bidirectional transcription</s223></s220><s220><s221>promoter</s221><s222>(3265)..(4213)</s222><s223>Corn PIIG promoter</s223></s220></s200><s400> 26aaaagtccca tgtggatcac tccgttgccc cgtcgctcac cgtgttgggg ggaaggtgca     60catggctcag ttctcaatgg aaattatctg cctaaccggc tcagttctgc gtagaaacca    120acatgcaagc tccaccgggt gcaaagcggc agcggcggca ggatatattc aattgtaaat    180ggcttcatgt ccgggaaatc tacatggatc agcaatgagt atgatggtca atatggagaa    240aaagaaagag taattaccaa ttttttttca attcaaaaat gtagatgtcc gcagcgttat    300tataaaatga aagtacattt tgataaaacg acaaattacg atccgtcgta tttataggcg    360aaagcaataa acaaattatt ctaattcgga aatctttatt tcgacgtgtc tacattcacg    420tccaaatggg ggcttagatg agaaacttca cgatcgatgc ggccaccact cgaggtcgag    480gtaccgttgt caatcaattg gcaagtcata aaatgcatta aaaaatattt tcatactcaa    540ctacaaatcc atgagtataa ctataattat aaagcaatga ttagaatctg acaaggattc    600tggaaaatta cataaaggaa agttcataaa tgtctaaaac acaagaggac atacttgtat    660tcagtaacat ttgcagcttt tctaggtctg aaaatatatt tgttgcctag tgaataagca    720taatggtaca actacaagtg ttttactcct catattaact tcggtcatta gaggccacga    780tttgacacat ttttactcaa aacaaaatgt ttgcatatct cttataattt caaattcaac    840acacaacaaa taagagaaaa aacaaataat attaatttga gaatgaacaa aaggaccata    900tcattcatta actcttctcc atccatttcc atttcacagt tcgatagcga aaaccgaata    960aaaaacacag taaattacaa gcacaacaaa tggtacaaga aaaacagttt tcccaatgcc   1020ataatactca aactcagtag gattctggtg tgtgcgcaat gaaactgatg cattgaactt   1080gacgaacgtt gtcgaaaccg atgatacgaa cgaaagctag gcctcagcga gtaccgctgg   1140cgatctaatc catgatatcg tgaacatcat ctacattcaa attcttatga gctttcttaa   1200gggcatctgc agcatttttc atagaatcta atacagcagt atttgtgcta gctccttcga   1260gggcttccct ctgcatttca atagttgtaa gggttccatc tatttgtagt tgggtctttt   1320ccaatcgttt cttctttttg agggcttgga gtgcaactct tttatttttc gacgcatttt   1380tctttgcgct cctgcaggcg gccgcgtgga tgaggagtta atcggtcgtg tgagagtagt   1440gatcgagtgg atgtcgtcga gagtgatgag tgttgatgtt gttagtgata tgtggtagaa   1500ggtatcgtga taaagcgtta acgcgatcgc agtacttgca aagaaaaatg cgtcgaaaaa   1560taaaagagtt gcactccaag ccctcaaaaa gaagaaacga ttggaaaaga cccaactaca   1620aatagatgga acccttacaa ctattgaaat gcagagggaa gccctcgaag gagctagcac   1680aaatactgct gtattagatt ctatgaaaaa tgctgcagat gcccttaaga aagctcataa   1740gaatttgaat gtagatgatg ttcacgatat catggatggt atcgcacagc gactgctgag   1800ggacgtcgag ctcccgcttg gtatctgcat tacaatgaaa tgagcaaaga ctatgtgagt   1860aacactggtc aacactaggg agaaggcatc gagcaagata cgtatgtaaa gagaagcaat   1920atagtgtcag ttggtagata ctagatacca tcaggaggta aggagagcaa caaaaaggaa   1980actctttatt tttaaatttt gttacaacaa acaagcagat caatgcatca aaatactgtc   2040agtacttatt tcttcagaca acaatattta aaacaagtgc atctgatctt gacttatggt   2100cacaataaag gagcagagat aaacatcaaa atttcgtcat ttatatttat tccttcaggc   2160gttaacaatt taacagcaca caaacaaaaa cagaatagga atatctaatt ttggcaaata   2220ataagctctg cagacgaaca aattattata gtatcgccta taatatgaat ccctatacta   2280ttgacccatg tagtatgaag cctgtgccta aattaacagc aaacttctga atccaagtgc   2340cctataacac caacatgtgc ttaaataaat accgctaagc accaaattac acatttctcg   2400tattgctgtg taggttctat cttcgtttcg tactaccatg tccctatatt ttgctgctac   2460aaaggacggc aagtaatcag cacaggcaga acacgatttc agagtgtaat tctagatcca   2520gctaaaccac tctcagcaat caccacacaa gagagcattc agagaaacgt ggcagtaaca   2580aaggcagagg gcggagtgag cgcgtaccga agacggttca gcgtgtcctc tccaaatgaa   2640atgaacttcc ttatatagag gaagggtctt gcgaaggata gtgggattgt gcgtcatccc   2700ttacgtcagt ggagatatca catcaatcca cttgctttga agacgtggtt ggaacgtctt   2760ctttttccac gatgctcctc gtgggtgggg gtccatcttt gggaccactg tcggcagagg   2820catcttcaac gatggccttt cctttatcgc aatgatggca tttgtaggag ccaccttcct   2880tttccactat cttcacaata aagtgacaga tagctgggca atggaatccg aggaggtttc   2940cggatattac cctttgttga aaagtctcaa tcggaccatc acatcaatcc acttgctttg   3000aagacgtggt tggaacgtct tctttttcca cgatgctcct cgtgggtggg ggtccatctt   3060tgggaccact gtcggcagag gcatcttcaa cgatggcctt tcctttatcg caatgatggc   3120atttgtagga gccaccttcc ttttccacta tcttcacaat aaagtgacag atagctgggc   3180aatggaatcc gaggaggttt ccggatatta ccctttgttg aaaagtctca atcggacctg   3240cagcctgcag gctagcggcg cgccacaaat cacaggccat gaaccctact catgcttcga   3300tttgtccaac acacacttac caaaactcaa atcatgtcct tgacagtcac tcgggactca   3360taacatgggt acgtatcgac tatgtcaact atatgtgttc tcatcagatt atagattggc   3420ctagtacgta gtgatatttc cactagcact gtggttatgg ctgtacctga tagtgatatc   3480agcaccgggt catggctcta ctaccaggta gtgagagtga cctttatact gtcagactgt   3540aactaaggat ttccaatcac tgttcggatc ctaggcttag aattaagtaa aactctatca   3600ctataggctg cagcacactc ggtatatatt gatgggccaa cagaaattgt gcgtactatg   3660cgcgatgtaa aatggacata aaccctaccc atatacaatg caataacttt tgtccggtct   3720gggccaccgg ttagcagagg tcctgatttc ggtggtagtg gtagcttgat ctggtcgtcg   3780tatcgtagag ggatatataa aatcatgtca cttttgaagg gagcgctcac agaaataata   3840ggtattcgcg ggagccgccc ccgcagaaca caaaataagg cgagcacgca cacgcatcag   3900tttcgataaa ataataatag cgccagctga tcggaacaat tccagctagc actaatgtat   3960ttctgcattg atctgtttat acaacatgct acctcgttga gtgattttga catgatttgt   4020caacttgctc cgatcctata tctcgatcga tctccacatg acgatggttg ttgtcctgta   4080tcccatgaca accaggcaac gctcaaagca cacatgcgtt gccgattacc cgtgcatgcc   4140gccaagcacg aaagcacctc cctccacacc gtccatcagc tataaaaacc atgccaagca   4200ccctgtgaaa agccccggga accatcttcc acacactcaa gccacactat tggagaacac   4260acagggacaa cacaccataa gatccaaggg aggcctccgc cgccgccggt aaccaccccg   4320cccctctcct ctttctttct ccgttttttt ttccgtctcg gtctcgatct ttggccttgg   4380tagtttgggt gggcgagagg cggcttcgtg cgcgcccaga tcggtgcgcg ggaggggcgg   4440gatctcgcgg ctggggctct cgccggcgtg gatccggccc ggatctcgcg gggaatgggg   4500ctctcggatg tagatctgcg atccgccgtt gttgggggag atgatggggg gtttaaaatt   4560tccgccgtgc taaacaagat caggaagagg ggaaaagggc actatggttt atatttttat   4620atatttctgc tgcttcgtca ggcttagatg tgctagatct ttctttcttc tttttgtggg   4680tagaatttga atccctcagc attgttcatc ggtagttttt cttttcatga tttgtgacaa   4740atgcagcctc gtgcggagct tttttgtagg tagaagtgat caaccatggc caaccccaac   4800aatcgctccg agcacgacac gatcaaggtc acccccaact ccgagctcca gaccaaccac   4860aaccagtacc cgctggccga caaccccaac tccaccctgg aagagctgaa ctacaaggag   4920ttcctgcgca tgaccgagga ctcctccacg gaggtcctgg acaactccac cgtcaaggac   4980gccgtcggga ccggcatctc cgtcgttggg cagatcctgg gcgtcgttgg cgtccccttc   5040gcaggtgctc tcacctcctt ctaccagtcc ttcctgaaca ccatctggcc ctccgacgcc   5100gacccctgga aggccttcat ggcccaagtc gaagtcctga tcgacaagaa gatcgaggag   5160tacgccaagt ccaaggccct ggccgagctg caaggcctgc aaaacaactt cgaggactac   5220gtcaacgcgc tgaactcctg gaagaagacg cctctgtccc tgcgctccaa gcgctcccag   5280gaccgcatcc gcgagctgtt ctcccaggcc gagtcccact tccgcaactc catgccgtcc   5340ttcgccgtct ccaagttcga ggtcctgttc ctgcccacct acgcccaggc tgccaacacc   5400cacctcctgt tgctgaagga cgcccaggtc ttcggcgagg aatggggcta ctcctcggag   5460gacgtcgccg agttctaccg tcgccagctg aagctgaccc aacagtacac cgaccactgc   5520gtcaactggt acaacgtcgg cctgaacggc ctgaggggct ccacctacga cgcatgggtc   5580aagttcaacc gcttccgcag ggagatgacc ctgaccgtcc tggacctgat cgtcctgttc   5640cccttctacg acatccgcct gtactccaag ggcgtcaaga ccgagctgac ccgcgacatc   5700ttcacggacc ccatcttcct gctcacgacc ctccagaagt acggtcccac cttcctgtcc   5760atcgagaact ccatccgcaa gccccacctg ttcgactacc tccagggcat cgagttccac   5820acgcgcctga ggccaggcta cttcggcaag gactccttca actactggtc cggcaactac   5880gtcgagacca ggccctccat cggctcctcg aagacgatca cctccccttt ctacggcgac   5940aagtccaccg agcccgtcca gaagctgtcc ttcgacggcc agaaggtcta ccgcaccatc   6000gccaacaccg acgtcgcggc ttggccgaac ggcaaggtct acctgggcgt cacgaaggtc   6060gacttctccc agtacgatga ccagaagaac gagacctcca cccagaccta cgactccaag   6120cgcaacaatg gccacgtctc cgcccaggac tccatcgacc agctgccgcc tgagaccact   6180gacgagcccc tggagaaggc ctactcccac cagctgaact acgcggagtg cttcctgatg   6240caagaccgca ggggcaccat ccccttcttc acctggaccc accgctccgt cgacttcttc   6300aacaccatcg acgccgagaa gatcacccag ctgcccgtgg tcaaggccta cgccctgtcc   6360tcgggtgcct ccatcattga gggtccaggc ttcaccggtg gcaacctgct gttcctgaag   6420gagtcctcga actccatcgc caagttcaag gtcaccctga actccgctgc cttgctgcaa   6480cgctaccgcg tccgcatccg ctacgcctcc accacgaacc tgcgcctgtt cgtccagaac   6540tccaacaatg acttcctggt catctacatc aacaagacca tgaacaagga cgatgacctg   6600acctaccaga ccttcgacct cgccaccacg aactccaaca tgggcttctc gggcgacaag   6660aatgaactga tcattggtgc tgagtccttc gtctccaacg agaagatcta catcgacaag   6720atcgagttca tccccgtcca gctgtgatag gaactctgat tgaattctgc atgcgtttgg   6780acgtatgctc attcaggttg gagccaattt ggttgatgtg tgtgcgagtt cttgcgagtc   6840tgatgagaca tctctgtatt gtgtttcttt ccccagtgtt ttctgtactt gtgtaatcgg   6900ctaatcgcca acagattcgg cgatgaataa atgagaaata aattgttctg attttgagtg   6960caaaaaaaaa ggaattagat ctgtgtgtgt tttttggatc ccattttcga caagcttgcc   7020tcgagacaac aacatgcttc tcatcaacat ggagggaaga gggagggaga aagtgtcgcc   7080tggtcacctc cattgtcaca ctagccactg gccagctctc ccacaccacc aatgccaggg   7140gcgagcttta gcacagccac cgcttcacct ccaccaccgc actaccctag cttcgcccaa   7200cagccaccgt caacgcctcc tctccgtcaa cataagagag agagagaaga ggagagtagc   7260catgtgggga ggaggaatag tacatggggc ctaccgtttg gcaagttatt ttgggttgcc   7320aagttaggcc aataagggga gggatttggc catccggttg gaaaggttat tggggtagta   7380tctttttact agaattgtca aaaaaaaata gtttgagagc catttggaga ggatgttgcc   7440tgttagaggt gctcttagga catcaaattc cataaaaaca tcagaaaaat tctctcgatg   7500aagatttata accactaaaa ctgccctcaa ttcgaaggga gttcaaaaca attaaaatca   7560tgttcgaatt gagtttcaat ttcactttaa cccctttgaa atctcaatgg taaaacatca   7620acccgtcagg tagcatggtt ctttttattc ctttcaaaaa gagttaatta caaacagaat   7680caaaactaac agttaggccc aaggcccatc cgagcaaaca atagatcatg ggccaggcct   7740gccaccaccc tccccctcct ggctcccgct cttgaatttc aaaatccaaa aatatcggca   7800cgactggccg ccgacggagc gggcggaaaa tgacggaaca acccctcgaa ttctacccca   7860actacgccca ccaacccaca cgccactgac aatccggtcc cacccttgtg ggcccaccta   7920caagcgagac gtcagtcgct cgcagcaacc agtgggccca cctcccagtg agcggcgggt   7980agatctggac tcttacccac ccacactaaa caaaacggca tgaatatttt gcactaaaac   8040cctcagaaaa attccgatat tccaaaccag tacagttcct gaccgttgga ggagccaaag   8100tggagcggag tgtaaaattg ggaaacttaa tcgagggggt taaacgcaaa aacgccgagg   8160cgcctcccgc tctatagaaa ggggaggagt gggaggtgga aaccctacca caccgcagag   8220aaaggcgtct tcgtactcgc ctctctccgc gccctcctcc gccgccgctc gccgccgttc   8280gtctccgccg ccaccggcta gccatccagg taaaacaaac aaaaacggat ctgatgcttc   8340cattcctccg tttctcgtag tagcgcgctt cgatctgtgg gtggatctgg gtgatcctgg   8400ggtgtggttc gttctgtttg atagatctgt cggtggatct ggccttctgt ggttgtcgat   8460gtccggatct gcgttttgat cagtggtagt tcgtggatct ggcgaaatgt tttggatctg   8520gcagtgagac gctaagaatc gggaaatgat gcaatattag gggggtttcg gatggggatc   8580cactgaatta gtctgtctcc ctgctgataa tctgttcctt tttggtagat ctggttagtg   8640tatgtttgtt tcggatagat ctgatcaatg cttgtttgtt ttttcaaatt ttctacctag   8700gttgtatagg aatggcatgc ggatctggtt ggattgccat gatccgtgct gaaatgcccc   8760tttggttgat ggatcttgat attttactgc tgttcaccta gatttgtact cccgtttata   8820cttaatttgt tgcttattat gaatagatct gtaacttagg cacatgtatg gacggagtat   8880gtggatctgt agtatgtaca ttgctgcgag ctaagaacta tttcagagca agcacagaaa   8940aaaatattta gacagattgg gcaactattt gatggtcttt ggtatcatgc tttgtagtgc   9000tcgtttctgc gtagtaatct tttgatctga tctgaagata ggtgctatta tattcttaaa   9060ggtcattaga acgctatctg aaaggctgta ttatgtggat tggttcacct gtgactccct   9120gttcgtcttg tcttgataaa tcctgtgata aaaaaaattc ttaaggcgta atttgttgaa   9180atcttgtttt gtcctatgca gcctgatcca tggcgcaagt tagcagaatc tgcaatggtg   9240tgcagaaccc atctcttatc tccaatctct cgaaatccag tcaacgcaaa tctcccttat   9300cggtttctct gaagacgcag cagcatccac gagcttatcc gatttcgtcg tcgtggggat   9360tgaagaagag tgggatgacg ttaattggct ctgagcttcg tcctcttaag gtcatgtctt   9420ctgtttccac ggcgtgcatg cttcacggtg caagcagccg gcccgcaacc gcccgcaaat   9480cctctggcct ttccggaacc gtccgcattc ccggcgacaa gtcgatctcc caccggtcct   9540tcatgttcgg cggtctcgcg agcggtgaaa cgcgcatcac cggccttctg gaaggcgagg   9600acgtcatcaa tacgggcaag gccatgcagg cgatgggcgc ccgcatccgt aaggaaggcg   9660acacctggat catcgatggc gtcggcaatg gcggcctcct ggcgcctgag gcgccgctcg   9720atttcggcaa tgccgccacg ggctgccgcc tgacgatggg cctcgtcggg gtctacgatt   9780tcgacagcac cttcatcggc gacgcctcgc tcacaaagcg cccgatgggc cgcgtgttga   9840acccgctgcg cgaaatgggc gtgcaggtga aatcggaaga cggtgaccgt cttcccgtta   9900ccttgcgcgg gccgaagacg ccgacgccga tcacctaccg cgtgccgatg gcctccgcac   9960aggtgaagtc cgccgtgctg ctcgccggcc tcaacacgcc cggcatcacg acggtcatcg  10020agccgatcat gacgcgcgat catacggaaa agatgctgca gggctttggc gccaacctta  10080ccgtcgagac ggatgcggac ggcgtgcgca ccatccgcct ggaaggccgc ggcaagctca  10140ccggccaagt catcgacgtg ccgggcgacc cgtcctcgac ggccttcccg ctggttgcgg  10200ccctgcttgt tccgggctcc gacgtcacca tcctcaacgt gctgatgaac cccacccgca  10260ccggcctcat cctgacgctg caggaaatgg gcgccgacat cgaagtcatc aacccgcgcc  10320ttgccggcgg cgaagacgtg gcggacctgc gcgttcgctc ctccacgctg aagggcgtca  10380cggtgccgga agaccgcgcg ccttcgatga tcgacgaata tccgattctc gctgtcgccg  10440ccgccttcgc ggaaggggcg accgtgatga acggtctgga agaactccgc gtcaaggaaa  10500gcgaccgcct ctcggccgtc gccaatggcc tcaagctcaa tggcgtggat tgcgatgagg  10560gcgagacgtc gctcgtcgtg cgtggccgcc ctgacggcaa ggggctcggc aacgcctcgg  10620gcgccgccgt cgccacccat ctcgatcacc gcatcgccat gagcttcctc gtcatgggcc  10680tcgtgtcgga aaaccctgtc acggtggacg atgccacgat gatcgccacg agcttcccgg  10740agttcatgga cctgatggcc gggctgggcg cgaagatcga actctccgat acgaaggctg  10800cctgatgagc tccagggttc ttgcctggtg ccttggcaat gcttgattac tgctgctatc  10860ctatgatctg tccgtgtggg cttctatcta tcagtttgtg tgtctggttt tgaaaaacat  10920ttgcttttcg attatgtagg gtttgcttgt agctttcgct gctgtgacct gtgttgttta  10980tgtgaacctt ctttgtggca tctttaatat ccaagttcgt ggtttgtcgt aaaacgaagc  11040ctctacttcg taaagttgtg tctatagcat tgaaatcgtt tttttgctcg agaataattg  11100tgacctttag ttggcgtgaa actagttttg gatatctgat tctctggttc gcaatcttga  11160gatcgtcgct gcttaggtga gctaagtgat gttcctaagt aaatgctcct caccagaata  11220cgtagctgtg tgaaaagaga acgcgtgaat acgtagctgt gtaaagattg tgtcccaagt  11280aaacctcagt gatttttgtt tggattttta atttagaaac attcgactgg gagcggctag  11340agccacaccc aagttcctaa ctatgataaa gttgctctgt aacagaaaac accatctaga  11400gcggccgcgt ttaaactatc agtgtttgac aggatatatt ggcgggtaaa cctaagagaa  11460aagagcgttt attagaataa tcggatattt aaaagggcgt gaaaaggttt atccgttcgt  11520ccatttgtat gtgcatgcca accacagggt tcccctcggg agtgcttggc attccgtgcg  11580ataatgactt ctgttcaacc acccaaacgt cggaaagcct gacgacggag cagcattcca  11640aaaagatccc ttggctcgtc tgggtcggct agaaggtcga gtgggctgct gtggcttgat  11700ccctcaacgc ggtcgcggac gtagcgcagc gccgaaaaat cct                    11743</s400><s200><s210>27</s210><s211>12322</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>DNA construct 416</s223></s220></s200><s400> 27aaaagtccca tgtggatcac tccgttgccc cgtcgctcac cgtgttgggg ggaaggtgca     60catggctcag ttctcaatgg aaattatctg cctaaccggc tcagttctgc gtagaaacca    120acatgcaagc tccaccgggt gcaaagcggc agcggcggca ggatatattc aattgtaaat    180ggcttcatgt ccgggaaatc tacatggatc agcaatgagt atgatggtca atatggagaa    240aaagaaagag taattaccaa ttttttttca attcaaaaat gtagatgtcc gcagcgttat    300tataaaatga aagtacattt tgataaaacg acaaattacg atccgtcgta tttataggcg    360aaagcaataa acaaattatt ctaattcgga aatctttatt tcgacgtgtc tacattcacg    420tccaaatggg ggcttagatg agaaacttca cgatcgatgc ggccaccact cgaggtcgag    480gtaccgttgt caatcaattg gcaagtcata aaatgcatta aaaaatattt tcatactcaa    540ctacaaatcc atgagtataa ctataattat aaagcaatga ttagaatctg acaaggattc    600tggaaaatta cataaaggaa agttcataaa tgtctaaaac acaagaggac atacttgtat    660tcagtaacat ttgcagcttt tctaggtctg aaaatatatt tgttgcctag tgaataagca    720taatggtaca actacaagtg ttttactcct catattaact tcggtcatta gaggccacga    780tttgacacat ttttactcaa aacaaaatgt ttgcatatct cttataattt caaattcaac    840acacaacaaa taagagaaaa aacaaataat attaatttga gaatgaacaa aaggaccata    900tcattcatta actcttctcc atccatttcc atttcacagt tcgatagcga aaaccgaata    960aaaaacacag taaattacaa gcacaacaaa tggtacaaga aaaacagttt tcccaatgcc   1020ataatactca aactcagtag gattctggtg tgtgcgcaat gaaactgatg cattgaactt   1080gacgaacgtt gtcgaaaccg atgatacgaa cgaaagctag gcctcagcga gtaccgctgg   1140cgatctaatc catgatatcg tgaacatcat ctacattcaa attcttatga gctttcttaa   1200gggcatctgc agcatttttc atagaatcta atacagcagt atttgtgcta gctccttcga   1260gggcttccct ctgcatttca atagttgtaa gggttccatc tatttgtagt tgggtctttt   1320ccaatcgttt cttctttttg agggcttgga gtgcaactct tttatttttc gacgcatttt   1380tctttgcgct cctgcaggcg gccgcgtgga tgaggagtta atcggtcgtg tgagagtagt   1440gatcgagtgg atgtcgtcga gagtgatgag tgttgatgtt gttagtgata tgtggtagaa   1500ggtatcgtga taaagcgtta acgcgatcgc agtacttgca aagaaaaatg cgtcgaaaaa   1560taaaagagtt gcactccaag ccctcaaaaa gaagaaacga ttggaaaaga cccaactaca   1620aatagatgga acccttacaa ctattgaaat gcagagggaa gccctcgaag gagctagcac   1680aaatactgct gtattagatt ctatgaaaaa tgctgcagat gcccttaaga aagctcataa   1740gaatttgaat gtagatgatg ttcacgatat catggatggt atcgcacagc gactgctgag   1800ggacgtcgag ctcccgcttg gtatctgcat tacaatgaaa tgagcaaaga ctatgtgagt   1860aacactggtc aacactaggg agaaggcatc gagcaagata cgtatgtaaa gagaagcaat   1920atagtgtcag ttggtagata ctagatacca tcaggaggta aggagagcaa caaaaaggaa   1980actctttatt tttaaatttt gttacaacaa acaagcagat caatgcatca aaatactgtc   2040agtacttatt tcttcagaca acaatattta aaacaagtgc atctgatctt gacttatggt   2100cacaataaag gagcagagat aaacatcaaa atttcgtcat ttatatttat tccttcaggc   2160gttaacaatt taacagcaca caaacaaaaa cagaatagga atatctaatt ttggcaaata   2220ataagctctg cagacgaaca aattattata gtatcgccta taatatgaat ccctatacta   2280ttgacccatg tagtatgaag cctgtgccta aattaacagc aaacttctga atccaagtgc   2340cctataacac caacatgtgc ttaaataaat accgctaagc accaaattac acatttctcg   2400tattgctgtg taggttctat cttcgtttcg tactaccatg tccctatatt ttgctgctac   2460aaaggacggc aagtaatcag cacaggcaga acacgatttc agagtgtaat tctagatcca   2520gctaaaccac tctcagcaat caccacacaa gagagcattc agagaaacgt ggcagtaaca   2580aaggcagagg gcggagtgag cgcgtaccga agacggttca gcgtgtcctc tccaaatgaa   2640atgaacttcc ttatatagag gaagggtctt gcgaaggata gtgggattgt gcgtcatccc   2700ttacgtcagt ggagatatca catcaatcca cttgctttga agacgtggtt ggaacgtctt   2760ctttttccac gatgctcctc gtgggtgggg gtccatcttt gggaccactg tcggcagagg   2820catcttcaac gatggccttt cctttatcgc aatgatggca tttgtaggag ccaccttcct   2880tttccactat cttcacaata aagtgacaga tagctgggca atggaatccg aggaggtttc   2940cggatattac cctttgttga aaagtctcaa tcggaccatc acatcaatcc acttgctttg   3000aagacgtggt tggaacgtct tctttttcca cgatgctcct cgtgggtggg ggtccatctt   3060tgggaccact gtcggcagag gcatcttcaa cgatggcctt tcctttatcg caatgatggc   3120atttgtagga gccaccttcc ttttccacta tcttcacaat aaagtgacag atagctgggc   3180aatggaatcc gaggaggttt ccggatatta ccctttgttg aaaagtctca atcggacctg   3240cagcctgcag gctagcggcg cgccggaagc taactagtca cggcgaatac atgacgacat   3300cggcctacaa cgcacaactt cttggcataa aagcttcaat ttcaatgccc ctatctggaa   3360gccctaggcg ccgcgcaaat gtaaaacatt cgcttcgctt ggcttgttat ccaaaataga   3420gtatggacct ccgacagatt ggcaacccgt gggtaatcga aaatggctcc atctgcccct   3480ttgtcgaagg aatcaggaaa cggccctcac ctcctggcgg agtgtagata tgtgaaagaa   3540tctaggcgac acttgcagac tggacaacat gtgaacaaat aagaccaacg ttatggcaac   3600aagcctcgac gctactcaag tggtgggagg ccaccgcatg ttccaacgaa gcgccaaaga   3660aagccttgca gactctaatg ctattagtcg cctaggatat ttggaatgaa aggaaccgca   3720gagtttttca gcaccaagag cttccggtgg ctagtctgat agccaaaatt aaggaggatg   3780ccaaaacatg ggtcttggcg ggcgcgaaac accttgatag gtggcttacc ttttaacatg   3840ttcgggccaa aggccttgag acggtaaagt tttctatttg cgcttgcgca tgtacaattt   3900tattcctcta ttcaatgaaa ttggtggctc actggttcat taaaaaaaaa agaatctagc   3960ctgttcggga agaagaggat tttattcgtg agagagagag agagagagag agagagaggg   4020agagagaagg aggaggagga ttttcaggct tcgcattgcc caacctctgc ttctgttggc   4080ccaagaagaa tcccaggcgc ccatgggctg gcagtttacc acggacctac ctagcctacc   4140ttagctatct aagcgggccg acctagtagc tacgtgccta gtgtagatta aagttggcgg   4200gccagcagga agccacgctg caatggcatc ttcccctgtc cttcgcgtac gtgaaaacaa   4260acccaggtaa gcttagaatc ttcttgcccg ttggactggg acacccacca atcccaccat   4320gccccgatat tcctccggtc tcggttcatg tgatgtcctc tcttgtgtga tcacggagca   4380agcattctta aacggcaaaa gaaaatcacc aacttgctca cgcagtcacg ctgcaccgcg   4440cgaagcgacg cccgataggc caagatcgcg agataaaata acaaccaatg atcataagga   4500aacaagcccg cgatgtgtcg tgtgcagcaa tcttggtcat ttgcgggatc gagtgcttca   4560cggctaacca aatattcggc cgatgattta acacattatc agcgtagatg tacgtacgat   4620ttgttaatta atctacgagc cttgctaggg caggtgttct gccagccaat ccagatcgcc   4680ctcgtatgca cgctcacatg atggcagggc agggttcaca tgagctctaa cggtcgatta   4740attaatcccg gggctcgact ataaatacct ccctaatccc atgatcaaaa cccccgggaa   4800ccatcttcca cacactcaag ccacactatt ggagaacaca cagggacaac acaccataag   4860atccaaggga ggcctccgcc gccgccggta accaccccgc ccctctcctc tttctttctc   4920cgtttttttt tccgtctcgg tctcgatctt tggccttggt agtttgggtg ggcgagaggc   4980ggcttcgtgc gcgcccagat cggtgcgcgg gaggggcggg atctcgcggc tggggctctc   5040gccggcgtgg atccggcccg gatctcgcgg ggaatggggc tctcggatgt agatctgcga   5100tccgccgttg ttgggggaga tgatgggggg tttaaaattt ccgccgtgct aaacaagatc   5160aggaagaggg gaaaagggca ctatggttta tatttttata tatttctgct gcttcgtcag   5220gcttagatgt gctagatctt tctttcttct ttttgtgggt agaatttgaa tccctcagca   5280ttgttcatcg gtagtttttc ttttcatgat ttgtgacaaa tgcagcctcg tgcggagctt   5340ttttgtaggt agaagtgatc aaccatggcc aaccccaaca atcgctccga gcacgacacg   5400atcaaggtca cccccaactc cgagctccag accaaccaca accagtaccc gctggccgac   5460aaccccaact ccaccctgga agagctgaac tacaaggagt tcctgcgcat gaccgaggac   5520tcctccacgg aggtcctgga caactccacc gtcaaggacg ccgtcgggac cggcatctcc   5580gtcgttgggc agatcctggg cgtcgttggc gtccccttcg caggtgctct cacctccttc   5640taccagtcct tcctgaacac catctggccc tccgacgccg acccctggaa ggccttcatg   5700gcccaagtcg aagtcctgat cgacaagaag atcgaggagt acgccaagtc caaggccctg   5760gccgagctgc aaggcctgca aaacaacttc gaggactacg tcaacgcgct gaactcctgg   5820aagaagacgc ctctgtccct gcgctccaag cgctcccagg accgcatccg cgagctgttc   5880tcccaggccg agtcccactt ccgcaactcc atgccgtcct tcgccgtctc caagttcgag   5940gtcctgttcc tgcccaccta cgcccaggct gccaacaccc acctcctgtt gctgaaggac   6000gcccaggtct tcggcgagga atggggctac tcctcggagg acgtcgccga gttctaccgt   6060cgccagctga agctgaccca acagtacacc gaccactgcg tcaactggta caacgtcggc   6120ctgaacggcc tgaggggctc cacctacgac gcatgggtca agttcaaccg cttccgcagg   6180gagatgaccc tgaccgtcct ggacctgatc gtcctgttcc ccttctacga catccgcctg   6240tactccaagg gcgtcaagac cgagctgacc cgcgacatct tcacggaccc catcttcctg   6300ctcacgaccc tccagaagta cggtcccacc ttcctgtcca tcgagaactc catccgcaag   6360ccccacctgt tcgactacct ccagggcatc gagttccaca cgcgcctgag gccaggctac   6420ttcggcaagg actccttcaa ctactggtcc ggcaactacg tcgagaccag gccctccatc   6480ggctcctcga agacgatcac ctcccctttc tacggcgaca agtccaccga gcccgtccag   6540aagctgtcct tcgacggcca gaaggtctac cgcaccatcg ccaacaccga cgtcgcggct   6600tggccgaacg gcaaggtcta cctgggcgtc acgaaggtcg acttctccca gtacgatgac   6660cagaagaacg agacctccac ccagacctac gactccaagc gcaacaatgg ccacgtctcc   6720gcccaggact ccatcgacca gctgccgcct gagaccactg acgagcccct ggagaaggcc   6780tactcccacc agctgaacta cgcggagtgc ttcctgatgc aagaccgcag gggcaccatc   6840cccttcttca cctggaccca ccgctccgtc gacttcttca acaccatcga cgccgagaag   6900atcacccagc tgcccgtggt caaggcctac gccctgtcct cgggtgcctc catcattgag   6960ggtccaggct tcaccggtgg caacctgctg ttcctgaagg agtcctcgaa ctccatcgcc   7020aagttcaagg tcaccctgaa ctccgctgcc ttgctgcaac gctaccgcgt ccgcatccgc   7080tacgcctcca ccacgaacct gcgcctgttc gtccagaact ccaacaatga cttcctggtc   7140atctacatca acaagaccat gaacaaggac gatgacctga cctaccagac cttcgacctc   7200gccaccacga actccaacat gggcttctcg ggcgacaaga atgaactgat cattggtgct   7260gagtccttcg tctccaacga gaagatctac atcgacaaga tcgagttcat ccccgtccag   7320ctgtgatagg aactctgatt gaattctgca tgcgtttgga cgtatgctca ttcaggttgg   7380agccaatttg gttgatgtgt gtgcgagttc ttgcgagtct gatgagacat ctctgtattg   7440tgtttctttc cccagtgttt tctgtacttg tgtaatcggc taatcgccaa cagattcggc   7500gatgaataaa tgagaaataa attgttctga ttttgagtgc aaaaaaaaag gaattagatc   7560tgtgtgtgtt ttttggatcc cattttcgac aagcttgcct cgagacaaca acatgcttct   7620catcaacatg gagggaagag ggagggagaa agtgtcgcct ggtcacctcc attgtcacac   7680tagccactgg ccagctctcc cacaccacca atgccagggg cgagctttag cacagccacc   7740gcttcacctc caccaccgca ctaccctagc ttcgcccaac agccaccgtc aacgcctcct   7800ctccgtcaac ataagagaga gagagaagag gagagtagcc atgtggggag gaggaatagt   7860acatggggcc taccgtttgg caagttattt tgggttgcca agttaggcca ataaggggag   7920ggatttggcc atccggttgg aaaggttatt ggggtagtat ctttttacta gaattgtcaa   7980aaaaaaatag tttgagagcc atttggagag gatgttgcct gttagaggtg ctcttaggac   8040atcaaattcc ataaaaacat cagaaaaatt ctctcgatga agatttataa ccactaaaac   8100tgccctcaat tcgaagggag ttcaaaacaa ttaaaatcat gttcgaattg agtttcaatt   8160tcactttaac ccctttgaaa tctcaatggt aaaacatcaa cccgtcaggt agcatggttc   8220tttttattcc tttcaaaaag agttaattac aaacagaatc aaaactaaca gttaggccca   8280aggcccatcc gagcaaacaa tagatcatgg gccaggcctg ccaccaccct ccccctcctg   8340gctcccgctc ttgaatttca aaatccaaaa atatcggcac gactggccgc cgacggagcg   8400ggcggaaaat gacggaacaa cccctcgaat tctaccccaa ctacgcccac caacccacac   8460gccactgaca atccggtccc acccttgtgg gcccacctac aagcgagacg tcagtcgctc   8520gcagcaacca gtgggcccac ctcccagtga gcggcgggta gatctggact cttacccacc   8580cacactaaac aaaacggcat gaatattttg cactaaaacc ctcagaaaaa ttccgatatt   8640ccaaaccagt acagttcctg accgttggag gagccaaagt ggagcggagt gtaaaattgg   8700gaaacttaat cgagggggtt aaacgcaaaa acgccgaggc gcctcccgct ctatagaaag   8760gggaggagtg ggaggtggaa accctaccac accgcagaga aaggcgtctt cgtactcgcc   8820tctctccgcg ccctcctccg ccgccgctcg ccgccgttcg tctccgccgc caccggctag   8880ccatccaggt aaaacaaaca aaaacggatc tgatgcttcc attcctccgt ttctcgtagt   8940agcgcgcttc gatctgtggg tggatctggg tgatcctggg gtgtggttcg ttctgtttga   9000tagatctgtc ggtggatctg gccttctgtg gttgtcgatg tccggatctg cgttttgatc   9060agtggtagtt cgtggatctg gcgaaatgtt ttggatctgg cagtgagacg ctaagaatcg   9120ggaaatgatg caatattagg ggggtttcgg atggggatcc actgaattag tctgtctccc   9180tgctgataat ctgttccttt ttggtagatc tggttagtgt atgtttgttt cggatagatc   9240tgatcaatgc ttgtttgttt tttcaaattt tctacctagg ttgtatagga atggcatgcg   9300gatctggttg gattgccatg atccgtgctg aaatgcccct ttggttgatg gatcttgata   9360ttttactgct gttcacctag atttgtactc ccgtttatac ttaatttgtt gcttattatg   9420aatagatctg taacttaggc acatgtatgg acggagtatg tggatctgta gtatgtacat   9480tgctgcgagc taagaactat ttcagagcaa gcacagaaaa aaatatttag acagattggg   9540caactatttg atggtctttg gtatcatgct ttgtagtgct cgtttctgcg tagtaatctt   9600ttgatctgat ctgaagatag gtgctattat attcttaaag gtcattagaa cgctatctga   9660aaggctgtat tatgtggatt ggttcacctg tgactccctg ttcgtcttgt cttgataaat   9720cctgtgataa aaaaaattct taaggcgtaa tttgttgaaa tcttgttttg tcctatgcag   9780cctgatccat ggcgcaagtt agcagaatct gcaatggtgt gcagaaccca tctcttatct   9840ccaatctctc gaaatccagt caacgcaaat ctcccttatc ggtttctctg aagacgcagc   9900agcatccacg agcttatccg atttcgtcgt cgtggggatt gaagaagagt gggatgacgt   9960taattggctc tgagcttcgt cctcttaagg tcatgtcttc tgtttccacg gcgtgcatgc  10020ttcacggtgc aagcagccgg cccgcaaccg cccgcaaatc ctctggcctt tccggaaccg  10080tccgcattcc cggcgacaag tcgatctccc accggtcctt catgttcggc ggtctcgcga  10140gcggtgaaac gcgcatcacc ggccttctgg aaggcgagga cgtcatcaat acgggcaagg  10200ccatgcaggc gatgggcgcc cgcatccgta aggaaggcga cacctggatc atcgatggcg  10260tcggcaatgg cggcctcctg gcgcctgagg cgccgctcga tttcggcaat gccgccacgg  10320gctgccgcct gacgatgggc ctcgtcgggg tctacgattt cgacagcacc ttcatcggcg  10380acgcctcgct cacaaagcgc ccgatgggcc gcgtgttgaa cccgctgcgc gaaatgggcg  10440tgcaggtgaa atcggaagac ggtgaccgtc ttcccgttac cttgcgcggg ccgaagacgc  10500cgacgccgat cacctaccgc gtgccgatgg cctccgcaca ggtgaagtcc gccgtgctgc  10560tcgccggcct caacacgccc ggcatcacga cggtcatcga gccgatcatg acgcgcgatc  10620atacggaaaa gatgctgcag ggctttggcg ccaaccttac cgtcgagacg gatgcggacg  10680gcgtgcgcac catccgcctg gaaggccgcg gcaagctcac cggccaagtc atcgacgtgc  10740cgggcgaccc gtcctcgacg gccttcccgc tggttgcggc cctgcttgtt ccgggctccg  10800acgtcaccat cctcaacgtg ctgatgaacc ccacccgcac cggcctcatc ctgacgctgc  10860aggaaatggg cgccgacatc gaagtcatca acccgcgcct tgccggcggc gaagacgtgg  10920cggacctgcg cgttcgctcc tccacgctga agggcgtcac ggtgccggaa gaccgcgcgc  10980cttcgatgat cgacgaatat ccgattctcg ctgtcgccgc cgccttcgcg gaaggggcga  11040ccgtgatgaa cggtctggaa gaactccgcg tcaaggaaag cgaccgcctc tcggccgtcg  11100ccaatggcct caagctcaat ggcgtggatt gcgatgaggg cgagacgtcg ctcgtcgtgc  11160gtggccgccc tgacggcaag gggctcggca acgcctcggg cgccgccgtc gccacccatc  11220tcgatcaccg catcgccatg agcttcctcg tcatgggcct cgtgtcggaa aaccctgtca  11280cggtggacga tgccacgatg atcgccacga gcttcccgga gttcatggac ctgatggccg  11340ggctgggcgc gaagatcgaa ctctccgata cgaaggctgc ctgatgagct ccagggttct  11400tgcctggtgc cttggcaatg cttgattact gctgctatcc tatgatctgt ccgtgtgggc  11460ttctatctat cagtttgtgt gtctggtttt gaaaaacatt tgcttttcga ttatgtaggg  11520tttgcttgta gctttcgctg ctgtgacctg tgttgtttat gtgaaccttc tttgtggcat  11580ctttaatatc caagttcgtg gtttgtcgta aaacgaagcc tctacttcgt aaagttgtgt  11640ctatagcatt gaaatcgttt ttttgctcga gaataattgt gacctttagt tggcgtgaaa  11700ctagttttgg atatctgatt ctctggttcg caatcttgag atcgtcgctg cttaggtgag  11760ctaagtgatg ttcctaagta aatgctcctc accagaatac gtagctgtgt gaaaagagaa  11820cgcgtgaata cgtagctgtg taaagattgt gtcccaagta aacctcagtg atttttgttt  11880ggatttttaa tttagaaaca ttcgactggg agcggctaga gccacaccca agttcctaac  11940tatgataaag ttgctctgta acagaaaaca ccatctagag cggccgcgtt taaactatca  12000gtgtttgaca ggatatattg gcgggtaaac ctaagagaaa agagcgttta ttagaataat  12060cggatattta aaagggcgtg aaaaggttta tccgttcgtc catttgtatg tgcatgccaa  12120ccacagggtt cccctcggga gtgcttggca ttccgtgcga taatgacttc tgttcaacca  12180cccaaacgtc ggaaagcctg acgacggagc agcattccaa aaagatccct tggctcgtct  12240gggtcggcta gaaggtcgag tgggctgctg tggcttgatc cctcaacgcg gtcgcggacg  12300tagcgcagcg ccgaaaaatc ct                                           12322</s400><s200><s210>28</s210><s211>11787</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>DNA construct 418</s223></s220></s200><s400> 28aaaagtccca tgtggatcac tccgttgccc cgtcgctcac cgtgttgggg ggaaggtgca     60catggctcag ttctcaatgg aaattatctg cctaaccggc tcagttctgc gtagaaacca    120acatgcaagc tccaccgggt gcaaagcggc agcggcggca ggatatattc aattgtaaat    180ggcttcatgt ccgggaaatc tacatggatc agcaatgagt atgatggtca atatggagaa    240aaagaaagag taattaccaa ttttttttca attcaaaaat gtagatgtcc gcagcgttat    300tataaaatga aagtacattt tgataaaacg acaaattacg atccgtcgta tttataggcg    360aaagcaataa acaaattatt ctaattcgga aatctttatt tcgacgtgtc tacattcacg    420tccaaatggg ggcttagatg agaaacttca cgatcgatgc ggccaccact cgaggtcgag    480gtaccgttgt caatcaattg gcaagtcata aaatgcatta aaaaatattt tcatactcaa    540ctacaaatcc atgagtataa ctataattat aaagcaatga ttagaatctg acaaggattc    600tggaaaatta cataaaggaa agttcataaa tgtctaaaac acaagaggac atacttgtat    660tcagtaacat ttgcagcttt tctaggtctg aaaatatatt tgttgcctag tgaataagca    720taatggtaca actacaagtg ttttactcct catattaact tcggtcatta gaggccacga    780tttgacacat ttttactcaa aacaaaatgt ttgcatatct cttataattt caaattcaac    840acacaacaaa taagagaaaa aacaaataat attaatttga gaatgaacaa aaggaccata    900tcattcatta actcttctcc atccatttcc atttcacagt tcgatagcga aaaccgaata    960aaaaacacag taaattacaa gcacaacaaa tggtacaaga aaaacagttt tcccaatgcc   1020ataatactca aactcagtag gattctggtg tgtgcgcaat gaaactgatg cattgaactt   1080gacgaacgtt gtcgaaaccg atgatacgaa cgaaagctag gcctcagcga gtaccgctgg   1140cgatctaatc catgatatcg tgaacatcat ctacattcaa attcttatga gctttcttaa   1200gggcatctgc agcatttttc atagaatcta atacagcagt atttgtgcta gctccttcga   1260gggcttccct ctgcatttca atagttgtaa gggttccatc tatttgtagt tgggtctttt   1320ccaatcgttt cttctttttg agggcttgga gtgcaactct tttatttttc gacgcatttt   1380tctttgcgct cctgcaggcg gccgcgtgga tgaggagtta atcggtcgtg tgagagtagt   1440gatcgagtgg atgtcgtcga gagtgatgag tgttgatgtt gttagtgata tgtggtagaa   1500ggtatcgtga taaagcgtta acgcgatcgc agtacttgca aagaaaaatg cgtcgaaaaa   1560taaaagagtt gcactccaag ccctcaaaaa gaagaaacga ttggaaaaga cccaactaca   1620aatagatgga acccttacaa ctattgaaat gcagagggaa gccctcgaag gagctagcac   1680aaatactgct gtattagatt ctatgaaaaa tgctgcagat gcccttaaga aagctcataa   1740gaatttgaat gtagatgatg ttcacgatat catggatggt atcgcacagc gactgctgag   1800ggacgtcgag ctcccgcttg gtatctgcat tacaatgaaa tgagcaaaga ctatgtgagt   1860aacactggtc aacactaggg agaaggcatc gagcaagata cgtatgtaaa gagaagcaat   1920atagtgtcag ttggtagata ctagatacca tcaggaggta aggagagcaa caaaaaggaa   1980actctttatt tttaaatttt gttacaacaa acaagcagat caatgcatca aaatactgtc   2040agtacttatt tcttcagaca acaatattta aaacaagtgc atctgatctt gacttatggt   2100cacaataaag gagcagagat aaacatcaaa atttcgtcat ttatatttat tccttcaggc   2160gttaacaatt taacagcaca caaacaaaaa cagaatagga atatctaatt ttggcaaata   2220ataagctctg cagacgaaca aattattata gtatcgccta taatatgaat ccctatacta   2280ttgacccatg tagtatgaag cctgtgccta aattaacagc aaacttctga atccaagtgc   2340cctataacac caacatgtgc ttaaataaat accgctaagc accaaattac acatttctcg   2400tattgctgtg taggttctat cttcgtttcg tactaccatg tccctatatt ttgctgctac   2460aaaggacggc aagtaatcag cacaggcaga acacgatttc agagtgtaat tctagatcca   2520gctaaaccac tctcagcaat caccacacaa gagagcattc agagaaacgt ggcagtaaca   2580aaggcagagg gcggagtgag cgcgtaccga agacggttca gcgtgtcctc tccaaatgaa   2640atgaacttcc ttatatagag gaagggtctt gcgaaggata gtgggattgt gcgtcatccc   2700ttacgtcagt ggagatatca catcaatcca cttgctttga agacgtggtt ggaacgtctt   2760ctttttccac gatgctcctc gtgggtgggg gtccatcttt gggaccactg tcggcagagg   2820catcttcaac gatggccttt cctttatcgc aatgatggca tttgtaggag ccaccttcct   2880tttccactat cttcacaata aagtgacaga tagctgggca atggaatccg aggaggtttc   2940cggatattac cctttgttga aaagtctcaa tcggaccatc acatcaatcc acttgctttg   3000aagacgtggt tggaacgtct tctttttcca cgatgctcct cgtgggtggg ggtccatctt   3060tgggaccact gtcggcagag gcatcttcaa cgatggcctt tcctttatcg caatgatggc   3120atttgtagga gccaccttcc ttttccacta tcttcacaat aaagtgacag atagctgggc   3180aatggaatcc gaggaggttt ccggatatta ccctttgttg aaaagtctca atcggacctg   3240cagcctgcag gctagcggcg cgccgggatc caaaaaacac acacagatct aattcctttt   3300tttttgcact caaaatcaga acaatttatt tctcatttat tcatcgccga atctgttggc   3360gattagccga ttacacaagt acagaaaaca ctggggaaag aaacacaata cagagatgtc   3420tcatcagact cgcaagaact cgcacacaca tcaaccaaat tggctccaac ctgaatgagc   3480atacgtccaa acgcatgcag aattcaatca gagttcctat cacagctgga cggggatgaa   3540ctcgatcttg tcgatgtaga tcttctcgtt ggagacgaag gactcagcac caatgatcag   3600ttcattcttg tcgcccgaga agcccatgtt ggagttcgtg gtggcgaggt cgaaggtctg   3660gtaggtcagg tcatcgtcct tgttcatggt cttgttgatg tagatgacca ggaagtcatt   3720gttggagttc tggacgaaca ggcgcaggtt cgtggtggag gcgtagcgga tgcggacgcg   3780gtagcgttgc agcaaggcag cggagttcag ggtgaccttg aacttggcga tggagttcga   3840ggactccttc aggaacagca ggttgccacc ggtgaagcct ggaccctcaa tgatggaggc   3900acccgaggac agggcgtagg ccttgaccac gggcagctgg gtgatcttct cggcgtcgat   3960ggtgttgaag aagtcgacgg agcggtgggt ccaggtgaag aaggggatgg tgcccctgcg   4020gtcttgcatc aggaagcact ccgcgtagtt cagctggtgg gagtaggcct tctccagggg   4080ctcgtcagtg gtctcaggcg gcagctggtc gatggagtcc tgggcggaga cgtggccatt   4140gttgcgcttg gagtcgtagg tctgggtgga ggtctcgttc ttctggtcat cgtactggga   4200gaagtcgacc ttcgtgacgc ccaggtagac cttgccgttc ggccaagccg cgacgtcggt   4260gttggcgatg gtgcggtaga ccttctggcc gtcgaaggac agcttctgga cgggctcggt   4320ggacttgtcg ccgtagaaag gggaggtgat cgtcttcgag gagccgatgg agggcctggt   4380ctcgacgtag ttgccggacc agtagttgaa ggagtccttg ccgaagtagc ctggcctcag   4440gcgcgtgtgg aactcgatgc cctggaggta gtcgaacagg tggggcttgc ggatggagtt   4500ctcgatggac aggaaggtgg gaccgtactt ctggagggtc gtgagcagga agatggggtc   4560cgtgaagatg tcgcgggtca gctcggtctt gacgcccttg gagtacaggc ggatgtcgta   4620gaaggggaac aggacgatca ggtccaggac ggtcagggtc atctccctgc ggaagcggtt   4680gaacttgacc catgcgtcgt aggtggagcc cctcaggccg ttcaggccga cgttgtacca   4740gttgacgcag tggtcggtgt actgttgggt cagcttcagc tggcgacggt agaactcggc   4800gacgtcctcc gaggagtagc cccattcctc gccgaagacc tgggcgtcct tcagcaacag   4860gaggtgggtg ttggcagcct gggcgtaggt gggcaggaac aggacctcga acttggagac   4920ggcgaaggac ggcatggagt tgcggaagtg ggactcggcc tgggagaaca gctcgcggat   4980gcggtcctgg gagcgcttgg agcgcaggga cagaggcgtc ttcttccagg agttcagcgc   5040gttgacgtag tcctcgaagt tgttttgcag gccttgcagc tcggccaggg ccttggactt   5100ggcgtactcc tcgatcttct tgtcgatcag gacttcgact tgggccatga aggccttcca   5160ggggtcggcg tcggagggcc agatggtgtt caggaaggac tggtagaagg aggtgagagc   5220acctgcgaag gggacgccaa cgacgcccag gatctgccca acgacggaga tgccggtccc   5280gacggcgtcc ttgacggtgg agttgtccag gacctccgtg gaggagtcct cggtcatgcg   5340caggaactcc ttgtagttca gctcttccag ggtggagttg gggttgtcgg ccagcgggta   5400ctggttgtgg ttggtctgga gctcggagtt gggggtgacc ttgatcgtgt cgtgctcgga   5460gcgattgttg gggttggcca tggttgatca cttctaccta caaaaaagct ccgcacgagg   5520ctgcatttgt cacaaatcat gaaaagaaaa actaccgatg aacaatgctg agggattcaa   5580attctaccca caaaaagaag aaagaaagat ctagcacatc taagcctgac gaagcagcag   5640aaatatataa aaatataaac catagtgccc ttttcccctc ttcctgatct tgtttagcac   5700ggcggaaatt ttaaaccccc catcatctcc cccaacaacg gcggatcgca gatctacatc   5760cgagagcccc attccccgcg agatccgggc cggatccacg ccggcgagag ccccagccgc   5820gagatcccgc ccctcccgcg caccgatctg ggcgcgcacg aagccgcctc tcgcccaccc   5880aaactaccaa ggccaaagat cgagaccgag acggaaaaaa aaacggagaa agaaagagga   5940gaggggcggg gtggttaccg gcggcggcgg aggcctccct tggatcttat ggtgtgttgt   6000ccctgtgtgt tctccaatag tgtggcttga gtgtgtggaa gatggttccc ggggtatctg   6060atgatccttc aaatgggaat gaatgccttc ttatatagag ggaattcttt tgtggtcgtc   6120actgcgttcg tcatacgcat tagtgagtgg gctgtcagga cagctctttt ccacgttatt   6180ttgttcccca cttgtactag aggaatctgc tttatctttg caataaaggc aaagatgctt   6240ttggtaggtg cgcctaacaa ttctgcacca ttcctttttt gtctggtccc cacaagccag   6300ctgctcgatg ttgacaagat tactttcaaa gatgcccact aactttaagt cttcggtgga   6360tgtctttttc tgaaacttac tgaccatgat gcatgtgctg gaacagtagt ttactttgat   6420tgaagattct tcattgatct cctgtagctt ttggctaatg gtttggagac tctgtaccct   6480gaccttgttg aggctttgga ctgagaattc ttccttacaa acctttgagg atgggagttc   6540cttcttggtt ttggcgatac caatttgaat aaagtgatat ggctcgtacc ttgttgattg   6600aacccaatct ggaatgctgc taaatcctga gctcaagcta attcttttgt ggtcgtcact   6660gcgttcgtca tacgcattag tgagtgggct gtcaggacag ctcttttcca cgttattttg   6720ttccccactt gtactagagg aatctgcttt atctttgcaa taaaggcaaa gatgcttttg   6780gtaggtgcgc ctaacaattc tgcaccattc cttttttgtc tggtccccac aagccagctg   6840ctcgatgttg acaagattac tttcaaagat gcccactaac tttaagtctt cggtggatgt   6900ctttttctga aacttactga ccatgatgca tgtgctggaa cagtagttta ctttgattga   6960agattcttca ttgatctcct gtagcttttg gctaatggtt tggagactct gtaccctgac   7020cttgttgagg ctttggactg agaattattt tcgacaagct tgcctcgaga caacaacatg   7080cttctcatca acatggaggg aagagggagg gagaaagtgt cgcctggtca cctccattgt   7140cacactagcc actggccagc tctcccacac caccaatgcc aggggcgagc tttagcacag   7200ccaccgcttc acctccacca ccgcactacc ctagcttcgc ccaacagcca ccgtcaacgc   7260ctcctctccg tcaacataag agagagagag aagaggagag tagccatgtg gggaggagga   7320atagtacatg gggcctaccg tttggcaagt tattttgggt tgccaagtta ggccaataag   7380gggagggatt tggccatccg gttggaaagg ttattggggt agtatctttt tactagaatt   7440gtcaaaaaaa aatagtttga gagccatttg gagaggatgt tgcctgttag aggtgctctt   7500aggacatcaa attccataaa aacatcagaa aaattctctc gatgaagatt tataaccact   7560aaaactgccc tcaattcgaa gggagttcaa aacaattaaa atcatgttcg aattgagttt   7620caatttcact ttaacccctt tgaaatctca atggtaaaac atcaacccgt caggtagcat   7680ggttcttttt attcctttca aaaagagtta attacaaaca gaatcaaaac taacagttag   7740gcccaaggcc catccgagca aacaatagat catgggccag gcctgccacc accctccccc   7800tcctggctcc cgctcttgaa tttcaaaatc caaaaatatc ggcacgactg gccgccgacg   7860gagcgggcgg aaaatgacgg aacaacccct cgaattctac cccaactacg cccaccaacc   7920cacacgccac tgacaatccg gtcccaccct tgtgggccca cctacaagcg agacgtcagt   7980cgctcgcagc aaccagtggg cccacctccc agtgagcggc gggtagatct ggactcttac   8040ccacccacac taaacaaaac ggcatgaata ttttgcacta aaaccctcag aaaaattccg   8100atattccaaa ccagtacagt tcctgaccgt tggaggagcc aaagtggagc ggagtgtaaa   8160attgggaaac ttaatcgagg gggttaaacg caaaaacgcc gaggcgcctc ccgctctata   8220gaaaggggag gagtgggagg tggaaaccct accacaccgc agagaaaggc gtcttcgtac   8280tcgcctctct ccgcgccctc ctccgccgcc gctcgccgcc gttcgtctcc gccgccaccg   8340gctagccatc caggtaaaac aaacaaaaac ggatctgatg cttccattcc tccgtttctc   8400gtagtagcgc gcttcgatct gtgggtggat ctgggtgatc ctggggtgtg gttcgttctg   8460tttgatagat ctgtcggtgg atctggcctt ctgtggttgt cgatgtccgg atctgcgttt   8520tgatcagtgg tagttcgtgg atctggcgaa atgttttgga tctggcagtg agacgctaag   8580aatcgggaaa tgatgcaata ttaggggggt ttcggatggg gatccactga attagtctgt   8640ctccctgctg ataatctgtt cctttttggt agatctggtt agtgtatgtt tgtttcggat   8700agatctgatc aatgcttgtt tgttttttca aattttctac ctaggttgta taggaatggc   8760atgcggatct ggttggattg ccatgatccg tgctgaaatg cccctttggt tgatggatct   8820tgatatttta ctgctgttca cctagatttg tactcccgtt tatacttaat ttgttgctta   8880ttatgaatag atctgtaact taggcacatg tatggacgga gtatgtggat ctgtagtatg   8940tacattgctg cgagctaaga actatttcag agcaagcaca gaaaaaaata tttagacaga   9000ttgggcaact atttgatggt ctttggtatc atgctttgta gtgctcgttt ctgcgtagta   9060atcttttgat ctgatctgaa gataggtgct attatattct taaaggtcat tagaacgcta   9120tctgaaaggc tgtattatgt ggattggttc acctgtgact ccctgttcgt cttgtcttga   9180taaatcctgt gataaaaaaa attcttaagg cgtaatttgt tgaaatcttg ttttgtccta   9240tgcagcctga tccatggcgc aagttagcag aatctgcaat ggtgtgcaga acccatctct   9300tatctccaat ctctcgaaat ccagtcaacg caaatctccc ttatcggttt ctctgaagac   9360gcagcagcat ccacgagctt atccgatttc gtcgtcgtgg ggattgaaga agagtgggat   9420gacgttaatt ggctctgagc ttcgtcctct taaggtcatg tcttctgttt ccacggcgtg   9480catgcttcac ggtgcaagca gccggcccgc aaccgcccgc aaatcctctg gcctttccgg   9540aaccgtccgc attcccggcg acaagtcgat ctcccaccgg tccttcatgt tcggcggtct   9600cgcgagcggt gaaacgcgca tcaccggcct tctggaaggc gaggacgtca tcaatacggg   9660caaggccatg caggcgatgg gcgcccgcat ccgtaaggaa ggcgacacct ggatcatcga   9720tggcgtcggc aatggcggcc tcctggcgcc tgaggcgccg ctcgatttcg gcaatgccgc   9780cacgggctgc cgcctgacga tgggcctcgt cggggtctac gatttcgaca gcaccttcat   9840cggcgacgcc tcgctcacaa agcgcccgat gggccgcgtg ttgaacccgc tgcgcgaaat   9900gggcgtgcag gtgaaatcgg aagacggtga ccgtcttccc gttaccttgc gcgggccgaa   9960gacgccgacg ccgatcacct accgcgtgcc gatggcctcc gcacaggtga agtccgccgt  10020gctgctcgcc ggcctcaaca cgcccggcat cacgacggtc atcgagccga tcatgacgcg  10080cgatcatacg gaaaagatgc tgcagggctt tggcgccaac cttaccgtcg agacggatgc  10140ggacggcgtg cgcaccatcc gcctggaagg ccgcggcaag ctcaccggcc aagtcatcga  10200cgtgccgggc gacccgtcct cgacggcctt cccgctggtt gcggccctgc ttgttccggg  10260ctccgacgtc accatcctca acgtgctgat gaaccccacc cgcaccggcc tcatcctgac  10320gctgcaggaa atgggcgccg acatcgaagt catcaacccg cgccttgccg gcggcgaaga  10380cgtggcggac ctgcgcgttc gctcctccac gctgaagggc gtcacggtgc cggaagaccg  10440cgcgccttcg atgatcgacg aatatccgat tctcgctgtc gccgccgcct tcgcggaagg  10500ggcgaccgtg atgaacggtc tggaagaact ccgcgtcaag gaaagcgacc gcctctcggc  10560cgtcgccaat ggcctcaagc tcaatggcgt ggattgcgat gagggcgaga cgtcgctcgt  10620cgtgcgtggc cgccctgacg gcaaggggct cggcaacgcc tcgggcgccg ccgtcgccac  10680ccatctcgat caccgcatcg ccatgagctt cctcgtcatg ggcctcgtgt cggaaaaccc  10740tgtcacggtg gacgatgcca cgatgatcgc cacgagcttc ccggagttca tggacctgat  10800ggccgggctg ggcgcgaaga tcgaactctc cgatacgaag gctgcctgat gagctccagg  10860gttcttgcct ggtgccttgg caatgcttga ttactgctgc tatcctatga tctgtccgtg  10920tgggcttcta tctatcagtt tgtgtgtctg gttttgaaaa acatttgctt ttcgattatg  10980tagggtttgc ttgtagcttt cgctgctgtg acctgtgttg tttatgtgaa ccttctttgt  11040ggcatcttta atatccaagt tcgtggtttg tcgtaaaacg aagcctctac ttcgtaaagt  11100tgtgtctata gcattgaaat cgtttttttg ctcgagaata attgtgacct ttagttggcg  11160tgaaactagt tttggatatc tgattctctg gttcgcaatc ttgagatcgt cgctgcttag  11220gtgagctaag tgatgttcct aagtaaatgc tcctcaccag aatacgtagc tgtgtgaaaa  11280gagaacgcgt gaatacgtag ctgtgtaaag attgtgtccc aagtaaacct cagtgatttt  11340tgtttggatt tttaatttag aaacattcga ctgggagcgg ctagagccac acccaagttc  11400ctaactatga taaagttgct ctgtaacaga aaacaccatc tagagcggcc gcgtttaaac  11460tatcagtgtt tgacaggata tattggcggg taaacctaag agaaaagagc gtttattaga  11520ataatcggat atttaaaagg gcgtgaaaag gtttatccgt tcgtccattt gtatgtgcat  11580gccaaccaca gggttcccct cgggagtgct tggcattccg tgcgataatg acttctgttc  11640aaccacccaa acgtcggaaa gcctgacgac ggagcagcat tccaaaaaga tcccttggct  11700cgtctgggtc ggctagaagg tcgagtgggc tgctgtggct tgatccctca acgcggtcgc  11760ggacgtagcg cagcgccgaa aaatcct                                      11787</s400><s200><s210>29</s210><s211>12322</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>DNA construct 419</s223></s220></s200><s400> 29aaaagtccca tgtggatcac tccgttgccc cgtcgctcac cgtgttgggg ggaaggtgca     60catggctcag ttctcaatgg aaattatctg cctaaccggc tcagttctgc gtagaaacca    120acatgcaagc tccaccgggt gcaaagcggc agcggcggca ggatatattc aattgtaaat    180ggcttcatgt ccgggaaatc tacatggatc agcaatgagt atgatggtca atatggagaa    240aaagaaagag taattaccaa ttttttttca attcaaaaat gtagatgtcc gcagcgttat    300tataaaatga aagtacattt tgataaaacg acaaattacg atccgtcgta tttataggcg    360aaagcaataa acaaattatt ctaattcgga aatctttatt tcgacgtgtc tacattcacg    420tccaaatggg ggcttagatg agaaacttca cgatcgatgc ggccaccact cgaggtcgag    480gtaccgttgt caatcaattg gcaagtcata aaatgcatta aaaaatattt tcatactcaa    540ctacaaatcc atgagtataa ctataattat aaagcaatga ttagaatctg acaaggattc    600tggaaaatta cataaaggaa agttcataaa tgtctaaaac acaagaggac atacttgtat    660tcagtaacat ttgcagcttt tctaggtctg aaaatatatt tgttgcctag tgaataagca    720taatggtaca actacaagtg ttttactcct catattaact tcggtcatta gaggccacga    780tttgacacat ttttactcaa aacaaaatgt ttgcatatct cttataattt caaattcaac    840acacaacaaa taagagaaaa aacaaataat attaatttga gaatgaacaa aaggaccata    900tcattcatta actcttctcc atccatttcc atttcacagt tcgatagcga aaaccgaata    960aaaaacacag taaattacaa gcacaacaaa tggtacaaga aaaacagttt tcccaatgcc   1020ataatactca aactcagtag gattctggtg tgtgcgcaat gaaactgatg cattgaactt   1080gacgaacgtt gtcgaaaccg atgatacgaa cgaaagctag gcctcagcga gtaccgctgg   1140cgatctaatc catgatatcg tgaacatcat ctacattcaa attcttatga gctttcttaa   1200gggcatctgc agcatttttc atagaatcta atacagcagt atttgtgcta gctccttcga   1260gggcttccct ctgcatttca atagttgtaa gggttccatc tatttgtagt tgggtctttt   1320ccaatcgttt cttctttttg agggcttgga gtgcaactct tttatttttc gacgcatttt   1380tctttgcgct cctgcaggcg gccgcgtgga tgaggagtta atcggtcgtg tgagagtagt   1440gatcgagtgg atgtcgtcga gagtgatgag tgttgatgtt gttagtgata tgtggtagaa   1500ggtatcgtga taaagcgtta acgcgatcgc agtacttgca aagaaaaatg cgtcgaaaaa   1560taaaagagtt gcactccaag ccctcaaaaa gaagaaacga ttggaaaaga cccaactaca   1620aatagatgga acccttacaa ctattgaaat gcagagggaa gccctcgaag gagctagcac   1680aaatactgct gtattagatt ctatgaaaaa tgctgcagat gcccttaaga aagctcataa   1740gaatttgaat gtagatgatg ttcacgatat catggatggt atcgcacagc gactgctgag   1800ggacgtcgag ctcccgcttg gtatctgcat tacaatgaaa tgagcaaaga ctatgtgagt   1860aacactggtc aacactaggg agaaggcatc gagcaagata cgtatgtaaa gagaagcaat   1920atagtgtcag ttggtagata ctagatacca tcaggaggta aggagagcaa caaaaaggaa   1980actctttatt tttaaatttt gttacaacaa acaagcagat caatgcatca aaatactgtc   2040agtacttatt tcttcagaca acaatattta aaacaagtgc atctgatctt gacttatggt   2100cacaataaag gagcagagat aaacatcaaa atttcgtcat ttatatttat tccttcaggc   2160gttaacaatt taacagcaca caaacaaaaa cagaatagga atatctaatt ttggcaaata   2220ataagctctg cagacgaaca aattattata gtatcgccta taatatgaat ccctatacta   2280ttgacccatg tagtatgaag cctgtgccta aattaacagc aaacttctga atccaagtgc   2340cctataacac caacatgtgc ttaaataaat accgctaagc accaaattac acatttctcg   2400tattgctgtg taggttctat cttcgtttcg tactaccatg tccctatatt ttgctgctac   2460aaaggacggc aagtaatcag cacaggcaga acacgatttc agagtgtaat tctagatcca   2520gctaaaccac tctcagcaat caccacacaa gagagcattc agagaaacgt ggcagtaaca   2580aaggcagagg gcggagtgag cgcgtaccga agacggttca gcgtgtcctc tccaaatgaa   2640atgaacttcc ttatatagag gaagggtctt gcgaaggata gtgggattgt gcgtcatccc   2700ttacgtcagt ggagatatca catcaatcca cttgctttga agacgtggtt ggaacgtctt   2760ctttttccac gatgctcctc gtgggtgggg gtccatcttt gggaccactg tcggcagagg   2820catcttcaac gatggccttt cctttatcgc aatgatggca tttgtaggag ccaccttcct   2880tttccactat cttcacaata aagtgacaga tagctgggca atggaatccg aggaggtttc   2940cggatattac cctttgttga aaagtctcaa tcggaccatc acatcaatcc acttgctttg   3000aagacgtggt tggaacgtct tctttttcca cgatgctcct cgtgggtggg ggtccatctt   3060tgggaccact gtcggcagag gcatcttcaa cgatggcctt tcctttatcg caatgatggc   3120atttgtagga gccaccttcc ttttccacta tcttcacaat aaagtgacag atagctgggc   3180aatggaatcc gaggaggttt ccggatatta ccctttgttg aaaagtctca atcggacctg   3240cagcctgcag gctagcggcg cgccgggatc caaaaaacac acacagatct aattcctttt   3300tttttgcact caaaatcaga acaatttatt tctcatttat tcatcgccga atctgttggc   3360gattagccga ttacacaagt acagaaaaca ctggggaaag aaacacaata cagagatgtc   3420tcatcagact cgcaagaact cgcacacaca tcaaccaaat tggctccaac ctgaatgagc   3480atacgtccaa acgcatgcag aattcaatca gagttcctat cacagctgga cggggatgaa   3540ctcgatcttg tcgatgtaga tcttctcgtt ggagacgaag gactcagcac caatgatcag   3600ttcattcttg tcgcccgaga agcccatgtt ggagttcgtg gtggcgaggt cgaaggtctg   3660gtaggtcagg tcatcgtcct tgttcatggt cttgttgatg tagatgacca ggaagtcatt   3720gttggagttc tggacgaaca ggcgcaggtt cgtggtggag gcgtagcgga tgcggacgcg   3780gtagcgttgc agcaaggcag cggagttcag ggtgaccttg aacttggcga tggagttcga   3840ggactccttc aggaacagca ggttgccacc ggtgaagcct ggaccctcaa tgatggaggc   3900acccgaggac agggcgtagg ccttgaccac gggcagctgg gtgatcttct cggcgtcgat   3960ggtgttgaag aagtcgacgg agcggtgggt ccaggtgaag aaggggatgg tgcccctgcg   4020gtcttgcatc aggaagcact ccgcgtagtt cagctggtgg gagtaggcct tctccagggg   4080ctcgtcagtg gtctcaggcg gcagctggtc gatggagtcc tgggcggaga cgtggccatt   4140gttgcgcttg gagtcgtagg tctgggtgga ggtctcgttc ttctggtcat cgtactggga   4200gaagtcgacc ttcgtgacgc ccaggtagac cttgccgttc ggccaagccg cgacgtcggt   4260gttggcgatg gtgcggtaga ccttctggcc gtcgaaggac agcttctgga cgggctcggt   4320ggacttgtcg ccgtagaaag gggaggtgat cgtcttcgag gagccgatgg agggcctggt   4380ctcgacgtag ttgccggacc agtagttgaa ggagtccttg ccgaagtagc ctggcctcag   4440gcgcgtgtgg aactcgatgc cctggaggta gtcgaacagg tggggcttgc ggatggagtt   4500ctcgatggac aggaaggtgg gaccgtactt ctggagggtc gtgagcagga agatggggtc   4560cgtgaagatg tcgcgggtca gctcggtctt gacgcccttg gagtacaggc ggatgtcgta   4620gaaggggaac aggacgatca ggtccaggac ggtcagggtc atctccctgc ggaagcggtt   4680gaacttgacc catgcgtcgt aggtggagcc cctcaggccg ttcaggccga cgttgtacca   4740gttgacgcag tggtcggtgt actgttgggt cagcttcagc tggcgacggt agaactcggc   4800gacgtcctcc gaggagtagc cccattcctc gccgaagacc tgggcgtcct tcagcaacag   4860gaggtgggtg ttggcagcct gggcgtaggt gggcaggaac aggacctcga acttggagac   4920ggcgaaggac ggcatggagt tgcggaagtg ggactcggcc tgggagaaca gctcgcggat   4980gcggtcctgg gagcgcttgg agcgcaggga cagaggcgtc ttcttccagg agttcagcgc   5040gttgacgtag tcctcgaagt tgttttgcag gccttgcagc tcggccaggg ccttggactt   5100ggcgtactcc tcgatcttct tgtcgatcag gacttcgact tgggccatga aggccttcca   5160ggggtcggcg tcggagggcc agatggtgtt caggaaggac tggtagaagg aggtgagagc   5220acctgcgaag gggacgccaa cgacgcccag gatctgccca acgacggaga tgccggtccc   5280gacggcgtcc ttgacggtgg agttgtccag gacctccgtg gaggagtcct cggtcatgcg   5340caggaactcc ttgtagttca gctcttccag ggtggagttg gggttgtcgg ccagcgggta   5400ctggttgtgg ttggtctgga gctcggagtt gggggtgacc ttgatcgtgt cgtgctcgga   5460gcgattgttg gggttggcca tggttgatca cttctaccta caaaaaagct ccgcacgagg   5520ctgcatttgt cacaaatcat gaaaagaaaa actaccgatg aacaatgctg agggattcaa   5580attctaccca caaaaagaag aaagaaagat ctagcacatc taagcctgac gaagcagcag   5640aaatatataa aaatataaac catagtgccc ttttcccctc ttcctgatct tgtttagcac   5700ggcggaaatt ttaaaccccc catcatctcc cccaacaacg gcggatcgca gatctacatc   5760cgagagcccc attccccgcg agatccgggc cggatccacg ccggcgagag ccccagccgc   5820gagatcccgc ccctcccgcg caccgatctg ggcgcgcacg aagccgcctc tcgcccaccc   5880aaactaccaa ggccaaagat cgagaccgag acggaaaaaa aaacggagaa agaaagagga   5940gaggggcggg gtggttaccg gcggcggcgg aggcctccct tggatcttat ggtgtgttgt   6000ccctgtgtgt tctccaatag tgtggcttga gtgtgtggaa gatggttccc gggggttttg   6060atcatgggat tagggaggta tttatagtcg agccccggga ttaattaatc gaccgttaga   6120gctcatgtga accctgccct gccatcatgt gagcgtgcat acgagggcga tctggattgg   6180ctggcagaac acctgcccta gcaaggctcg tagattaatt aacaaatcgt acgtacatct   6240acgctgataa tgtgttaaat catcggccga atatttggtt agccgtgaag cactcgatcc   6300cgcaaatgac caagattgct gcacacgaca catcgcgggc ttgtttcctt atgatcattg   6360gttgttattt tatctcgcga tcttggccta tcgggcgtcg cttcgcgcgg tgcagcgtga   6420ctgcgtgagc aagttggtga ttttcttttg ccgtttaaga atgcttgctc cgtgatcaca   6480caagagagga catcacatga accgagaccg gaggaatatc ggggcatggt gggattggtg   6540ggtgtcccag tccaacgggc aagaagattc taagcttacc tgggtttgtt ttcacgtacg   6600cgaaggacag gggaagatgc cattgcagcg tggcttcctg ctggcccgcc aactttaatc   6660tacactaggc acgtagctac taggtcggcc cgcttagata gctaaggtag gctaggtagg   6720tccgtggtaa actgccagcc catgggcgcc tgggattctt cttgggccaa cagaagcaga   6780ggttgggcaa tgcgaagcct gaaaatcctc ctcctccttc tctctccctc tctctctctc   6840tctctctctc tctctcacga ataaaatcct cttcttcccg aacaggctag attctttttt   6900ttttaatgaa ccagtgagcc accaatttca ttgaatagag gaataaaatt gtacatgcgc   6960aagcgcaaat agaaaacttt accgtctcaa ggcctttggc ccgaacatgt taaaaggtaa   7020gccacctatc aaggtgtttc gcgcccgcca agacccatgt tttggcatcc tccttaattt   7080tggctatcag actagccacc ggaagctctt ggtgctgaaa aactctgcgg ttcctttcat   7140tccaaatatc ctaggcgact aatagcatta gagtctgcaa ggctttcttt ggcgcttcgt   7200tggaacatgc ggtggcctcc caccacttga gtagcgtcga ggcttgttgc cataacgttg   7260gtcttatttg ttcacatgtt gtccagtctg caagtgtcgc ctagattctt tcacatatct   7320acactccgcc aggaggtgag ggccgtttcc tgattccttc gacaaagggg cagatggagc   7380cattttcgat tacccacggg ttgccaatct gtcggaggtc catactctat tttggataac   7440aagccaagcg aagcgaatgt tttacatttg cgcggcgcct agggcttcca gataggggca   7500ttgaaattga agcttttatg ccaagaagtt gtgcgttgta ggccgatgtc gtcatgtatt   7560cgccgtgact agttagcttc cattttcgac aagcttgcct cgagacaaca acatgcttct   7620catcaacatg gagggaagag ggagggagaa agtgtcgcct ggtcacctcc attgtcacac   7680tagccactgg ccagctctcc cacaccacca atgccagggg cgagctttag cacagccacc   7740gcttcacctc caccaccgca ctaccctagc ttcgcccaac agccaccgtc aacgcctcct   7800ctccgtcaac ataagagaga gagagaagag gagagtagcc atgtggggag gaggaatagt   7860acatggggcc taccgtttgg caagttattt tgggttgcca agttaggcca ataaggggag   7920ggatttggcc atccggttgg aaaggttatt ggggtagtat ctttttacta gaattgtcaa   7980aaaaaaatag tttgagagcc atttggagag gatgttgcct gttagaggtg ctcttaggac   8040atcaaattcc ataaaaacat cagaaaaatt ctctcgatga agatttataa ccactaaaac   8100tgccctcaat tcgaagggag ttcaaaacaa ttaaaatcat gttcgaattg agtttcaatt   8160tcactttaac ccctttgaaa tctcaatggt aaaacatcaa cccgtcaggt agcatggttc   8220tttttattcc tttcaaaaag agttaattac aaacagaatc aaaactaaca gttaggccca   8280aggcccatcc gagcaaacaa tagatcatgg gccaggcctg ccaccaccct ccccctcctg   8340gctcccgctc ttgaatttca aaatccaaaa atatcggcac gactggccgc cgacggagcg   8400ggcggaaaat gacggaacaa cccctcgaat tctaccccaa ctacgcccac caacccacac   8460gccactgaca atccggtccc acccttgtgg gcccacctac aagcgagacg tcagtcgctc   8520gcagcaacca gtgggcccac ctcccagtga gcggcgggta gatctggact cttacccacc   8580cacactaaac aaaacggcat gaatattttg cactaaaacc ctcagaaaaa ttccgatatt   8640ccaaaccagt acagttcctg accgttggag gagccaaagt ggagcggagt gtaaaattgg   8700gaaacttaat cgagggggtt aaacgcaaaa acgccgaggc gcctcccgct ctatagaaag   8760gggaggagtg ggaggtggaa accctaccac accgcagaga aaggcgtctt cgtactcgcc   8820tctctccgcg ccctcctccg ccgccgctcg ccgccgttcg tctccgccgc caccggctag   8880ccatccaggt aaaacaaaca aaaacggatc tgatgcttcc attcctccgt ttctcgtagt   8940agcgcgcttc gatctgtggg tggatctggg tgatcctggg gtgtggttcg ttctgtttga   9000tagatctgtc ggtggatctg gccttctgtg gttgtcgatg tccggatctg cgttttgatc   9060agtggtagtt cgtggatctg gcgaaatgtt ttggatctgg cagtgagacg ctaagaatcg   9120ggaaatgatg caatattagg ggggtttcgg atggggatcc actgaattag tctgtctccc   9180tgctgataat ctgttccttt ttggtagatc tggttagtgt atgtttgttt cggatagatc   9240tgatcaatgc ttgtttgttt tttcaaattt tctacctagg ttgtatagga atggcatgcg   9300gatctggttg gattgccatg atccgtgctg aaatgcccct ttggttgatg gatcttgata   9360ttttactgct gttcacctag atttgtactc ccgtttatac ttaatttgtt gcttattatg   9420aatagatctg taacttaggc acatgtatgg acggagtatg tggatctgta gtatgtacat   9480tgctgcgagc taagaactat ttcagagcaa gcacagaaaa aaatatttag acagattggg   9540caactatttg atggtctttg gtatcatgct ttgtagtgct cgtttctgcg tagtaatctt   9600ttgatctgat ctgaagatag gtgctattat attcttaaag gtcattagaa cgctatctga   9660aaggctgtat tatgtggatt ggttcacctg tgactccctg ttcgtcttgt cttgataaat   9720cctgtgataa aaaaaattct taaggcgtaa tttgttgaaa tcttgttttg tcctatgcag   9780cctgatccat ggcgcaagtt agcagaatct gcaatggtgt gcagaaccca tctcttatct   9840ccaatctctc gaaatccagt caacgcaaat ctcccttatc ggtttctctg aagacgcagc   9900agcatccacg agcttatccg atttcgtcgt cgtggggatt gaagaagagt gggatgacgt   9960taattggctc tgagcttcgt cctcttaagg tcatgtcttc tgtttccacg gcgtgcatgc  10020ttcacggtgc aagcagccgg cccgcaaccg cccgcaaatc ctctggcctt tccggaaccg  10080tccgcattcc cggcgacaag tcgatctccc accggtcctt catgttcggc ggtctcgcga  10140gcggtgaaac gcgcatcacc ggccttctgg aaggcgagga cgtcatcaat acgggcaagg  10200ccatgcaggc gatgggcgcc cgcatccgta aggaaggcga cacctggatc atcgatggcg  10260tcggcaatgg cggcctcctg gcgcctgagg cgccgctcga tttcggcaat gccgccacgg  10320gctgccgcct gacgatgggc ctcgtcgggg tctacgattt cgacagcacc ttcatcggcg  10380acgcctcgct cacaaagcgc ccgatgggcc gcgtgttgaa cccgctgcgc gaaatgggcg  10440tgcaggtgaa atcggaagac ggtgaccgtc ttcccgttac cttgcgcggg ccgaagacgc  10500cgacgccgat cacctaccgc gtgccgatgg cctccgcaca ggtgaagtcc gccgtgctgc  10560tcgccggcct caacacgccc ggcatcacga cggtcatcga gccgatcatg acgcgcgatc  10620atacggaaaa gatgctgcag ggctttggcg ccaaccttac cgtcgagacg gatgcggacg  10680gcgtgcgcac catccgcctg gaaggccgcg gcaagctcac cggccaagtc atcgacgtgc  10740cgggcgaccc gtcctcgacg gccttcccgc tggttgcggc cctgcttgtt ccgggctccg  10800acgtcaccat cctcaacgtg ctgatgaacc ccacccgcac cggcctcatc ctgacgctgc  10860aggaaatggg cgccgacatc gaagtcatca acccgcgcct tgccggcggc gaagacgtgg  10920cggacctgcg cgttcgctcc tccacgctga agggcgtcac ggtgccggaa gaccgcgcgc  10980cttcgatgat cgacgaatat ccgattctcg ctgtcgccgc cgccttcgcg gaaggggcga  11040ccgtgatgaa cggtctggaa gaactccgcg tcaaggaaag cgaccgcctc tcggccgtcg  11100ccaatggcct caagctcaat ggcgtggatt gcgatgaggg cgagacgtcg ctcgtcgtgc  11160gtggccgccc tgacggcaag gggctcggca acgcctcggg cgccgccgtc gccacccatc  11220tcgatcaccg catcgccatg agcttcctcg tcatgggcct cgtgtcggaa aaccctgtca  11280cggtggacga tgccacgatg atcgccacga gcttcccgga gttcatggac ctgatggccg  11340ggctgggcgc gaagatcgaa ctctccgata cgaaggctgc ctgatgagct ccagggttct  11400tgcctggtgc cttggcaatg cttgattact gctgctatcc tatgatctgt ccgtgtgggc  11460ttctatctat cagtttgtgt gtctggtttt gaaaaacatt tgcttttcga ttatgtaggg  11520tttgcttgta gctttcgctg ctgtgacctg tgttgtttat gtgaaccttc tttgtggcat  11580ctttaatatc caagttcgtg gtttgtcgta aaacgaagcc tctacttcgt aaagttgtgt  11640ctatagcatt gaaatcgttt ttttgctcga gaataattgt gacctttagt tggcgtgaaa  11700ctagttttgg atatctgatt ctctggttcg caatcttgag atcgtcgctg cttaggtgag  11760ctaagtgatg ttcctaagta aatgctcctc accagaatac gtagctgtgt gaaaagagaa  11820cgcgtgaata cgtagctgtg taaagattgt gtcccaagta aacctcagtg atttttgttt  11880ggatttttaa tttagaaaca ttcgactggg agcggctaga gccacaccca agttcctaac  11940tatgataaag ttgctctgta acagaaaaca ccatctagag cggccgcgtt taaactatca  12000gtgtttgaca ggatatattg gcgggtaaac ctaagagaaa agagcgttta ttagaataat  12060cggatattta aaagggcgtg aaaaggttta tccgttcgtc catttgtatg tgcatgccaa  12120ccacagggtt cccctcggga gtgcttggca ttccgtgcga taatgacttc tgttcaacca  12180cccaaacgtc ggaaagcctg acgacggagc agcattccaa aaagatccct tggctcgtct  12240gggtcggcta gaaggtcgag tgggctgctg tggcttgatc cctcaacgcg gtcgcggacg  12300tagcgcagcg ccgaaaaatc ct                                           12322</s400><s200><s210>30</s210><s211>12797</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>DNA construct 402</s223></s220></s200><s400> 30aaaagtccca tgtggatcac tccgttgccc cgtcgctcac cgtgttgggg ggaaggtgca     60catggctcag ttctcaatgg aaattatctg cctaaccggc tcagttctgc gtagaaacca    120acatgcaagc tccaccgggt gcaaagcggc agcggcggca ggatatattc aattgtaaat    180ggcttcatgt ccgggaaatc tacatggatc agcaatgagt atgatggtca atatggagaa    240aaagaaagag taattaccaa ttttttttca attcaaaaat gtagatgtcc gcagcgttat    300tataaaatga aagtacattt tgataaaacg acaaattacg atccgtcgta tttataggcg    360aaagcaataa acaaattatt ctaattcgga aatctttatt tcgacgtgtc tacattcacg    420tccaaatggg ggcttagatg agaaacttca cgatcgatgc ggccaccact cgaggtcgag    480gtaccgttgt caatcaattg gcaagtcata aaatgcatta aaaaatattt tcatactcaa    540ctacaaatcc atgagtataa ctataattat aaagcaatga ttagaatctg acaaggattc    600tggaaaatta cataaaggaa agttcataaa tgtctaaaac acaagaggac atacttgtat    660tcagtaacat ttgcagcttt tctaggtctg aaaatatatt tgttgcctag tgaataagca    720taatggtaca actacaagtg ttttactcct catattaact tcggtcatta gaggccacga    780tttgacacat ttttactcaa aacaaaatgt ttgcatatct cttataattt caaattcaac    840acacaacaaa taagagaaaa aacaaataat attaatttga gaatgaacaa aaggaccata    900tcattcatta actcttctcc atccatttcc atttcacagt tcgatagcga aaaccgaata    960aaaaacacag taaattacaa gcacaacaaa tggtacaaga aaaacagttt tcccaatgcc   1020ataatactca aactcagtag gattctggtg tgtgcgcaat gaaactgatg cattgaactt   1080gacgaacgtt gtcgaaaccg atgatacgaa cgaaagctag gcctcagcga gtaccgctgg   1140cgatctaatc catgatatcg tgaacatcat ctacattcaa attcttatga gctttcttaa   1200gggcatctgc agcatttttc atagaatcta atacagcagt atttgtgcta gctccttcga   1260gggcttccct ctgcatttca atagttgtaa gggttccatc tatttgtagt tgggtctttt   1320ccaatcgttt cttctttttg agggcttgga gtgcaactct tttatttttc gacgcatttt   1380tctttgcgct cctgcaggcg gccgcgtgga tgaggagtta atcggtcgtg tgagagtagt   1440gatcgagtgg atgtcgtcga gagtgatgag tgttgatgtt gttagtgata tgtggtagaa   1500ggtatcgtga taaagcgtta acgcgatcgc agtacttgca aagaaaaatg cgtcgaaaaa   1560taaaagagtt gcactccaag ccctcaaaaa gaagaaacga ttggaaaaga cccaactaca   1620aatagatgga acccttacaa ctattgaaat gcagagggaa gccctcgaag gagctagcac   1680aaatactgct gtattagatt ctatgaaaaa tgctgcagat gcccttaaga aagctcataa   1740gaatttgaat gtagatgatg ttcacgatat catggatggt atcgcacagc gactgctgag   1800ggacgtcggt ccatggagat cctctagagg ccgcttggta tctgcattac aatgaaatga   1860gcaaagacta tgtgagtaac actggtcaac actagggaga aggcatcgag caagatacgt   1920atgtaaagag aagcaatata gtgtcagttg gtagatacta gataccatca ggaggtaagg   1980agagcaacaa aaaggaaact ctttattttt aaattttgtt acaacaaaca agcagatcaa   2040tgcatcaaaa tactgtcagt acttatttct tcagacaaca atatttaaaa caagtgcatc   2100tgatcttgac ttatggtcac aataaaggag cagagataaa catcaaaatt tcgtcattta   2160tatttattcc ttcaggcgtt aacaatttaa cagcacacaa acaaaaacag aataggaata   2220tctaattttg gcaaataata agctctgcag acgaacaaat tattatagta tcgcctataa   2280tatgaatccc tatactattg acccatgtag tatgaagcct gtgcctaaat taacagcaaa   2340cttctgaatc caagtgccct ataacaccaa catgtgctta aataaatacc gctaagcacc   2400aaattacaca tttctcgtat tgctgtgtag gttctatctt cgtttcgtac taccatgtcc   2460ctatattttg ctgctacaaa ggacggcaag taatcagcac aggcagaaca cgatttcaga   2520gtgtaattct agatccagct aaaccactct cagcaatcac cacacaagag agcattcaga   2580gaaacgtggc agtaacaaag gcagagggcg gagtgagcgc gtaccgaaga cggtgggccg   2640cttatggtgt gttgtccctg tgtgttctcc aatagtgtgg cttgagtgtg tggaagatgg   2700ttgtatctga tgatccttca aatgggaatg aatgccttct tatatagagg gaattctttt   2760gtggtcgtca ctgcgttcgt catacgcatt agtgagtggg ctgtcaggac agctcttttc   2820cacgttattt tgttccccac ttgtactaga ggaatctgct ttatctttgc aataaaggca   2880aagatgcttt tggtaggtgc gcctaacaat tctgcaccat tccttttttg tctggtcccc   2940acaagccagc tgctcgatgt tgacaagatt actttcaaag atgcccacta actttaagtc   3000ttcggtggat gtctttttct gaaacttact gaccatgatg catgtgctgg aacagtagtt   3060tactttgatt gaagattctt cattgatctc ctgtagcttt tggctaatgg tttggagact   3120ctgtaccctg accttgttga ggctttggac tgagaattct tccttacaaa cctttgagga   3180tgggagttcc ttcttggttt tggcgatacc aatttgaata aagtgatatg gctcgtacct   3240tgttgattga acccaatctg gaatgctgct aaatcctgag ctcaagctaa ttcttttgtg   3300gtcgtcactg cgttcgtcat acgcattagt gagtgggctg tcaggacagc tcttttccac   3360gttattttgt tccccacttg tactagagga atctgcttta tctttgcaat aaaggcaaag   3420atgcttttgg taggtgcgcc taacaattct gcaccattcc ttttttgtct ggtccccaca   3480agccagctgc tcgatgttga caagattact ttcaaagatg cccactaact ttaagtcttc   3540ggtggatgtc tttttctgaa acttactgac catgatgcat gtgctggaac agtagtttac   3600tttgattgaa gattcttcat tgatctcctg tagcttttgg ctaatggttt ggagactctg   3660taccctgacc ttgttgaggc tttggactga gaattagctt ccactcgaag cttgttaacc   3720tgcaggctag cggcgcgccg gaagctaact agtcacggcg aatacatgac gacatcggcc   3780tacaacgcac aacttcttgg cataaaagct tcaatttcaa tgcccctatc tggaagccct   3840aggcgccgcg caaatgtaaa acattcgctt cgcttggctt gttatccaaa atagagtatg   3900gacctccgac agattggcaa cccgtgggta atcgaaaatg gctccatctg cccctttgtc   3960gaaggaatca ggaaacggcc ctcacctcct ggcggagtgt agatatgtga aagaatctag   4020gcgacacttg cagactggac aacatgtgaa caaataagac caacgttatg gcaacaagcc   4080tcgacgctac tcaagtggtg ggaggccacc gcatgttcca acgaagcgcc aaagaaagcc   4140ttgcagactc taatgctatt agtcgcctag gatatttgga atgaaaggaa ccgcagagtt   4200tttcagcacc aagagcttcc ggtggctagt ctgatagcca aaattaagga ggatgccaaa   4260acatgggtct tggcgggcgc gaaacacctt gataggtggc ttacctttta acatgttcgg   4320gccaaaggcc ttgagacggt aaagttttct atttgcgctt gcgcatgtac aattttattc   4380ctctattcaa tgaaattggt ggctcactgg ttcattaaaa aaaaaagaat ctagcctgtt   4440cgggaagaag aggattttat tcgtgagaga gagagagaga gagagagaga gagggagaga   4500gaaggaggag gaggattttc aggcttcgca ttgcccaacc tctgcttctg ttggcccaag   4560aagaatccca ggcgcccatg ggctggcagt ttaccacgga cctacctagc ctaccttagc   4620tatctaagcg ggccgaccta gtagctacgt gcctagtgta gattaaagtt ggcgggccag   4680caggaagcca cgctgcaatg gcatcttccc ctgtccttcg cgtacgtgaa aacaaaccca   4740ggtaagctta gaatcttctt gcccgttgga ctgggacacc caccaatccc accatgcccc   4800gatattcctc cggtctcggt tcatgtgatg tcctctcttg tgtgatcacg gagcaagcat   4860tcttaaacgg caaaagaaaa tcaccaactt gctcacgcag tcacgctgca ccgcgcgaag   4920cgacgcccga taggccaaga tcgcgagata aaataacaac caatgatcat aaggaaacaa   4980gcccgcgatg tgtcgtgtgc agcaatcttg gtcatttgcg ggatcgagtg cttcacggct   5040aaccaaatat tcggccgatg atttaacaca ttatcagcgt agatgtacgt acgatttgtt   5100aattaatcta cgagccttgc tagggcaggt gttctgccag ccaatccaga tcgccctcgt   5160atgcacgctc acatgatggc agggcagggt tcacatgagc tctaacggtc gattaattaa   5220tcccggggct cgactataaa tacctcccta atcccatgat caaaaccccc gggaaccatc   5280ttccacacac tcaagccaca ctattggaga acacacaggg acaacacacc ataagatcca   5340agggaggcct ccgccgccgc cggtaaccac cccgcccctc tcctctttct ttctccgttt   5400ttttttccgt ctcggtctcg atctttggcc ttggtagttt gggtgggcga gaggcggctt   5460cgtgcgcgcc cagatcggtg cgcgggaggg gcgggatctc gcggctgggg ctctcgccgg   5520cgtggatccg gcccggatct cgcggggaat ggggctctcg gatgtagatc tgcgatccgc   5580cgttgttggg ggagatgatg gggggtttaa aatttccgcc gtgctaaaca agatcaggaa   5640gaggggaaaa gggcactatg gtttatattt ttatatattt ctgctgcttc gtcaggctta   5700gatgtgctag atctttcttt cttctttttg tgggtagaat ttgaatccct cagcattgtt   5760catcggtagt ttttcttttc atgatttgtg acaaatgcag cctcgtgcgg agcttttttg   5820taggtagaag tgatcaacca tggccaaccc caacaatcgc tccgagcacg acacgatcaa   5880ggtcaccccc aactccgagc tccagaccaa ccacaaccag tacccgctgg ccgacaaccc   5940caactccacc ctggaagagc tgaactacaa ggagttcctg cgcatgaccg aggactcctc   6000cacggaggtc ctggacaact ccaccgtcaa ggacgccgtc gggaccggca tctccgtcgt   6060tgggcagatc ctgggcgtcg ttggcgtccc cttcgcaggt gctctcacct ccttctacca   6120gtccttcctg aacaccatct ggccctccga cgccgacccc tggaaggcct tcatggccca   6180agtcgaagtc ctgatcgaca agaagatcga ggagtacgcc aagtccaagg ccctggccga   6240gctgcaaggc ctgcaaaaca acttcgagga ctacgtcaac gcgctgaact cctggaagaa   6300gacgcctctg tccctgcgct ccaagcgctc ccaggaccgc atccgcgagc tgttctccca   6360ggccgagtcc cacttccgca actccatgcc gtccttcgcc gtctccaagt tcgaggtcct   6420gttcctgccc acctacgccc aggctgccaa cacccacctc ctgttgctga aggacgccca   6480ggtcttcggc gaggaatggg gctactcctc ggaggacgtc gccgagttct accgtcgcca   6540gctgaagctg acccaacagt acaccgacca ctgcgtcaac tggtacaacg tcggcctgaa   6600cggcctgagg ggctccacct acgacgcatg ggtcaagttc aaccgcttcc gcagggagat   6660gaccctgacc gtcctggacc tgatcgtcct gttccccttc tacgacatcc gcctgtactc   6720caagggcgtc aagaccgagc tgacccgcga catcttcacg gaccccatct tcctgctcac   6780gaccctccag aagtacggtc ccaccttcct gtccatcgag aactccatcc gcaagcccca   6840cctgttcgac tacctccagg gcatcgagtt ccacacgcgc ctgaggccag gctacttcgg   6900caaggactcc ttcaactact ggtccggcaa ctacgtcgag accaggccct ccatcggctc   6960ctcgaagacg atcacctccc ctttctacgg cgacaagtcc accgagcccg tccagaagct   7020gtccttcgac ggccagaagg tctaccgcac catcgccaac accgacgtcg cggcttggcc   7080gaacggcaag gtctacctgg gcgtcacgaa ggtcgacttc tcccagtacg atgaccagaa   7140gaacgagacc tccacccaga cctacgactc caagcgcaac aatggccacg tctccgccca   7200ggactccatc gaccagctgc cgcctgagac cactgacgag cccctggaga aggcctactc   7260ccaccagctg aactacgcgg agtgcttcct gatgcaagac cgcaggggca ccatcccctt   7320cttcacctgg acccaccgct ccgtcgactt cttcaacacc atcgacgccg agaagatcac   7380ccagctgccc gtggtcaagg cctacgccct gtcctcgggt gcctccatca ttgagggtcc   7440aggcttcacc ggtggcaacc tgctgttcct gaaggagtcc tcgaactcca tcgccaagtt   7500caaggtcacc ctgaactccg ctgccttgct gcaacgctac cgcgtccgca tccgctacgc   7560ctccaccacg aacctgcgcc tgttcgtcca gaactccaac aatgacttcc tggtcatcta   7620catcaacaag accatgaaca aggacgatga cctgacctac cagaccttcg acctcgccac   7680cacgaactcc aacatgggct tctcgggcga caagaatgaa ctgatcattg gtgctgagtc   7740cttcgtctcc aacgagaaga tctacatcga caagatcgag ttcatccccg tccagctgtg   7800ataggaactc tgattgaatt ctgcatgcgt ttggacgtat gctcattcag gttggagcca   7860atttggttga tgtgtgtgcg agttcttgcg agtctgatga gacatctctg tattgtgttt   7920ctttccccag tgttttctgt acttgtgtaa tcggctaatc gccaacagat tcggcgatga   7980ataaatgaga aataaattgt tctgattttg agtgcaaaaa aaaaggaatt agatctgtgt   8040gtgttttttg gatcccattt tcgacaagct tgcctcgaga caacaacatg cttctcatca   8100acatggaggg aagagggagg gagaaagtgt cgcctggtca cctccattgt cacactagcc   8160actggccagc tctcccacac caccaatgcc aggggcgagc tttagcacag ccaccgcttc   8220acctccacca ccgcactacc ctagcttcgc ccaacagcca ccgtcaacgc ctcctctccg   8280tcaacataag agagagagag aagaggagag tagccatgtg gggaggagga atagtacatg   8340gggcctaccg tttggcaagt tattttgggt tgccaagtta ggccaataag gggagggatt   8400tggccatccg gttggaaagg ttattggggt agtatctttt tactagaatt gtcaaaaaaa   8460aatagtttga gagccatttg gagaggatgt tgcctgttag aggtgctctt aggacatcaa   8520attccataaa aacatcagaa aaattctctc gatgaagatt tataaccact aaaactgccc   8580tcaattcgaa gggagttcaa aacaattaaa atcatgttcg aattgagttt caatttcact   8640ttaacccctt tgaaatctca atggtaaaac atcaacccgt caggtagcat ggttcttttt   8700attcctttca aaaagagtta attacaaaca gaatcaaaac taacagttag gcccaaggcc   8760catccgagca aacaatagat catgggccag gcctgccacc accctccccc tcctggctcc   8820cgctcttgaa tttcaaaatc caaaaatatc ggcacgactg gccgccgacg gagcgggcgg   8880aaaatgacgg aacaacccct cgaattctac cccaactacg cccaccaacc cacacgccac   8940tgacaatccg gtcccaccct tgtgggccca cctacaagcg agacgtcagt cgctcgcagc   9000aaccagtggg cccacctccc agtgagcggc gggtagatct ggactcttac ccacccacac   9060taaacaaaac ggcatgaata ttttgcacta aaaccctcag aaaaattccg atattccaaa   9120ccagtacagt tcctgaccgt tggaggagcc aaagtggagc ggagtgtaaa attgggaaac   9180ttaatcgagg gggttaaacg caaaaacgcc gaggcgcctc ccgctctata gaaaggggag   9240gagtgggagg tggaaaccct accacaccgc agagaaaggc gtcttcgtac tcgcctctct   9300ccgcgccctc ctccgccgcc gctcgccgcc gttcgtctcc gccgccaccg gctagccatc   9360caggtaaaac aaacaaaaac ggatctgatg cttccattcc tccgtttctc gtagtagcgc   9420gcttcgatct gtgggtggat ctgggtgatc ctggggtgtg gttcgttctg tttgatagat   9480ctgtcggtgg atctggcctt ctgtggttgt cgatgtccgg atctgcgttt tgatcagtgg   9540tagttcgtgg atctggcgaa atgttttgga tctggcagtg agacgctaag aatcgggaaa   9600tgatgcaata ttaggggggt ttcggatggg gatccactga attagtctgt ctccctgctg   9660ataatctgtt cctttttggt agatctggtt agtgtatgtt tgtttcggat agatctgatc   9720aatgcttgtt tgttttttca aattttctac ctaggttgta taggaatggc atgcggatct   9780ggttggattg ccatgatccg tgctgaaatg cccctttggt tgatggatct tgatatttta   9840ctgctgttca cctagatttg tactcccgtt tatacttaat ttgttgctta ttatgaatag   9900atctgtaact taggcacatg tatggacgga gtatgtggat ctgtagtatg tacattgctg   9960cgagctaaga actatttcag agcaagcaca gaaaaaaata tttagacaga ttgggcaact  10020atttgatggt ctttggtatc atgctttgta gtgctcgttt ctgcgtagta atcttttgat  10080ctgatctgaa gataggtgct attatattct taaaggtcat tagaacgcta tctgaaaggc  10140tgtattatgt ggattggttc acctgtgact ccctgttcgt cttgtcttga taaatcctgt  10200gataaaaaaa attcttaagg cgtaatttgt tgaaatcttg ttttgtccta tgcagcctga  10260tccatggcgc aagttagcag aatctgcaat ggtgtgcaga acccatctct tatctccaat  10320ctctcgaaat ccagtcaacg caaatctccc ttatcggttt ctctgaagac gcagcagcat  10380ccacgagctt atccgatttc gtcgtcgtgg ggattgaaga agagtgggat gacgttaatt  10440ggctctgagc ttcgtcctct taaggtcatg tcttctgttt ccacggcgtg catgcttcac  10500ggtgcaagca gccggcccgc aaccgcccgc aaatcctctg gcctttccgg aaccgtccgc  10560attcccggcg acaagtcgat ctcccaccgg tccttcatgt tcggcggtct cgcgagcggt  10620gaaacgcgca tcaccggcct tctggaaggc gaggacgtca tcaatacggg caaggccatg  10680caggcgatgg gcgcccgcat ccgtaaggaa ggcgacacct ggatcatcga tggcgtcggc  10740aatggcggcc tcctggcgcc tgaggcgccg ctcgatttcg gcaatgccgc cacgggctgc  10800cgcctgacga tgggcctcgt cggggtctac gatttcgaca gcaccttcat cggcgacgcc  10860tcgctcacaa agcgcccgat gggccgcgtg ttgaacccgc tgcgcgaaat gggcgtgcag  10920gtgaaatcgg aagacggtga ccgtcttccc gttaccttgc gcgggccgaa gacgccgacg  10980ccgatcacct accgcgtgcc gatggcctcc gcacaggtga agtccgccgt gctgctcgcc  11040ggcctcaaca cgcccggcat cacgacggtc atcgagccga tcatgacgcg cgatcatacg  11100gaaaagatgc tgcagggctt tggcgccaac cttaccgtcg agacggatgc ggacggcgtg  11160cgcaccatcc gcctggaagg ccgcggcaag ctcaccggcc aagtcatcga cgtgccgggc  11220gacccgtcct cgacggcctt cccgctggtt gcggccctgc ttgttccggg ctccgacgtc  11280accatcctca acgtgctgat gaaccccacc cgcaccggcc tcatcctgac gctgcaggaa  11340atgggcgccg acatcgaagt catcaacccg cgccttgccg gcggcgaaga cgtggcggac  11400ctgcgcgttc gctcctccac gctgaagggc gtcacggtgc cggaagaccg cgcgccttcg  11460atgatcgacg aatatccgat tctcgctgtc gccgccgcct tcgcggaagg ggcgaccgtg  11520atgaacggtc tggaagaact ccgcgtcaag gaaagcgacc gcctctcggc cgtcgccaat  11580ggcctcaagc tcaatggcgt ggattgcgat gagggcgaga cgtcgctcgt cgtgcgtggc  11640cgccctgacg gcaaggggct cggcaacgcc tcgggcgccg ccgtcgccac ccatctcgat  11700caccgcatcg ccatgagctt cctcgtcatg ggcctcgtgt cggaaaaccc tgtcacggtg  11760gacgatgcca cgatgatcgc cacgagcttc ccggagttca tggacctgat ggccgggctg  11820ggcgcgaaga tcgaactctc cgatacgaag gctgcctgat gagctccagg gttcttgcct  11880ggtgccttgg caatgcttga ttactgctgc tatcctatga tctgtccgtg tgggcttcta  11940tctatcagtt tgtgtgtctg gttttgaaaa acatttgctt ttcgattatg tagggtttgc  12000ttgtagcttt cgctgctgtg acctgtgttg tttatgtgaa ccttctttgt ggcatcttta  12060atatccaagt tcgtggtttg tcgtaaaacg aagcctctac ttcgtaaagt tgtgtctata  12120gcattgaaat cgtttttttg ctcgagaata attgtgacct ttagttggcg tgaaactagt  12180tttggatatc tgattctctg gttcgcaatc ttgagatcgt cgctgcttag gtgagctaag  12240tgatgttcct aagtaaatgc tcctcaccag aatacgtagc tgtgtgaaaa gagaacgcgt  12300gaatacgtag ctgtgtaaag attgtgtccc aagtaaacct cagtgatttt tgtttggatt  12360tttaatttag aaacattcga ctgggagcgg ctagagccac acccaagttc ctaactatga  12420taaagttgct ctgtaacaga aaacaccatc tagagcggcc gcgtttaaac tatcagtgtt  12480tgacaggata tattggcggg taaacctaag agaaaagagc gtttattaga ataatcggat  12540atttaaaagg gcgtgaaaag gtttatccgt tcgtccattt gtatgtgcat gccaaccaca  12600gggttcccct cgggagtgct tggcattccg tgcgataatg acttctgttc aaccacccaa  12660acgtcggaaa gcctgacgac ggagcagcat tccaaaaaga tcccttggct cgtctgggtc  12720ggctagaagg tcgagtgggc tgctgtggct tgatccctca acgcggtcgc ggacgtagcg  12780cagcgccgaa aaatcct                                                 12797</s400><s200><s210>31</s210><s211>12218</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>DNA construct 403</s223></s220></s200><s400> 31aaaagtccca tgtggatcac tccgttgccc cgtcgctcac cgtgttgggg ggaaggtgca     60catggctcag ttctcaatgg aaattatctg cctaaccggc tcagttctgc gtagaaacca    120acatgcaagc tccaccgggt gcaaagcggc agcggcggca ggatatattc aattgtaaat    180ggcttcatgt ccgggaaatc tacatggatc agcaatgagt atgatggtca atatggagaa    240aaagaaagag taattaccaa ttttttttca attcaaaaat gtagatgtcc gcagcgttat    300tataaaatga aagtacattt tgataaaacg acaaattacg atccgtcgta tttataggcg    360aaagcaataa acaaattatt ctaattcgga aatctttatt tcgacgtgtc tacattcacg    420tccaaatggg ggcttagatg agaaacttca cgatcgatgc ggccaccact cgaggtcgag    480gtaccgttgt caatcaattg gcaagtcata aaatgcatta aaaaatattt tcatactcaa    540ctacaaatcc atgagtataa ctataattat aaagcaatga ttagaatctg acaaggattc    600tggaaaatta cataaaggaa agttcataaa tgtctaaaac acaagaggac atacttgtat    660tcagtaacat ttgcagcttt tctaggtctg aaaatatatt tgttgcctag tgaataagca    720taatggtaca actacaagtg ttttactcct catattaact tcggtcatta gaggccacga    780tttgacacat ttttactcaa aacaaaatgt ttgcatatct cttataattt caaattcaac    840acacaacaaa taagagaaaa aacaaataat attaatttga gaatgaacaa aaggaccata    900tcattcatta actcttctcc atccatttcc atttcacagt tcgatagcga aaaccgaata    960aaaaacacag taaattacaa gcacaacaaa tggtacaaga aaaacagttt tcccaatgcc   1020ataatactca aactcagtag gattctggtg tgtgcgcaat gaaactgatg cattgaactt   1080gacgaacgtt gtcgaaaccg atgatacgaa cgaaagctag gcctcagcga gtaccgctgg   1140cgatctaatc catgatatcg tgaacatcat ctacattcaa attcttatga gctttcttaa   1200gggcatctgc agcatttttc atagaatcta atacagcagt atttgtgcta gctccttcga   1260gggcttccct ctgcatttca atagttgtaa gggttccatc tatttgtagt tgggtctttt   1320ccaatcgttt cttctttttg agggcttgga gtgcaactct tttatttttc gacgcatttt   1380tctttgcgct cctgcaggcg gccgcgtgga tgaggagtta atcggtcgtg tgagagtagt   1440gatcgagtgg atgtcgtcga gagtgatgag tgttgatgtt gttagtgata tgtggtagaa   1500ggtatcgtga taaagcgtta acgcgatcgc agtacttgca aagaaaaatg cgtcgaaaaa   1560taaaagagtt gcactccaag ccctcaaaaa gaagaaacga ttggaaaaga cccaactaca   1620aatagatgga acccttacaa ctattgaaat gcagagggaa gccctcgaag gagctagcac   1680aaatactgct gtattagatt ctatgaaaaa tgctgcagat gcccttaaga aagctcataa   1740gaatttgaat gtagatgatg ttcacgatat catggatggt atcgcacagc gactgctgag   1800ggacgtcggt ccatggagat cctctagagg ccgcttggta tctgcattac aatgaaatga   1860gcaaagacta tgtgagtaac actggtcaac actagggaga aggcatcgag caagatacgt   1920atgtaaagag aagcaatata gtgtcagttg gtagatacta gataccatca ggaggtaagg   1980agagcaacaa aaaggaaact ctttattttt aaattttgtt acaacaaaca agcagatcaa   2040tgcatcaaaa tactgtcagt acttatttct tcagacaaca atatttaaaa caagtgcatc   2100tgatcttgac ttatggtcac aataaaggag cagagataaa catcaaaatt tcgtcattta   2160tatttattcc ttcaggcgtt aacaatttaa cagcacacaa acaaaaacag aataggaata   2220tctaattttg gcaaataata agctctgcag acgaacaaat tattatagta tcgcctataa   2280tatgaatccc tatactattg acccatgtag tatgaagcct gtgcctaaat taacagcaaa   2340cttctgaatc caagtgccct ataacaccaa catgtgctta aataaatacc gctaagcacc   2400aaattacaca tttctcgtat tgctgtgtag gttctatctt cgtttcgtac taccatgtcc   2460ctatattttg ctgctacaaa ggacggcaag taatcagcac aggcagaaca cgatttcaga   2520gtgtaattct agatccagct aaaccactct cagcaatcac cacacaagag agcattcaga   2580gaaacgtggc agtaacaaag gcagagggcg gagtgagcgc gtaccgaaga cggtgggccg   2640cttatggtgt gttgtccctg tgtgttctcc aatagtgtgg cttgagtgtg tggaagatgg   2700ttgtatctga tgatccttca aatgggaatg aatgccttct tatatagagg gaattctttt   2760gtggtcgtca ctgcgttcgt catacgcatt agtgagtggg ctgtcaggac agctcttttc   2820cacgttattt tgttccccac ttgtactaga ggaatctgct ttatctttgc aataaaggca   2880aagatgcttt tggtaggtgc gcctaacaat tctgcaccat tccttttttg tctggtcccc   2940acaagccagc tgctcgatgt tgacaagatt actttcaaag atgcccacta actttaagtc   3000ttcggtggat gtctttttct gaaacttact gaccatgatg catgtgctgg aacagtagtt   3060tactttgatt gaagattctt cattgatctc ctgtagcttt tggctaatgg tttggagact   3120ctgtaccctg accttgttga ggctttggac tgagaattct tccttacaaa cctttgagga   3180tgggagttcc ttcttggttt tggcgatacc aatttgaata aagtgatatg gctcgtacct   3240tgttgattga acccaatctg gaatgctgct aaatcctgag ctcaagctaa ttcttttgtg   3300gtcgtcactg cgttcgtcat acgcattagt gagtgggctg tcaggacagc tcttttccac   3360gttattttgt tccccacttg tactagagga atctgcttta tctttgcaat aaaggcaaag   3420atgcttttgg taggtgcgcc taacaattct gcaccattcc ttttttgtct ggtccccaca   3480agccagctgc tcgatgttga caagattact ttcaaagatg cccactaact ttaagtcttc   3540ggtggatgtc tttttctgaa acttactgac catgatgcat gtgctggaac agtagtttac   3600tttgattgaa gattcttcat tgatctcctg tagcttttgg ctaatggttt ggagactctg   3660taccctgacc ttgttgaggc tttggactga gaattagctt ccactcgaag cttgttaacc   3720tgcaggctag cggcgcgcca caaatcacag gccatgaacc ctactcatgc ttcgatttgt   3780ccaacacaca cttaccaaaa ctcaaatcat gtccttgaca gtcactcggg actcataaca   3840tgggtacgta tcgactatgt caactatatg tgttctcatc agattataga ttggcctagt   3900acgtagtgat atttccacta gcactgtggt tatggctgta cctgatagtg atatcagcac   3960cgggtcatgg ctctactacc aggtagtgag agtgaccttt atactgtcag actgtaacta   4020aggatttcca atcactgttc ggatcctagg cttagaatta agtaaaactc tatcactata   4080ggctgcagca cactcggtat atattgatgg gccaacagaa attgtgcgta ctatgcgcga   4140tgtaaaatgg acataaaccc tacccatata caatgcaata acttttgtcc ggtctgggcc   4200accggttagc agaggtcctg atttcggtgg tagtggtagc ttgatctggt cgtcgtatcg   4260tagagggata tataaaatca tgtcactttt gaagggagcg ctcacagaaa taataggtat   4320tcgcgggagc cgcccccgca gaacacaaaa taaggcgagc acgcacacgc atcagtttcg   4380ataaaataat aatagcgcca gctgatcgga acaattccag ctagcactaa tgtatttctg   4440cattgatctg tttatacaac atgctacctc gttgagtgat tttgacatga tttgtcaact   4500tgctccgatc ctatatctcg atcgatctcc acatgacgat ggttgttgtc ctgtatccca   4560tgacaaccag gcaacgctca aagcacacat gcgttgccga ttacccgtgc atgccgccaa   4620gcacgaaagc acctccctcc acaccgtcca tcagctataa aaaccatgcc aagcaccctg   4680tgaaaagccc cgggaaccat cttccacaca ctcaagccac actattggag aacacacagg   4740gacaacacac cataagatcc aagggaggcc tccgccgccg ccggtaacca ccccgcccct   4800ctcctctttc tttctccgtt tttttttccg tctcggtctc gatctttggc cttggtagtt   4860tgggtgggcg agaggcggct tcgtgcgcgc ccagatcggt gcgcgggagg ggcgggatct   4920cgcggctggg gctctcgccg gcgtggatcc ggcccggatc tcgcggggaa tggggctctc   4980ggatgtagat ctgcgatccg ccgttgttgg gggagatgat ggggggttta aaatttccgc   5040cgtgctaaac aagatcagga agaggggaaa agggcactat ggtttatatt tttatatatt   5100tctgctgctt cgtcaggctt agatgtgcta gatctttctt tcttcttttt gtgggtagaa   5160tttgaatccc tcagcattgt tcatcggtag tttttctttt catgatttgt gacaaatgca   5220gcctcgtgcg gagctttttt gtaggtagaa gtgatcaacc atggccaacc ccaacaatcg   5280ctccgagcac gacacgatca aggtcacccc caactccgag ctccagacca accacaacca   5340gtacccgctg gccgacaacc ccaactccac cctggaagag ctgaactaca aggagttcct   5400gcgcatgacc gaggactcct ccacggaggt cctggacaac tccaccgtca aggacgccgt   5460cgggaccggc atctccgtcg ttgggcagat cctgggcgtc gttggcgtcc ccttcgcagg   5520tgctctcacc tccttctacc agtccttcct gaacaccatc tggccctccg acgccgaccc   5580ctggaaggcc ttcatggccc aagtcgaagt cctgatcgac aagaagatcg aggagtacgc   5640caagtccaag gccctggccg agctgcaagg cctgcaaaac aacttcgagg actacgtcaa   5700cgcgctgaac tcctggaaga agacgcctct gtccctgcgc tccaagcgct cccaggaccg   5760catccgcgag ctgttctccc aggccgagtc ccacttccgc aactccatgc cgtccttcgc   5820cgtctccaag ttcgaggtcc tgttcctgcc cacctacgcc caggctgcca acacccacct   5880cctgttgctg aaggacgccc aggtcttcgg cgaggaatgg ggctactcct cggaggacgt   5940cgccgagttc taccgtcgcc agctgaagct gacccaacag tacaccgacc actgcgtcaa   6000ctggtacaac gtcggcctga acggcctgag gggctccacc tacgacgcat gggtcaagtt   6060caaccgcttc cgcagggaga tgaccctgac cgtcctggac ctgatcgtcc tgttcccctt   6120ctacgacatc cgcctgtact ccaagggcgt caagaccgag ctgacccgcg acatcttcac   6180ggaccccatc ttcctgctca cgaccctcca gaagtacggt cccaccttcc tgtccatcga   6240gaactccatc cgcaagcccc acctgttcga ctacctccag ggcatcgagt tccacacgcg   6300cctgaggcca ggctacttcg gcaaggactc cttcaactac tggtccggca actacgtcga   6360gaccaggccc tccatcggct cctcgaagac gatcacctcc cctttctacg gcgacaagtc   6420caccgagccc gtccagaagc tgtccttcga cggccagaag gtctaccgca ccatcgccaa   6480caccgacgtc gcggcttggc cgaacggcaa ggtctacctg ggcgtcacga aggtcgactt   6540ctcccagtac gatgaccaga agaacgagac ctccacccag acctacgact ccaagcgcaa   6600caatggccac gtctccgccc aggactccat cgaccagctg ccgcctgaga ccactgacga   6660gcccctggag aaggcctact cccaccagct gaactacgcg gagtgcttcc tgatgcaaga   6720ccgcaggggc accatcccct tcttcacctg gacccaccgc tccgtcgact tcttcaacac   6780catcgacgcc gagaagatca cccagctgcc cgtggtcaag gcctacgccc tgtcctcggg   6840tgcctccatc attgagggtc caggcttcac cggtggcaac ctgctgttcc tgaaggagtc   6900ctcgaactcc atcgccaagt tcaaggtcac cctgaactcc gctgccttgc tgcaacgcta   6960ccgcgtccgc atccgctacg cctccaccac gaacctgcgc ctgttcgtcc agaactccaa   7020caatgacttc ctggtcatct acatcaacaa gaccatgaac aaggacgatg acctgaccta   7080ccagaccttc gacctcgcca ccacgaactc caacatgggc ttctcgggcg acaagaatga   7140actgatcatt ggtgctgagt ccttcgtctc caacgagaag atctacatcg acaagatcga   7200gttcatcccc gtccagctgt gataggaact ctgattgaat tctgcatgcg tttggacgta   7260tgctcattca ggttggagcc aatttggttg atgtgtgtgc gagttcttgc gagtctgatg   7320agacatctct gtattgtgtt tctttcccca gtgttttctg tacttgtgta atcggctaat   7380cgccaacaga ttcggcgatg aataaatgag aaataaattg ttctgatttt gagtgcaaaa   7440aaaaaggaat tagatctgtg tgtgtttttt ggatcccatt ttcgacaagc ttgcctcgag   7500acaacaacat gcttctcatc aacatggagg gaagagggag ggagaaagtg tcgcctggtc   7560acctccattg tcacactagc cactggccag ctctcccaca ccaccaatgc caggggcgag   7620ctttagcaca gccaccgctt cacctccacc accgcactac cctagcttcg cccaacagcc   7680accgtcaacg cctcctctcc gtcaacataa gagagagaga gaagaggaga gtagccatgt   7740ggggaggagg aatagtacat ggggcctacc gtttggcaag ttattttggg ttgccaagtt   7800aggccaataa ggggagggat ttggccatcc ggttggaaag gttattgggg tagtatcttt   7860ttactagaat tgtcaaaaaa aaatagtttg agagccattt ggagaggatg ttgcctgtta   7920gaggtgctct taggacatca aattccataa aaacatcaga aaaattctct cgatgaagat   7980ttataaccac taaaactgcc ctcaattcga agggagttca aaacaattaa aatcatgttc   8040gaattgagtt tcaatttcac tttaacccct ttgaaatctc aatggtaaaa catcaacccg   8100tcaggtagca tggttctttt tattcctttc aaaaagagtt aattacaaac agaatcaaaa   8160ctaacagtta ggcccaaggc ccatccgagc aaacaataga tcatgggcca ggcctgccac   8220caccctcccc ctcctggctc ccgctcttga atttcaaaat ccaaaaatat cggcacgact   8280ggccgccgac ggagcgggcg gaaaatgacg gaacaacccc tcgaattcta ccccaactac   8340gcccaccaac ccacacgcca ctgacaatcc ggtcccaccc ttgtgggccc acctacaagc   8400gagacgtcag tcgctcgcag caaccagtgg gcccacctcc cagtgagcgg cgggtagatc   8460tggactctta cccacccaca ctaaacaaaa cggcatgaat attttgcact aaaaccctca   8520gaaaaattcc gatattccaa accagtacag ttcctgaccg ttggaggagc caaagtggag   8580cggagtgtaa aattgggaaa cttaatcgag ggggttaaac gcaaaaacgc cgaggcgcct   8640cccgctctat agaaagggga ggagtgggag gtggaaaccc taccacaccg cagagaaagg   8700cgtcttcgta ctcgcctctc tccgcgccct cctccgccgc cgctcgccgc cgttcgtctc   8760cgccgccacc ggctagccat ccaggtaaaa caaacaaaaa cggatctgat gcttccattc   8820ctccgtttct cgtagtagcg cgcttcgatc tgtgggtgga tctgggtgat cctggggtgt   8880ggttcgttct gtttgataga tctgtcggtg gatctggcct tctgtggttg tcgatgtccg   8940gatctgcgtt ttgatcagtg gtagttcgtg gatctggcga aatgttttgg atctggcagt   9000gagacgctaa gaatcgggaa atgatgcaat attagggggg tttcggatgg ggatccactg   9060aattagtctg tctccctgct gataatctgt tcctttttgg tagatctggt tagtgtatgt   9120ttgtttcgga tagatctgat caatgcttgt ttgttttttc aaattttcta cctaggttgt   9180ataggaatgg catgcggatc tggttggatt gccatgatcc gtgctgaaat gcccctttgg   9240ttgatggatc ttgatatttt actgctgttc acctagattt gtactcccgt ttatacttaa   9300tttgttgctt attatgaata gatctgtaac ttaggcacat gtatggacgg agtatgtgga   9360tctgtagtat gtacattgct gcgagctaag aactatttca gagcaagcac agaaaaaaat   9420atttagacag attgggcaac tatttgatgg tctttggtat catgctttgt agtgctcgtt   9480tctgcgtagt aatcttttga tctgatctga agataggtgc tattatattc ttaaaggtca   9540ttagaacgct atctgaaagg ctgtattatg tggattggtt cacctgtgac tccctgttcg   9600tcttgtcttg ataaatcctg tgataaaaaa aattcttaag gcgtaatttg ttgaaatctt   9660gttttgtcct atgcagcctg atccatggcg caagttagca gaatctgcaa tggtgtgcag   9720aacccatctc ttatctccaa tctctcgaaa tccagtcaac gcaaatctcc cttatcggtt   9780tctctgaaga cgcagcagca tccacgagct tatccgattt cgtcgtcgtg gggattgaag   9840aagagtggga tgacgttaat tggctctgag cttcgtcctc ttaaggtcat gtcttctgtt   9900tccacggcgt gcatgcttca cggtgcaagc agccggcccg caaccgcccg caaatcctct   9960ggcctttccg gaaccgtccg cattcccggc gacaagtcga tctcccaccg gtccttcatg  10020ttcggcggtc tcgcgagcgg tgaaacgcgc atcaccggcc ttctggaagg cgaggacgtc  10080atcaatacgg gcaaggccat gcaggcgatg ggcgcccgca tccgtaagga aggcgacacc  10140tggatcatcg atggcgtcgg caatggcggc ctcctggcgc ctgaggcgcc gctcgatttc  10200ggcaatgccg ccacgggctg ccgcctgacg atgggcctcg tcggggtcta cgatttcgac  10260agcaccttca tcggcgacgc ctcgctcaca aagcgcccga tgggccgcgt gttgaacccg  10320ctgcgcgaaa tgggcgtgca ggtgaaatcg gaagacggtg accgtcttcc cgttaccttg  10380cgcgggccga agacgccgac gccgatcacc taccgcgtgc cgatggcctc cgcacaggtg  10440aagtccgccg tgctgctcgc cggcctcaac acgcccggca tcacgacggt catcgagccg  10500atcatgacgc gcgatcatac ggaaaagatg ctgcagggct ttggcgccaa ccttaccgtc  10560gagacggatg cggacggcgt gcgcaccatc cgcctggaag gccgcggcaa gctcaccggc  10620caagtcatcg acgtgccggg cgacccgtcc tcgacggcct tcccgctggt tgcggccctg  10680cttgttccgg gctccgacgt caccatcctc aacgtgctga tgaaccccac ccgcaccggc  10740ctcatcctga cgctgcagga aatgggcgcc gacatcgaag tcatcaaccc gcgccttgcc  10800ggcggcgaag acgtggcgga cctgcgcgtt cgctcctcca cgctgaaggg cgtcacggtg  10860ccggaagacc gcgcgccttc gatgatcgac gaatatccga ttctcgctgt cgccgccgcc  10920ttcgcggaag gggcgaccgt gatgaacggt ctggaagaac tccgcgtcaa ggaaagcgac  10980cgcctctcgg ccgtcgccaa tggcctcaag ctcaatggcg tggattgcga tgagggcgag  11040acgtcgctcg tcgtgcgtgg ccgccctgac ggcaaggggc tcggcaacgc ctcgggcgcc  11100gccgtcgcca cccatctcga tcaccgcatc gccatgagct tcctcgtcat gggcctcgtg  11160tcggaaaacc ctgtcacggt ggacgatgcc acgatgatcg ccacgagctt cccggagttc  11220atggacctga tggccgggct gggcgcgaag atcgaactct ccgatacgaa ggctgcctga  11280tgagctccag ggttcttgcc tggtgccttg gcaatgcttg attactgctg ctatcctatg  11340atctgtccgt gtgggcttct atctatcagt ttgtgtgtct ggttttgaaa aacatttgct  11400tttcgattat gtagggtttg cttgtagctt tcgctgctgt gacctgtgtt gtttatgtga  11460accttctttg tggcatcttt aatatccaag ttcgtggttt gtcgtaaaac gaagcctcta  11520cttcgtaaag ttgtgtctat agcattgaaa tcgttttttt gctcgagaat aattgtgacc  11580tttagttggc gtgaaactag ttttggatat ctgattctct ggttcgcaat cttgagatcg  11640tcgctgctta ggtgagctaa gtgatgttcc taagtaaatg ctcctcacca gaatacgtag  11700ctgtgtgaaa agagaacgcg tgaatacgta gctgtgtaaa gattgtgtcc caagtaaacc  11760tcagtgattt ttgtttggat ttttaattta gaaacattcg actgggagcg gctagagcca  11820cacccaagtt cctaactatg ataaagttgc tctgtaacag aaaacaccat ctagagcggc  11880cgcgtttaaa ctatcagtgt ttgacaggat atattggcgg gtaaacctaa gagaaaagag  11940cgtttattag aataatcgga tatttaaaag ggcgtgaaaa ggtttatccg ttcgtccatt  12000tgtatgtgca tgccaaccac agggttcccc tcgggagtgc ttggcattcc gtgcgataat  12060gacttctgtt caaccaccca aacgtcggaa agcctgacga cggagcagca ttccaaaaag  12120atcccttggc tcgtctgggt cggctagaag gtcgagtggg ctgctgtggc ttgatccctc  12180aacgcggtcg cggacgtagc gcagcgccga aaaatcct                          12218</s400><s200><s210>32</s210><s211>12797</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>DNA construct 404</s223></s220></s200><s400> 32aaaagtccca tgtggatcac tccgttgccc cgtcgctcac cgtgttgggg ggaaggtgca     60catggctcag ttctcaatgg aaattatctg cctaaccggc tcagttctgc gtagaaacca    120acatgcaagc tccaccgggt gcaaagcggc agcggcggca ggatatattc aattgtaaat    180ggcttcatgt ccgggaaatc tacatggatc agcaatgagt atgatggtca atatggagaa    240aaagaaagag taattaccaa ttttttttca attcaaaaat gtagatgtcc gcagcgttat    300tataaaatga aagtacattt tgataaaacg acaaattacg atccgtcgta tttataggcg    360aaagcaataa acaaattatt ctaattcgga aatctttatt tcgacgtgtc tacattcacg    420tccaaatggg ggcttagatg agaaacttca cgatcgatgc ggccaccact cgaggtcgag    480gtaccgttgt caatcaattg gcaagtcata aaatgcatta aaaaatattt tcatactcaa    540ctacaaatcc atgagtataa ctataattat aaagcaatga ttagaatctg acaaggattc    600tggaaaatta cataaaggaa agttcataaa tgtctaaaac acaagaggac atacttgtat    660tcagtaacat ttgcagcttt tctaggtctg aaaatatatt tgttgcctag tgaataagca    720taatggtaca actacaagtg ttttactcct catattaact tcggtcatta gaggccacga    780tttgacacat ttttactcaa aacaaaatgt ttgcatatct cttataattt caaattcaac    840acacaacaaa taagagaaaa aacaaataat attaatttga gaatgaacaa aaggaccata    900tcattcatta actcttctcc atccatttcc atttcacagt tcgatagcga aaaccgaata    960aaaaacacag taaattacaa gcacaacaaa tggtacaaga aaaacagttt tcccaatgcc   1020ataatactca aactcagtag gattctggtg tgtgcgcaat gaaactgatg cattgaactt   1080gacgaacgtt gtcgaaaccg atgatacgaa cgaaagctag gcctcagcga gtaccgctgg   1140cgatctaatc catgatatcg tgaacatcat ctacattcaa attcttatga gctttcttaa   1200gggcatctgc agcatttttc atagaatcta atacagcagt atttgtgcta gctccttcga   1260gggcttccct ctgcatttca atagttgtaa gggttccatc tatttgtagt tgggtctttt   1320ccaatcgttt cttctttttg agggcttgga gtgcaactct tttatttttc gacgcatttt   1380tctttgcgct cctgcaggcg gccgcgtgga tgaggagtta atcggtcgtg tgagagtagt   1440gatcgagtgg atgtcgtcga gagtgatgag tgttgatgtt gttagtgata tgtggtagaa   1500ggtatcgtga taaagcgtta acgcgatcgc agtacttgca aagaaaaatg cgtcgaaaaa   1560taaaagagtt gcactccaag ccctcaaaaa gaagaaacga ttggaaaaga cccaactaca   1620aatagatgga acccttacaa ctattgaaat gcagagggaa gccctcgaag gagctagcac   1680aaatactgct gtattagatt ctatgaaaaa tgctgcagat gcccttaaga aagctcataa   1740gaatttgaat gtagatgatg ttcacgatat catggatggt atcgcacagc gactgctgag   1800ggacgtcggt ccatggagat cctctagagg ccgcttggta tctgcattac aatgaaatga   1860gcaaagacta tgtgagtaac actggtcaac actagggaga aggcatcgag caagatacgt   1920atgtaaagag aagcaatata gtgtcagttg gtagatacta gataccatca ggaggtaagg   1980agagcaacaa aaaggaaact ctttattttt aaattttgtt acaacaaaca agcagatcaa   2040tgcatcaaaa tactgtcagt acttatttct tcagacaaca atatttaaaa caagtgcatc   2100tgatcttgac ttatggtcac aataaaggag cagagataaa catcaaaatt tcgtcattta   2160tatttattcc ttcaggcgtt aacaatttaa cagcacacaa acaaaaacag aataggaata   2220tctaattttg gcaaataata agctctgcag acgaacaaat tattatagta tcgcctataa   2280tatgaatccc tatactattg acccatgtag tatgaagcct gtgcctaaat taacagcaaa   2340cttctgaatc caagtgccct ataacaccaa catgtgctta aataaatacc gctaagcacc   2400aaattacaca tttctcgtat tgctgtgtag gttctatctt cgtttcgtac taccatgtcc   2460ctatattttg ctgctacaaa ggacggcaag taatcagcac aggcagaaca cgatttcaga   2520gtgtaattct agatccagct aaaccactct cagcaatcac cacacaagag agcattcaga   2580gaaacgtggc agtaacaaag gcagagggcg gagtgagcgc gtaccgaaga cggtgggccg   2640cttatggtgt gttgtccctg tgtgttctcc aatagtgtgg cttgagtgtg tggaagatgg   2700ttgtatctga tgatccttca aatgggaatg aatgccttct tatatagagg gaattctttt   2760gtggtcgtca ctgcgttcgt catacgcatt agtgagtggg ctgtcaggac agctcttttc   2820cacgttattt tgttccccac ttgtactaga ggaatctgct ttatctttgc aataaaggca   2880aagatgcttt tggtaggtgc gcctaacaat tctgcaccat tccttttttg tctggtcccc   2940acaagccagc tgctcgatgt tgacaagatt actttcaaag atgcccacta actttaagtc   3000ttcggtggat gtctttttct gaaacttact gaccatgatg catgtgctgg aacagtagtt   3060tactttgatt gaagattctt cattgatctc ctgtagcttt tggctaatgg tttggagact   3120ctgtaccctg accttgttga ggctttggac tgagaattct tccttacaaa cctttgagga   3180tgggagttcc ttcttggttt tggcgatacc aatttgaata aagtgatatg gctcgtacct   3240tgttgattga acccaatctg gaatgctgct aaatcctgag ctcaagctaa ttcttttgtg   3300gtcgtcactg cgttcgtcat acgcattagt gagtgggctg tcaggacagc tcttttccac   3360gttattttgt tccccacttg tactagagga atctgcttta tctttgcaat aaaggcaaag   3420atgcttttgg taggtgcgcc taacaattct gcaccattcc ttttttgtct ggtccccaca   3480agccagctgc tcgatgttga caagattact ttcaaagatg cccactaact ttaagtcttc   3540ggtggatgtc tttttctgaa acttactgac catgatgcat gtgctggaac agtagtttac   3600tttgattgaa gattcttcat tgatctcctg tagcttttgg ctaatggttt ggagactctg   3660taccctgacc ttgttgaggc tttggactga gaattagctt ccactcgaag cttgttaacc   3720tgcaggctag cggcgcgccg ggatccaaaa aacacacaca gatctaattc cttttttttt   3780gcactcaaaa tcagaacaat ttatttctca tttattcatc gccgaatctg ttggcgatta   3840gccgattaca caagtacaga aaacactggg gaaagaaaca caatacagag atgtctcatc   3900agactcgcaa gaactcgcac acacatcaac caaattggct ccaacctgaa tgagcatacg   3960tccaaacgca tgcagaattc aatcagagtt cctatcacag ctggacgggg atgaactcga   4020tcttgtcgat gtagatcttc tcgttggaga cgaaggactc agcaccaatg atcagttcat   4080tcttgtcgcc cgagaagccc atgttggagt tcgtggtggc gaggtcgaag gtctggtagg   4140tcaggtcatc gtccttgttc atggtcttgt tgatgtagat gaccaggaag tcattgttgg   4200agttctggac gaacaggcgc aggttcgtgg tggaggcgta gcggatgcgg acgcggtagc   4260gttgcagcaa ggcagcggag ttcagggtga ccttgaactt ggcgatggag ttcgaggact   4320ccttcaggaa cagcaggttg ccaccggtga agcctggacc ctcaatgatg gaggcacccg   4380aggacagggc gtaggccttg accacgggca gctgggtgat cttctcggcg tcgatggtgt   4440tgaagaagtc gacggagcgg tgggtccagg tgaagaaggg gatggtgccc ctgcggtctt   4500gcatcaggaa gcactccgcg tagttcagct ggtgggagta ggccttctcc aggggctcgt   4560cagtggtctc aggcggcagc tggtcgatgg agtcctgggc ggagacgtgg ccattgttgc   4620gcttggagtc gtaggtctgg gtggaggtct cgttcttctg gtcatcgtac tgggagaagt   4680cgaccttcgt gacgcccagg tagaccttgc cgttcggcca agccgcgacg tcggtgttgg   4740cgatggtgcg gtagaccttc tggccgtcga aggacagctt ctggacgggc tcggtggact   4800tgtcgccgta gaaaggggag gtgatcgtct tcgaggagcc gatggagggc ctggtctcga   4860cgtagttgcc ggaccagtag ttgaaggagt ccttgccgaa gtagcctggc ctcaggcgcg   4920tgtggaactc gatgccctgg aggtagtcga acaggtgggg cttgcggatg gagttctcga   4980tggacaggaa ggtgggaccg tacttctgga gggtcgtgag caggaagatg gggtccgtga   5040agatgtcgcg ggtcagctcg gtcttgacgc ccttggagta caggcggatg tcgtagaagg   5100ggaacaggac gatcaggtcc aggacggtca gggtcatctc cctgcggaag cggttgaact   5160tgacccatgc gtcgtaggtg gagcccctca ggccgttcag gccgacgttg taccagttga   5220cgcagtggtc ggtgtactgt tgggtcagct tcagctggcg acggtagaac tcggcgacgt   5280cctccgagga gtagccccat tcctcgccga agacctgggc gtccttcagc aacaggaggt   5340gggtgttggc agcctgggcg taggtgggca ggaacaggac ctcgaacttg gagacggcga   5400aggacggcat ggagttgcgg aagtgggact cggcctggga gaacagctcg cggatgcggt   5460cctgggagcg cttggagcgc agggacagag gcgtcttctt ccaggagttc agcgcgttga   5520cgtagtcctc gaagttgttt tgcaggcctt gcagctcggc cagggccttg gacttggcgt   5580actcctcgat cttcttgtcg atcaggactt cgacttgggc catgaaggcc ttccaggggt   5640cggcgtcgga gggccagatg gtgttcagga aggactggta gaaggaggtg agagcacctg   5700cgaaggggac gccaacgacg cccaggatct gcccaacgac ggagatgccg gtcccgacgg   5760cgtccttgac ggtggagttg tccaggacct ccgtggagga gtcctcggtc atgcgcagga   5820actccttgta gttcagctct tccagggtgg agttggggtt gtcggccagc gggtactggt   5880tgtggttggt ctggagctcg gagttggggg tgaccttgat cgtgtcgtgc tcggagcgat   5940tgttggggtt ggccatggtt gatcacttct acctacaaaa aagctccgca cgaggctgca   6000tttgtcacaa atcatgaaaa gaaaaactac cgatgaacaa tgctgaggga ttcaaattct   6060acccacaaaa agaagaaaga aagatctagc acatctaagc ctgacgaagc agcagaaata   6120tataaaaata taaaccatag tgcccttttc ccctcttcct gatcttgttt agcacggcgg   6180aaattttaaa ccccccatca tctcccccaa caacggcgga tcgcagatct acatccgaga   6240gccccattcc ccgcgagatc cgggccggat ccacgccggc gagagcccca gccgcgagat   6300cccgcccctc ccgcgcaccg atctgggcgc gcacgaagcc gcctctcgcc cacccaaact   6360accaaggcca aagatcgaga ccgagacgga aaaaaaaacg gagaaagaaa gaggagaggg   6420gcggggtggt taccggcggc ggcggaggcc tcccttggat cttatggtgt gttgtccctg   6480tgtgttctcc aatagtgtgg cttgagtgtg tggaagatgg ttcccggggg ttttgatcat   6540gggattaggg aggtatttat agtcgagccc cgggattaat taatcgaccg ttagagctca   6600tgtgaaccct gccctgccat catgtgagcg tgcatacgag ggcgatctgg attggctggc   6660agaacacctg ccctagcaag gctcgtagat taattaacaa atcgtacgta catctacgct   6720gataatgtgt taaatcatcg gccgaatatt tggttagccg tgaagcactc gatcccgcaa   6780atgaccaaga ttgctgcaca cgacacatcg cgggcttgtt tccttatgat cattggttgt   6840tattttatct cgcgatcttg gcctatcggg cgtcgcttcg cgcggtgcag cgtgactgcg   6900tgagcaagtt ggtgattttc ttttgccgtt taagaatgct tgctccgtga tcacacaaga   6960gaggacatca catgaaccga gaccggagga atatcggggc atggtgggat tggtgggtgt   7020cccagtccaa cgggcaagaa gattctaagc ttacctgggt ttgttttcac gtacgcgaag   7080gacaggggaa gatgccattg cagcgtggct tcctgctggc ccgccaactt taatctacac   7140taggcacgta gctactaggt cggcccgctt agatagctaa ggtaggctag gtaggtccgt   7200ggtaaactgc cagcccatgg gcgcctggga ttcttcttgg gccaacagaa gcagaggttg   7260ggcaatgcga agcctgaaaa tcctcctcct ccttctctct ccctctctct ctctctctct   7320ctctctctct cacgaataaa atcctcttct tcccgaacag gctagattct ttttttttta   7380atgaaccagt gagccaccaa tttcattgaa tagaggaata aaattgtaca tgcgcaagcg   7440caaatagaaa actttaccgt ctcaaggcct ttggcccgaa catgttaaaa ggtaagccac   7500ctatcaaggt gtttcgcgcc cgccaagacc catgttttgg catcctcctt aattttggct   7560atcagactag ccaccggaag ctcttggtgc tgaaaaactc tgcggttcct ttcattccaa   7620atatcctagg cgactaatag cattagagtc tgcaaggctt tctttggcgc ttcgttggaa   7680catgcggtgg cctcccacca cttgagtagc gtcgaggctt gttgccataa cgttggtctt   7740atttgttcac atgttgtcca gtctgcaagt gtcgcctaga ttctttcaca tatctacact   7800ccgccaggag gtgagggccg tttcctgatt ccttcgacaa aggggcagat ggagccattt   7860tcgattaccc acgggttgcc aatctgtcgg aggtccatac tctattttgg ataacaagcc   7920aagcgaagcg aatgttttac atttgcgcgg cgcctagggc ttccagatag gggcattgaa   7980attgaagctt ttatgccaag aagttgtgcg ttgtaggccg atgtcgtcat gtattcgccg   8040tgactagtta gcttccattt tcgacaagct tgcctcgaga caacaacatg cttctcatca   8100acatggaggg aagagggagg gagaaagtgt cgcctggtca cctccattgt cacactagcc   8160actggccagc tctcccacac caccaatgcc aggggcgagc tttagcacag ccaccgcttc   8220acctccacca ccgcactacc ctagcttcgc ccaacagcca ccgtcaacgc ctcctctccg   8280tcaacataag agagagagag aagaggagag tagccatgtg gggaggagga atagtacatg   8340gggcctaccg tttggcaagt tattttgggt tgccaagtta ggccaataag gggagggatt   8400tggccatccg gttggaaagg ttattggggt agtatctttt tactagaatt gtcaaaaaaa   8460aatagtttga gagccatttg gagaggatgt tgcctgttag aggtgctctt aggacatcaa   8520attccataaa aacatcagaa aaattctctc gatgaagatt tataaccact aaaactgccc   8580tcaattcgaa gggagttcaa aacaattaaa atcatgttcg aattgagttt caatttcact   8640ttaacccctt tgaaatctca atggtaaaac atcaacccgt caggtagcat ggttcttttt   8700attcctttca aaaagagtta attacaaaca gaatcaaaac taacagttag gcccaaggcc   8760catccgagca aacaatagat catgggccag gcctgccacc accctccccc tcctggctcc   8820cgctcttgaa tttcaaaatc caaaaatatc ggcacgactg gccgccgacg gagcgggcgg   8880aaaatgacgg aacaacccct cgaattctac cccaactacg cccaccaacc cacacgccac   8940tgacaatccg gtcccaccct tgtgggccca cctacaagcg agacgtcagt cgctcgcagc   9000aaccagtggg cccacctccc agtgagcggc gggtagatct ggactcttac ccacccacac   9060taaacaaaac ggcatgaata ttttgcacta aaaccctcag aaaaattccg atattccaaa   9120ccagtacagt tcctgaccgt tggaggagcc aaagtggagc ggagtgtaaa attgggaaac   9180ttaatcgagg gggttaaacg caaaaacgcc gaggcgcctc ccgctctata gaaaggggag   9240gagtgggagg tggaaaccct accacaccgc agagaaaggc gtcttcgtac tcgcctctct   9300ccgcgccctc ctccgccgcc gctcgccgcc gttcgtctcc gccgccaccg gctagccatc   9360caggtaaaac aaacaaaaac ggatctgatg cttccattcc tccgtttctc gtagtagcgc   9420gcttcgatct gtgggtggat ctgggtgatc ctggggtgtg gttcgttctg tttgatagat   9480ctgtcggtgg atctggcctt ctgtggttgt cgatgtccgg atctgcgttt tgatcagtgg   9540tagttcgtgg atctggcgaa atgttttgga tctggcagtg agacgctaag aatcgggaaa   9600tgatgcaata ttaggggggt ttcggatggg gatccactga attagtctgt ctccctgctg   9660ataatctgtt cctttttggt agatctggtt agtgtatgtt tgtttcggat agatctgatc   9720aatgcttgtt tgttttttca aattttctac ctaggttgta taggaatggc atgcggatct   9780ggttggattg ccatgatccg tgctgaaatg cccctttggt tgatggatct tgatatttta   9840ctgctgttca cctagatttg tactcccgtt tatacttaat ttgttgctta ttatgaatag   9900atctgtaact taggcacatg tatggacgga gtatgtggat ctgtagtatg tacattgctg   9960cgagctaaga actatttcag agcaagcaca gaaaaaaata tttagacaga ttgggcaact  10020atttgatggt ctttggtatc atgctttgta gtgctcgttt ctgcgtagta atcttttgat  10080ctgatctgaa gataggtgct attatattct taaaggtcat tagaacgcta tctgaaaggc  10140tgtattatgt ggattggttc acctgtgact ccctgttcgt cttgtcttga taaatcctgt  10200gataaaaaaa attcttaagg cgtaatttgt tgaaatcttg ttttgtccta tgcagcctga  10260tccatggcgc aagttagcag aatctgcaat ggtgtgcaga acccatctct tatctccaat  10320ctctcgaaat ccagtcaacg caaatctccc ttatcggttt ctctgaagac gcagcagcat  10380ccacgagctt atccgatttc gtcgtcgtgg ggattgaaga agagtgggat gacgttaatt  10440ggctctgagc ttcgtcctct taaggtcatg tcttctgttt ccacggcgtg catgcttcac  10500ggtgcaagca gccggcccgc aaccgcccgc aaatcctctg gcctttccgg aaccgtccgc  10560attcccggcg acaagtcgat ctcccaccgg tccttcatgt tcggcggtct cgcgagcggt  10620gaaacgcgca tcaccggcct tctggaaggc gaggacgtca tcaatacggg caaggccatg  10680caggcgatgg gcgcccgcat ccgtaaggaa ggcgacacct ggatcatcga tggcgtcggc  10740aatggcggcc tcctggcgcc tgaggcgccg ctcgatttcg gcaatgccgc cacgggctgc  10800cgcctgacga tgggcctcgt cggggtctac gatttcgaca gcaccttcat cggcgacgcc  10860tcgctcacaa agcgcccgat gggccgcgtg ttgaacccgc tgcgcgaaat gggcgtgcag  10920gtgaaatcgg aagacggtga ccgtcttccc gttaccttgc gcgggccgaa gacgccgacg  10980ccgatcacct accgcgtgcc gatggcctcc gcacaggtga agtccgccgt gctgctcgcc  11040ggcctcaaca cgcccggcat cacgacggtc atcgagccga tcatgacgcg cgatcatacg  11100gaaaagatgc tgcagggctt tggcgccaac cttaccgtcg agacggatgc ggacggcgtg  11160cgcaccatcc gcctggaagg ccgcggcaag ctcaccggcc aagtcatcga cgtgccgggc  11220gacccgtcct cgacggcctt cccgctggtt gcggccctgc ttgttccggg ctccgacgtc  11280accatcctca acgtgctgat gaaccccacc cgcaccggcc tcatcctgac gctgcaggaa  11340atgggcgccg acatcgaagt catcaacccg cgccttgccg gcggcgaaga cgtggcggac  11400ctgcgcgttc gctcctccac gctgaagggc gtcacggtgc cggaagaccg cgcgccttcg  11460atgatcgacg aatatccgat tctcgctgtc gccgccgcct tcgcggaagg ggcgaccgtg  11520atgaacggtc tggaagaact ccgcgtcaag gaaagcgacc gcctctcggc cgtcgccaat  11580ggcctcaagc tcaatggcgt ggattgcgat gagggcgaga cgtcgctcgt cgtgcgtggc  11640cgccctgacg gcaaggggct cggcaacgcc tcgggcgccg ccgtcgccac ccatctcgat  11700caccgcatcg ccatgagctt cctcgtcatg ggcctcgtgt cggaaaaccc tgtcacggtg  11760gacgatgcca cgatgatcgc cacgagcttc ccggagttca tggacctgat ggccgggctg  11820ggcgcgaaga tcgaactctc cgatacgaag gctgcctgat gagctccagg gttcttgcct  11880ggtgccttgg caatgcttga ttactgctgc tatcctatga tctgtccgtg tgggcttcta  11940tctatcagtt tgtgtgtctg gttttgaaaa acatttgctt ttcgattatg tagggtttgc  12000ttgtagcttt cgctgctgtg acctgtgttg tttatgtgaa ccttctttgt ggcatcttta  12060atatccaagt tcgtggtttg tcgtaaaacg aagcctctac ttcgtaaagt tgtgtctata  12120gcattgaaat cgtttttttg ctcgagaata attgtgacct ttagttggcg tgaaactagt  12180tttggatatc tgattctctg gttcgcaatc ttgagatcgt cgctgcttag gtgagctaag  12240tgatgttcct aagtaaatgc tcctcaccag aatacgtagc tgtgtgaaaa gagaacgcgt  12300gaatacgtag ctgtgtaaag attgtgtccc aagtaaacct cagtgatttt tgtttggatt  12360tttaatttag aaacattcga ctgggagcgg ctagagccac acccaagttc ctaactatga  12420taaagttgct ctgtaacaga aaacaccatc tagagcggcc gcgtttaaac tatcagtgtt  12480tgacaggata tattggcggg taaacctaag agaaaagagc gtttattaga ataatcggat  12540atttaaaagg gcgtgaaaag gtttatccgt tcgtccattt gtatgtgcat gccaaccaca  12600gggttcccct cgggagtgct tggcattccg tgcgataatg acttctgttc aaccacccaa  12660acgtcggaaa gcctgacgac ggagcagcat tccaaaaaga tcccttggct cgtctgggtc  12720ggctagaagg tcgagtgggc tgctgtggct tgatccctca acgcggtcgc ggacgtagcg  12780cagcgccgaa aaatcct                                                 12797</s400><s200><s210>33</s210><s211>11906</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>DNA construct 423</s223></s220></s200><s400> 33aaaagtccca tgtggatcac tccgttgccc cgtcgctcac cgtgttgggg ggaaggtgca     60catggctcag ttctcaatgg aaattatctg cctaaccggc tcagttctgc gtagaaacca    120acatgcaagc tccaccgggt gcaaagcggc agcggcggca ggatatattc aattgtaaat    180ggcttcatgt ccgggaaatc tacatggatc agcaatgagt atgatggtca atatggagaa    240aaagaaagag taattaccaa ttttttttca attcaaaaat gtagatgtcc gcagcgttat    300tataaaatga aagtacattt tgataaaacg acaaattacg atccgtcgta tttataggcg    360aaagcaataa acaaattatt ctaattcgga aatctttatt tcgacgtgtc tacattcacg    420tccaaatggg ggcttagatg agaaacttca cgatcgatgc ggccaccact cgaggtcgag    480gtaccacaca cagatctaat tccttttttt ttgcactcaa aatcagaaca atttatttct    540catttattca tcgccgaatc tgttggcgat tagccgatta cacaagtaca gaaaacactg    600gggaaagaaa cacaatacag agatgtctca tcagactcgc aagaactcgc acacacatca    660accaaattgg ctccaacctg aatgagcata cgtccaaacg catgcagaat tcaatcagag    720ttcctatcac agctggacgg ggatgaactc gatcttgtcg atgtagatct tctcgttgga    780gacgaaggac tcagcaccaa tgatcagttc attcttgtcg cccgagaagc ccatgttgga    840gttcgtggtg gcgaggtcga aggtctggta ggtcaggtca tcgtccttgt tcatggtctt    900gttgatgtag atgaccagga agtcattgtt ggagttctgg acgaacaggc gcaggttcgt    960ggtggaggcg tagcggatgc ggacgcggta gcgttgcagc aaggcagcgg agttcagggt   1020gaccttgaac ttggcgatgg agttcgagga ctccttcagg aacagcaggt tgccaccggt   1080gaagcctgga ccctcaatga tggaggcacc cgaggacagg gcgtaggcct tgaccacggg   1140cagctgggtg atcttctcgg cgtcgatggt gttgaagaag tcgacggagc ggtgggtcca   1200ggtgaagaag gggatggtgc ccctgcggtc ttgcatcagg aagcactccg cgtagttcag   1260ctggtgggag taggccttct ccaggggctc gtcagtggtc tcaggcggca gctggtcgat   1320ggagtcctgg gcggagacgt ggccattgtt gcgcttggag tcgtaggtct gggtggaggt   1380ctcgttcttc tggtcatcgt actgggagaa gtcgaccttc gtgacgccca ggtagacctt   1440gccgttcggc caagccgcga cgtcggtgtt ggcgatggtg cggtagacct tctggccgtc   1500gaaggacagc ttctggacgg gctcggtgga cttgtcgccg tagaaagggg aggtgatcgt   1560cttcgaggag ccgatggagg gcctggtctc gacgtagttg ccggaccagt agttgaagga   1620gtccttgccg aagtagcctg gcctcaggcg cgtgtggaac tcgatgccct ggaggtagtc   1680gaacaggtgg ggcttgcgga tggagttctc gatggacagg aaggtgggac cgtacttctg   1740gagggtcgtg agcaggaaga tggggtccgt gaagatgtcg cgggtcagct cggtcttgac   1800gcccttggag tacaggcgga tgtcgtagaa ggggaacagg acgatcaggt ccaggacggt   1860cagggtcatc tccctgcgga agcggttgaa cttgacccat gcgtcgtagg tggagcccct   1920caggccgttc aggccgacgt tgtaccagtt gacgcagtgg tcggtgtact gttgggtcag   1980cttcagctgg cgacggtaga actcggcgac gtcctccgag gagtagcccc attcctcgcc   2040gaagacctgg gcgtccttca gcaacaggag gtgggtgttg gcagcctggg cgtaggtggg   2100caggaacagg acctcgaact tggagacggc gaaggacggc atggagttgc ggaagtggga   2160ctcggcctgg gagaacagct cgcggatgcg gtcctgggag cgcttggagc gcagggacag   2220aggcgtcttc ttccaggagt tcagcgcgtt gacgtagtcc tcgaagttgt tttgcaggcc   2280ttgcagctcg gccagggcct tggacttggc gtactcctcg atcttcttgt cgatcaggac   2340ttcgacttgg gccatgaagg ccttccaggg gtcggcgtcg gagggccaga tggtgttcag   2400gaaggactgg tagaaggagg tgagagcacc tgcgaagggg acgccaacga cgcccaggat   2460ctgcccaacg acggagatgc cggtcccgac ggcgtccttg acggtggagt tgtccaggac   2520ctccgtggag gagtcctcgg tcatgcgcag gaactccttg tagttcagct cttccagggt   2580ggagttgggg ttgtcggcca gcgggtactg gttgtggttg gtctggagct cggagttggg   2640ggtgaccttg atcgtgtcgt gctcggagcg attgttgggg ttggccatgg ttgatcactt   2700ctacctacaa aaaagctccg cacgaggctg catttgtcac aaatcatgaa aagaaaaact   2760accgatgaac aatgctgagg gattcaaatt ctacccacaa aaagaagaaa gaaagatcta   2820gcacatctaa gcctgacgaa gcagcagaaa tatataaaaa tataaaccat agtgcccttt   2880tcccctcttc ctgatcttgt ttagcacggc ggaaatttta aaccccccat catctccccc   2940aacaacggcg gatcgcagat ctacatccga gagccccatt ccccgcgaga tccgggccgg   3000atccacgccg gcgagagccc cagccgcgag atcccgcccc tcccgcgcac cgatctgggc   3060gcgcacgaag ccgcctctcg cccacccaaa ctaccaaggc caaagatcga gaccgagacg   3120gaaaaaaaaa cggagaaaga aagaggagag gggcggggtg gttaccggcg gcggcggagg   3180cctcccttgg atcttatggt gtgttgtccc tgtgtgttct ccaatagtgt ggcttgagtg   3240tgtggaagat ggttctagag gatctgctag agtcagcttg tcagcgtgtc ctctccaaat   3300gaaatgaact tccttatata gaggaagggt cttgcgaagg atagtgggat tgtgcgtcat   3360cccttacgtc agtggagata tcacatcaat ccacttgctt tgaagacgtg gttggaacgt   3420cttctttttc cacgatgctc ctcgtgggtg ggggtccatc tttgggacca ctgtcggcag   3480aggcatcttc aacgatggcc tttcctttat cgcaatgatg gcatttgtag gagccacctt   3540ccttttccac tatcttcaca ataaagtgac agatagctgg gcaatggaat ccgaggaggt   3600ttccggatat taccctttgt tgaaaagtct caatcggacc atcacatcaa tccacttgct   3660ttgaagacgt ggttggaacg tcttcttttt ccacgatgct cctcgtgggt gggggtccat   3720ctttgggacc actgtcggca gaggcatctt caacgatggc ctttccttta tcgcaatgat   3780ggcatttgta ggagccacct tccttttcca ctatcttcac aataaagtga cagatagctg   3840ggcaatggaa tccgaggagg tttccggata ttaccctttg ttgaaaagtc tcaatcggac   3900ctggtaccgt tgtcaatcaa ttggcaagtc ataaaatgca ttaaaaaata ttttcatact   3960caactacaaa tccatgagta taactataat tataaagcaa tgattagaat ctgacaagga   4020ttctggaaaa ttacataaag gaaagttcat aaatgtctaa aacacaagag gacatacttg   4080tattcagtaa catttgcagc ttttctaggt ctgaaaatat atttgttgcc tagtgaataa   4140gcataatggt acaactacaa gtgttttact cctcatatta acttcggtca ttagaggcca   4200cgatttgaca catttttact caaaacaaaa tgtttgcata tctcttataa tttcaaattc   4260aacacacaac aaataagaga aaaaacaaat aatattaatt tgagaatgaa caaaaggacc   4320atatcattca ttaactcttc tccatccatt tccatttcac agttcgatag cgaaaaccga   4380ataaaaaaca cagtaaatta caagcacaac aaatggtaca agaaaaacag ttttcccaat   4440gccataatac tcaaactcag taggattctg gtgtgtgcgc aatgaaactg atgcattgaa   4500cttgacgaac gttgtcgaaa ccgatgatac gaacgaaagc taggcctcag cgagtaccgc   4560tggcgatcta atccatgata tcgtgaacat catctacatt caaattctta tgagctttct   4620taagggcatc tgcagcattt ttcatagaat ctaatacagc agtatttgtg ctagctcctt   4680cgagggcttc cctctgcatt tcaatagttg taagggttcc atctatttgt agttgggtct   4740tttccaatcg tttcttcttt ttgagggctt ggagtgcaac tcttttattt ttcgacgcat   4800ttttctttgc gctcctgcag gcggccgcgt ggatgaggag ttaatcggtc gtgtgagagt   4860agtgatcgag tggatgtcgt cgagagtgat gagtgttgat gttgttagtg atatgtggta   4920gaaggtatcg tgataaagcg ttaacgcgat cgcagtactt gcaaagaaaa atgcgtcgaa   4980aaataaaaga gttgcactcc aagccctcaa aaagaagaaa cgattggaaa agacccaact   5040acaaatagat ggaaccctta caactattga aatgcagagg gaagccctcg aaggagctag   5100cacaaatact gctgtattag attctatgaa aaatgctgca gatgccctta agaaagctca   5160taagaatttg aatgtagatg atgttcacga tatcatggat ggtatcgcac agcgactgct   5220gagggacgtc ggtccatgga gatcctctag aggccgcttg gtatctgcat tacaatgaaa   5280tgagcaaaga ctatgtgagt aacactggtc aacactaggg agaaggcatc gagcaagata   5340cgtatgtaaa gagaagcaat atagtgtcag ttggtagata ctagatacca tcaggaggta   5400aggagagcaa caaaaaggaa actctttatt tttaaatttt gttacaacaa acaagcagat   5460caatgcatca aaatactgtc agtacttatt tcttcagaca acaatattta aaacaagtgc   5520atctgatctt gacttatggt cacaataaag gagcagagat aaacatcaaa atttcgtcat   5580ttatatttat tccttcaggc gttaacaatt taacagcaca caaacaaaaa cagaatagga   5640atatctaatt ttggcaaata ataagctctg cagacgaaca aattattata gtatcgccta   5700taatatgaat ccctatacta ttgacccatg tagtatgaag cctgtgccta aattaacagc   5760aaacttctga atccaagtgc cctataacac caacatgtgc ttaaataaat accgctaagc   5820accaaattac acatttctcg tattgctgtg taggttctat cttcgtttcg tactaccatg   5880tccctatatt ttgctgctac aaaggacggc aagtaatcag cacaggcaga acacgatttc   5940agagtgtaat tctagatcca gctaaaccac tctcagcaat caccacacaa gagagcattc   6000agagaaacgt ggcagtaaca aaggcagagg gcggagtgag cgcgtaccga agacggtggg   6060ccgcttatgg tgtgttgtcc ctgtgtgttc tccaatagtg tggcttgagt gtgtggaaga   6120tggttgtatc tgatgatcct tcaaatggga atgaatgcct tcttatatag agggaattct   6180tttgtggtcg tcactgcgtt cgtcatacgc attagtgagt gggctgtcag gacagctctt   6240ttccacgtta ttttgttccc cacttgtact agaggaatct gctttatctt tgcaataaag   6300gcaaagatgc ttttggtagg tgcgcctaac aattctgcac cattcctttt ttgtctggtc   6360cccacaagcc agctgctcga tgttgacaag attactttca aagatgccca ctaactttaa   6420gtcttcggtg gatgtctttt tctgaaactt actgaccatg atgcatgtgc tggaacagta   6480gtttactttg attgaagatt cttcattgat ctcctgtagc ttttggctaa tggtttggag   6540actctgtacc ctgaccttgt tgaggctttg gactgagaat tcttccttac aaacctttga   6600ggatgggagt tccttcttgg ttttggcgat accaatttga ataaagtgat atggctcgta   6660ccttgttgat tgaacccaat ctggaatgct gctaaatcct gagctcaagc taattctttt   6720gtggtcgtca ctgcgttcgt catacgcatt agtgagtggg ctgtcaggac agctcttttc   6780cacgttattt tgttccccac ttgtactaga ggaatctgct ttatctttgc aataaaggca   6840aagatgcttt tggtaggtgc gcctaacaat tctgcaccat tccttttttg tctggtcccc   6900acaagccagc tgctcgatgt tgacaagatt actttcaaag atgcccacta actttaagtc   6960ttcggtggat gtctttttct gaaacttact gaccatgatg catgtgctgg aacagtagtt   7020tactttgatt gaagattctt cattgatctc ctgtagcttt tggctaatgg tttggagact   7080ctgtaccctg accttgttga ggctttggac tgagaattag cttccactcg aagcttgtta   7140acctgcaggc tagcggcgcg ccagtctagt cgacaagctt gcctcgagac aacaacatgc   7200ttctcatcaa catggaggga agagggaggg agaaagtgtc gcctggtcac ctccattgtc   7260acactagcca ctggccagct ctcccacacc accaatgcca ggggcgagct ttagcacagc   7320caccgcttca cctccaccac cgcactaccc tagcttcgcc caacagccac cgtcaacgcc   7380tcctctccgt caacataaga gagagagaga agaggagagt agccatgtgg ggaggaggaa   7440tagtacatgg ggcctaccgt ttggcaagtt attttgggtt gccaagttag gccaataagg   7500ggagggattt ggccatccgg ttggaaaggt tattggggta gtatcttttt actagaattg   7560tcaaaaaaaa atagtttgag agccatttgg agaggatgtt gcctgttaga ggtgctctta   7620ggacatcaaa ttccataaaa acatcagaaa aattctctcg atgaagattt ataaccacta   7680aaactgccct caattcgaag ggagttcaaa acaattaaaa tcatgttcga attgagtttc   7740aatttcactt taaccccttt gaaatctcaa tggtaaaaca tcaacccgtc aggtagcatg   7800gttcttttta ttcctttcaa aaagagttaa ttacaaacag aatcaaaact aacagttagg   7860cccaaggccc atccgagcaa acaatagatc atgggccagg cctgccacca ccctccccct   7920cctggctccc gctcttgaat ttcaaaatcc aaaaatatcg gcacgactgg ccgccgacgg   7980agcgggcgga aaatgacgga acaacccctc gaattctacc ccaactacgc ccaccaaccc   8040acacgccact gacaatccgg tcccaccctt gtgggcccac ctacaagcga gacgtcagtc   8100gctcgcagca accagtgggc ccacctccca gtgagcggcg ggtagatctg gactcttacc   8160cacccacact aaacaaaacg gcatgaatat tttgcactaa aaccctcaga aaaattccga   8220tattccaaac cagtacagtt cctgaccgtt ggaggagcca aagtggagcg gagtgtaaaa   8280ttgggaaact taatcgaggg ggttaaacgc aaaaacgccg aggcgcctcc cgctctatag   8340aaaggggagg agtgggaggt ggaaacccta ccacaccgca gagaaaggcg tcttcgtact   8400cgcctctctc cgcgccctcc tccgccgccg ctcgccgccg ttcgtctccg ccgccaccgg   8460ctagccatcc aggtaaaaca aacaaaaacg gatctgatgc ttccattcct ccgtttctcg   8520tagtagcgcg cttcgatctg tgggtggatc tgggtgatcc tggggtgtgg ttcgttctgt   8580ttgatagatc tgtcggtgga tctggccttc tgtggttgtc gatgtccgga tctgcgtttt   8640gatcagtggt agttcgtgga tctggcgaaa tgttttggat ctggcagtga gacgctaaga   8700atcgggaaat gatgcaatat taggggggtt tcggatgggg atccactgaa ttagtctgtc   8760tccctgctga taatctgttc ctttttggta gatctggtta gtgtatgttt gtttcggata   8820gatctgatca atgcttgttt gttttttcaa attttctacc taggttgtat aggaatggca   8880tgcggatctg gttggattgc catgatccgt gctgaaatgc ccctttggtt gatggatctt   8940gatattttac tgctgttcac ctagatttgt actcccgttt atacttaatt tgttgcttat   9000tatgaataga tctgtaactt aggcacatgt atggacggag tatgtggatc tgtagtatgt   9060acattgctgc gagctaagaa ctatttcaga gcaagcacag aaaaaaatat ttagacagat   9120tgggcaacta tttgatggtc tttggtatca tgctttgtag tgctcgtttc tgcgtagtaa   9180tcttttgatc tgatctgaag ataggtgcta ttatattctt aaaggtcatt agaacgctat   9240ctgaaaggct gtattatgtg gattggttca cctgtgactc cctgttcgtc ttgtcttgat   9300aaatcctgtg ataaaaaaaa ttcttaaggc gtaatttgtt gaaatcttgt tttgtcctat   9360gcagcctgat ccatggcgca agttagcaga atctgcaatg gtgtgcagaa cccatctctt   9420atctccaatc tctcgaaatc cagtcaacgc aaatctccct tatcggtttc tctgaagacg   9480cagcagcatc cacgagctta tccgatttcg tcgtcgtggg gattgaagaa gagtgggatg   9540acgttaattg gctctgagct tcgtcctctt aaggtcatgt cttctgtttc cacggcgtgc   9600atgcttcacg gtgcaagcag ccggcccgca accgcccgca aatcctctgg cctttccgga   9660accgtccgca ttcccggcga caagtcgatc tcccaccggt ccttcatgtt cggcggtctc   9720gcgagcggtg aaacgcgcat caccggcctt ctggaaggcg aggacgtcat caatacgggc   9780aaggccatgc aggcgatggg cgcccgcatc cgtaaggaag gcgacacctg gatcatcgat   9840ggcgtcggca atggcggcct cctggcgcct gaggcgccgc tcgatttcgg caatgccgcc   9900acgggctgcc gcctgacgat gggcctcgtc ggggtctacg atttcgacag caccttcatc   9960ggcgacgcct cgctcacaaa gcgcccgatg ggccgcgtgt tgaacccgct gcgcgaaatg  10020ggcgtgcagg tgaaatcgga agacggtgac cgtcttcccg ttaccttgcg cgggccgaag  10080acgccgacgc cgatcaccta ccgcgtgccg atggcctccg cacaggtgaa gtccgccgtg  10140ctgctcgccg gcctcaacac gcccggcatc acgacggtca tcgagccgat catgacgcgc  10200gatcatacgg aaaagatgct gcagggcttt ggcgccaacc ttaccgtcga gacggatgcg  10260gacggcgtgc gcaccatccg cctggaaggc cgcggcaagc tcaccggcca agtcatcgac  10320gtgccgggcg acccgtcctc gacggccttc ccgctggttg cggccctgct tgttccgggc  10380tccgacgtca ccatcctcaa cgtgctgatg aaccccaccc gcaccggcct catcctgacg  10440ctgcaggaaa tgggcgccga catcgaagtc atcaacccgc gccttgccgg cggcgaagac  10500gtggcggacc tgcgcgttcg ctcctccacg ctgaagggcg tcacggtgcc ggaagaccgc  10560gcgccttcga tgatcgacga atatccgatt ctcgctgtcg ccgccgcctt cgcggaaggg  10620gcgaccgtga tgaacggtct ggaagaactc cgcgtcaagg aaagcgaccg cctctcggcc  10680gtcgccaatg gcctcaagct caatggcgtg gattgcgatg agggcgagac gtcgctcgtc  10740gtgcgtggcc gccctgacgg caaggggctc ggcaacgcct cgggcgccgc cgtcgccacc  10800catctcgatc accgcatcgc catgagcttc ctcgtcatgg gcctcgtgtc ggaaaaccct  10860gtcacggtgg acgatgccac gatgatcgcc acgagcttcc cggagttcat ggacctgatg  10920gccgggctgg gcgcgaagat cgaactctcc gatacgaagg ctgcctgatg agctccaggg  10980ttcttgcctg gtgccttggc aatgcttgat tactgctgct atcctatgat ctgtccgtgt  11040gggcttctat ctatcagttt gtgtgtctgg ttttgaaaaa catttgcttt tcgattatgt  11100agggtttgct tgtagctttc gctgctgtga cctgtgttgt ttatgtgaac cttctttgtg  11160gcatctttaa tatccaagtt cgtggtttgt cgtaaaacga agcctctact tcgtaaagtt  11220gtgtctatag cattgaaatc gtttttttgc tcgagaataa ttgtgacctt tagttggcgt  11280gaaactagtt ttggatatct gattctctgg ttcgcaatct tgagatcgtc gctgcttagg  11340tgagctaagt gatgttccta agtaaatgct cctcaccaga atacgtagct gtgtgaaaag  11400agaacgcgtg aatacgtagc tgtgtaaaga ttgtgtccca agtaaacctc agtgattttt  11460gtttggattt ttaatttaga aacattcgac tgggagcggc tagagccaca cccaagttcc  11520taactatgat aaagttgctc tgtaacagaa aacaccatct agagcggccg cgtttaaact  11580atcagtgttt gacaggatat attggcgggt aaacctaaga gaaaagagcg tttattagaa  11640taatcggata tttaaaaggg cgtgaaaagg tttatccgtt cgtccatttg tatgtgcatg  11700ccaaccacag ggttcccctc gggagtgctt ggcattccgt gcgataatga cttctgttca  11760accacccaaa cgtcggaaag cctgacgacg gagcagcatt ccaaaaagat cccttggctc  11820gtctgggtcg gctagaaggt cgagtgggct gctgtggctt gatccctcaa cgcggtcgcg  11880gacgtagcgc agcgccgaaa aatcct                                       11906</s400><s200><s210>34</s210><s211>7158</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>DNA construct 405</s223></s220></s200><s400> 34aaaagtccca tgtggatcac tccgttgccc cgtcgctcac cgtgttgggg ggaaggtgca     60catggctcag ttctcaatgg aaattatctg cctaaccggc tcagttctgc gtagaaacca    120acatgcaagc tccaccgggt gcaaagcggc agcggcggca ggatatattc aattgtaaat    180ggcttcatgt ccgggaaatc tacatggatc agcaatgagt atgatggtca atatggagaa    240aaagaaagag taattaccaa ttttttttca attcaaaaat gtagatgtcc gcagcgttat    300tataaaatga aagtacattt tgataaaacg acaaattacg atccgtcgta tttataggcg    360aaagcaataa acaaattatt ctaattcgga aatctttatt tcgacgtgtc tacattcacg    420tccaaatggg ggcttagatg agaaacttca cgatcgatgc ggcccacgtg gattaccctg    480ttatccctag aattcgatat cagttcgctc gtggccgtca cggccagcgc ctgcgttggc    540ctagtaggcc aagcaggacg tattcgtttg ttgtgcggcc gctacctcag caaatcaacc    600tcactctatt taaatgaggt ggtaggattt gctgaggagg ctgctccgtt gtcctgcagg    660agacgagaaa cacctttaat taacctcagc gcgtgttctg ctggcgatcg caacaggcac    720agcgctgagg gtaccgttgt caatcaattg gcaagtcata aaatgcatta aaaaatattt    780tcatactcaa ctacaaatcc atgagtataa ctataattat aaagcaatga ttagaatctg    840acaaggattc tggaaaatta cataaaggaa agttcataaa tgtctaaaac acaagaggac    900atacttgtat tcagtaacat ttgcagcttt tctaggtctg aaaatatatt tgttgcctag    960tgaataagca taatggtaca actacaagtg ttttactcct catattaact tcggtcatta   1020gaggccacga tttgacacat ttttactcaa aacaaaatgt ttgcatatct cttataattt   1080caaattcaac acacaacaaa taagagaaaa aacaaataat attaatttga gaatgaacaa   1140aaggaccata tcattcatta actcttctcc atccatttcc atttcacagt tcgatagcga   1200aaaccgaata aaaaacacag taaattacaa gcacaacaaa tggtacaaga aaaacagttt   1260tcccaatgcc ataatactca aactcagtag gattctggtg tgtgcgcaat gaaactgatg   1320cattgaactt gacgaacgtt gtcgaaaccg atgatacgaa cgaaagctag gcctcagcga   1380gtaccgctgg cgatctaatc catgatatcg tgaacatcat ctacattcaa attcttatga   1440gctttcttaa gggcatctgc agcatttttc atagaatcta atacagcagt atttgtgcta   1500gctccttcga gggcttccct ctgcatttca atagttgtaa gggttccatc tatttgtagt   1560tgggtctttt ccaatcgttt cttctttttg agggcttgga gtgcaactct tttatttttc   1620gacgcatttt tctttgcgct cctgcaggcg gccgcgtgga tgaggagtta atcggtcgtg   1680tgagagtagt gatcgagtgg atgtcgtcga gagtgatgag tgttgatgtt gttagtgata   1740tgtggtagaa ggtatcgtga taaagcgtta acgcgatcgc agtacttgca aagaaaaatg   1800cgtcgaaaaa taaaagagtt gcactccaag ccctcaaaaa gaagaaacga ttggaaaaga   1860cccaactaca aatagatgga acccttacaa ctattgaaat gcagagggaa gccctcgaag   1920gagctagcac aaatactgct gtattagatt ctatgaaaaa tgctgcagat gcccttaaga   1980aagctcataa gaatttgaat gtagatgatg ttcacgatat catggatggt atcgcacagc   2040gactgctgag ggacgtcgag ctcccgcttg gtatctgcat tacaatgaaa tgagcaaaga   2100ctatgtgagt aacactggtc aacactaggg agaaggcatc gagcaagata cgtatgtaaa   2160gagaagcaat atagtgtcag ttggtagata ctagatacca tcaggaggta aggagagcaa   2220caaaaaggaa actctttatt tttaaatttt gttacaacaa acaagcagat caatgcatca   2280aaatactgtc agtacttatt tcttcagaca acaatattta aaacaagtgc atctgatctt   2340gacttatggt cacaataaag gagcagagat aaacatcaaa atttcgtcat ttatatttat   2400tccttcaggc gttaacaatt taacagcaca caaacaaaaa cagaatagga atatctaatt   2460ttggcaaata ataagctctg cagacgaaca aattattata gtatcgccta taatatgaat   2520ccctatacta ttgacccatg tagtatgaag cctgtgccta aattaacagc aaacttctga   2580atccaagtgc cctataacac caacatgtgc ttaaataaat accgctaagc accaaattac   2640acatttctcg tattgctgtg taggttctat cttcgtttcg tactaccatg tccctatatt   2700ttgctgctac aaaggacggc aagtaatcag cacaggcaga acacgatttc agagtgtaat   2760tctagatcca gctaaaccac tctcagcaat caccacacaa gagagcattc agagaaacgt   2820ggcagtaaca aaggcagagg gcggagtgag cgcgtaccga agacggtcct tcaaatggga   2880atgaatgcct tcttatatag agggaattct tttgtggtcg tcactgcgtt cgtcatacgc   2940attagtgagt gggctgtcag gacagctctt ttccacgtta ttttgttccc cacttgtact   3000agaggaatct gctttatctt tgcaataaag gcaaagatgc ttttggtagg tgcgcctaac   3060aattctgcac cattcctttt ttgtctggtc cccacaagcc agctgctcga tgttgacaag   3120attactttca aagatgccca ctaactttaa gtcttcggtg gatgtctttt tctgaaactt   3180actgaccatg atgcatgtgc tggaacagta gtttactttg attgaagatt cttcattgat   3240ctcctgtagc ttttggctaa tggtttggag actctgtacc ctgaccttgt tgaggctttg   3300gactgagaat tcttccttac aaacctttga ggatgggagt tccttcttgg ttttggcgat   3360accaatttga ataaagtgat atggctcgta ccttgttgat tgaacccaat ctggaatgcg   3420gcgcgccaag cttctgcagg tccgattgag acttttcaac aaagggtaat atccggaaac   3480ctcctcggat tccattgccc agctatctgt cactttattg tgaagatagt ggaaaaggaa   3540ggtggctcct acaaatgcca tcattgcgat aaaggaaagg ccatcgttga agatgcctct   3600gccgacagtg gtcccaaaga tggaccccca cccacgagga gcatcgtgga aaaagaagac   3660gttccaacca cgtcttcaaa gcaagtggat tgatgtgatg gtccgattga gacttttcaa   3720caaagggtaa tatccggaaa cctcctcgga ttccattgcc cagctatctg tcactttatt   3780gtgaagatag tggaaaagga aggtggctcc tacaaatgcc atcattgcga taaaggaaag   3840gccatcgttg aagatgcctc tgccgacagt ggtcccaaag atggaccccc acccacgagg   3900agcatcgtgg aaaaagaaga cgttccaacc acgtcttcaa agcaagtgga ttgatgtgat   3960atctccactg acgtaaggga tgacgcacaa tcccactatc cttcgcaaga cccttcctct   4020atataaggaa gttcatttca tttggagagg acacgctgac aagctgactc tagcagatcc   4080tctagaacca tcttccacac actcaagcca cactattgga gaacacacag ggacaacaca   4140ccataagatc caagggaggc ctccgccgcc gccggtaacc accccgcccc tctcctcttt   4200ctttctccgt ttttttttcc gtctcggtct cgatctttgg ccttggtagt ttgggtgggc   4260gagaggcggc ttcgtgcgcg cccagatcgg tgcgcgggag gggcgggatc tcgcggctgg   4320ggctctcgcc ggcgtggatc cggcccggat ctcgcgggga atggggctct cggatgtaga   4380tctgcgatcc gccgttgttg ggggagatga tggggggttt aaaatttccg ccgtgctaaa   4440caagatcagg aagaggggaa aagggcacta tggtttatat ttttatatat ttctgctgct   4500tcgtcaggct tagatgtgct agatctttct ttcttctttt tgtgggtaga atttgaatcc   4560ctcagcattg ttcatcggta gtttttcttt tcatgatttg tgacaaatgc agcctcgtgc   4620ggagcttttt tgtaggtaga agtgatcaac catggccaac cccaacaatc gctccgagca   4680cgacacgatc aaggtcaccc ccaactccga gctccagacc aaccacaacc agtacccgct   4740ggccgacaac cccaactcca ccctggaaga gctgaactac aaggagttcc tgcgcatgac   4800cgaggactcc tccacggagg tcctggacaa ctccaccgtc aaggacgccg tcgggaccgg   4860catctccgtc gttgggcaga tcctgggcgt cgttggcgtc cccttcgcag gtgctctcac   4920ctccttctac cagtccttcc tgaacaccat ctggccctcc gacgccgacc cctggaaggc   4980cttcatggcc caagtcgaag tcctgatcga caagaagatc gaggagtacg ccaagtccaa   5040ggccctggcc gagctgcaag gcctgcaaaa caacttcgag gactacgtca acgcgctgaa   5100ctcctggaag aagacgcctc tgtccctgcg ctccaagcgc tcccaggacc gcatccgcga   5160gctgttctcc caggccgagt cccacttccg caactccatg ccgtccttcg ccgtctccaa   5220gttcgaggtc ctgttcctgc ccacctacgc ccaggctgcc aacacccacc tcctgttgct   5280gaaggacgcc caggtcttcg gcgaggaatg gggctactcc tcggaggacg tcgccgagtt   5340ctaccgtcgc cagctgaagc tgacccaaca gtacaccgac cactgcgtca actggtacaa   5400cgtcggcctg aacggcctga ggggctccac ctacgacgca tgggtcaagt tcaaccgctt   5460ccgcagggag atgaccctga ccgtcctgga cctgatcgtc ctgttcccct tctacgacat   5520ccgcctgtac tccaagggcg tcaagaccga gctgacccgc gacatcttca cggaccccat   5580cttcctgctc acgaccctcc agaagtacgg tcccaccttc ctgtccatcg agaactccat   5640ccgcaagccc cacctgttcg actacctcca gggcatcgag ttccacacgc gcctgaggcc   5700aggctacttc ggcaaggact ccttcaacta ctggtccggc aactacgtcg agaccaggcc   5760ctccatcggc tcctcgaaga cgatcacctc ccctttctac ggcgacaagt ccaccgagcc   5820cgtccagaag ctgtccttcg acggccagaa ggtctaccgc accatcgcca acaccgacgt   5880cgcggcttgg ccgaacggca aggtctacct gggcgtcacg aaggtcgact tctcccagta   5940cgatgaccag aagaacgaga cctccaccca gacctacgac tccaagcgca acaatggcca   6000cgtctccgcc caggactcca tcgaccagct gccgcctgag accactgacg agcccctgga   6060gaaggcctac tcccaccagc tgaactacgc ggagtgcttc ctgatgcaag accgcagggg   6120caccatcccc ttcttcacct ggacccaccg ctccgtcgac ttcttcaaca ccatcgacgc   6180cgagaagatc acccagctgc ccgtggtcaa ggcctacgcc ctgtcctcgg gtgcctccat   6240cattgagggt ccaggcttca ccggtggcaa cctgctgttc ctgaaggagt cctcgaactc   6300catcgccaag ttcaaggtca ccctgaactc cgctgccttg ctgcaacgct accgcgtccg   6360catccgctac gcctccacca cgaacctgcg cctgttcgtc cagaactcca acaatgactt   6420cctggtcatc tacatcaaca agaccatgaa caaggacgat gacctgacct accagacctt   6480cgacctcgcc accacgaact ccaacatggg cttctcgggc gacaagaatg aactgatcat   6540tggtgctgag tccttcgtct ccaacgagaa gatctacatc gacaagatcg agttcatccc   6600cgtccagctg tgataggaac tctgattgaa ttctgcatgc gtttggacgt atgctcattc   6660aggttggagc caatttggtt gatgtgtgtg cgagttcttg cgagtctgat gagacatctc   6720tgtattgtgt ttctttcccc agtgttttct gtacttgtgt aatcggctaa tcgccaacag   6780attcggcgat gaataaatga gaaataaatt gttctgattt tgagtgcaaa aaaaaaggaa   6840ttagatctgt gtgtgttttt tggatccgtc gacagacctc aattgcgagc tttctaattt   6900caaactattc gggcctaact tttggtgtga tgatgctgac tggcaggata tataccgttg   6960taatttgagc tcgtgtgaat aagtcgctgt gtatgtttgt ttgattgttt ctgttggagt   7020gcagcccatt tcaccggaca agtcggctag attgatttag ccctgatgaa ctgccgaggg   7080gaagccatct tgagcgcgga atgggaatgg atttcgttgt acaacgagac gacagaacac   7140ccacgggacc gagcttcg                                                 7158</s400><s200><s210>35</s210><s211>8208</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>DNA construct 406</s223></s220></s200><s400> 35aaaagtccca tgtggatcac tccgttgccc cgtcgctcac cgtgttgggg ggaaggtgca     60catggctcag ttctcaatgg aaattatctg cctaaccggc tcagttctgc gtagaaacca    120acatgcaagc tccaccgggt gcaaagcggc agcggcggca ggatatattc aattgtaaat    180ggcttcatgt ccgggaaatc tacatggatc agcaatgagt atgatggtca atatggagaa    240aaagaaagag taattaccaa ttttttttca attcaaaaat gtagatgtcc gcagcgttat    300tataaaatga aagtacattt tgataaaacg acaaattacg atccgtcgta tttataggcg    360aaagcaataa acaaattatt ctaattcgga aatctttatt tcgacgtgtc tacattcacg    420tccaaatggg ggcttagatg agaaacttca cgatcgatgc ggcccacgtg gattaccctg    480ttatccctag aattcgatat cagttcgctc gtggccgtca cggccagcgc ctgcgttggc    540ctagtaggcc aagcaggacg tattcgtttg ttgtgcggcc gcgttaacaa gcttctgcag    600gtccgattga gacttttcaa caaagggtaa tatccggaaa cctcctcgga ttccattgcc    660cagctatctg tcactttatt gtgaagatag tggaaaagga aggtggctcc tacaaatgcc    720atcattgcga taaaggaaag gccatcgttg aagatgcctc tgccgacagt ggtcccaaag    780atggaccccc acccacgagg agcatcgtgg aaaaagaaga cgttccaacc acgtcttcaa    840agcaagtgga ttgatgtgat ggtccgattg agacttttca acaaagggta atatccggaa    900acctcctcgg attccattgc ccagctatct gtcactttat tgtgaagata gtggaaaagg    960aaggtggctc ctacaaatgc catcattgcg ataaaggaaa ggccatcgtt gaagatgcct   1020ctgccgacag tggtcccaaa gatggacccc cacccacgag gagcatcgtg gaaaaagaag   1080acgttccaac cacgtcttca aagcaagtgg attgatgtga tatctccact gacgtaaggg   1140atgacgcaca atcccactat ccttcgcaag acccttcctc tatataagga agttcatttc   1200atttggagag gacacgctga caagctgact ctagcagatc ctctagaacc atcttccaca   1260cactcaagcc acactattgg agaacacaca gggacaacac accataagat ccaagggagg   1320cctccgccgc cgccggtaac caccccgccc ctctcctctt tctttctccg tttttttttc   1380cgtctcggtc tcgatctttg gccttggtag tttgggtggg cgagaggcgg cttcgtgcgc   1440gcccagatcg gtgcgcggga ggggcgggat ctcgcggctg gggctctcgc cggcgtggat   1500ccggcccgga tctcgcgggg aatggggctc tcggatgtag atctgcgatc cgccgttgtt   1560gggggagatg atggggggtt taaaatttcc gccgtgctaa acaagatcag gaagagggga   1620aaagggcact atggtttata tttttatata tttctgctgc ttcgtcaggc ttagatgtgc   1680tagatctttc tttcttcttt ttgtgggtag aatttgaatc cctcagcatt gttcatcggt   1740agtttttctt ttcatgattt gtgacaaatg cagcctcgtg cggagctttt ttgtaggtag   1800aagtgatcaa ccatggccaa ccccaacaat cgctccgagc acgacacgat caaggtcacc   1860cccaactccg agctccagac caaccacaac cagtacccgc tggccgacaa ccccaactcc   1920accctggaag agctgaacta caaggagttc ctgcgcatga ccgaggactc ctccacggag   1980gtcctggaca actccaccgt caaggacgcc gtcgggaccg gcatctccgt cgttgggcag   2040atcctgggcg tcgttggcgt ccccttcgca ggtgctctca cctccttcta ccagtccttc   2100ctgaacacca tctggccctc cgacgccgac ccctggaagg ccttcatggc ccaagtcgaa   2160gtcctgatcg acaagaagat cgaggagtac gccaagtcca aggccctggc cgagctgcaa   2220ggcctgcaaa acaacttcga ggactacgtc aacgcgctga actcctggaa gaagacgcct   2280ctgtccctgc gctccaagcg ctcccaggac cgcatccgcg agctgttctc ccaggccgag   2340tcccacttcc gcaactccat gccgtccttc gccgtctcca agttcgaggt cctgttcctg   2400cccacctacg cccaggctgc caacacccac ctcctgttgc tgaaggacgc ccaggtcttc   2460ggcgaggaat ggggctactc ctcggaggac gtcgccgagt tctaccgtcg ccagctgaag   2520ctgacccaac agtacaccga ccactgcgtc aactggtaca acgtcggcct gaacggcctg   2580aggggctcca cctacgacgc atgggtcaag ttcaaccgct tccgcaggga gatgaccctg   2640accgtcctgg acctgatcgt cctgttcccc ttctacgaca tccgcctgta ctccaagggc   2700gtcaagaccg agctgacccg cgacatcttc acggacccca tcttcctgct cacgaccctc   2760cagaagtacg gtcccacctt cctgtccatc gagaactcca tccgcaagcc ccacctgttc   2820gactacctcc agggcatcga gttccacacg cgcctgaggc caggctactt cggcaaggac   2880tccttcaact actggtccgg caactacgtc gagaccaggc cctccatcgg ctcctcgaag   2940acgatcacct cccctttcta cggcgacaag tccaccgagc ccgtccagaa gctgtccttc   3000gacggccaga aggtctaccg caccatcgcc aacaccgacg tcgcggcttg gccgaacggc   3060aaggtctacc tgggcgtcac gaaggtcgac ttctcccagt acgatgacca gaagaacgag   3120acctccaccc agacctacga ctccaagcgc aacaatggcc acgtctccgc ccaggactcc   3180atcgaccagc tgccgcctga gaccactgac gagcccctgg agaaggccta ctcccaccag   3240ctgaactacg cggagtgctt cctgatgcaa gaccgcaggg gcaccatccc cttcttcacc   3300tggacccacc gctccgtcga cttcttcaac accatcgacg ccgagaagat cacccagctg   3360cccgtggtca aggcctacgc cctgtcctcg ggtgcctcca tcattgaggg tccaggcttc   3420accggtggca acctgctgtt cctgaaggag tcctcgaact ccatcgccaa gttcaaggtc   3480accctgaact ccgctgcctt gctgcaacgc taccgcgtcc gcatccgcta cgcctccacc   3540acgaacctgc gcctgttcgt ccagaactcc aacaatgact tcctggtcat ctacatcaac   3600aagaccatga acaaggacga tgacctgacc taccagacct tcgacctcgc caccacgaac   3660tccaacatgg gcttctcggg cgacaagaat gaactgatca ttggtgctga gtccttcgtc   3720tccaacgaga agatctacat cgacaagatc gagttcatcc ccgtccagct gtgataggaa   3780ctctgattga attctgcatg cgtttggacg tatgctcatt caggttggag ccaatttggt   3840tgatgtgtgt gcgagttctt gcgagtctga tgagacatct ctgtattgtg tttctttccc   3900cagtgttttc tgtacttgtg taatcggcta atcgccaaca gattcggcga tgaataaatg   3960agaaataaat tgttctgatt ttgagtgcaa aaaaaaagga attagatctg tgtgtgtttt   4020ttggatcccc ggggcggccg ctacctcagc aaatcaacct cactctattt aaatgaggtg   4080gtaggatttg ctgaggaggc tgctccgttg tcctgcagga gacgagaaac acctttaatt   4140aacaaatcac aggccatgaa ccctactcat gcttcgattt gtccaacaca cacttaccaa   4200aactcaaatc atgtccttga cagtcactcg ggactcataa catgggtacg tatcgactat   4260gtcaactata tgtgttctca tcagattata gattggccta gtacgtagtg atatttccac   4320tagcactgtg gttatggctg tacctgatag tgatatcagc accgggtcat ggctctacta   4380ccaggtagtg agagtgacct ttatactgtc agactgtaac taaggatttc caatcactgt   4440tcggatccta ggcttagaat taagtaaaac tctatcacta taggctgcag cacactcggt   4500atatattgat gggccaacag aaattgtgcg tactatgcgc gatgtaaaat ggacataaac   4560cctacccata tacaatgcaa taacttttgt ccggtctggg ccaccggtta gcagaggtcc   4620tgatttcggt ggtagtggta gcttgatctg gtcgtcgtat cgtagaggga tatataaaat   4680catgtcactt ttgaagggag cgctcacaga aataataggt attcgcggga gccgcccccg   4740cagaacacaa aataaggcga gcacgcacac gcatcagttt cgataaaata ataatagcgc   4800cagctgatcg gaacaattcc agctagcact aatgtatttc tgcattgatc tgtttataca   4860acatgctacc tcgttgagtg attttgacat gatttgtcaa cttgctccga tcctatatct   4920cgatcgatct ccacatgacg atggttgttg tcctgtatcc catgacaacc aggcaacgct   4980caaagcacac atgcgttgcc gattacccgt gcatgccgcc aagcacgaaa gcacctccct   5040ccacaccgtc catcagcggt ccgattgaga cttttcaaca aagggtaata tccggaaacc   5100tcctcggatt ccattgccca gctatctgtc actttattgt gaagatagtg gaaaaggaag   5160gtggctccta caaatgccat cattgcgata aaggaaaggc catcgttgaa gatgcctctg   5220ccgacagtgg tcccaaagat ggacccccac ccacgaggag catcgtggaa aaagaagacg   5280ttccaaccac gtcttcaaag caagtggatt gatgtgatgg tccgattgag acttttcaac   5340aaagggtaat atccggaaac ctcctcggat tccattgccc agctatctgt cactttattg   5400tgaagatagt ggaaaaggaa ggtggctcct acaaatgcca tcattgcgat aaaggaaagg   5460ccatcgttga agatgcctct gccgacagtg gtcccaaaga tggaccccca cccacgagga   5520gcatcgtgga aaaagaagac gttccaacca cgtcttcaaa gcaagtggat tgatgtgata   5580tctccactga cgtaagggat gacgcacaat cccactatcc ttcgcaagac ccttcctcta   5640tataaggaag ttcatttcat ttggagagga cacgctgaac cgtcttcggt acgcgctcac   5700tccgccctct gcctttgtta ctgccacgtt tctctgaatg ctctcttgtg tggtgattgc   5760tgagagtggt ttagctggat ctagaattac actctgaaat cgtgttctgc ctgtgctgat   5820tacttgccgt cctttgtagc agcaaaatat agggacatgg tagtacgaaa cgaagataga   5880acctacacag caatacgaga aatgtgtaat ttggtgctta gcggtattta tttaagcaca   5940tgttggtgtt atagggcact tggattcaga agtttgctgt taatttaggc acaggcttca   6000tactacatgg gtcaatagta tagggattca tattataggc gatactataa taatttgttc   6060gtctgcagag cttattattt gccaaaatta gatattccta ttctgttttt gtttgtgtgc   6120tgttaaattg ttaacgcctg aaggaataaa tataaatgac gaaattttga tgtttatctc   6180tgctccttta ttgtgaccat aagtcaagat cagatgcact tgttttaaat attgttgtct   6240gaagaaataa gtactgacag tattttgatg cattgatctg cttgtttgtt gtaacaaaat   6300ttaaaaataa agagtttcct ttttgttgct ctccttacct cctgatggta tctagtatct   6360accaactgac actatattgc ttctctttac atacgtatct tgctcgatgc cttctcccta   6420gtgttgacca gtgttactca catagtcttt gctcatttca ttgtaatgca gataccaagc   6480gggagctcga cgtccctcag cagtcgctgt gcgataccat ccatgatatc gtgaacatca   6540tctacattca aattcttatg agctttctta agggcatctg cagcattttt catagaatct   6600aatacagcag tatttgtgct agctccttcg agggcttccc tctgcatttc aatagttgta   6660agggttccat ctatttgtag ttgggtcttt tccaatcgtt tcttcttttt gagggcttgg   6720agtgcaactc ttttattttt cgacgcattt ttctttgcaa gtactgcgat cgcgttaacg   6780ctttatcacg ataccttcta ccacatatca ctaacaacat caacactcat cactctcgac   6840gacatccact cgatcactac tctcacacga ccgattaact cctcatccac gcggccgcct   6900gcaggagcgc aaagaaaaat gcgtcgaaaa ataaaagagt tgcactccaa gccctcaaaa   6960agaagaaacg attggaaaag acccaactac aaatagatgg aacccttaca actattgaaa   7020tgcagaggga agccctcgaa ggagctagca caaatactgc tgtattagat tctatgaaaa   7080atgctgcaga tgcccttaag aaagctcata agaatttgaa tgtagatgat gttcacgata   7140tcatggatta gatcgccagc ggtactcgct gaggcctagc tttcgttcgt atcatcggtt   7200tcgacaacgt tcgtcaagtt caatgcatca gtttcattgc gcacacacca gaatcctact   7260gagtttgagt attatggcat tgggaaaact gtttttcttg taccatttgt tgtgcttgta   7320atttactgtg ttttttattc ggttttcgct atcgaactgt gaaatggaaa tggatggaga   7380agagttaatg aatgatatgg tccttttgtt cattctcaaa ttaatattat ttgttttttc   7440tcttatttgt tgtgtgttga atttgaaatt ataagagata tgcaaacatt ttgttttgag   7500taaaaatgtg tcaaatcgtg gcctctaatg accgaagtta atatgaggag taaaacactt   7560gtagttgtac cattatgctt attcactagg caacaaatat attttcagac ctagaaaagc   7620tgcaaatgtt actgaataca agtatgtcct cttgtgtttt agacatttat gaactttcct   7680ttatgtaatt ttccagaatc cttgtcagat tctaatcatt gctttataat tatagttata   7740ctcatggatt tgtagttgag tatgaaaata ttttttaatg cattttatga cttgccaatt   7800gattgacaac ggtaccgtcg gtccgagttt gcgtcttggc gcgccaagaa gaacgattcg   7860ctaccttagg accgttatag ttagaattcg atatctagtt agggataaca gggtaatgtc   7920gacagacctc aattgcgagc tttctaattt caaactattc gggcctaact tttggtgtga   7980tgatgctgac tggcaggata tataccgttg taatttgagc tcgtgtgaat aagtcgctgt   8040gtatgtttgt ttgattgttt ctgttggagt gcagcccatt tcaccggaca agtcggctag   8100attgatttag ccctgatgaa ctgccgaggg gaagccatct tgagcgcgga atgggaatgg   8160atttcgttgt acaacgagac gacagaacac ccacgggacc gagcttcg                8208</s400><s200><s210>36</s210><s211>2632</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>DNA construct 890</s223></s220></s200><s400> 36aaaagtccca tgtggatcac tccgttgccc cgtcgctcac cgtgttgggg ggaaggtgca     60catggctcag ttctcaatgg aaattatctg cctaaccggc tcagttctgc gtagaaacca    120acatgcaagc tccaccgggt gcaaagcggc agcggcggca ggatatattc aattgtaaat    180ggcttcatgt ccgggaaatc tacatggatc agcaatgagt atgatggtca atatggagaa    240aaagaaagag taattaccaa ttttttttca attcaaaaat gtagatgtcc gcagcgttat    300tataaaatga aagtacattt tgataaaacg acaaattacg atccgtcgta tttataggcg    360aaagcaataa acaaattatt ctaattcgga aatctttatt tcgacgtgtc tacattcacg    420tccaaatggg ggcttagatg agaaacttca cgatcgatgc ggccgcttaa ttaaggcgcg    480ccgctagcct gcaggctgca ggtccgattg agacttttca acaaagggta atatccggaa    540acctcctcgg attccattgc ccagctatct gtcactttat tgtgaagata gtggaaaagg    600aaggtggctc ctacaaatgc catcattgcg ataaaggaaa ggccatcgtt gaagatgcct    660ctgccgacag tggtcccaaa gatggacccc cacccacgag gagcatcgtg gaaaaagaag    720acgttccaac cacgtcttca aagcaagtgg attgatgtga tggtccgatt gagacttttc    780aacaaagggt aatatccgga aacctcctcg gattccattg cccagctatc tgtcacttta    840ttgtgaagat agtggaaaag gaaggtggct cctacaaatg ccatcattgc gataaaggaa    900aggccatcgt tgaagatgcc tctgccgaca gtggtcccaa agatggaccc ccacccacga    960ggagcatcgt ggaaaaagaa gacgttccaa ccacgtcttc aaagcaagtg gattgatgtg   1020atatctccac tgacgtaagg gatgacgcac aatcccacta tccttcgcaa gacccttcct   1080ctatataagg aagttcattt catttggaga ggacacgctg agggcccacc gtcttcggta   1140cgcgctcact ccgccctctg cctttgttac tgccacgttt ctctgaatgc tctcttgtgt   1200ggtgattgct gagagtggtt tagctggatc tagaattaca ctctgaaatc gtgttctgcc   1260tgtgctgatt acttgccgtc ctttgtagca gcaaaatata gggacatggt agtacgaaac   1320gaagatagaa cctacacagc aatacgagaa atgtgtaatt tggtgcttag cggtatttat   1380ttaagcacat gttggtgtta tagggcactt ggattcagaa gtttgctgtt aatttaggca   1440caggcttcat actacatggg tcaatagtat agggattcat attataggcg atactataat   1500aatttgttcg tctgcagagc ttattatttg ccaaaattag atattcctat tctgtttttg   1560tttgtgtgct gttaaattgt taacgcctga aggaataaat ataaatgacg aaattttgat   1620gtttatctct gctcctttat tgtgaccata agtcaagatc agatgcactt gttttaaata   1680ttgttgtctg aagaaataag tactgacagt attttgatgc attgatctgc ttgtttgttg   1740taacaaaatt taaaaataaa gagtttcctt tttgttgctc tccttacctc ctgatggtat   1800ctagtatcta ccaactgaca ctatattgct tctctttaca tacgtatctt gctcgatgcc   1860ttctccctag tgttgaccag tgttactcac atagtctttg ctcatttcat tgtaatgcag   1920ataccaagcg ggagctcgac gtccctcagc agtcgctgtg cgataccatc catgatatcg   1980tgaacatcat ctacattcaa attcttatga gctttcttaa gggcatctgc agcatttttc   2040atagaatcta atacagcagt atttgtgcta gctccttcga gggcttccct ctgcatttca   2100atagttgtaa gggttccatc tatttgtagt tgggtctttt ccaatcgttt cttctttttg   2160agggcttgga gtgcaactct tttatttttc gacgcatttt tctttgcaag tactgcgatc   2220gcgttaacgc tttatcacga taccttctac cacatatcac taacaacatc aacactcatc   2280actctcgacg acatccactc gatcactact ctcacacgac cgattaactc ctcatccacg   2340cggccgcctg caggagcgca aagaaaaatg cgtcgaaaaa taaaagagtt gcactccaag   2400ccctcaaaaa gaagaaacga ttggaaaaga cccaactaca aatagatgga acccttacaa   2460ctattgaaat gcagagggaa gccctcgaag gagctagcac aaatactgct gtattagatt   2520ctatgaaaaa tgctgcagat gcccttaaga aagctcataa gaatttgaat gtagatgatg   2580ttcacgatat catggattag atcgccagcg gtactcgctg aggcctagct tt           2632</s400><s200><s210>37</s210><s211>193</s211><s212>DNA</s212><s213>Zea mays</s213><s220><s221>misc_feature</s221><s223>represents a segment of the integration site in      the LH244 corn genome at which TDNA from DNA construct #417 was      inserted to create Event MON 87411</s223></s220></s200><s400> 37aaggaaaata aaaaggcaaa acactaatga atagttaagt ggttaacttt gtgaaattaa     60tctcatgtaa tatatgatcc cacccctgaa ataactttag taattcatta agatagctat    120agttaagtta tgtaatacat tgagatgggt agtacttaga gaatcacaaa cctctagatg    180tattaatcta ccc                                                       193</s400><s200><s210>38</s210><s211>28</s211><s212>DNA</s212><s213>artificial sequence</s213><s220><s223>is a nucleotide sequence representing a      synthetic oligonucleotide, and is referred to as SQ20221</s223></s220></s200><s400> 38gttgctatgt actaacagaa ctgcatgt                                        28</s400><s200><s210>39</s210><s211>24</s211><s212>DNA</s212><s213>artificial sequence</s213><s220><s223>is a nucleotide sequence representing a      synthetic oligonucleotide, and is referred to as PB10065</s223></s220></s200><s400> 39gccctatgac ttaccgagag ttca                                            24</s400><s200><s210>40</s210><s211>29</s211><s212>DNA</s212><s213>artificial sequence</s213><s220><s223>is a nucleotide sequence representing a      synthetic oligonucleotide, and is referred to as SQ20222</s223></s220></s200><s400> 40ttgttgtgtg gctccattct gacttgtga                                       29</s400><s200><s210>41</s210><s211>60</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>is a nucleotide sequence of event MON 87411</s223></s220></s200><s400> 41gatgcggcca ccactcgagg tcgaggtacc gttgtcaatc aattggcaag tcataaaatg     60</s400><s200><s210>42</s210><s211>89</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>a unique junction sequence within the      transgenic insert of event MON 87411</s223></s220></s200><s400> 42ttgtcgaaac cgatgatacg aacgaaagct aggcctcagc gagtaccgct ggcgatctaa     60tccatgatat cgtgaacatc atctacatt                                       89</s400><s200><s210>43</s210><s211>96</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>a unique junction sequence within the      transgenic insert of event MON 87411</s223></s220></s200><s400> 43aatgtagatg atgttcacga tatcatggat ggtatcgcac agcgactgct gagggacgtc     60gagctcccgc ttggtatctg cattacaatg aaatga                               96</s400><s200><s210>44</s210><s211>347</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>a unique junction sequence within the      transgenic insert of event MON 87411</s223></s220></s200><s400> 44taccctttgt tgaaaagtct caatcggacc atcacatcaa tccacttgct ttgaagacgt     60ggttggaacg tcttcttttt ccacgatgct cctcgtgggt gggggtccat ctttgggacc    120actgtcggca gaggcatctt caacgatggc ctttccttta tcgcaatgat ggcatttgta    180ggagccacct tccttttcca ctatcttcac aataaagtga cagatagctg ggcaatggaa    240tccgaggagg tttccggata ttaccctttg ttgaaaagtc tcaatcggac ctgcagcctg    300caggctagcg gcgcgccaca aatcacaggc catgaaccct actcatg                  347</s400><s200><s210>45</s210><s211>76</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>a unique junction sequence within the      transgenic insert of event MON 87411</s223></s220></s200><s400> 45gctataaaaa ccatgccaag caccctgtga aaagccccgg gaaccatctt ccacacactc     60aagccacact attgga                                                     76</s400><s200><s210>46</s210><s211>86</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>a junction sequence within the transgenic      insert of event MON 87411</s223></s220></s200><s400> 46actattggag aacacacagg gacaacacac cataagatcc aagggaggcc tccgccgccg     60ccggtaacca ccccgcccct ctcctc                                          86</s400><s200><s210>47</s210><s211>79</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>a junction sequence within the transgenic      insert of event MON 87411</s223></s220></s200><s400> 47tgcagcctcg tgcggagctt ttttgtaggt agaagtgatc aaccatggcc aaccccaaca     60atcgctccga gcacgacac                                                  79</s400><s200><s210>48</s210><s211>89</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>a junction sequence within the transgenic      insert of event MON 87411</s223></s220></s200><s400> 48tcgacaagat cgagttcatc cccgtccagc tgtgatagga actctgattg aattctgcat     60gcgtttggac gtatgctcat tcaggttgg                                       89</s400><s200><s210>49</s210><s211>108</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>a unique junction sequence within the      transgenic insert of event MON 87411</s223></s220></s200><s400> 49tctgattttg agtgcaaaaa aaaaggaatt agatctgtgt gtgttttttg gatcccattt     60tcgacaagct tgcctcgaga caacaacatg cttctcatca acatggag                 108</s400><s200><s210>50</s210><s211>104</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>a unique junction sequence within the      transgenic insert of event MON 87411</s223></s220></s200><s400> 50aattcttaag gcgtaatttg ttgaaatctt gttttgtcct atgcagcctg atccatggcg     60caagttagca gaatctgcaa tggtgtgcag aacccatctc ttat                     104</s400><s200><s210>51</s210><s211>107</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>a unique junction sequence within the      transgenic insert of event MON 87411</s223></s220></s200><s400> 51tggccgggct gggcgcgaag atcgaactct ccgatacgaa ggctgcctga tgagctccag     60ggttcttgcc tggtgccttg gcaatgcttg attactgctg ctatcct                  107</s400><s200><s210>52</s210><s211>103</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>is a nucleotide sequence of event MON 87411</s223></s220></s200><s400> 52tatgataaag ttgctctgta acagaaaaca ccatctagag cggccgcgtt taaactatca     60gtgtttagag aatcacaaac ctctagatgt attaatctac cct                      103</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002784A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221220" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002784</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17615773</doc-number><date>20200605</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>86</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>491</main-group><subgroup>052</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>491</main-group><subgroup>048</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>498</main-group><subgroup>18</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>86</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>491</main-group><subgroup>052</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>491</main-group><subgroup>048</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>498</main-group><subgroup>18</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOTIC CELLS</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>62857587</doc-number><date>20190605</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Orchard Therapeutics (Europe) Limited</orgname><address><city>London</city><country>GB</country></address></addressbook><residence><country>GB</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>WOLFE</last-name><first-name>Jia</first-name><address><city>Winchester</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>SAGOO</last-name><first-name>Pervinder</first-name><address><city>St Albans</city><country>GB</country></address></addressbook></inventor></inventors></us-parties><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/US2020/036415</doc-number><date>20200605</date></document-id><us-371c12-date><date>20211201</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Described herein are compositions and methods for modifying eukaryotic cells, for example, to express a transgene of interest and/or to produce an expanded population of cells ex vivo. Using the compositions and methods of the disclosure, a population of eukaryotic cells, such as a population of pluripotent cells (e.g., CD34+ hematopoietic stem or progenitor cells) may be transduced to express a gene of interest by contacting the cells with a viral vector, such as a lentiviral vector, and a poloxamer. Additionally, the compositions and methods described herein can be used to promote the proliferation or survival of a population of pluripotent cells (e.g., CD34+ hematopoietic stem or progenitor cells) ex vivo, for example, by contacting the cells with a poloxamer. Examples of poloxamers that may be used in conjunction with the compositions and methods of the disclosure are those having a molar mass in excess of 10,000 g/mol, as well as those having a molar mass of polyoxypropylene subunits greater than 2,000 g/mol and/or an ethylene oxide content of greater than 40% by mass.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="104.39mm" wi="158.75mm" file="US20230002784A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="170.94mm" wi="131.91mm" orientation="landscape" file="US20230002784A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="257.47mm" wi="80.35mm" orientation="landscape" file="US20230002784A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="150.96mm" wi="107.10mm" orientation="landscape" file="US20230002784A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="240.71mm" wi="94.40mm" orientation="landscape" file="US20230002784A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">SEQUENCE LISTING</heading><p id="p-0002" num="0001">The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created Jun. 5, 2020, is named 51139-018WO2_Sequence_Listing_6.5.20_ST25 and is 2,314 bytes in size.</p><heading id="h-0002" level="1">FIELD OF THE INVENTION</heading><p id="p-0003" num="0002">The disclosure relates to compositions and methods for the modification of eukaryotic cells, such as for genetically modifying eukaryotic cells to express a transgene of interest, as well as for promoting cell proliferation and survival.</p><heading id="h-0003" level="1">BACKGROUND</heading><p id="p-0004" num="0003">Genetic diseases associated with protein deficiencies and loss-of-function mutations represent a challenging class of conditions that have historically been difficult to treat. Cell-based therapies represent a promising path forward, allowing a gene of interest to be functionally expressed in a patient in a stable manner. Preparing cells for this form of therapy often requires that the cells be genetically modified so as to express the desired gene. There exists a need for improved methods for enhancing the genetic modification of eukaryotic cells.</p><heading id="h-0004" level="1">SUMMARY OF THE INVENTION</heading><p id="p-0005" num="0004">The present disclosure relates to compositions and methods for modifying eukaryotic cells, such as pluripotent cells, including hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). The compositions and methods described herein can be used to genetically modify such cells, for example, so as to promote the expression of a transgene of interest in the cells. For example, using the compositions and methods of the disclosure, a population of pluripotent cells, such as a population of HSCs and/or HPCs, may be contacted with a viral vector encoding a transgene of interest so as to transduce the cells to express a desired gene. The viral vector may be a retrovirus, such as a lentivirus. To stimulate viral transduction of the target cells, the cells may be contacted with the viral vector, as well as a poloxamer, such as a poloxamer having a molar mass in excess of 10,000 g/mol, a molar mass of polyoxypropylene subunits greater than 2,000 g/mol, and/or an ethylene oxide content of greater than 40% by mass. The compositions and methods of the disclosure provide a series of important medicinal benefits, as the cells prepared in accordance with the procedures described herein can be provided to a subject (e.g., a mammalian subject, such as a human patient) having a pathology associated with an endogenous deficiency in the gene of interest. By administration of the modified cells to the subject, the subject may experience restored expression of the deficient gene. Without being limited by mechanism, this therapeutic approach represents a means by which a subject having a genetic disorder may be treated, as well as a methodology for alleviating the symptoms of the disorder.</p><p id="p-0006" num="0005">The compositions and methods of the disclosure are based, in part, on a series of surprising discoveries. It has presently been found, for example, that poloxamers, including those that have been shown previously to be ineffective at improving viral transduction efficiency, are indeed capable of promoting viral transduction when contacted with a target cell at a concentration of less than 10 &#x3bc;g/ml (e.g., a concentration of from about 10 ng/ml to about 9 &#x3bc;g/ml, such as a concentration of 10 ng/ml, 50 ng/ml, 100 ng/ml, 500 ng/ml, or 1 &#x3bc;g/ml, among other concentrations described herein). This unexpected observation engenders a variety of benefits. For example, by virtue of the transduction-enhancing activity of poloxamers at lower concentrations, a reduced quantity of poloxamer may be used to effectuate transduction of a target cell, while still maintaining robust genetic modification.</p><p id="p-0007" num="0006">In a first aspect, the disclosure features a method of transducing a eukaryotic cell to express a transgene by contacting the cell with (i) a viral vector encoding the transgene, and (ii) a poloxamer.</p><p id="p-0008" num="0007">In a further aspect, the disclosure features a method of expressing a transgene in a eukaryotic cell by contacting the cell with (i) a viral vector encoding the transgene, and (ii) a poloxamer.</p><p id="p-0009" num="0008">In an additional aspect, the disclosure features a method of promoting migration of a viral vector encoding a transgene to the nucleus of a eukaryotic cell by contacting the cell with (i) the viral vector, and (ii) a poloxamer.</p><p id="p-0010" num="0009">In some embodiments of any of the three preceding aspects of the disclosure, the method further includes contacting the cell with a substance that reduces activity and/or expression of protein kinase C (PKC).</p><p id="p-0011" num="0010">In an additional aspect, the disclosure features a method of transducing a eukaryotic cell to express a transgene by contacting the cell with (i) a viral vector encoding the transgene, (ii) a substance that reduces activity and/or expression of PKC, and (iii) a poloxamer.</p><p id="p-0012" num="0011">In a further aspect, the disclosure features a method of expressing a transgene in a eukaryotic cell by contacting the cell with (i) a viral vector encoding the transgene, (ii) a substance that reduces activity and/or expression of PKC, and (iii) a poloxamer.</p><p id="p-0013" num="0012">In an additional aspect, the disclosure features a method of promoting migration of a viral vector encoding a transgene to the nucleus of a eukaryotic cell by contacting the cell with (i) the viral vector, (ii) a substance that reduces activity and/or expression of PKC, and (iii) a poloxamer.</p><p id="p-0014" num="0013">In yet another aspect, the disclosure features a method of promoting actin depolymerization in a eukaryotic cell by contacting the cell with (i) a substance that reduces activity and/or expression of PKC, and (ii) a poloxamer.</p><p id="p-0015" num="0014">In an additional aspect, the disclosure features a method of inhibiting cofilin phosphorylation in a eukaryotic cell by contacting the cell with (i) a substance that reduces activity and/or expression of PKC, and (ii) a poloxamer.</p><p id="p-0016" num="0015">In a further aspect, the disclosure features a method of increasing the concentration of dephosphorylated cofilin in a eukaryotic cell, the method including contacting the cell with (i) a substance that reduces activity and/or expression of PKC, and (ii) a poloxamer.</p><p id="p-0017" num="0016">Methods of measuring actin depolymerization, cofilin phosphorylation, and the amount of dephosphorylated cofilin in a eukaryotic cell are known in the art and include those described, e.g., in Yoder et al., Cell 134:782-792 (2008), the disclosure of which is incorporated herein by reference in its entirety.</p><p id="p-0018" num="0017">In an additional aspect, the disclosure features a method of promoting survival and/or proliferation of a eukaryotic cell, the method including contacting the cell with (i) a substance that reduces activity and/or expression of PKC, and (ii) a poloxamer.</p><p id="p-0019" num="0018">In some embodiments of any of the three preceding aspects of the disclosure, the method further includes contacting the cell with a viral vector encoding a transgene, thereby transducing the cell to express the transgene.</p><p id="p-0020" num="0019">In some embodiments of any of the above aspects of the disclosure, the cell is a mammalian cell, such as a human cell. In some embodiments, the cell is a pluripotent cell. The cell may be a CD34+ cell.</p><p id="p-0021" num="0020">In some embodiments, the cell is an embryonic stem cell or an induced pluripotent stem cell. In some embodiments, the cell is an HSC or HPC.</p><p id="p-0022" num="0021">In some embodiments, the substance that reduces activity and/or expression of PKC activates Akt signal transduction. The substance that reduces activity and/or expression of PKC may be a PKC inhibitor or an agent that reduces translation of a ribonucleic acid (RNA) transcript encoding PKC (i.e., a messenger RNA transcript encoding PKC).</p><p id="p-0023" num="0022">In some embodiments, the substance that reduces activity and/or expression of PKC is an agent that reduces translation of an RNA transcript encoding PKC. In some embodiments, the agent contains a nucleic acid. The nucleic acid may contain an interfering RNA, such as a short interfering RNA (siRNA), short hairpin RNA (shRNA), or micro RNA (miRNA). In some embodiments, the nucleic acid contains an antisense oligonucleotide.</p><p id="p-0024" num="0023">In some embodiments, the nucleic acid anneals to an endogenous RNA transcript encoding PKC.</p><p id="p-0025" num="0024">The nucleic acid may be, for example at least 85% complementary (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary) to a region of the endogenous RNA transcript encoding PKC.</p><p id="p-0026" num="0025">In some embodiments, the substance that reduces activity and/or expression of PKC is a PKC inhibitor. The PKC inhibitor may be staurosporine or a variant thereof. For example, the PKC inhibitor may be a compound represented by formula (I)</p><p id="p-0027" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="35.39mm" wi="65.02mm" file="US20230002784A1-20230105-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0028" num="0026">wherein R<sub>1 </sub>is H, OH, optionally substituted alkoxy, optionally substituted acyloxy, optionally substituted amino, optionally substituted alkylamino, optionally substituted amido, halogen, optionally substituted C<sub>1-6 </sub>alkyl, optionally substituted C<sub>2-6 </sub>alkenyl, optionally substituted C<sub>2-6 </sub>alkynyl, optionally substituted acyl, optionally substituted alkoxycarbonyl, oxo, thiocarbonyl, optionally substituted carboxy, or ureido;</p><p id="p-0029" num="0027">R<sub>2 </sub>is H, optionally substituted C<sub>1-6 </sub>alkyl, optionally substituted C<sub>2-6 </sub>alkenyl, optionally substituted C<sub>2-6 </sub>alkynyl, or optionally substituted acyl;</p><p id="p-0030" num="0028">R<sub>a </sub>and R<sub>b </sub>are each, independently, H, optionally substituted C<sub>1-6 </sub>alkyl, optionally substituted C<sub>2-6 </sub>alkenyl, or optionally substituted C<sub>2-6 </sub>alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl, or R<sub>a </sub>and R<sub>b</sub>, together with the atoms to which they are bound, are joined to form an optionally substituted and optionally fused heterocycloalkyl ring;</p><p id="p-0031" num="0029">R<sub>c </sub>is O, NR<sub>d</sub>, or S;</p><p id="p-0032" num="0030">R<sub>d </sub>is H, optionally substituted C<sub>1-6 </sub>alkyl, optionally substituted C<sub>2-6 </sub>alkenyl, or optionally substituted C<sub>2-6 </sub>alkynyl;</p><p id="p-0033" num="0031">each X is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0034" num="0032">each Y is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0035" num="0033"><img id="CUSTOM-CHARACTER-00001" he="2.12mm" wi="5.33mm" file="US20230002784A1-20230105-P00001.TIF" alt="custom-character" img-content="character" img-format="tif"/> represents a bond that is optionally present;</p><p id="p-0036" num="0034">n is an integer from 0-4; and</p><p id="p-0037" num="0035">m is an integer from 0-4;</p><p id="p-0038" num="0036">or a salt thereof.</p><p id="p-0039" num="0037">In some embodiments, the PKC inhibitor is a compound represented by formula (II)</p><p id="p-0040" num="0000"><chemistry id="CHEM-US-00002" num="00002"><img id="EMI-C00002" he="35.39mm" wi="65.45mm" file="US20230002784A1-20230105-C00002.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0041" num="0038">wherein R<sub>1 </sub>is H, OH, optionally substituted alkoxy, optionally substituted acyloxy, optionally substituted amino, optionally substituted alkylamino, optionally substituted amido, halogen, oxo, or thiocarbonyl;</p><p id="p-0042" num="0039">R<sub>2 </sub>is H, optionally substituted C<sub>1-6 </sub>alkyl, optionally substituted C<sub>2-6 </sub>alkenyl, optionally substituted C<sub>2-6 </sub>alkynyl, or optionally substituted acyl;</p><p id="p-0043" num="0040">R<sub>a </sub>and R<sub>b</sub>, together with the atoms to which they are bound, are joined to form an optionally substituted and optionally fused heterocycloalkyl ring;</p><p id="p-0044" num="0041">R<sub>c </sub>is O or S;</p><p id="p-0045" num="0042">each X is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0046" num="0043">each Y is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0047" num="0044">n is an integer from 0-4; and</p><p id="p-0048" num="0045">m is an integer from 0-4;</p><p id="p-0049" num="0046">or a salt thereof.</p><p id="p-0050" num="0047">In some embodiments, the PKC inhibitor is a compound represented by formula (III)</p><p id="p-0051" num="0000"><chemistry id="CHEM-US-00003" num="00003"><img id="EMI-C00003" he="46.14mm" wi="65.87mm" file="US20230002784A1-20230105-C00003.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0052" num="0048">wherein R<sub>1 </sub>is H, OH, oxo, or thiocarbonyl;</p><p id="p-0053" num="0049">R<sub>2 </sub>is H, optionally substituted C<sub>1-6 </sub>alkyl, optionally substituted C<sub>2-6 </sub>alkenyl, optionally substituted C<sub>2-6 </sub>alkynyl, or optionally substituted acyl;</p><p id="p-0054" num="0050">Ring A is an optionally substituted and optionally fused heterocycloalkyl ring;</p><p id="p-0055" num="0051">R<sub>c </sub>is O or S;</p><p id="p-0056" num="0052">each X is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0057" num="0053">each Y is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0058" num="0054">n is an integer from 0-4; and</p><p id="p-0059" num="0055">m is an integer from 0-4;</p><p id="p-0060" num="0056">or a salt thereof.</p><p id="p-0061" num="0057">In some embodiments, the PKC inhibitor is a compound represented by formula (IV)</p><p id="p-0062" num="0000"><chemistry id="CHEM-US-00004" num="00004"><img id="EMI-C00004" he="46.23mm" wi="65.96mm" file="US20230002784A1-20230105-C00004.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0063" num="0058">wherein R<sub>1 </sub>is H, OH, or oxo;</p><p id="p-0064" num="0059">Ring B is an optionally substituted heteroaryl or heterocycloalkyl ring;</p><p id="p-0065" num="0060">R<sub>c </sub>is O or S;</p><p id="p-0066" num="0061">W is O, NH, or S;</p><p id="p-0067" num="0062">each X is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0068" num="0063">each Y is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0069" num="0064">n is an integer from 0-4; and</p><p id="p-0070" num="0065">m is an integer from 0-4;</p><p id="p-0071" num="0066">or a salt thereof.</p><p id="p-0072" num="0067">In some embodiments, the PKC inhibitor is a compound represented by formula (V)</p><p id="p-0073" num="0000"><chemistry id="CHEM-US-00005" num="00005"><img id="EMI-C00005" he="43.94mm" wi="61.89mm" file="US20230002784A1-20230105-C00005.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0074" num="0068">wherein R<sub>1 </sub>is H, OH, or oxo;</p><p id="p-0075" num="0069">R<sub>c </sub>is O or S;</p><p id="p-0076" num="0070">W is O, NH, or S;</p><p id="p-0077" num="0071">each Z is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl; and</p><p id="p-0078" num="0072">p is 0 or 1;</p><p id="p-0079" num="0073">or a salt thereof.</p><p id="p-0080" num="0074">In some embodiments, the PKC inhibitor is a compound represented by formula (VI)</p><p id="p-0081" num="0000"><chemistry id="CHEM-US-00006" num="00006"><img id="EMI-C00006" he="42.50mm" wi="62.31mm" file="US20230002784A1-20230105-C00006.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0082" num="0075">wherein R<sub>1 </sub>is H, OH, or oxo;</p><p id="p-0083" num="0076">each Z is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl; and</p><p id="p-0084" num="0077">s is an integer from 0-8;</p><p id="p-0085" num="0078">or a salt thereof.</p><p id="p-0086" num="0079">In some embodiments, the PKC inhibitor is a compound represented by formula (VII)</p><p id="p-0087" num="0000"><chemistry id="CHEM-US-00007" num="00007"><img id="EMI-C00007" he="49.45mm" wi="62.74mm" file="US20230002784A1-20230105-C00007.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0088" num="0080">wherein R<sub>1 </sub>is H, OH, or oxo;</p><p id="p-0089" num="0081">R<sub>2 </sub>is H, OH, optionally substituted alkoxy, or optionally substituted acyloxy; and</p><p id="p-0090" num="0082">R<sub>3 </sub>is H, OH, optionally substituted alkoxy, optionally substituted acyloxy, optionally substituted amino, or optionally substituted amido or a salt thereof.</p><p id="p-0091" num="0083">In some embodiments, the PKC inhibitor is a compound represented by formula (VIII)</p><p id="p-0092" num="0000"><chemistry id="CHEM-US-00008" num="00008"><img id="EMI-C00008" he="49.45mm" wi="63.08mm" file="US20230002784A1-20230105-C00008.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0093" num="0084">wherein R<sub>1 </sub>is H, OH, or oxo;</p><p id="p-0094" num="0085">R<sub>2 </sub>is H, OH, optionally substituted alkoxy, or optionally substituted acyloxy; and</p><p id="p-0095" num="0086">R<sub>3 </sub>is H, OH, optionally substituted alkoxy, optionally substituted acyloxy, optionally substituted amino, or optionally substituted amido or a salt thereof.</p><p id="p-0096" num="0087">In some embodiments, the PKC inhibitor is a compound represented by formula (IX)</p><p id="p-0097" num="0000"><chemistry id="CHEM-US-00009" num="00009"><img id="EMI-C00009" he="50.97mm" wi="66.89mm" file="US20230002784A1-20230105-C00009.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0098" num="0088">wherein each X is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0099" num="0089">each Y is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0100" num="0090">n is an integer from 0-4; and</p><p id="p-0101" num="0091">m is an integer from 0-4;</p><p id="p-0102" num="0092">or a salt thereof.</p><p id="p-0103" num="0093">In some embodiments, the PKC inhibitor is a compound represented by formula (I)</p><p id="p-0104" num="0000"><chemistry id="CHEM-US-00010" num="00010"><img id="EMI-C00010" he="50.97mm" wi="61.64mm" file="US20230002784A1-20230105-C00010.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0105" num="0094">or a salt thereof.</p><p id="p-0106" num="0095">In some embodiments, the PKC inhibitor is staurosporine, (2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one, represented by formula (2)</p><p id="p-0107" num="0000"><chemistry id="CHEM-US-00011" num="00011"><img id="EMI-C00011" he="50.88mm" wi="61.64mm" file="US20230002784A1-20230105-C00011.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0108" num="0096">or a salt thereof.</p><p id="p-0109" num="0097">In some embodiments, the PKC inhibitor is a compound represented by formula (X)</p><p id="p-0110" num="0000"><chemistry id="CHEM-US-00012" num="00012"><img id="EMI-C00012" he="51.14mm" wi="61.72mm" file="US20230002784A1-20230105-C00012.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0111" num="0098">wherein R<sub>1 </sub>is H, OH, or oxo;</p><p id="p-0112" num="0099">each Z is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl; and</p><p id="p-0113" num="0100">t is an integer from 0-6;</p><p id="p-0114" num="0101">or a salt thereof.</p><p id="p-0115" num="0102">In some embodiments, the PKC inhibitor is a compound represented by formula (XI)</p><p id="p-0116" num="0000"><chemistry id="CHEM-US-00013" num="00013"><img id="EMI-C00013" he="40.05mm" wi="61.98mm" file="US20230002784A1-20230105-C00013.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0117" num="0103">wherein R<sub>1 </sub>is H, OH, or oxo; and</p><p id="p-0118" num="0104">R<sub>4 </sub>is H, OH, optionally substituted alkoxy, or optionally substituted acyloxy;</p><p id="p-0119" num="0105">or a salt thereof.</p><p id="p-0120" num="0106">In some embodiments, the PKC inhibitor is a compound represented by formula (XII)</p><p id="p-0121" num="0000"><chemistry id="CHEM-US-00014" num="00014"><img id="EMI-C00014" he="45.89mm" wi="62.74mm" file="US20230002784A1-20230105-C00014.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0122" num="0107">wherein R<sub>1 </sub>is H, OH, or oxo; and</p><p id="p-0123" num="0108">R<sub>4 </sub>is H, OH, optionally substituted alkoxy, or optionally substituted acyloxy;</p><p id="p-0124" num="0109">or a salt thereof.</p><p id="p-0125" num="0110">In some embodiments, the PKC inhibitor is a compound represented by formula (XIII)</p><p id="p-0126" num="0000"><chemistry id="CHEM-US-00015" num="00015"><img id="EMI-C00015" he="45.89mm" wi="68.07mm" file="US20230002784A1-20230105-C00015.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0127" num="0111">wherein each X is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0128" num="0112">each Y is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0129" num="0113">n is an integer from 0-4; and</p><p id="p-0130" num="0114">m is an integer from 0-4;</p><p id="p-0131" num="0115">or a salt thereof.</p><p id="p-0132" num="0116">In some embodiments, the PKC inhibitor is a compound represented by formula (3)</p><p id="p-0133" num="0000"><chemistry id="CHEM-US-00016" num="00016"><img id="EMI-C00016" he="45.89mm" wi="61.72mm" file="US20230002784A1-20230105-C00016.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0134" num="0117">or a salt thereof.</p><p id="p-0135" num="0118">In some embodiments, the PKC inhibitor is a compound represented by formula (4)</p><p id="p-0136" num="0000"><chemistry id="CHEM-US-00017" num="00017"><img id="EMI-C00017" he="45.89mm" wi="61.72mm" file="US20230002784A1-20230105-C00017.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0137" num="0119">or a salt thereof.</p><p id="p-0138" num="0120">In some embodiments the PKC inhibitor is a compound selected from:</p><p id="p-0139" num="0000"><chemistry id="CHEM-US-00018" num="00018"><img id="EMI-C00018" he="214.71mm" wi="62.06mm" file="US20230002784A1-20230105-C00018.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00019" num="00019"><img id="EMI-C00019" he="235.63mm" wi="62.65mm" file="US20230002784A1-20230105-C00019.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00020" num="00020"><img id="EMI-C00020" he="160.44mm" wi="66.04mm" file="US20230002784A1-20230105-C00020.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0140" num="0000">or a salt thereof.</p><p id="p-0141" num="0121">In some embodiments, the PKC inhibitor is a compound represented by formula (XIV)</p><p id="p-0142" num="0000"><chemistry id="CHEM-US-00021" num="00021"><img id="EMI-C00021" he="55.29mm" wi="63.25mm" file="US20230002784A1-20230105-C00021.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0143" num="0122">wherein R<sub>1 </sub>is H or optionally substituted C<sub>1-6 </sub>alkyl; and</p><p id="p-0144" num="0123">R<sub>2 </sub>is optionally substituted C<sub>1-6 </sub>alkyl;</p><p id="p-0145" num="0124">or a salt thereof.</p><p id="p-0146" num="0125">In some embodiments, the PKC inhibitor is a compound represented by formula (XV)</p><p id="p-0147" num="0000"><chemistry id="CHEM-US-00022" num="00022"><img id="EMI-C00022" he="55.29mm" wi="62.82mm" file="US20230002784A1-20230105-C00022.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0148" num="0126">wherein R<sub>1 </sub>is H or optionally substituted C<sub>1-6 </sub>alkyl; and</p><p id="p-0149" num="0127">R<sub>2 </sub>is optionally substituted C<sub>1-6 </sub>alkyl;</p><p id="p-0150" num="0128">or a salt thereof.</p><p id="p-0151" num="0129">In some embodiments, the PKC inhibitor is a compound selected from:</p><p id="p-0152" num="0000"><chemistry id="CHEM-US-00023" num="00023"><img id="EMI-C00023" he="123.61mm" wi="64.52mm" file="US20230002784A1-20230105-C00023.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0153" num="0000">or a salt thereof.</p><p id="p-0154" num="0130">In some embodiments, the PKC inhibitor is a compound represented by formula (XVI)</p><p id="p-0155" num="0000"><chemistry id="CHEM-US-00024" num="00024"><img id="EMI-C00024" he="51.82mm" wi="63.25mm" file="US20230002784A1-20230105-C00024.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0156" num="0131">wherein R is H, optionally substituted alkyl, optionally substituted acyl, optionally substituted sulfonyl, optionally substituted sulfinyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;</p><p id="p-0157" num="0132">or a salt or quaternized variant thereof.</p><p id="p-0158" num="0133">In some embodiments, the PKC inhibitor is a compound represented by formula (XVII)</p><p id="p-0159" num="0000"><chemistry id="CHEM-US-00025" num="00025"><img id="EMI-C00025" he="51.82mm" wi="63.67mm" file="US20230002784A1-20230105-C00025.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0160" num="0134">wherein R is H, optionally substituted alkyl, optionally substituted acyl, optionally substituted sulfonyl, optionally substituted sulfinyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;</p><p id="p-0161" num="0135">or a salt or quaternized variant thereof.</p><p id="p-0162" num="0136">In some embodiments, the PKC inhibitor is a compound selected from:</p><p id="p-0163" num="0000"><chemistry id="CHEM-US-00026" num="00026"><img id="EMI-C00026" he="169.84mm" wi="62.65mm" file="US20230002784A1-20230105-C00026.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00027" num="00027"><img id="EMI-C00027" he="167.72mm" wi="62.65mm" file="US20230002784A1-20230105-C00027.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00028" num="00028"><img id="EMI-C00028" he="168.66mm" wi="66.55mm" file="US20230002784A1-20230105-C00028.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00029" num="00029"><img id="EMI-C00029" he="165.02mm" wi="62.65mm" file="US20230002784A1-20230105-C00029.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00030" num="00030"><img id="EMI-C00030" he="196.85mm" wi="64.94mm" file="US20230002784A1-20230105-C00030.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00031" num="00031"><img id="EMI-C00031" he="203.28mm" wi="64.01mm" file="US20230002784A1-20230105-C00031.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00032" num="00032"><img id="EMI-C00032" he="184.40mm" wi="64.18mm" file="US20230002784A1-20230105-C00032.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00033" num="00033"><img id="EMI-C00033" he="192.96mm" wi="64.35mm" file="US20230002784A1-20230105-C00033.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00034" num="00034"><img id="EMI-C00034" he="183.47mm" wi="65.45mm" file="US20230002784A1-20230105-C00034.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00035" num="00035"><img id="EMI-C00035" he="183.81mm" wi="66.63mm" file="US20230002784A1-20230105-C00035.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00036" num="00036"><img id="EMI-C00036" he="120.57mm" wi="69.00mm" file="US20230002784A1-20230105-C00036.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00037" num="00037"><img id="EMI-C00037" he="184.15mm" wi="65.45mm" file="US20230002784A1-20230105-C00037.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00038" num="00038"><img id="EMI-C00038" he="180.51mm" wi="69.00mm" file="US20230002784A1-20230105-C00038.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00039" num="00039"><img id="EMI-C00039" he="194.90mm" wi="68.92mm" file="US20230002784A1-20230105-C00039.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00040" num="00040"><img id="EMI-C00040" he="186.52mm" wi="69.34mm" file="US20230002784A1-20230105-C00040.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00041" num="00041"><img id="EMI-C00041" he="181.27mm" wi="69.34mm" file="US20230002784A1-20230105-C00041.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00042" num="00042"><img id="EMI-C00042" he="124.97mm" wi="72.05mm" file="US20230002784A1-20230105-C00042.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00043" num="00043"><img id="EMI-C00043" he="124.46mm" wi="69.26mm" file="US20230002784A1-20230105-C00043.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00044" num="00044"><img id="EMI-C00044" he="185.08mm" wi="66.55mm" file="US20230002784A1-20230105-C00044.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0164" num="0000">or a salt thereof.</p><p id="p-0165" num="0137">In some embodiments, the PKC inhibitor is a compound represented by formula (XVIII)</p><p id="p-0166" num="0000"><chemistry id="CHEM-US-00045" num="00045"><img id="EMI-C00045" he="52.49mm" wi="64.09mm" file="US20230002784A1-20230105-C00045.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0167" num="0138">wherein R is H, OH, C<sub>1-6 </sub>alkoxy, or oxo; and</p><p id="p-0168" num="0000"><chemistry id="CHEM-US-00046" num="00046"><img id="EMI-C00046" he="24.55mm" wi="41.91mm" file="US20230002784A1-20230105-C00046.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0169" num="0139">R<sub>2 </sub>is, optionally wherein the configuration of the sugar moiety is derived from D-glucose, D-galactose, or D-mannose;</p><p id="p-0170" num="0140">R<sub>3 </sub>is H, OH, C<sub>1-6 </sub>alkanoyloxy, C<sub>1-6 </sub>alkoxy, benzyloxy, benzoyloxy or phenyloxy, each of which is optionally substituted in the phenyl moiety by halogen, hydroxyl, trifluoromethyl, C<sub>1-6 </sub>alkyl, or C<sub>1-6 </sub>alkoxy;</p><p id="p-0171" num="0141">R<sub>4 </sub>is OH, C<sub>1-6 </sub>alkanoyloxy, benzoyloxy, benzyloxy, amino, C<sub>1-6 </sub>alkylamino, di-C<sub>1-6 </sub>alkylamino, C<sub>1-6 </sub>alkoxycarbonylamino, C<sub>2-20 </sub>alkanoylamino, benzoylamino, benzyloxycarbonylamino, or phenyloxycarbonylamino, each of which is optionally substituted in the phenyl moiety by halogen, hydroxyl, trifluoromethyl, C<sub>1-6 </sub>alkyl, C<sub>1-6 </sub>alkoxy;</p><p id="p-0172" num="0142">R<sub>5 </sub>is H or C<sub>1-6 </sub>alkyl;</p><p id="p-0173" num="0143">R<sub>6 </sub>is hydroxyl which is free or esterified with an aliphatic C<sub>2-22 </sub>carboxylic acid, or is C<sub>1-6 </sub>alkoxycarbonyloxy, C<sub>1-6 </sub>alkylsulfonyloxy, amino which is free or acylated with an aliphatic C<sub>2-22 </sub>carboxylic acid, C<sub>1-6 </sub>alkoxycarbonylamino, azido, benzoyloxy, benzyloxycarbonyloxy, benzoylamino, benzyloxycarbonylamino, or phenylsulfonyloxy, each of which is optionally substituted in the phenyl moiety by halogen, hydroxyl, trifluoromethyl, C<sub>1-6 </sub>alkyl, or C<sub>1-6 </sub>alkoxy; and</p><p id="p-0174" num="0144">R<sub>7 </sub>is OH which is free or esterified with an aliphatic C<sub>2-22 </sub>carboxylic acid, C<sub>1-6 </sub>alkoxycarbonyloxy, C<sub>1-6 </sub>alkylsulfonyloxy, azido, amino which is free or acylated with an aliphatic C<sub>2-22 </sub>carboxylic acid, C<sub>1-6 </sub>alkylamino, di-C<sub>1-6 </sub>alkylamino, C<sub>1-6 </sub>alkoxycarbonylamino, carbamoylamino, benzoyloxy, benzyloxycarbonyloxy, phenylsulfonyloxy, benzoylamino, benzylamino or benzyloxycarbonylamino, each of which is optionally substituted in the phenyl moiety by halogen, hydroxyl, trifluoromethyl, C<sub>1-6 </sub>alkyl, C<sub>1-6 </sub>alkoxy, or C<sub>1-6 </sub>alkoxycarbonyl;</p><p id="p-0175" num="0145">or a salt thereof.</p><p id="p-0176" num="0146">In some embodiments, the PKC inhibitor is a compound represented by formula (XIX)</p><p id="p-0177" num="0000"><chemistry id="CHEM-US-00047" num="00047"><img id="EMI-C00047" he="52.49mm" wi="63.25mm" file="US20230002784A1-20230105-C00047.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0178" num="0147">wherein R is H, OH, 1-6 alkoxy, or oxo; and</p><p id="p-0179" num="0148">R<sub>2 </sub>is</p><p id="p-0180" num="0000"><chemistry id="CHEM-US-00048" num="00048"><img id="EMI-C00048" he="23.71mm" wi="37.85mm" file="US20230002784A1-20230105-C00048.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0181" num="0149">R<sub>3 </sub>is H, OH, C<sub>1-6 </sub>alkanoyloxy, C<sub>1-6 </sub>alkoxy, benzyloxy, benzoyloxy or phenyloxy, each of which is optionally substituted in the phenyl moiety by halogen, hydroxyl, trifluoromethyl, C<sub>1-6 </sub>alkyl, or C<sub>1-6 </sub>alkoxy;</p><p id="p-0182" num="0150">R<sub>4 </sub>is OH, C<sub>1-6 </sub>alkanoyloxy, benzoyloxy, benzyloxy, amino, C<sub>1-6 </sub>alkylamino, di-C<sub>1-6 </sub>alkylamino, C<sub>1-6 </sub>alkoxycarbonylamino, C<sub>2-20 </sub>alkanoylamino, benzoylamino, benzyloxycarbonylamino, or phenyloxycarbonylamino, each of which is optionally substituted in the phenyl moiety by halogen, hydroxyl, trifluoromethyl, C<sub>1-6 </sub>alkyl, C<sub>1-6 </sub>alkoxy;</p><p id="p-0183" num="0151">R<sub>5 </sub>is H or C<sub>1-6 </sub>alkyl;</p><p id="p-0184" num="0152">R<sub>6 </sub>is hydroxyl which is free or esterified with an aliphatic C<sub>2-22 </sub>carboxylic acid, or is C<sub>1-6 </sub>alkoxycarbonyloxy, C<sub>1-6 </sub>alkylsulfonyloxy, amino which is free or acylated with an aliphatic C<sub>2-22 </sub>carboxylic acid, C<sub>1-6 </sub>alkoxycarbonylamino, azido, benzoyloxy, benzyloxycarbonyloxy, benzoylamino, benzyloxycarbonylamino, or phenylsulfonyloxy, each of which is optionally substituted in the phenyl moiety by halogen, hydroxyl, trifluoromethyl, C<sub>1-6 </sub>alkyl, or C<sub>1-6 </sub>alkoxy; and</p><p id="p-0185" num="0153">R<sub>7 </sub>is OH which is free or esterified with an aliphatic C<sub>2-22 </sub>carboxylic acid, C<sub>1-6 </sub>alkoxycarbonyloxy, C<sub>1-6 </sub>alkylsulfonyloxy, azido, amino which is free or acylated with an aliphatic C<sub>2-22 </sub>carboxylic acid, C<sub>1-6 </sub>alkylamino, di-C<sub>1-6 </sub>alkylamino, C<sub>1-6 </sub>alkoxycarbonylamino, carbamoylamino, benzoyloxy, benzyloxycarbonyloxy, phenylsulfonyloxy, benzoylamino, benzylamino or benzyloxycarbonylamino, each of which is optionally substituted in the phenyl moiety by halogen, hydroxyl, trifluoromethyl, C<sub>1-6 </sub>alkyl, C<sub>1-6 </sub>alkoxy, or C<sub>1-6 </sub>alkoxycarbonyl;</p><p id="p-0186" num="0154">or a salt thereof.</p><p id="p-0187" num="0155">In some embodiments, the PKC inhibitor is a compound selected from N-(1-&#x3b1;-O-Benzyl-2-N-acetylmuramyl)staurosporine, N-(2-N-Acetyl-muramyl)staurosporine, N-(6-O-Mesyl-1-&#x3b1;-O-benzyl-2-N-acetylmuramyl)staurosporine, N-(6-Azido-1-&#x3b1;-O-benzyl-2-N-acetyl-6-deoxymuramyl)staurosporine, N-(6-Amino-1-&#x3b1;-O-benzyl-2-N-acetyl-6-deoxymuramyl)staurosporine, N-(6-Amino-6-deoxy-2-N-acetylmuramyl)staurosporine, N-(6-O-Mesyl-2-N-acetylmuramyl)staurosporine, N-(2-N-Acetyl-demethylmuramyl)staurosporine, N-(1-&#x3b1;-O-Benzyl-2-N-acetylhomomuramyl)staurosporine, N-(1-&#x3b1;-O-Benzyl-2&#x2014;N-acetyl-L-homomuramyl)staurosporine, the 1-&#x3b1;-anomer of N-(2-N-acetyl-L-homomuramyl)staurosporine, N-(1-&#x3b1;-O-Benzyl-4,6-O-diacetyl-2-N-acetylmuramyl)staurosporine, N-(1-&#x3b1;-O-Benzyl-4-O-acetyl-6-O-stearoyl-2-N-acetylmuramyl)staurosporin, N-(1-Deoxy-2-N-acetylmuramyl)staurosporine, the 1-&#x3b1;-anomer of N-(4-O-acetyl-6-O-stearoyl-2-N-acetylmuramyl)staurosporine, the 1-&#x3b1;-anomer of N-(4,6-O-diacetyl-2-N-acetylmuramyl)staurosporine, N-(1-&#x3b1;,4-O-diacetyl-6-O-stearoyl-2-N-acetylmuramyl)staurosporine, N-(1-&#x3b1;,4,6-O-Triacetyl-2-N-acetylmuramyl)staurosporine, N-(1-Deoxy-6-O-acetyl-2-N-acetylmuramyl)staurosporine, N-(1-Deoxy-6-O-mesyl-2&#x2014;N-acetylmuramyl)staurosporine, N-(1-Deoxy-6-O-toluylsulfonyl-2-N-acetylmuramyl)staurosporine, N-(1-Deoxy-6-azido-2-N-acetylmuramyl)staurosporine, and N-(1-Deoxy-6-O-mesyl-2-N-acetylmuramyl)staurosporine, or a salt thereof.</p><p id="p-0188" num="0156">In some embodiments, the PKC inhibitor is a compound represented by formula (XX)</p><p id="p-0189" num="0000"><chemistry id="CHEM-US-00049" num="00049"><img id="EMI-C00049" he="47.33mm" wi="69.93mm" file="US20230002784A1-20230105-C00049.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0190" num="0157">wherein Z<sub>1 </sub>is H or OH;</p><p id="p-0191" num="0158">Z<sub>2 </sub>is H or OH;</p><p id="p-0192" num="0159">R<sub>1 </sub>is H, halogen, or optionally substituted alkyl;</p><p id="p-0193" num="0160">R<sub>2 </sub>is H or halogen;</p><p id="p-0194" num="0161">R is OH or optionally substituted alkoxy; and</p><p id="p-0195" num="0162">X is optionally substituted alkyl or optionally substituted acyl, optionally wherein X is CH<sub>2</sub>&#x2014;NH-serine, CO<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>NHCO<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, CONHC<sub>6</sub>H<sub>5</sub>, or CH<sub>2</sub>NHCO<sub>2</sub>CH3, wherein C<sub>6</sub>H<sub>5 </sub>denotes a phenyl moiety;</p><p id="p-0196" num="0163">or a salt thereof.</p><p id="p-0197" num="0164">In some embodiments, the PKC inhibitor is a compound represented by formula (XXI)</p><p id="p-0198" num="0000"><chemistry id="CHEM-US-00050" num="00050"><img id="EMI-C00050" he="47.41mm" wi="70.36mm" file="US20230002784A1-20230105-C00050.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0199" num="0165">wherein Z<sub>1 </sub>is H or OH;</p><p id="p-0200" num="0166">Z<sub>2 </sub>is H or OH;</p><p id="p-0201" num="0167">R<sub>1 </sub>is H, halogen, or optionally substituted alkyl;</p><p id="p-0202" num="0168">R<sub>2 </sub>is H or halogen;</p><p id="p-0203" num="0169">R is OH or optionally substituted alkoxy; and</p><p id="p-0204" num="0170">X is optionally substituted alkyl or optionally substituted acyl, optionally wherein X is CH<sub>2</sub>&#x2014;NH-serine, CO<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>NHCO<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, CONHC<sub>6</sub>H<sub>5</sub>, or CH<sub>2</sub>NHCO<sub>2</sub>CH<sub>3</sub>, wherein C<sub>6</sub>H<sub>5 </sub>denotes a phenyl moiety;</p><p id="p-0205" num="0171">or a salt thereof.</p><p id="p-0206" num="0172">In some embodiments, the PKC inhibitor is a compound represented by formula (XXII), (XXIII), (XXIV), or (XXV)</p><p id="p-0207" num="0000"><chemistry id="CHEM-US-00051" num="00051"><img id="EMI-C00051" he="160.19mm" wi="73.07mm" file="US20230002784A1-20230105-C00051.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0208" num="0173">wherein each R<sub>1 </sub>is, independently, optionally substituted alkyl, hydrogen, halogen, hydroxy, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl, or N-mono- or N,N-di-substituted aminosulfonyl;</p><p id="p-0209" num="0174">each R<sub>2 </sub>is, independently, optionally substituted alkyl, hydrogen, halogen, hydroxy, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl, or N-mono- or N,N-di-substituted aminosulfonyl;</p><p id="p-0210" num="0175">each R<sub>5 </sub>is, independently, H, an aliphatic, carbocyclic, or carbocyclic-aliphatic radical with up to 29 carbon atoms in each case, or a heterocyclic or heterocyclic-aliphatic radical with up to 20 carbon atoms in each case, and in each case up to 9 heteroatoms, or acyl with up to 30 carbon atoms; and</p><p id="p-0211" num="0176">each X is, independently, O, OH and H, or a pair of hydrogen atoms;</p><p id="p-0212" num="0177">each Q is, independently, H, OH, halogen, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl or N-mono- or N,N-di-substituted aminosulfonyl;</p><p id="p-0213" num="0178">each Q&#x2032; is, independently, H, OH, halogen, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl or N-mono- or N,N-di-substituted aminosulfonyl;</p><p id="p-0214" num="0179">each n is, independently, an integer from 0-4; and</p><p id="p-0215" num="0180">each m is, independently, an integer from 0-4;</p><p id="p-0216" num="0181">or a salt thereof.</p><p id="p-0217" num="0182">In some embodiments, the PKC inhibitor is a compound represented by formula (XXVI) or (XXVII)</p><p id="p-0218" num="0000"><chemistry id="CHEM-US-00052" num="00052"><img id="EMI-C00052" he="91.95mm" wi="71.20mm" file="US20230002784A1-20230105-C00052.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0219" num="0183">wherein each R<sub>1 </sub>is, independently, optionally substituted alkyl, hydrogen, halogen, hydroxy, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl or N-mono- or N,N-di-substituted aminosulfonyl;</p><p id="p-0220" num="0184">each R<sub>2 </sub>is, independently, optionally substituted alkyl, hydrogen, halogen, hydroxy, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl or N-mono- or N,N-di-substituted aminosulfonyl;</p><p id="p-0221" num="0185">each R<sub>5 </sub>is, independently, H, an aliphatic, carbocyclic, or carbocyclic-aliphatic radical with up to 29 carbon atoms in each case, or a heterocyclic or heterocyclic-aliphatic radical with up to 20 carbon atoms in each case, and in each case up to 9 heteroatoms, or acyl with up to 30 carbon atoms;</p><p id="p-0222" num="0186">each R<sub>8 </sub>is, independently, acyl with up to 30 carbon atoms, an aliphatic, carbocyclic, or carbocyclic-aliphatic radical with up to 29 carbon atoms in each case, a heterocyclic or heterocyclic-aliphatic radical with up to 20 carbon atoms in each case, and in each case up to 9 heteroatoms;</p><p id="p-0223" num="0187">each R<sub>9 </sub>is, independently, optionally substituted acyl, optionally substituted alkyl, hydrogen, halogen, hydroxy, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, carbonyl, carbonyldioxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl or N-mono- or N,N-di-substituted aminosulfonyl;</p><p id="p-0224" num="0188">each R<sub>10 </sub>is, independently, acyl with up to 30 carbon atoms, an aliphatic, carbocyclic, or carbocyclic-aliphatic radical with up to 29 carbon atoms in each case, a heterocyclic or heterocyclic-aliphatic radical with up to 20 carbon atoms in each case, and in each case up to 9 heteroatoms;</p><p id="p-0225" num="0189">each X is, independently, O, OH and H, or a pair of hydrogen atoms;</p><p id="p-0226" num="0190">each n is, independently, an integer from 0-4;</p><p id="p-0227" num="0191">each m is, independently, an integer from 0-4;</p><p id="p-0228" num="0192">each n&#x2032; is, independently, an integer from 0-4; and</p><p id="p-0229" num="0193">each m&#x2032; is, independently, an integer from 0-4;</p><p id="p-0230" num="0194">or a salt thereof.</p><p id="p-0231" num="0195">In some embodiments, the PKC inhibitor is a compound represented by formula (XXVIII)</p><p id="p-0232" num="0000"><chemistry id="CHEM-US-00053" num="00053"><img id="EMI-C00053" he="43.77mm" wi="69.85mm" file="US20230002784A1-20230105-C00053.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0233" num="0196">wherein R<sub>1 </sub>is H or optionally substituted C<sub>1-6 </sub>alkyl; and</p><p id="p-0234" num="0197">R<sub>2 </sub>is optionally substituted C<sub>1-6 </sub>alkyl;</p><p id="p-0235" num="0198">or a salt thereof.</p><p id="p-0236" num="0199">In some embodiments, the PKC inhibitor is a compound represented by formula (XXIX)</p><p id="p-0237" num="0000"><chemistry id="CHEM-US-00054" num="00054"><img id="EMI-C00054" he="48.09mm" wi="65.70mm" file="US20230002784A1-20230105-C00054.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0238" num="0200">wherein R<sub>1 </sub>is H or optionally substituted C<sub>1-6 </sub>alkyl; and</p><p id="p-0239" num="0201">R<sub>2 </sub>is optionally substituted C<sub>1-6 </sub>alkyl;</p><p id="p-0240" num="0202">or a salt thereof.</p><p id="p-0241" num="0203">In some embodiments, the PKC inhibitor is a compound represented by formula (XXX)</p><p id="p-0242" num="0000"><chemistry id="CHEM-US-00055" num="00055"><img id="EMI-C00055" he="50.80mm" wi="65.28mm" file="US20230002784A1-20230105-C00055.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0243" num="0204">wherein R<sub>1 </sub>is H or optionally substituted C<sub>1-6 </sub>alkyl; and</p><p id="p-0244" num="0205">R<sub>2 </sub>is optionally substituted C<sub>1-6 </sub>alkyl;</p><p id="p-0245" num="0206">or a salt thereof.</p><p id="p-0246" num="0207">In some embodiments, the PKC inhibitor is a compound represented by formula (XXXI)</p><p id="p-0247" num="0000"><chemistry id="CHEM-US-00056" num="00056"><img id="EMI-C00056" he="50.88mm" wi="65.70mm" file="US20230002784A1-20230105-C00056.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0248" num="0208">wherein R<sub>1 </sub>is H or optionally substituted C<sub>1-6 </sub>alkyl; and</p><p id="p-0249" num="0209">R<sub>2 </sub>is optionally substituted C<sub>1-6 </sub>alkyl;</p><p id="p-0250" num="0210">or a salt thereof.</p><p id="p-0251" num="0211">In some embodiments, the PKC inhibitor is a compound selected from:</p><p id="p-0252" num="0000"><chemistry id="CHEM-US-00057" num="00057"><img id="EMI-C00057" he="164.51mm" wi="62.65mm" file="US20230002784A1-20230105-C00057.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00058" num="00058"><img id="EMI-C00058" he="154.69mm" wi="62.65mm" file="US20230002784A1-20230105-C00058.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00059" num="00059"><img id="EMI-C00059" he="166.96mm" wi="64.94mm" file="US20230002784A1-20230105-C00059.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00060" num="00060"><img id="EMI-C00060" he="212.26mm" wi="66.04mm" file="US20230002784A1-20230105-C00060.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00061" num="00061"><img id="EMI-C00061" he="235.03mm" wi="67.56mm" file="US20230002784A1-20230105-C00061.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00062" num="00062"><img id="EMI-C00062" he="213.95mm" wi="62.65mm" file="US20230002784A1-20230105-C00062.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00063" num="00063"><img id="EMI-C00063" he="215.05mm" wi="72.05mm" file="US20230002784A1-20230105-C00063.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00064" num="00064"><img id="EMI-C00064" he="223.18mm" wi="67.90mm" file="US20230002784A1-20230105-C00064.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00065" num="00065"><img id="EMI-C00065" he="225.98mm" wi="73.24mm" file="US20230002784A1-20230105-C00065.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00066" num="00066"><img id="EMI-C00066" he="214.21mm" wi="66.80mm" file="US20230002784A1-20230105-C00066.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00067" num="00067"><img id="EMI-C00067" he="52.41mm" wi="63.25mm" file="US20230002784A1-20230105-C00067.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0253" num="0212">In some embodiments of any of the above aspects or embodiments of the disclosure, the concentration of the substance that reduces activity and/or expression of PKC, when contacted with the cell, is from about 100 &#x3bc;M to about 1 mM (e.g., about 100 &#x3bc;M, 105 &#x3bc;M, 110 &#x3bc;M, 115 &#x3bc;M, 120 &#x3bc;M, 125 &#x3bc;M, 130 &#x3bc;M, 135 &#x3bc;M, 140 &#x3bc;M, 145 &#x3bc;M, 150 &#x3bc;M, 155 &#x3bc;M, 160 &#x3bc;M, 165 &#x3bc;M, 170 &#x3bc;M, 175 &#x3bc;M, 180 &#x3bc;M, 185 &#x3bc;M, 190 &#x3bc;M, 195 &#x3bc;M, 200 &#x3bc;M, 205 &#x3bc;M, 210 &#x3bc;M, 215 &#x3bc;M, 220 &#x3bc;M, 225 &#x3bc;M, 230 &#x3bc;M, 235 &#x3bc;M, 240 &#x3bc;M, 245 &#x3bc;M, 250 &#x3bc;M, 255 &#x3bc;M, 260 &#x3bc;M, 265 &#x3bc;M, 270 &#x3bc;M, 275 &#x3bc;M, 280 &#x3bc;M, 285 &#x3bc;M, 290 &#x3bc;M, 295 &#x3bc;M, 300 &#x3bc;M, 305 &#x3bc;M, 310 &#x3bc;M, 315 &#x3bc;M, 320 &#x3bc;M, 325 &#x3bc;M, 330 &#x3bc;M, 335 &#x3bc;M, 340 &#x3bc;M, 345 &#x3bc;M, 350 &#x3bc;M, 355 &#x3bc;M, 360 &#x3bc;M, 365 &#x3bc;M, 370 &#x3bc;M, 375 &#x3bc;M, 380 &#x3bc;M, 385 &#x3bc;M, 390 &#x3bc;M, 395 &#x3bc;M, 400 &#x3bc;M, 405 &#x3bc;M, 410 &#x3bc;M, 415 &#x3bc;M, 420 &#x3bc;M, 425 &#x3bc;M, 430 &#x3bc;M, 435 &#x3bc;M, 440 &#x3bc;M, 445 &#x3bc;M, 450 &#x3bc;M, 455 &#x3bc;M, 460 &#x3bc;M, 465 &#x3bc;M, 470 &#x3bc;M, 475 &#x3bc;M, 480 &#x3bc;M, 485 &#x3bc;M, 490 &#x3bc;M, 495 &#x3bc;M, 500 &#x3bc;M, 505 &#x3bc;M, 510 &#x3bc;M, 515 &#x3bc;M, 520 &#x3bc;M, 525 &#x3bc;M, 530 &#x3bc;M, 535 &#x3bc;M, 540 &#x3bc;M, 545 &#x3bc;M, 550 &#x3bc;M, 555 &#x3bc;M, 560 &#x3bc;M, 565 &#x3bc;M, 570 &#x3bc;M, 575 &#x3bc;M, 580 &#x3bc;M, 585 &#x3bc;M, 590 &#x3bc;M, 595 &#x3bc;M, 600 &#x3bc;M, 605 &#x3bc;M, 610 &#x3bc;M, 615 &#x3bc;M, 620 &#x3bc;M, 625 &#x3bc;M, 630 &#x3bc;M, 635 &#x3bc;M, 640 &#x3bc;M, 645 &#x3bc;M, 650 &#x3bc;M, 655 &#x3bc;M, 660 &#x3bc;M, 665 &#x3bc;M, 670 &#x3bc;M, 675 &#x3bc;M, 680 &#x3bc;M, 685 &#x3bc;M, 690 &#x3bc;M, 695 &#x3bc;M, 700 &#x3bc;M, 705 &#x3bc;M, 710 &#x3bc;M, 715 &#x3bc;M, 720 &#x3bc;M, 725 &#x3bc;M, 730 &#x3bc;M, 735 &#x3bc;M, 740 &#x3bc;M, 745 &#x3bc;M, 750 &#x3bc;M, 755 &#x3bc;M, 760 &#x3bc;M, 765 &#x3bc;M, 770 &#x3bc;M, 775 &#x3bc;M, 780 &#x3bc;M, 785 &#x3bc;M, 790 &#x3bc;M, 795 &#x3bc;M, 800 &#x3bc;M, 805 &#x3bc;M, 810 &#x3bc;M, 815 &#x3bc;M, 820 &#x3bc;M, 825 &#x3bc;M, 830 &#x3bc;M, 835 &#x3bc;M, 840 &#x3bc;M, 845 &#x3bc;M, 850 &#x3bc;M, 855 &#x3bc;M, 860 &#x3bc;M, 865 &#x3bc;M, 870 &#x3bc;M, 875 &#x3bc;M, 880 &#x3bc;M, 885 &#x3bc;M, 890 &#x3bc;M, 895 &#x3bc;M, 900 &#x3bc;M, 905 &#x3bc;M, 910 &#x3bc;M, 915 &#x3bc;M, 920 &#x3bc;M, 925 &#x3bc;M, 930 &#x3bc;M, 935 &#x3bc;M, 940 &#x3bc;M, 945 &#x3bc;M, 950 &#x3bc;M, 955 &#x3bc;M, 960 &#x3bc;M, 965 &#x3bc;M, 970 &#x3bc;M, 975 &#x3bc;M, 980 &#x3bc;M, 985 &#x3bc;M, 990 &#x3bc;M, 995 &#x3bc;M, or 1 mM). In some embodiments, the concentration of the substance that reduces activity and/or expression of PKC, when contacted with the cell, is from about 200 &#x3bc;M to about 600 &#x3bc;M (e.g., about 200 &#x3bc;M, 205 &#x3bc;M, 210 &#x3bc;M, 215 &#x3bc;M, 220 &#x3bc;M, 225 &#x3bc;M, 230 &#x3bc;M, 235 &#x3bc;M, 240 &#x3bc;M, 245 &#x3bc;M, 250 &#x3bc;M, 255 &#x3bc;M, 260 &#x3bc;M, 265 &#x3bc;M, 270 &#x3bc;M, 275 &#x3bc;M, 280 &#x3bc;M, 285 &#x3bc;M, 290 &#x3bc;M, 295 &#x3bc;M, 300 &#x3bc;M, 305 &#x3bc;M, 310 &#x3bc;M, 315 &#x3bc;M, 320 &#x3bc;M, 325 &#x3bc;M, 330 &#x3bc;M, 335 &#x3bc;M, 340 &#x3bc;M, 345 &#x3bc;M, 350 &#x3bc;M, 355 &#x3bc;M, 360 &#x3bc;M, 365 &#x3bc;M, 370 &#x3bc;M, 375 &#x3bc;M, 380 &#x3bc;M, 385 &#x3bc;M, 390 &#x3bc;M, 395 &#x3bc;M, 400 &#x3bc;M, 405 &#x3bc;M, 410 &#x3bc;M, 415 &#x3bc;M, 420 &#x3bc;M, 425 &#x3bc;M, 430 &#x3bc;M, 435 &#x3bc;M, 440 &#x3bc;M, 445 &#x3bc;M, 450 &#x3bc;M, 455 &#x3bc;M, 460 &#x3bc;M, 465 &#x3bc;M, 470 &#x3bc;M, 475 &#x3bc;M, 480 &#x3bc;M, 485 &#x3bc;M, 490 &#x3bc;M, 495 &#x3bc;M, 500 &#x3bc;M, 505 &#x3bc;M, 510 &#x3bc;M, 515 &#x3bc;M, 520 &#x3bc;M, 525 &#x3bc;M, 530 &#x3bc;M, 535 &#x3bc;M, 540 &#x3bc;M, 545 &#x3bc;M, 550 &#x3bc;M, 555 &#x3bc;M, 560 &#x3bc;M, 565 &#x3bc;M, 570 &#x3bc;M, 575 &#x3bc;M, 580 &#x3bc;M, 585 &#x3bc;M, 590 &#x3bc;M, 595 &#x3bc;M, or 600 &#x3bc;M). In some embodiments, the concentration of the substance that reduces activity and/or expression of PKC, when contacted with the cell, is about 400 &#x3bc;M.</p><p id="p-0254" num="0213">In some embodiments, the concentration of the poloxamer, when contacted with the cell, is from about 10 ng/ml to about 9.5 &#x3bc;g/ml (e.g., about 10 ng/ml, 15 ng/ml, 20 ng/ml, 25 ng/ml, 30 ng/ml, 35 ng/ml, 40 ng/ml, 45 ng/ml, 50 ng/ml, 55 ng/ml, 60 ng/ml, 65 ng/ml, 70 ng/ml, 75 ng/ml, 80 ng/ml, 85 ng/ml, 90 ng/ml, 95 ng/ml, 100 ng/ml, 105 ng/ml, 110 ng/ml, 115 ng/ml, 120 ng/ml, 125 ng/ml, 130 ng/ml, 135 ng/ml, 140 ng/ml, 145 ng/ml, 150 ng/ml, 155 ng/ml, 160 ng/ml, 165 ng/ml, 170 ng/ml, 175 ng/ml, 180 ng/ml, 185 ng/ml, 190 ng/ml, 195 ng/ml, 200 ng/ml, 205 ng/ml, 210 ng/ml, 215 ng/ml, 220 ng/ml, 225 ng/ml, 230 ng/ml, 235 ng/ml, 240 ng/ml, 245 ng/ml, 250 ng/ml, 255 ng/ml, 260 ng/ml, 265 ng/ml, 270 ng/ml, 275 ng/ml, 280 ng/ml, 285 ng/ml, 290 ng/ml, 295 ng/ml, 300 ng/ml, 305 ng/ml, 310 ng/ml, 315 ng/ml, 320 ng/ml, 325 ng/ml, 330 ng/ml, 335 ng/ml, 340 ng/ml, 345 ng/ml, 350 ng/ml, 355 ng/ml, 360 ng/ml, 365 ng/ml, 370 ng/ml, 375 ng/ml, 380 ng/ml, 385 ng/ml, 390 ng/ml, 395 ng/ml, 400 ng/ml, 405 ng/ml, 410 ng/ml, 415 ng/ml, 420 ng/ml, 425 ng/ml, 430 ng/ml, 435 ng/ml, 440 ng/ml, 445 ng/ml, 450 ng/ml, 455 ng/ml, 460 ng/ml, 465 ng/ml, 470 ng/ml, 475 ng/ml, 480 ng/ml, 485 ng/ml, 490 ng/ml, 495 ng/ml, 500 ng/ml, 505 ng/ml, 510 ng/ml, 515 ng/ml, 520 ng/ml, 525 ng/ml, 530 ng/ml, 535 ng/ml, 540 ng/ml, 545 ng/ml, 550 ng/ml, 555 ng/ml, 560 ng/ml, 565 ng/ml, 570 ng/ml, 575 ng/ml, 580 ng/ml, 585 ng/ml, 590 ng/ml, 595 ng/ml, 600 ng/ml, 605 ng/ml, 610 ng/ml, 615 ng/ml, 620 ng/ml, 625 ng/ml, 630 ng/ml, 635 ng/ml, 640 ng/ml, 645 ng/ml, 650 ng/ml, 655 ng/ml, 660 ng/ml, 665 ng/ml, 670 ng/ml, 675 ng/ml, 680 ng/ml, 685 ng/ml, 690 ng/ml, 695 ng/ml, 700 ng/ml, 705 ng/ml, 710 ng/ml, 715 ng/ml, 720 ng/ml, 725 ng/ml, 730 ng/ml, 735 ng/ml, 740 ng/ml, 745 ng/ml, 750 ng/ml, 755 ng/ml, 760 ng/ml, 765 ng/ml, 770 ng/ml, 775 ng/ml, 780 ng/ml, 785 ng/ml, 790 ng/ml, 795 ng/ml, 800 ng/ml, 805 ng/ml, 810 ng/ml, 815 ng/ml, 820 ng/ml, 825 ng/ml, 830 ng/ml, 835 ng/ml, 840 ng/ml, 845 ng/ml, 850 ng/ml, 855 ng/ml, 860 ng/ml, 865 ng/ml, 870 ng/ml, 875 ng/ml, 880 ng/ml, 885 ng/ml, 890 ng/ml, 895 ng/ml, 900 ng/ml, 905 ng/ml, 910 ng/ml, 915 ng/ml, 920 ng/ml, 925 ng/ml, 930 ng/ml, 935 ng/ml, 940 ng/ml, 945 ng/ml, 950 ng/ml, 955 ng/ml, 960 ng/ml, 965 ng/ml, 970 ng/ml, 975 ng/ml, 980 ng/ml, 985 ng/ml, 990 ng/ml, 995 ng/ml, 1 &#x3bc;g/ml, 1.1 &#x3bc;g/ml, 1.2 &#x3bc;g/ml, 1.3 &#x3bc;g/ml, 1.4 &#x3bc;g/ml, 1.5 &#x3bc;g/ml, 1.6 &#x3bc;g/ml, 1.7 &#x3bc;g/ml, 1.8 &#x3bc;g/ml, 1.9 &#x3bc;g/ml, 2 &#x3bc;g/ml, 2.1 &#x3bc;g/ml, 2.2 &#x3bc;g/ml, 2.3 &#x3bc;g/ml, 2.4 &#x3bc;g/ml, 2.5 &#x3bc;g/ml, 2.6 &#x3bc;g/ml, 2.7 &#x3bc;g/ml, 2.8 &#x3bc;g/ml, 2.9 &#x3bc;g/ml, 3 &#x3bc;g/ml, 3.1 &#x3bc;g/ml, 3.2 &#x3bc;g/ml, 3.3 &#x3bc;g/ml, 3.4 &#x3bc;g/ml, 3.5 &#x3bc;g/ml, 3.6 &#x3bc;g/ml, 3.7 &#x3bc;g/ml, 3.8 &#x3bc;g/ml, 3.9 &#x3bc;g/ml, 4 &#x3bc;g/ml, 4.1 &#x3bc;g/ml, 4.2 &#x3bc;g/ml, 4.3 &#x3bc;g/ml, 4.4 &#x3bc;g/ml, 4.5 &#x3bc;g/ml, 4.6 &#x3bc;g/ml, 4.7 &#x3bc;g/ml, 4.8 &#x3bc;g/ml, 4.9 &#x3bc;g/ml, 5 &#x3bc;g/ml, 5.1 &#x3bc;g/ml, 5.2 &#x3bc;g/ml, 5.3 &#x3bc;g/ml, 5.4 &#x3bc;g/ml, 5.5 &#x3bc;g/ml, 5.6 &#x3bc;g/ml, 5.7 &#x3bc;g/ml, 5.8 &#x3bc;g/ml, 5.9 &#x3bc;g/ml, 6 &#x3bc;g/ml, 6.1 &#x3bc;g/ml, 6.2 &#x3bc;g/ml, 6.3 &#x3bc;g/ml, 6.4 &#x3bc;g/ml, 6.5 &#x3bc;g/ml, 6.6 &#x3bc;g/ml, 6.7 &#x3bc;g/ml, 6.8 &#x3bc;g/ml, 6.9 &#x3bc;g/ml, 7 &#x3bc;g/ml, 7.1 &#x3bc;g/ml, 7.2 &#x3bc;g/ml, 7.3 &#x3bc;g/ml, 7.4 &#x3bc;g/ml, 7.5 &#x3bc;g/ml, 7.6 &#x3bc;g/ml, 7.7 &#x3bc;g/ml, 7.8 &#x3bc;g/ml, 7.9 &#x3bc;g/ml, 8 &#x3bc;g/ml, 8.1 &#x3bc;g/ml, 8.2 &#x3bc;g/ml, 8.3 &#x3bc;g/ml, 8.4 &#x3bc;g/ml, 8.5 &#x3bc;g/ml, 8.6 &#x3bc;g/ml, 8.7 &#x3bc;g/ml, 8.8 &#x3bc;g/ml, 8.9 &#x3bc;g/ml, 9 &#x3bc;g/ml, 9.1 &#x3bc;g/ml, 9.2 &#x3bc;g/ml, 9.3 &#x3bc;g/ml, 9.4 &#x3bc;g/ml, or 9.5 &#x3bc;g/ml).</p><p id="p-0255" num="0214">In some embodiments, the concentration of the poloxamer, when contacted with the cell, is from about 10 ng/ml to about 9 &#x3bc;g/ml (e.g., about 10 ng/ml, 15 ng/ml, 20 ng/ml, 25 ng/ml, 30 ng/ml, 35 ng/ml, 40 ng/ml, 45 ng/ml, 50 ng/ml, 55 ng/ml, 60 ng/ml, 65 ng/ml, 70 ng/ml, 75 ng/ml, 80 ng/ml, 85 ng/ml, 90 ng/ml, 95 ng/ml, 100 ng/ml, 105 ng/ml, 110 ng/ml, 115 ng/ml, 120 ng/ml, 125 ng/ml, 130 ng/ml, 135 ng/ml, 140 ng/ml, 145 ng/ml, 150 ng/ml, 155 ng/ml, 160 ng/ml, 165 ng/ml, 170 ng/ml, 175 ng/ml, 180 ng/ml, 185 ng/ml, 190 ng/ml, 195 ng/ml, 200 ng/ml, 205 ng/ml, 210 ng/ml, 215 ng/ml, 220 ng/ml, 225 ng/ml, 230 ng/ml, 235 ng/ml, 240 ng/ml, 245 ng/ml, 250 ng/ml, 255 ng/ml, 260 ng/ml, 265 ng/ml, 270 ng/ml, 275 ng/ml, 280 ng/ml, 285 ng/ml, 290 ng/ml, 295 ng/ml, 300 ng/ml, 305 ng/ml, 310 ng/ml, 315 ng/ml, 320 ng/ml, 325 ng/ml, 330 ng/ml, 335 ng/ml, 340 ng/ml, 345 ng/ml, 350 ng/ml, 355 ng/ml, 360 ng/ml, 365 ng/ml, 370 ng/ml, 375 ng/ml, 380 ng/ml, 385 ng/ml, 390 ng/ml, 395 ng/ml, 400 ng/ml, 405 ng/ml, 410 ng/ml, 415 ng/ml, 420 ng/ml, 425 ng/ml, 430 ng/ml, 435 ng/ml, 440 ng/ml, 445 ng/ml, 450 ng/ml, 455 ng/ml, 460 ng/ml, 465 ng/ml, 470 ng/ml, 475 ng/ml, 480 ng/ml, 485 ng/ml, 490 ng/ml, 495 ng/ml, 500 ng/ml, 505 ng/ml, 510 ng/ml, 515 ng/ml, 520 ng/ml, 525 ng/ml, 530 ng/ml, 535 ng/ml, 540 ng/ml, 545 ng/ml, 550 ng/ml, 555 ng/ml, 560 ng/ml, 565 ng/ml, 570 ng/ml, 575 ng/ml, 580 ng/ml, 585 ng/ml, 590 ng/ml, 595 ng/ml, 600 ng/ml, 605 ng/ml, 610 ng/ml, 615 ng/ml, 620 ng/ml, 625 ng/ml, 630 ng/ml, 635 ng/ml, 640 ng/ml, 645 ng/ml, 650 ng/ml, 655 ng/ml, 660 ng/ml, 665 ng/ml, 670 ng/ml, 675 ng/ml, 680 ng/ml, 685 ng/ml, 690 ng/ml, 695 ng/ml, 700 ng/ml, 705 ng/ml, 710 ng/ml, 715 ng/ml, 720 ng/ml, 725 ng/ml, 730 ng/ml, 735 ng/ml, 740 ng/ml, 745 ng/ml, 750 ng/ml, 755 ng/ml, 760 ng/ml, 765 ng/ml, 770 ng/ml, 775 ng/ml, 780 ng/ml, 785 ng/ml, 790 ng/ml, 795 ng/ml, 800 ng/ml, 805 ng/ml, 810 ng/ml, 815 ng/ml, 820 ng/ml, 825 ng/ml, 830 ng/ml, 835 ng/ml, 840 ng/ml, 845 ng/ml, 850 ng/ml, 855 ng/ml, 860 ng/ml, 865 ng/ml, 870 ng/ml, 875 ng/ml, 880 ng/ml, 885 ng/ml, 890 ng/ml, 895 ng/ml, 900 ng/ml, 905 ng/ml, 910 ng/ml, 915 ng/ml, 920 ng/ml, 925 ng/ml, 930 ng/ml, 935 ng/ml, 940 ng/ml, 945 ng/ml, 950 ng/ml, 955 ng/ml, 960 ng/ml, 965 ng/ml, 970 ng/ml, 975 ng/ml, 980 ng/ml, 985 ng/ml, 990 ng/ml, 995 ng/ml, 1 &#x3bc;g/ml, 1.1 &#x3bc;g/ml, 1.2 &#x3bc;g/ml, 1.3 &#x3bc;g/ml, 1.4 &#x3bc;g/ml, 1.5 &#x3bc;g/ml, 1.6 &#x3bc;g/ml, 1.7 &#x3bc;g/ml, 1.8 &#x3bc;g/ml, 1.9 &#x3bc;g/ml, 2 &#x3bc;g/ml, 2.1 &#x3bc;g/ml, 2.2 &#x3bc;g/ml, 2.3 &#x3bc;g/ml, 2.4 &#x3bc;g/ml, 2.5 &#x3bc;g/ml, 2.6 &#x3bc;g/ml, 2.7 &#x3bc;g/ml, 2.8 &#x3bc;g/ml, 2.9 &#x3bc;g/ml, 3 &#x3bc;g/ml, 3.1 &#x3bc;g/ml, 3.2 &#x3bc;g/ml, 3.3 &#x3bc;g/ml, 3.4 &#x3bc;g/ml, 3.5 &#x3bc;g/ml, 3.6 &#x3bc;g/ml, 3.7 &#x3bc;g/ml, 3.8 &#x3bc;g/ml, 3.9 &#x3bc;g/ml, 4 &#x3bc;g/ml, 4.1 &#x3bc;g/ml, 4.2 &#x3bc;g/ml, 4.3 &#x3bc;g/ml, 4.4 &#x3bc;g/ml, 4.5 &#x3bc;g/ml, 4.6 &#x3bc;g/ml, 4.7 &#x3bc;g/ml, 4.8 &#x3bc;g/ml, 4.9 &#x3bc;g/ml, 5 &#x3bc;g/ml, 5.1 &#x3bc;g/ml, 5.2 &#x3bc;g/ml, 5.3 &#x3bc;g/ml, 5.4 &#x3bc;g/ml, 5.5 &#x3bc;g/ml, 5.6 &#x3bc;g/ml, 5.7 &#x3bc;g/ml, 5.8 &#x3bc;g/ml, 5.9 &#x3bc;g/ml, 6 &#x3bc;g/ml, 6.1 &#x3bc;g/ml, 6.2 &#x3bc;g/ml, 6.3 &#x3bc;g/ml, 6.4 &#x3bc;g/ml, 6.5 &#x3bc;g/ml, 6.6 &#x3bc;g/ml, 6.7 &#x3bc;g/ml, 6.8 &#x3bc;g/ml, 6.9 &#x3bc;g/ml, 7 &#x3bc;g/ml, 7.1 &#x3bc;g/ml, 7.2 &#x3bc;g/ml, 7.3 &#x3bc;g/ml, 7.4 &#x3bc;g/ml, 7.5 &#x3bc;g/ml, 7.6 &#x3bc;g/ml, 7.7 &#x3bc;g/ml, 7.8 &#x3bc;g/ml, 7.9 &#x3bc;g/ml, 8 &#x3bc;g/ml, 8.1 &#x3bc;g/ml, 8.2 &#x3bc;g/ml, 8.3 &#x3bc;g/ml, 8.4 &#x3bc;g/ml, 8.5 &#x3bc;g/ml, 8.6 &#x3bc;g/ml, 8.7 &#x3bc;g/ml, 8.8 &#x3bc;g/ml, 8.9 &#x3bc;g/ml, or 9 &#x3bc;g/ml).</p><p id="p-0256" num="0215">In some embodiments, the concentration of the poloxamer, when contacted with the cell, is from about 50 ng/ml to about 8 &#x3bc;g/ml (e.g., about 50 ng/ml, 55 ng/ml, 60 ng/ml, 65 ng/ml, 70 ng/ml, 75 ng/ml, 80 ng/ml, 85 ng/ml, 90 ng/ml, 95 ng/ml, 100 ng/ml, 105 ng/ml, 110 ng/ml, 115 ng/ml, 120 ng/ml, 125 ng/ml, 130 ng/ml, 135 ng/ml, 140 ng/ml, 145 ng/ml, 150 ng/ml, 155 ng/ml, 160 ng/ml, 165 ng/ml, 170 ng/ml, 175 ng/ml, 180 ng/ml, 185 ng/ml, 190 ng/ml, 195 ng/ml, 200 ng/ml, 205 ng/ml, 210 ng/ml, 215 ng/ml, 220 ng/ml, 225 ng/ml, 230 ng/ml, 235 ng/ml, 240 ng/ml, 245 ng/ml, 250 ng/ml, 255 ng/ml, 260 ng/ml, 265 ng/ml, 270 ng/ml, 275 ng/ml, 280 ng/ml, 285 ng/ml, 290 ng/ml, 295 ng/ml, 300 ng/ml, 305 ng/ml, 310 ng/ml, 315 ng/ml, 320 ng/ml, 325 ng/ml, 330 ng/ml, 335 ng/ml, 340 ng/ml, 345 ng/ml, 350 ng/ml, 355 ng/ml, 360 ng/ml, 365 ng/ml, 370 ng/ml, 375 ng/ml, 380 ng/ml, 385 ng/ml, 390 ng/ml, 395 ng/ml, 400 ng/ml, 405 ng/ml, 410 ng/ml, 415 ng/ml, 420 ng/ml, 425 ng/ml, 430 ng/ml, 435 ng/ml, 440 ng/ml, 445 ng/ml, 450 ng/ml, 455 ng/ml, 460 ng/ml, 465 ng/ml, 470 ng/ml, 475 ng/ml, 480 ng/ml, 485 ng/ml, 490 ng/ml, 495 ng/ml, 500 ng/ml, 505 ng/ml, 510 ng/ml, 515 ng/ml, 520 ng/ml, 525 ng/ml, 530 ng/ml, 535 ng/ml, 540 ng/ml, 545 ng/ml, 550 ng/ml, 555 ng/ml, 560 ng/ml, 565 ng/ml, 570 ng/ml, 575 ng/ml, 580 ng/ml, 585 ng/ml, 590 ng/ml, 595 ng/ml, 600 ng/ml, 605 ng/ml, 610 ng/ml, 615 ng/ml, 620 ng/ml, 625 ng/ml, 630 ng/ml, 635 ng/ml, 640 ng/ml, 645 ng/ml, 650 ng/ml, 655 ng/ml, 660 ng/ml, 665 ng/ml, 670 ng/ml, 675 ng/ml, 680 ng/ml, 685 ng/ml, 690 ng/ml, 695 ng/ml, 700 ng/ml, 705 ng/ml, 710 ng/ml, 715 ng/ml, 720 ng/ml, 725 ng/ml, 730 ng/ml, 735 ng/ml, 740 ng/ml, 745 ng/ml, 750 ng/ml, 755 ng/ml, 760 ng/ml, 765 ng/ml, 770 ng/ml, 775 ng/ml, 780 ng/ml, 785 ng/ml, 790 ng/ml, 795 ng/ml, 800 ng/ml, 805 ng/ml, 810 ng/ml, 815 ng/ml, 820 ng/ml, 825 ng/ml, 830 ng/ml, 835 ng/ml, 840 ng/ml, 845 ng/ml, 850 ng/ml, 855 ng/ml, 860 ng/ml, 865 ng/ml, 870 ng/ml, 875 ng/ml, 880 ng/ml, 885 ng/ml, 890 ng/ml, 895 ng/ml, 900 ng/ml, 905 ng/ml, 910 ng/ml, 915 ng/ml, 920 ng/ml, 925 ng/ml, 930 ng/ml, 935 ng/ml, 940 ng/ml, 945 ng/ml, 950 ng/ml, 955 ng/ml, 960 ng/ml, 965 ng/ml, 970 ng/ml, 975 ng/ml, 980 ng/ml, 985 ng/ml, 990 ng/ml, 995 ng/ml, 1 &#x3bc;g/ml, 1.1 &#x3bc;g/ml, 1.2 &#x3bc;g/ml, 1.3 &#x3bc;g/ml, 1.4 &#x3bc;g/ml, 1.5 &#x3bc;g/ml, 1.6 &#x3bc;g/ml, 1.7 &#x3bc;g/ml, 1.8 &#x3bc;g/ml, 1.9 &#x3bc;g/ml, 2 &#x3bc;g/ml, 2.1 &#x3bc;g/ml, 2.2 &#x3bc;g/ml, 2.3 &#x3bc;g/ml, 2.4 &#x3bc;g/ml, 2.5 &#x3bc;g/ml, 2.6 &#x3bc;g/ml, 2.7 &#x3bc;g/ml, 2.8 &#x3bc;g/ml, 2.9 &#x3bc;g/ml, 3 &#x3bc;g/ml, 3.1 &#x3bc;g/ml, 3.2 &#x3bc;g/ml, 3.3 &#x3bc;g/ml, 3.4 &#x3bc;g/ml, 3.5 &#x3bc;g/ml, 3.6 &#x3bc;g/ml, 3.7 &#x3bc;g/ml, 3.8 &#x3bc;g/ml, 3.9 &#x3bc;g/ml, 4 &#x3bc;g/ml, 4.1 &#x3bc;g/ml, 4.2 &#x3bc;g/ml, 4.3 &#x3bc;g/ml, 4.4 &#x3bc;g/ml, 4.5 &#x3bc;g/ml, 4.6 &#x3bc;g/ml, 4.7 &#x3bc;g/ml, 4.8 &#x3bc;g/ml, 4.9 &#x3bc;g/ml, 5 &#x3bc;g/ml, 5.1 &#x3bc;g/ml, 5.2 &#x3bc;g/ml, 5.3 &#x3bc;g/ml, 5.4 &#x3bc;g/ml, 5.5 &#x3bc;g/ml, 5.6 &#x3bc;g/ml, 5.7 &#x3bc;g/ml, 5.8 &#x3bc;g/ml, 5.9 &#x3bc;g/ml, 6 &#x3bc;g/ml, 6.1 &#x3bc;g/ml, 6.2 &#x3bc;g/ml, 6.3 &#x3bc;g/ml, 6.4 &#x3bc;g/ml, 6.5 &#x3bc;g/ml, 6.6 &#x3bc;g/ml, 6.7 &#x3bc;g/ml, 6.8 &#x3bc;g/ml, 6.9 &#x3bc;g/ml, 7 &#x3bc;g/ml, 7.1 &#x3bc;g/ml, 7.2 &#x3bc;g/ml, 7.3 &#x3bc;g/ml, 7.4 &#x3bc;g/ml, 7.5 &#x3bc;g/ml, 7.6 &#x3bc;g/ml, 7.7 &#x3bc;g/ml, 7.8 &#x3bc;g/ml, 7.9 &#x3bc;g/ml, or 8 &#x3bc;g/ml).</p><p id="p-0257" num="0216">In some embodiments, the concentration of the poloxamer, when contacted with the cell, is from about 100 ng/ml to about 7 &#x3bc;g/ml (e.g., about 100 ng/ml, 105 ng/ml, 110 ng/ml, 115 ng/ml, 120 ng/ml, 125 ng/ml, 130 ng/ml, 135 ng/ml, 140 ng/ml, 145 ng/ml, 150 ng/ml, 155 ng/ml, 160 ng/ml, 165 ng/ml, 170 ng/ml, 175 ng/ml, 180 ng/ml, 185 ng/ml, 190 ng/ml, 195 ng/ml, 200 ng/ml, 205 ng/ml, 210 ng/ml, 215 ng/ml, 220 ng/ml, 225 ng/ml, 230 ng/ml, 235 ng/ml, 240 ng/ml, 245 ng/ml, 250 ng/ml, 255 ng/ml, 260 ng/ml, 265 ng/ml, 270 ng/ml, 275 ng/ml, 280 ng/ml, 285 ng/ml, 290 ng/ml, 295 ng/ml, 300 ng/ml, 305 ng/ml, 310 ng/ml, 315 ng/ml, 320 ng/ml, 325 ng/ml, 330 ng/ml, 335 ng/ml, 340 ng/ml, 345 ng/ml, 350 ng/ml, 355 ng/ml, 360 ng/ml, 365 ng/ml, 370 ng/ml, 375 ng/ml, 380 ng/ml, 385 ng/ml, 390 ng/ml, 395 ng/ml, 400 ng/ml, 405 ng/ml, 410 ng/ml, 415 ng/ml, 420 ng/ml, 425 ng/ml, 430 ng/ml, 435 ng/ml, 440 ng/ml, 445 ng/ml, 450 ng/ml, 455 ng/ml, 460 ng/ml, 465 ng/ml, 470 ng/ml, 475 ng/ml, 480 ng/ml, 485 ng/ml, 490 ng/ml, 495 ng/ml, 500 ng/ml, 505 ng/ml, 510 ng/ml, 515 ng/ml, 520 ng/ml, 525 ng/ml, 530 ng/ml, 535 ng/ml, 540 ng/ml, 545 ng/ml, 550 ng/ml, 555 ng/ml, 560 ng/ml, 565 ng/ml, 570 ng/ml, 575 ng/ml, 580 ng/ml, 585 ng/ml, 590 ng/ml, 595 ng/ml, 600 ng/ml, 605 ng/ml, 610 ng/ml, 615 ng/ml, 620 ng/ml, 625 ng/ml, 630 ng/ml, 635 ng/ml, 640 ng/ml, 645 ng/ml, 650 ng/ml, 655 ng/ml, 660 ng/ml, 665 ng/ml, 670 ng/ml, 675 ng/ml, 680 ng/ml, 685 ng/ml, 690 ng/ml, 695 ng/ml, 700 ng/ml, 705 ng/ml, 710 ng/ml, 715 ng/ml, 720 ng/ml, 725 ng/ml, 730 ng/ml, 735 ng/ml, 740 ng/ml, 745 ng/ml, 750 ng/ml, 755 ng/ml, 760 ng/ml, 765 ng/ml, 770 ng/ml, 775 ng/ml, 780 ng/ml, 785 ng/ml, 790 ng/ml, 795 ng/ml, 800 ng/ml, 805 ng/ml, 810 ng/ml, 815 ng/ml, 820 ng/ml, 825 ng/ml, 830 ng/ml, 835 ng/ml, 840 ng/ml, 845 ng/ml, 850 ng/ml, 855 ng/ml, 860 ng/ml, 865 ng/ml, 870 ng/ml, 875 ng/ml, 880 ng/ml, 885 ng/ml, 890 ng/ml, 895 ng/ml, 900 ng/ml, 905 ng/ml, 910 ng/ml, 915 ng/ml, 920 ng/ml, 925 ng/ml, 930 ng/ml, 935 ng/ml, 940 ng/ml, 945 ng/ml, 950 ng/ml, 955 ng/ml, 960 ng/ml, 965 ng/ml, 970 ng/ml, 975 ng/ml, 980 ng/ml, 985 ng/ml, 990 ng/ml, 995 ng/ml, 1 &#x3bc;g/ml, 1.1 &#x3bc;g/ml, 1.2 &#x3bc;g/ml, 1.3 &#x3bc;g/ml, 1.4 &#x3bc;g/ml, 1.5 &#x3bc;g/ml, 1.6 &#x3bc;g/ml, 1.7 &#x3bc;g/ml, 1.8 &#x3bc;g/ml, 1.9 &#x3bc;g/ml, 2 &#x3bc;g/ml, 2.1 &#x3bc;g/ml, 2.2 &#x3bc;g/ml, 2.3 &#x3bc;g/ml, 2.4 &#x3bc;g/ml, 2.5 &#x3bc;g/ml, 2.6 &#x3bc;g/ml, 2.7 &#x3bc;g/ml, 2.8 &#x3bc;g/ml, 2.9 &#x3bc;g/ml, 3 &#x3bc;g/ml, 3.1 &#x3bc;g/ml, 3.2 &#x3bc;g/ml, 3.3 &#x3bc;g/ml, 3.4 &#x3bc;g/ml, 3.5 &#x3bc;g/ml, 3.6 &#x3bc;g/ml, 3.7 &#x3bc;g/ml, 3.8 &#x3bc;g/ml, 3.9 &#x3bc;g/ml, 4 &#x3bc;g/ml, 4.1 &#x3bc;g/ml, 4.2 &#x3bc;g/ml, 4.3 &#x3bc;g/ml, 4.4 &#x3bc;g/ml, 4.5 &#x3bc;g/ml, 4.6 &#x3bc;g/ml, 4.7 &#x3bc;g/ml, 4.8 &#x3bc;g/ml, 4.9 &#x3bc;g/ml, 5 &#x3bc;g/ml, 5.1 &#x3bc;g/ml, 5.2 &#x3bc;g/ml, 5.3 &#x3bc;g/ml, 5.4 &#x3bc;g/ml, 5.5 &#x3bc;g/ml, 5.6 &#x3bc;g/ml, 5.7 &#x3bc;g/ml, 5.8 &#x3bc;g/ml, 5.9 &#x3bc;g/ml, 6 &#x3bc;g/ml, 6.1 &#x3bc;g/ml, 6.2 &#x3bc;g/ml, 6.3 &#x3bc;g/ml, 6.4 &#x3bc;g/ml, 6.5 &#x3bc;g/ml, 6.6 &#x3bc;g/ml, 6.7 &#x3bc;g/ml, 6.8 &#x3bc;g/ml, 6.9 &#x3bc;g/ml, or 7 &#x3bc;g/ml).</p><p id="p-0258" num="0217">In some embodiments, the concentration of the poloxamer, when contacted with the cell, is from about 250 ng/ml to about 6 &#x3bc;g/ml (e.g., about 250 ng/ml, 255 ng/ml, 260 ng/ml, 265 ng/ml, 270 ng/ml, 275 ng/ml, 280 ng/ml, 285 ng/ml, 290 ng/ml, 295 ng/ml, 300 ng/ml, 305 ng/ml, 310 ng/ml, 315 ng/ml, 320 ng/ml, 325 ng/ml, 330 ng/ml, 335 ng/ml, 340 ng/ml, 345 ng/ml, 350 ng/ml, 355 ng/ml, 360 ng/ml, 365 ng/ml, 370 ng/ml, 375 ng/ml, 380 ng/ml, 385 ng/ml, 390 ng/ml, 395 ng/ml, 400 ng/ml, 405 ng/ml, 410 ng/ml, 415 ng/ml, 420 ng/ml, 425 ng/ml, 430 ng/ml, 435 ng/ml, 440 ng/ml, 445 ng/ml, 450 ng/ml, 455 ng/ml, 460 ng/ml, 465 ng/ml, 470 ng/ml, 475 ng/ml, 480 ng/ml, 485 ng/ml, 490 ng/ml, 495 ng/ml, 500 ng/ml, 505 ng/ml, 510 ng/ml, 515 ng/ml, 520 ng/ml, 525 ng/ml, 530 ng/ml, 535 ng/ml, 540 ng/ml, 545 ng/ml, 550 ng/ml, 555 ng/ml, 560 ng/ml, 565 ng/ml, 570 ng/ml, 575 ng/ml, 580 ng/ml, 585 ng/ml, 590 ng/ml, 595 ng/ml, 600 ng/ml, 605 ng/ml, 610 ng/ml, 615 ng/ml, 620 ng/ml, 625 ng/ml, 630 ng/ml, 635 ng/ml, 640 ng/ml, 645 ng/ml, 650 ng/ml, 655 ng/ml, 660 ng/ml, 665 ng/ml, 670 ng/ml, 675 ng/ml, 680 ng/ml, 685 ng/ml, 690 ng/ml, 695 ng/ml, 700 ng/ml, 705 ng/ml, 710 ng/ml, 715 ng/ml, 720 ng/ml, 725 ng/ml, 730 ng/ml, 735 ng/ml, 740 ng/ml, 745 ng/ml, 750 ng/ml, 755 ng/ml, 760 ng/ml, 765 ng/ml, 770 ng/ml, 775 ng/ml, 780 ng/ml, 785 ng/ml, 790 ng/ml, 795 ng/ml, 800 ng/ml, 805 ng/ml, 810 ng/ml, 815 ng/ml, 820 ng/ml, 825 ng/ml, 830 ng/ml, 835 ng/ml, 840 ng/ml, 845 ng/ml, 850 ng/ml, 855 ng/ml, 860 ng/ml, 865 ng/ml, 870 ng/ml, 875 ng/ml, 880 ng/ml, 885 ng/ml, 890 ng/ml, 895 ng/ml, 900 ng/ml, 905 ng/ml, 910 ng/ml, 915 ng/ml, 920 ng/ml, 925 ng/ml, 930 ng/ml, 935 ng/ml, 940 ng/ml, 945 ng/ml, 950 ng/ml, 955 ng/ml, 960 ng/ml, 965 ng/ml, 970 ng/ml, 975 ng/ml, 980 ng/ml, 985 ng/ml, 990 ng/ml, 995 ng/ml, 1 &#x3bc;g/ml, 1.1 &#x3bc;g/ml, 1.2 &#x3bc;g/ml, 1.3 &#x3bc;g/ml, 1.4 &#x3bc;g/ml, 1.5 &#x3bc;g/ml, 1.6 &#x3bc;g/ml, 1.7 &#x3bc;g/ml, 1.8 &#x3bc;g/ml, 1.9 &#x3bc;g/ml, 2 &#x3bc;g/ml, 2.1 &#x3bc;g/ml, 2.2 &#x3bc;g/ml, 2.3 &#x3bc;g/ml, 2.4 &#x3bc;g/ml, 2.5 &#x3bc;g/ml, 2.6 &#x3bc;g/ml, 2.7 &#x3bc;g/ml, 2.8 &#x3bc;g/ml, 2.9 &#x3bc;g/ml, 3 &#x3bc;g/ml, 3.1 &#x3bc;g/ml, 3.2 &#x3bc;g/ml, 3.3 &#x3bc;g/ml, 3.4 &#x3bc;g/ml, 3.5 &#x3bc;g/ml, 3.6 &#x3bc;g/ml, 3.7 &#x3bc;g/ml, 3.8 &#x3bc;g/ml, 3.9 &#x3bc;g/ml, 4 &#x3bc;g/ml, 4.1 &#x3bc;g/ml, 4.2 &#x3bc;g/ml, 4.3 &#x3bc;g/ml, 4.4 &#x3bc;g/ml, 4.5 &#x3bc;g/ml, 4.6 &#x3bc;g/ml, 4.7 &#x3bc;g/ml, 4.8 &#x3bc;g/ml, 4.9 &#x3bc;g/ml, 5 &#x3bc;g/ml, 5.1 &#x3bc;g/ml, 5.2 &#x3bc;g/ml, 5.3 &#x3bc;g/ml, 5.4 &#x3bc;g/ml, 5.5 &#x3bc;g/ml, 5.6 &#x3bc;g/ml, 5.7 &#x3bc;g/ml, 5.8 &#x3bc;g/ml, 5.9 &#x3bc;g/ml, or 6 &#x3bc;g/ml).</p><p id="p-0259" num="0218">In some embodiments, the concentration of the poloxamer, when contacted with the cell, is from about 500 ng/ml to about 5 &#x3bc;g/ml (e.g., about 500 ng/ml, 505 ng/ml, 510 ng/ml, 515 ng/ml, 520 ng/ml, 525 ng/ml, 530 ng/ml, 535 ng/ml, 540 ng/ml, 545 ng/ml, 550 ng/ml, 555 ng/ml, 560 ng/ml, 565 ng/ml, 570 ng/ml, 575 ng/ml, 580 ng/ml, 585 ng/ml, 590 ng/ml, 595 ng/ml, 600 ng/ml, 605 ng/ml, 610 ng/ml, 615 ng/ml, 620 ng/ml, 625 ng/ml, 630 ng/ml, 635 ng/ml, 640 ng/ml, 645 ng/ml, 650 ng/ml, 655 ng/ml, 660 ng/ml, 665 ng/ml, 670 ng/ml, 675 ng/ml, 680 ng/ml, 685 ng/ml, 690 ng/ml, 695 ng/ml, 700 ng/ml, 705 ng/ml, 710 ng/ml, 715 ng/ml, 720 ng/ml, 725 ng/ml, 730 ng/ml, 735 ng/ml, 740 ng/ml, 745 ng/ml, 750 ng/ml, 755 ng/ml, 760 ng/ml, 765 ng/ml, 770 ng/ml, 775 ng/ml, 780 ng/ml, 785 ng/ml, 790 ng/ml, 795 ng/ml, 800 ng/ml, 805 ng/ml, 810 ng/ml, 815 ng/ml, 820 ng/ml, 825 ng/ml, 830 ng/ml, 835 ng/ml, 840 ng/ml, 845 ng/ml, 850 ng/ml, 855 ng/ml, 860 ng/ml, 865 ng/ml, 870 ng/ml, 875 ng/ml, 880 ng/ml, 885 ng/ml, 890 ng/ml, 895 ng/ml, 900 ng/ml, 905 ng/ml, 910 ng/ml, 915 ng/ml, 920 ng/ml, 925 ng/ml, 930 ng/ml, 935 ng/ml, 940 ng/ml, 945 ng/ml, 950 ng/ml, 955 ng/ml, 960 ng/ml, 965 ng/ml, 970 ng/ml, 975 ng/ml, 980 ng/ml, 985 ng/ml, 990 ng/ml, 995 ng/ml, 1 &#x3bc;g/ml, 1.1 &#x3bc;g/ml, 1.2 &#x3bc;g/ml, 1.3 &#x3bc;g/ml, 1.4 &#x3bc;g/ml, 1.5 &#x3bc;g/ml, 1.6 &#x3bc;g/ml, 1.7 &#x3bc;g/ml, 1.8 &#x3bc;g/ml, 1.9 &#x3bc;g/ml, 2 &#x3bc;g/ml, 2.1 &#x3bc;g/ml, 2.2 &#x3bc;g/ml, 2.3 &#x3bc;g/ml, 2.4 &#x3bc;g/ml, 2.5 &#x3bc;g/ml, 2.6 &#x3bc;g/ml, 2.7 &#x3bc;g/ml, 2.8 &#x3bc;g/ml, 2.9 &#x3bc;g/ml, 3 &#x3bc;g/ml, 3.1 &#x3bc;g/ml, 3.2 &#x3bc;g/ml, 3.3 &#x3bc;g/ml, 3.4 &#x3bc;g/ml, 3.5 &#x3bc;g/ml, 3.6 &#x3bc;g/ml, 3.7 &#x3bc;g/ml, 3.8 &#x3bc;g/ml, 3.9 &#x3bc;g/ml, 4 &#x3bc;g/ml, 4.1 &#x3bc;g/ml, 4.2 &#x3bc;g/ml, 4.3 &#x3bc;g/ml, 4.4 &#x3bc;g/ml, 4.5 &#x3bc;g/ml, 4.6 &#x3bc;g/ml, 4.7 &#x3bc;g/ml, 4.8 &#x3bc;g/ml, 4.9 &#x3bc;g/ml, or 5 &#x3bc;g/ml).</p><p id="p-0260" num="0219">In some embodiments, the concentration of the poloxamer, when contacted with the cell, is from about 750 ng/ml to about 3 &#x3bc;g/ml (e.g., about 750 ng/ml, 755 ng/ml, 760 ng/ml, 765 ng/ml, 770 ng/ml, 775 ng/ml, 780 ng/ml, 785 ng/ml, 790 ng/ml, 795 ng/ml, 800 ng/ml, 805 ng/ml, 810 ng/ml, 815 ng/ml, 820 ng/ml, 825 ng/ml, 830 ng/ml, 835 ng/ml, 840 ng/ml, 845 ng/ml, 850 ng/ml, 855 ng/ml, 860 ng/ml, 865 ng/ml, 870 ng/ml, 875 ng/ml, 880 ng/ml, 885 ng/ml, 890 ng/ml, 895 ng/ml, 900 ng/ml, 905 ng/ml, 910 ng/ml, 915 ng/ml, 920 ng/ml, 925 ng/ml, 930 ng/ml, 935 ng/ml, 940 ng/ml, 945 ng/ml, 950 ng/ml, 955 ng/ml, 960 ng/ml, 965 ng/ml, 970 ng/ml, 975 ng/ml, 980 ng/ml, 985 ng/ml, 990 ng/ml, 995 ng/ml, 1 &#x3bc;g/ml, 1.1 &#x3bc;g/ml, 1.2 &#x3bc;g/ml, 1.3 &#x3bc;g/ml, 1.4 &#x3bc;g/ml, 1.5 &#x3bc;g/ml, 1.6 &#x3bc;g/ml, 1.7 &#x3bc;g/ml, 1.8 &#x3bc;g/ml, 1.9 &#x3bc;g/ml, 2 &#x3bc;g/ml, 2.1 &#x3bc;g/ml, 2.2 &#x3bc;g/ml, 2.3 &#x3bc;g/ml, 2.4 &#x3bc;g/ml, 2.5 &#x3bc;g/ml, 2.6 &#x3bc;g/ml, 2.7 &#x3bc;g/ml, 2.8 &#x3bc;g/ml, 2.9 &#x3bc;g/ml, or 3 &#x3bc;g/ml).</p><p id="p-0261" num="0220">In some embodiments, the concentration of the poloxamer, when contacted with the cell, is from about 800 ng/ml to about 2 &#x3bc;g/ml (e.g., about 800 ng/ml, 805 ng/ml, 810 ng/ml, 815 ng/ml, 820 ng/ml, 825 ng/ml, 830 ng/ml, 835 ng/ml, 840 ng/ml, 845 ng/ml, 850 ng/ml, 855 ng/ml, 860 ng/ml, 865 ng/ml, 870 ng/ml, 875 ng/ml, 880 ng/ml, 885 ng/ml, 890 ng/ml, 895 ng/ml, 900 ng/ml, 905 ng/ml, 910 ng/ml, 915 ng/ml, 920 ng/ml, 925 ng/ml, 930 ng/ml, 935 ng/ml, 940 ng/ml, 945 ng/ml, 950 ng/ml, 955 ng/ml, 960 ng/ml, 965 ng/ml, 970 ng/ml, 975 ng/ml, 980 ng/ml, 985 ng/ml, 990 ng/ml, 995 ng/ml, 1 &#x3bc;g/ml, 1.1 &#x3bc;g/ml, 1.2 &#x3bc;g/ml, 1.3 &#x3bc;g/ml, 1.4 &#x3bc;g/ml, 1.5 &#x3bc;g/ml, 1.6 &#x3bc;g/ml, 1.7 &#x3bc;g/ml, 1.8 &#x3bc;g/ml, 1.9 &#x3bc;g/ml, or 2 &#x3bc;g/ml).</p><p id="p-0262" num="0221">In some embodiments, the concentration of the poloxamer, when contacted with the cell, is from about 900 ng/ml to about 1.1 &#x3bc;g/ml (e.g., about 900 ng/ml, 905 ng/ml, 910 ng/ml, 915 ng/ml, 920 ng/ml, 925 ng/ml, 930 ng/ml, 935 ng/ml, 940 ng/ml, 945 ng/ml, 950 ng/ml, 955 ng/ml, 960 ng/ml, 965 ng/ml, 970 ng/ml, 975 ng/ml, 980 ng/ml, 985 ng/ml, 990 ng/ml, 995 ng/ml, 1 &#x3bc;g/ml, 1.01 &#x3bc;g/ml, 1.02 &#x3bc;g/ml, 1.03 &#x3bc;g/ml, 1.04 &#x3bc;g/ml, 1.05 &#x3bc;g/ml, 1.06 &#x3bc;g/ml, 1.07 &#x3bc;g/ml, 1.08 &#x3bc;g/ml, 1.09 &#x3bc;g/ml, or 1.1 &#x3bc;g/ml). In some embodiments, the concentration of the poloxamer, when contacted with the cell, is about 1 &#x3bc;g/ml.</p><p id="p-0263" num="0222">In some embodiments, the poloxamer has an average molar mass of polyoxypropylene subunits of greater than 2,050 g/mol (e.g., an average molar mass of polyoxypropylene subunits of about 2,055 g/mol, 2,060 g/mol, 2,075 g/mol, 2,080 g/mol, 2,085 g/mol, 2,090 g/mol, 2,095 g/mol, 2,100 g/mol, 2,200 g/mol, 2,300 g/mol, 2,400 g/mol, 2,500 g/mol, 2,600 g/mol, 2,700 g/mol, 2,800 g/mol, 2,900 g/mol, 3,000 g/mol, 3,100 g/mol, 3,200 g/mol, 3,300 g/mol, 3,400 g/mol, 3,500 g/mol, 3,600 g/mol, 3,700 g/mol, 3,800 g/mol, 3,900 g/mol, 4,000 g/mol, 4,100 g/mol, 4,200 g/mol, 4,300 g/mol, 4,400 g/mol, 4,500 g/mol, 4,600 g/mol, 4,700 g/mol, 4,800 g/mol, 4,900 g/mol, or 5,000 g/mol, or more).</p><p id="p-0264" num="0223">In some embodiments, the poloxamer has an average molar mass of polyoxypropylene subunits of greater than 2,250 g/mol (e.g., an average molar mass of polyoxypropylene subunits of about 2,300 g/mol, 2,400 g/mol, 2,500 g/mol, 2,600 g/mol, 2,700 g/mol, 2,800 g/mol, 2,900 g/mol, 3,000 g/mol, 3,100 g/mol, 3,200 g/mol, 3,300 g/mol, 3,400 g/mol, 3,500 g/mol, 3,600 g/mol, 3,700 g/mol, 3,800 g/mol, 3,900 g/mol, 4,000 g/mol, 4,100 g/mol, 4,200 g/mol, 4,300 g/mol, 4,400 g/mol, 4,500 g/mol, 4,600 g/mol, 4,700 g/mol, 4,800 g/mol, 4,900 g/mol, or 5,000 g/mol, or more).</p><p id="p-0265" num="0224">In some embodiments, the poloxamer has an average molar mass of polyoxypropylene subunits of greater than 2,750 g/mol (e.g., an average molar mass of polyoxypropylene subunits of about 2,800 g/mol, 2,900 g/mol, 3,000 g/mol, 3,100 g/mol, 3,200 g/mol, 3,300 g/mol, 3,400 g/mol, 3,500 g/mol, 3,600 g/mol, 3,700 g/mol, 3,800 g/mol, 3,900 g/mol, 4,000 g/mol, 4,100 g/mol, 4,200 g/mol, 4,300 g/mol, 4,400 g/mol, 4,500 g/mol, 4,600 g/mol, 4,700 g/mol, 4,800 g/mol, 4,900 g/mol, or 5,000 g/mol, or more).</p><p id="p-0266" num="0225">In some embodiments, the poloxamer has an average molar mass of polyoxypropylene subunits of greater than 3,250 g/mol (e.g., an average molar mass of polyoxypropylene subunits of about 3,300 g/mol, 3,400 g/mol, 3,500 g/mol, 3,600 g/mol, 3,700 g/mol, 3,800 g/mol, 3,900 g/mol, 4,000 g/mol, 4,100 g/mol, 4,200 g/mol, 4,300 g/mol, 4,400 g/mol, 4,500 g/mol, 4,600 g/mol, 4,700 g/mol, 4,800 g/mol, 4,900 g/mol, or 5,000 g/mol, or more).</p><p id="p-0267" num="0226">In some embodiments, the poloxamer has an average molar mass of polyoxypropylene subunits of greater than 3,625 g/mol (e.g., an average molar mass of polyoxypropylene subunits of about 3,700 g/mol, 3,800 g/mol, 3,900 g/mol, 4,000 g/mol, 4,100 g/mol, 4,200 g/mol, 4,300 g/mol, 4,400 g/mol, 4,500 g/mol, 4,600 g/mol, 4,700 g/mol, 4,800 g/mol, 4,900 g/mol, or 5,000 g/mol, or more).</p><p id="p-0268" num="0227">In some embodiments, the poloxamer has an average molar mass of polyoxypropylene subunits of from about 2,050 g/mol to about 4,000 g/mol (e.g., about 2,050 g/mol, 2,055 g/mol, 2,060 g/mol, 2,065 g/mol, 2,070 g/mol, 2,075 g/mol, 2,080 g/mol, 2,085 g/mol, 2,090 g/mol, 2,095 g/mol, 2,100 g/mol, 2,105 g/mol, 2,110 g/mol, 2,115 g/mol, 2,120 g/mol, 2,125 g/mol, 2,130 g/mol, 2,135 g/mol, 2,140 g/mol, 2,145 g/mol, 2,150 g/mol, 2,155 g/mol, 2,160 g/mol, 2,165 g/mol, 2,170 g/mol, 2,175 g/mol, 2,180 g/mol, 2,185 g/mol, 2,190 g/mol, 2,195 g/mol, 2,200 g/mol, 2,205 g/mol, 2,210 g/mol, 2,215 g/mol, 2,220 g/mol, 2,225 g/mol, 2,230 g/mol, 2,235 g/mol, 2,240 g/mol, 2,245 g/mol, 2,250 g/mol, 2,255 g/mol, 2,260 g/mol, 2,265 g/mol, 2,270 g/mol, 2,275 g/mol, 2,280 g/mol, 2,285 g/mol, 2,290 g/mol, 2,295 g/mol, 2,300 g/mol, 2,305 g/mol, 2,310 g/mol, 2,315 g/mol, 2,320 g/mol, 2,325 g/mol, 2,330 g/mol, 2,335 g/mol, 2,340 g/mol, 2,345 g/mol, 2,350 g/mol, 2,355 g/mol, 2,360 g/mol, 2,365 g/mol, 2,370 g/mol, 2,375 g/mol, 2,380 g/mol, 2,385 g/mol, 2,390 g/mol, 2,395 g/mol, 2,400 g/mol, 2,405 g/mol, 2,410 g/mol, 2,415 g/mol, 2,420 g/mol, 2,425 g/mol, 2,430 g/mol, 2,435 g/mol, 2,440 g/mol, 2,445 g/mol, 2,450 g/mol, 2,455 g/mol, 2,460 g/mol, 2,465 g/mol, 2,470 g/mol, 2,475 g/mol, 2,480 g/mol, 2,485 g/mol, 2,490 g/mol, 2,495 g/mol, 2,500 g/mol, 2,505 g/mol, 2,510 g/mol, 2,515 g/mol, 2,520 g/mol, 2,525 g/mol, 2,530 g/mol, 2,535 g/mol, 2,540 g/mol, 2,545 g/mol, 2,550 g/mol, 2,555 g/mol, 2,560 g/mol, 2,565 g/mol, 2,570 g/mol, 2,575 g/mol, 2,580 g/mol, 2,585 g/mol, 2,590 g/mol, 2,595 g/mol, 2,600 g/mol, 2,605 g/mol, 2,610 g/mol, 2,615 g/mol, 2,620 g/mol, 2,625 g/mol, 2,630 g/mol, 2,635 g/mol, 2,640 g/mol, 2,645 g/mol, 2,650 g/mol, 2,655 g/mol, 2,660 g/mol, 2,665 g/mol, 2,670 g/mol, 2,675 g/mol, 2,680 g/mol, 2,685 g/mol, 2,690 g/mol, 2,695 g/mol, 2,700 g/mol, 2,705 g/mol, 2,710 g/mol, 2,715 g/mol, 2,720 g/mol, 2,725 g/mol, 2,730 g/mol, 2,735 g/mol, 2,740 g/mol, 2,745 g/mol, 2,750 g/mol, 2,755 g/mol, 2,760 g/mol, 2,765 g/mol, 2,770 g/mol, 2,775 g/mol, 2,780 g/mol, 2,785 g/mol, 2,790 g/mol, 2,795 g/mol, 2,800 g/mol, 2,805 g/mol, 2,810 g/mol, 2,815 g/mol, 2,820 g/mol, 2,825 g/mol, 2,830 g/mol, 2,835 g/mol, 2,840 g/mol, 2,845 g/mol, 2,850 g/mol, 2,855 g/mol, 2,860 g/mol, 2,865 g/mol, 2,870 g/mol, 2,875 g/mol, 2,880 g/mol, 2,885 g/mol, 2,890 g/mol, 2,895 g/mol, 2,900 g/mol, 2,905 g/mol, 2,910 g/mol, 2,915 g/mol, 2,920 g/mol, 2,925 g/mol, 2,930 g/mol, 2,935 g/mol, 2,940 g/mol, 2,945 g/mol, 2,950 g/mol, 2,955 g/mol, 2,960 g/mol, 2,965 g/mol, 2,970 g/mol, 2,975 g/mol, 2,980 g/mol, 2,985 g/mol, 2,990 g/mol, 2,995 g/mol, 3,000 g/mol, 3,005 g/mol, 3,010 g/mol, 3,015 g/mol, 3,020 g/mol, 3,025 g/mol, 3,030 g/mol, 3,035 g/mol, 3,040 g/mol, 3,045 g/mol, 3,050 g/mol, 3,055 g/mol, 3,060 g/mol, 3,065 g/mol, 3,070 g/mol, 3,075 g/mol, 3,080 g/mol, 3,085 g/mol, 3,090 g/mol, 3,095 g/mol, 3,100 g/mol, 3,105 g/mol, 3,110 g/mol, 3,115 g/mol, 3,120 g/mol, 3,125 g/mol, 3,130 g/mol, 3,135 g/mol, 3,140 g/mol, 3,145 g/mol, 3,150 g/mol, 3,155 g/mol, 3,160 g/mol, 3,165 g/mol, 3,170 g/mol, 3,175 g/mol, 3,180 g/mol, 3,185 g/mol, 3,190 g/mol, 3,195 g/mol, 3,200 g/mol, 3,205 g/mol, 3,210 g/mol, 3,215 g/mol, 3,220 g/mol, 3,225 g/mol, 3,230 g/mol, 3,235 g/mol, 3,240 g/mol, 3,245 g/mol, 3,250 g/mol, 3,255 g/mol, 3,260 g/mol, 3,265 g/mol, 3,270 g/mol, 3,275 g/mol, 3,280 g/mol, 3,285 g/mol, 3,290 g/mol, 3,295 g/mol, 3,300 g/mol, 3,305 g/mol, 3,310 g/mol, 3,315 g/mol, 3,320 g/mol, 3,325 g/mol, 3,330 g/mol, 3,335 g/mol, 3,340 g/mol, 3,345 g/mol, 3,350 g/mol, 3,355 g/mol, 3,360 g/mol, 3,365 g/mol, 3,370 g/mol, 3,375 g/mol, 3,380 g/mol, 3,385 g/mol, 3,390 g/mol, 3,395 g/mol, 3,400 g/mol, 3,405 g/mol, 3,410 g/mol, 3,415 g/mol, 3,420 g/mol, 3,425 g/mol, 3,430 g/mol, 3,435 g/mol, 3,440 g/mol, 3,445 g/mol, 3,450 g/mol, 3,455 g/mol, 3,460 g/mol, 3,465 g/mol, 3,470 g/mol, 3,475 g/mol, 3,480 g/mol, 3,485 g/mol, 3,490 g/mol, 3,495 g/mol, 3,500 g/mol, 3,505 g/mol, 3,510 g/mol, 3,515 g/mol, 3,520 g/mol, 3,525 g/mol, 3,530 g/mol, 3,535 g/mol, 3,540 g/mol, 3,545 g/mol, 3,550 g/mol, 3,555 g/mol, 3,560 g/mol, 3,565 g/mol, 3,570 g/mol, 3,575 g/mol, 3,580 g/mol, 3,585 g/mol, 3,590 g/mol, 3,595 g/mol, 3,600 g/mol, 3,605 g/mol, 3,610 g/mol, 3,615 g/mol, 3,620 g/mol, 3,625 g/mol, 3,630 g/mol, 3,635 g/mol, 3,640 g/mol, 3,645 g/mol, 3,650 g/mol, 3,655 g/mol, 3,660 g/mol, 3,665 g/mol, 3,670 g/mol, 3,675 g/mol, 3,680 g/mol, 3,685 g/mol, 3,690 g/mol, 3,695 g/mol, 3,700 g/mol, 3,705 g/mol, 3,710 g/mol, 3,715 g/mol, 3,720 g/mol, 3,725 g/mol, 3,730 g/mol, 3,735 g/mol, 3,740 g/mol, 3,745 g/mol, 3,750 g/mol, 3,755 g/mol, 3,760 g/mol, 3,765 g/mol, 3,770 g/mol, 3,775 g/mol, 3,780 g/mol, 3,785 g/mol, 3,790 g/mol, 3,795 g/mol, 3,800 g/mol, 3,805 g/mol, 3,810 g/mol, 3,815 g/mol, 3,820 g/mol, 3,825 g/mol, 3,830 g/mol, 3,835 g/mol, 3,840 g/mol, 3,845 g/mol, 3,850 g/mol, 3,855 g/mol, 3,860 g/mol, 3,865 g/mol, 3,870 g/mol, 3,875 g/mol, 3,880 g/mol, 3,885 g/mol, 3,890 g/mol, 3,895 g/mol, 3,900 g/mol, 3,905 g/mol, 3,910 g/mol, 3,915 g/mol, 3,920 g/mol, 3,925 g/mol, 3,930 g/mol, 3,935 g/mol, 3,940 g/mol, 3,945 g/mol, 3,950 g/mol, 3,955 g/mol, 3,960 g/mol, 3,965 g/mol, 3,970 g/mol, 3,975 g/mol, 3,980 g/mol, 3,985 g/mol, 3,990 g/mol, 3,995 g/mol, or 4,000 g/mol).</p><p id="p-0269" num="0228">In some embodiments, the poloxamer has an average molar mass of polyoxypropylene subunits of from about 2,750 g/mol to about 4,000 g/mol (e.g., about 2,750 g/mol, 2,755 g/mol, 2,760 g/mol, 2,765 g/mol, 2,770 g/mol, 2,775 g/mol, 2,780 g/mol, 2,785 g/mol, 2,790 g/mol, 2,795 g/mol, 2,800 g/mol, 2,805 g/mol, 2,810 g/mol, 2,815 g/mol, 2,820 g/mol, 2,825 g/mol, 2,830 g/mol, 2,835 g/mol, 2,840 g/mol, 2,845 g/mol, 2,850 g/mol, 2,855 g/mol, 2,860 g/mol, 2,865 g/mol, 2,870 g/mol, 2,875 g/mol, 2,880 g/mol, 2,885 g/mol, 2,890 g/mol, 2,895 g/mol, 2,900 g/mol, 2,905 g/mol, 2,910 g/mol, 2,915 g/mol, 2,920 g/mol, 2,925 g/mol, 2,930 g/mol, 2,935 g/mol, 2,940 g/mol, 2,945 g/mol, 2,950 g/mol, 2,955 g/mol, 2,960 g/mol, 2,965 g/mol, 2,970 g/mol, 2,975 g/mol, 2,980 g/mol, 2,985 g/mol, 2,990 g/mol, 2,995 g/mol, 3,000 g/mol, 3,005 g/mol, 3,010 g/mol, 3,015 g/mol, 3,020 g/mol, 3,025 g/mol, 3,030 g/mol, 3,035 g/mol, 3,040 g/mol, 3,045 g/mol, 3,050 g/mol, 3,055 g/mol, 3,060 g/mol, 3,065 g/mol, 3,070 g/mol, 3,075 g/mol, 3,080 g/mol, 3,085 g/mol, 3,090 g/mol, 3,095 g/mol, 3,100 g/mol, 3,105 g/mol, 3,110 g/mol, 3,115 g/mol, 3,120 g/mol, 3,125 g/mol, 3,130 g/mol, 3,135 g/mol, 3,140 g/mol, 3,145 g/mol, 3,150 g/mol, 3,155 g/mol, 3,160 g/mol, 3,165 g/mol, 3,170 g/mol, 3,175 g/mol, 3,180 g/mol, 3,185 g/mol, 3,190 g/mol, 3,195 g/mol, 3,200 g/mol, 3,205 g/mol, 3,210 g/mol, 3,215 g/mol, 3,220 g/mol, 3,225 g/mol, 3,230 g/mol, 3,235 g/mol, 3,240 g/mol, 3,245 g/mol, 3,250 g/mol, 3,255 g/mol, 3,260 g/mol, 3,265 g/mol, 3,270 g/mol, 3,275 g/mol, 3,280 g/mol, 3,285 g/mol, 3,290 g/mol, 3,295 g/mol, 3,300 g/mol, 3,305 g/mol, 3,310 g/mol, 3,315 g/mol, 3,320 g/mol, 3,325 g/mol, 3,330 g/mol, 3,335 g/mol, 3,340 g/mol, 3,345 g/mol, 3,350 g/mol, 3,355 g/mol, 3,360 g/mol, 3,365 g/mol, 3,370 g/mol, 3,375 g/mol, 3,380 g/mol, 3,385 g/mol, 3,390 g/mol, 3,395 g/mol, 3,400 g/mol, 3,405 g/mol, 3,410 g/mol, 3,415 g/mol, 3,420 g/mol, 3,425 g/mol, 3,430 g/mol, 3,435 g/mol, 3,440 g/mol, 3,445 g/mol, 3,450 g/mol, 3,455 g/mol, 3,460 g/mol, 3,465 g/mol, 3,470 g/mol, 3,475 g/mol, 3,480 g/mol, 3,485 g/mol, 3,490 g/mol, 3,495 g/mol, 3,500 g/mol, 3,505 g/mol, 3,510 g/mol, 3,515 g/mol, 3,520 g/mol, 3,525 g/mol, 3,530 g/mol, 3,535 g/mol, 3,540 g/mol, 3,545 g/mol, 3,550 g/mol, 3,555 g/mol, 3,560 g/mol, 3,565 g/mol, 3,570 g/mol, 3,575 g/mol, 3,580 g/mol, 3,585 g/mol, 3,590 g/mol, 3,595 g/mol, 3,600 g/mol, 3,605 g/mol, 3,610 g/mol, 3,615 g/mol, 3,620 g/mol, 3,625 g/mol, 3,630 g/mol, 3,635 g/mol, 3,640 g/mol, 3,645 g/mol, 3,650 g/mol, 3,655 g/mol, 3,660 g/mol, 3,665 g/mol, 3,670 g/mol, 3,675 g/mol, 3,680 g/mol, 3,685 g/mol, 3,690 g/mol, 3,695 g/mol, 3,700 g/mol, 3,705 g/mol, 3,710 g/mol, 3,715 g/mol, 3,720 g/mol, 3,725 g/mol, 3,730 g/mol, 3,735 g/mol, 3,740 g/mol, 3,745 g/mol, 3,750 g/mol, 3,755 g/mol, 3,760 g/mol, 3,765 g/mol, 3,770 g/mol, 3,775 g/mol, 3,780 g/mol, 3,785 g/mol, 3,790 g/mol, 3,795 g/mol, 3,800 g/mol, 3,805 g/mol, 3,810 g/mol, 3,815 g/mol, 3,820 g/mol, 3,825 g/mol, 3,830 g/mol, 3,835 g/mol, 3,840 g/mol, 3,845 g/mol, 3,850 g/mol, 3,855 g/mol, 3,860 g/mol, 3,865 g/mol, 3,870 g/mol, 3,875 g/mol, 3,880 g/mol, 3,885 g/mol, 3,890 g/mol, 3,895 g/mol, 3,900 g/mol, 3,905 g/mol, 3,910 g/mol, 3,915 g/mol, 3,920 g/mol, 3,925 g/mol, 3,930 g/mol, 3,935 g/mol, 3,940 g/mol, 3,945 g/mol, 3,950 g/mol, 3,955 g/mol, 3,960 g/mol, 3,965 g/mol, 3,970 g/mol, 3,975 g/mol, 3,980 g/mol, 3,985 g/mol, 3,990 g/mol, 3,995 g/mol, or 4,000 g/mol).</p><p id="p-0270" num="0229">In some embodiments, the poloxamer has an average molar mass of polyoxypropylene subunits of from about 3,250 g/mol to about 4,000 g/mol (e.g., about 3,250 g/mol, 3,255 g/mol, 3,260 g/mol, 3,265 g/mol, 3,270 g/mol, 3,275 g/mol, 3,280 g/mol, 3,285 g/mol, 3,290 g/mol, 3,295 g/mol, 3,300 g/mol, 3,305 g/mol, 3,310 g/mol, 3,315 g/mol, 3,320 g/mol, 3,325 g/mol, 3,330 g/mol, 3,335 g/mol, 3,340 g/mol, 3,345 g/mol, 3,350 g/mol, 3,355 g/mol, 3,360 g/mol, 3,365 g/mol, 3,370 g/mol, 3,375 g/mol, 3,380 g/mol, 3,385 g/mol, 3,390 g/mol, 3,395 g/mol, 3,400 g/mol, 3,405 g/mol, 3,410 g/mol, 3,415 g/mol, 3,420 g/mol, 3,425 g/mol, 3,430 g/mol, 3,435 g/mol, 3,440 g/mol, 3,445 g/mol, 3,450 g/mol, 3,455 g/mol, 3,460 g/mol, 3,465 g/mol, 3,470 g/mol, 3,475 g/mol, 3,480 g/mol, 3,485 g/mol, 3,490 g/mol, 3,495 g/mol, 3,500 g/mol, 3,505 g/mol, 3,510 g/mol, 3,515 g/mol, 3,520 g/mol, 3,525 g/mol, 3,530 g/mol, 3,535 g/mol, 3,540 g/mol, 3,545 g/mol, 3,550 g/mol, 3,555 g/mol, 3,560 g/mol, 3,565 g/mol, 3,570 g/mol, 3,575 g/mol, 3,580 g/mol, 3,585 g/mol, 3,590 g/mol, 3,595 g/mol, 3,600 g/mol, 3,605 g/mol, 3,610 g/mol, 3,615 g/mol, 3,620 g/mol, 3,625 g/mol, 3,630 g/mol, 3,635 g/mol, 3,640 g/mol, 3,645 g/mol, 3,650 g/mol, 3,655 g/mol, 3,660 g/mol, 3,665 g/mol, 3,670 g/mol, 3,675 g/mol, 3,680 g/mol, 3,685 g/mol, 3,690 g/mol, 3,695 g/mol, 3,700 g/mol, 3,705 g/mol, 3,710 g/mol, 3,715 g/mol, 3,720 g/mol, 3,725 g/mol, 3,730 g/mol, 3,735 g/mol, 3,740 g/mol, 3,745 g/mol, 3,750 g/mol, 3,755 g/mol, 3,760 g/mol, 3,765 g/mol, 3,770 g/mol, 3,775 g/mol, 3,780 g/mol, 3,785 g/mol, 3,790 g/mol, 3,795 g/mol, 3,800 g/mol, 3,805 g/mol, 3,810 g/mol, 3,815 g/mol, 3,820 g/mol, 3,825 g/mol, 3,830 g/mol, 3,835 g/mol, 3,840 g/mol, 3,845 g/mol, 3,850 g/mol, 3,855 g/mol, 3,860 g/mol, 3,865 g/mol, 3,870 g/mol, 3,875 g/mol, 3,880 g/mol, 3,885 g/mol, 3,890 g/mol, 3,895 g/mol, 3,900 g/mol, 3,905 g/mol, 3,910 g/mol, 3,915 g/mol, 3,920 g/mol, 3,925 g/mol, 3,930 g/mol, 3,935 g/mol, 3,940 g/mol, 3,945 g/mol, 3,950 g/mol, 3,955 g/mol, 3,960 g/mol, 3,965 g/mol, 3,970 g/mol, 3,975 g/mol, 3,980 g/mol, 3,985 g/mol, 3,990 g/mol, 3,995 g/mol, or 4,000 g/mol).</p><p id="p-0271" num="0230">In some embodiments, the poloxamer has an average molar mass of polyoxypropylene subunits of from about 3,625 g/mol to about 4,000 g/mol (e.g., about 3,625 g/mol, 3,630 g/mol, 3,635 g/mol, 3,640 g/mol, 3,645 g/mol, 3,650 g/mol, 3,655 g/mol, 3,660 g/mol, 3,665 g/mol, 3,670 g/mol, 3,675 g/mol, 3,680 g/mol, 3,685 g/mol, 3,690 g/mol, 3,695 g/mol, 3,700 g/mol, 3,705 g/mol, 3,710 g/mol, 3,715 g/mol, 3,720 g/mol, 3,725 g/mol, 3,730 g/mol, 3,735 g/mol, 3,740 g/mol, 3,745 g/mol, 3,750 g/mol, 3,755 g/mol, 3,760 g/mol, 3,765 g/mol, 3,770 g/mol, 3,775 g/mol, 3,780 g/mol, 3,785 g/mol, 3,790 g/mol, 3,795 g/mol, 3,800 g/mol, 3,805 g/mol, 3,810 g/mol, 3,815 g/mol, 3,820 g/mol, 3,825 g/mol, 3,830 g/mol, 3,835 g/mol, 3,840 g/mol, 3,845 g/mol, 3,850 g/mol, 3,855 g/mol, 3,860 g/mol, 3,865 g/mol, 3,870 g/mol, 3,875 g/mol, 3,880 g/mol, 3,885 g/mol, 3,890 g/mol, 3,895 g/mol, 3,900 g/mol, 3,905 g/mol, 3,910 g/mol, 3,915 g/mol, 3,920 g/mol, 3,925 g/mol, 3,930 g/mol, 3,935 g/mol, 3,940 g/mol, 3,945 g/mol, 3,950 g/mol, 3,955 g/mol, 3,960 g/mol, 3,965 g/mol, 3,970 g/mol, 3,975 g/mol, 3,980 g/mol, 3,985 g/mol, 3,990 g/mol, 3,995 g/mol, or 4,000 g/mol).</p><p id="p-0272" num="0231">In some embodiments, the poloxamer has an average ethylene oxide content of greater than 40% by mass (e.g., about 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, or more).</p><p id="p-0273" num="0232">In some embodiments, the poloxamer has an average ethylene oxide content of greater than 50% by mass (e.g., about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, or more).</p><p id="p-0274" num="0233">In some embodiments, the poloxamer has an average ethylene oxide content of greater than 60% by mass (e.g., about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, or more).</p><p id="p-0275" num="0234">In some embodiments, the poloxamer has an average ethylene oxide content of greater than 70% by mass (e.g., about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, or more).</p><p id="p-0276" num="0235">In some embodiments, the poloxamer has an average ethylene oxide content of from about 40% to about 90% (e.g., about 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%).</p><p id="p-0277" num="0236">In some embodiments, the poloxamer has an average ethylene oxide content of from about 50% to about 85% (e.g., about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, or 85%).</p><p id="p-0278" num="0237">In some embodiments, the poloxamer has an average ethylene oxide content of from about 60% to about 80% (e.g., about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%).</p><p id="p-0279" num="0238">In some embodiments, the poloxamer has an average molar mass of greater than 10,000 g/mol (e.g., about 10,100 g/mol, 10,200 g/mol, 10,300 g/mol, 10,400 g/mol, 10,500 g/mol, 10,600 g/mol, 10,700 g/mol, 10,800 g/mol, 10,900 g/mol, 11,000 g/mol, 11,100 g/mol, 11,200 g/mol, 11,300 g/mol, 11,400 g/mol, 11,500 g/mol, 11,600 g/mol, 11,700 g/mol, 11,800 g/mol, 11,900 g/mol, 12,000 g/mol, 12,100 g/mol, 12,200 g/mol, 12,300 g/mol, 12,400 g/mol, 12,500 g/mol, 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0280" num="0239">In some embodiments, the poloxamer has an average molar mass of greater than 11,000 g/mol (e.g., about 11,100 g/mol, 11,200 g/mol, 11,300 g/mol, 11,400 g/mol, 11,500 g/mol, 11,600 g/mol, 11,700 g/mol, 11,800 g/mol, 11,900 g/mol, 12,000 g/mol, 12,100 g/mol, 12,200 g/mol, 12,300 g/mol, 12,400 g/mol, 12,500 g/mol, 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0281" num="0240">In some embodiments, the poloxamer has an average molar mass of greater than 12,000 g/mol (e.g., about 12,100 g/mol, 12,200 g/mol, 12,300 g/mol, 12,400 g/mol, 12,500 g/mol, 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0282" num="0241">In some embodiments, the poloxamer has an average molar mass of greater than 12,500 g/mol (e.g., about 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0283" num="0242">In some embodiments, the poloxamer has an average molar mass of from about 10,000 g/mol to about 15,000 g/mol (e.g., about 10,000 g/mol, 10,100 g/mol, 10,200 g/mol, 10,300 g/mol, 10,400 g/mol, 10,500 g/mol, 10,600 g/mol, 10,700 g/mol, 10,800 g/mol, 10,900 g/mol, 11,000 g/mol, 11,100 g/mol, 11,200 g/mol, 11,300 g/mol, 11,400 g/mol, 11,500 g/mol, 11,600 g/mol, 11,700 g/mol, 11,800 g/mol, 11,900 g/mol, 12,000 g/mol, 12,100 g/mol, 12,200 g/mol, 12,300 g/mol, 12,400 g/mol, 12,500 g/mol, 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0284" num="0243">In some embodiments, the poloxamer has an average molar mass of from about 11,000 g/mol to about 15,000 g/mol (e.g., about 11,000 g/mol, 11,100 g/mol, 11,200 g/mol, 11,300 g/mol, 11,400 g/mol, 11,500 g/mol, 11,600 g/mol, 11,700 g/mol, 11,800 g/mol, 11,900 g/mol, 12,000 g/mol, 12,100 g/mol, 12,200 g/mol, 12,300 g/mol, 12,400 g/mol, 12,500 g/mol, 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0285" num="0244">In some embodiments, the poloxamer has an average molar mass of from about 11,500 g/mol to about 15,000 g/mol (e.g., about 11,500 g/mol, 11,600 g/mol, 11,700 g/mol, 11,800 g/mol, 11,900 g/mol, 12,000 g/mol, 12,100 g/mol, 12,200 g/mol, 12,300 g/mol, 12,400 g/mol, 12,500 g/mol, 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0286" num="0245">In some embodiments, the poloxamer has an average molar mass of from about 12,000 g/mol to about 15,000 g/mol (e.g., about 12,000 g/mol, 12,100 g/mol, 12,200 g/mol, 12,300 g/mol, 12,400 g/mol, 12,500 g/mol, 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0287" num="0246">In some embodiments, the poloxamer has an average molar mass of from about 12,500 g/mol to about 15,000 g/mol (e.g., about 12,500 g/mol, 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0288" num="0247">In some embodiments, the poloxamer is P407.</p><p id="p-0289" num="0248">In some embodiments, the poloxamer is P338.</p><p id="p-0290" num="0249">In some embodiments, the poloxamer is P288.</p><p id="p-0291" num="0250">In some embodiments, the poloxamer is P188.</p><p id="p-0292" num="0251">In some embodiments, the viral vector is selected from the group consisting of a Retroviridae family virus, an adeno-associated virus, an adenovirus, a parvovirus, a coronavirus, a rhabdovirus, a paramyxovirus, a picornavirus, an alphavirus, a herpes virus, and a poxvirus. The viral vector may be, for example, a Retroviridae family viral vector, such as a lentiviral vector, an alpharetroviral vector, or a gammaretroviral vector. In some embodiments, the Retroviridae family viral vector includes a central polypurine tract, a woodchuck hepatitis virus post-transcriptional regulatory element, a 5&#x2032;-LTR, HIV signal sequence, HIV Psi signal 5&#x2032;-splice site, delta-GAG element, 3&#x2032;-splice site, and a 3&#x2032;-self inactivating LTR.</p><p id="p-0293" num="0252">In some embodiments, the viral vector is a pseudotyped viral vector that contains a viral genome originating from one type of virus and one or more viral capsid or envelope proteins that derive from a different type of virus. The pseudotyped viral vector may contain, for example, one or more viral envelope proteins from a virus selected from vesicular stomatitis virus (VSV), RD114 virus, murine leukemia virus (MLV), feline leukemia virus (FeLV), Venezuelan equine encephalitis virus (VEE), human foamy virus (HFV), walleye dermal sarcoma virus (WDSV), Semliki Forest virus (SFV), Rabies virus, avian leukosis virus (ALV), bovine immunodeficiency virus (BIV), bovine leukemia virus (BLV), Epstein-Barr virus (EBV), Caprine arthritis encephalitis virus (CAEV), Sin Nombre virus (SNV), Cherry Twisted Leaf virus (ChTLV), Simian T-cell leukemia virus (STLV), Mason-Pfizer monkey virus (MPMV), squirrel monkey retrovirus (SMRV), Rous-associated virus (RAV), Fujinami sarcoma virus (FuSV), avian carcinoma virus (MH2), avian encephalomyelitis virus (AEV), Alfa mosaic virus (AMV), avian sarcoma virus CT10, and equine infectious anemia virus (EIAV).</p><p id="p-0294" num="0253">In some embodiments, the contacting of the cell with the one or more agents described above or herein occurs ex vivo. The cell may have been freshly cultured prior to the contacting or may have been cryopreserved and thawed prior to the contacting.</p><p id="p-0295" num="0254">In some embodiments, the cell is first contacted with the substance that reduces activity and/or expression of PKC before the cell is contacted with the poloxamer. For example, the cell may first be contacted with the substance that reduces activity and/or expression of PKC for from about 30 minutes to about 6 hours before the cell is contacted with the poloxamer (e.g., about 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, or 6 hours before the cell is contacted with the poloxamer). In some embodiments, the cell is first contacted with the substance that reduces activity and/or expression of PKC for from about 1 hour to about 3 hours before the cell is contacted with the poloxamer (e.g., about 1 hour, 2 hours, or 3 hours before the cell is contacted with the poloxamer). In some embodiments, the cell is first contacted with the substance that reduces activity and/or expression of PKC about 2 hours before the cell is contacted with the poloxamer.</p><p id="p-0296" num="0255">In some embodiments, when the cell is first contacted with the substance that reduces activity and/or expression of PKC before the cell is contacted with the poloxamer, the cell is washed to remove the substance that reduces activity and/or expression of PKC before the cell is contacted with the poloxamer.</p><p id="p-0297" num="0256">In some embodiments, the cell is simultaneously contacted with the substance that reduces activity and/or expression of PKC and with the poloxamer. For example, the cell may be simultaneously contacted with the substance that reduces activity and/or expression of PKC, with the poloxamer, and with the viral vector.</p><p id="p-0298" num="0257">In some embodiments, the cell is contacted with the viral vector after having been exposed to the substance that reduces PKC activity and/or expression. In these instances, the cell may be simultaneously contacted with the viral vector and the poloxamer. Alternatively, the cell may be contacted with the poloxamer before being contacted with the viral vector. In some embodiments, the cell is contacted with the viral vector before being contacted with the poloxamer.</p><p id="p-0299" num="0258">Thus, in some embodiments of the disclosure, the cell is first contacted with the substance that reduces PKC activity and/or expression, is next contacted with the poloxamer, and is subsequently contacted with the viral vector. In some embodiments, the cell is first contacted with the substance that reduces PKC activity and/or expression, is next contacted with the viral vector, and is subsequently contacted with the poloxamer.</p><p id="p-0300" num="0259">In some embodiments, the cell is further contacted with a cyclosporine, such as cyclosporine A (CsA) or cyclosporine H (CsH). The cell may be contacted with the poloxamer and with the cyclosporine simultaneously. Alternatively, the cell may be contacted with the poloxamer before being contacted with the staurosporine. In some embodiments, the cell is contacted with the cyclosporine before being contacted with the poloxamer.</p><p id="p-0301" num="0260">In some embodiments, the concentration of the cyclosporine, when contacted with the cell, is from about 1 &#x3bc;M to about 10 &#x3bc;M (e.g., about 1 &#x3bc;M, 1.1 &#x3bc;M, 1.2 &#x3bc;M, 1.3 &#x3bc;M, 1.4 &#x3bc;M, 1.5 &#x3bc;M, 1.6 &#x3bc;M, 1.7 &#x3bc;M, 1.8 &#x3bc;M, 1.9 &#x3bc;M, 2 &#x3bc;M, 2.1 &#x3bc;M, 2.2 &#x3bc;M, 2.3 &#x3bc;M, 2.4 &#x3bc;M, 2.5 &#x3bc;M, 2.6 &#x3bc;M, 2.7 &#x3bc;M, 2.8 &#x3bc;M, 2.9 &#x3bc;M, 3 &#x3bc;M, 3.1 &#x3bc;M, 3.2 &#x3bc;M, 3.3 &#x3bc;M, 3.4 &#x3bc;M, 3.5 &#x3bc;M, 3.6 &#x3bc;M, 3.7 &#x3bc;M, 3.8 &#x3bc;M, 3.9 &#x3bc;M, 4 &#x3bc;M, 4.1 &#x3bc;M, 4.2 &#x3bc;M, 4.3 &#x3bc;M, 4.4 &#x3bc;M, 4.5 &#x3bc;M, 4.6 &#x3bc;M, 4.7 &#x3bc;M, 4.8 &#x3bc;M, 4.9 &#x3bc;M, 5 &#x3bc;M, 5.1 &#x3bc;M, 5.2 &#x3bc;M, 5.3 &#x3bc;M, 5.4 &#x3bc;M, 5.5 &#x3bc;M, 5.6 &#x3bc;M, 5.7 &#x3bc;M, 5.8 &#x3bc;M, 5.9 &#x3bc;M, 6 &#x3bc;M, 6.1 &#x3bc;M, 6.2 &#x3bc;M, 6.3 &#x3bc;M, 6.4 &#x3bc;M, 6.5 &#x3bc;M, 6.6 &#x3bc;M, 6.7 &#x3bc;M, 6.8 &#x3bc;M, 6.9 &#x3bc;M, 7 &#x3bc;M, 7.1 &#x3bc;M, 7.2 &#x3bc;M, 7.3 &#x3bc;M, 7.4 &#x3bc;M, 7.5 &#x3bc;M, 7.6 &#x3bc;M, 7.7 &#x3bc;M, 7.8 &#x3bc;M, 7.9 &#x3bc;M, 8 &#x3bc;M, 8.1 &#x3bc;M, 8.2 &#x3bc;M, 8.3 &#x3bc;M, 8.4 &#x3bc;M, 8.5 &#x3bc;M, 8.6 &#x3bc;M, 8.7 &#x3bc;M, 8.8 &#x3bc;M, 8.9 &#x3bc;M, 9 &#x3bc;M, 9.1 &#x3bc;M, 9.2 &#x3bc;M, 9.3 &#x3bc;M, 9.4 &#x3bc;M, 9.5 &#x3bc;M, 9.6 &#x3bc;M, 9.7 &#x3bc;M, 9.8 &#x3bc;M, 9.9 &#x3bc;M, or 10 &#x3bc;M). In some embodiments, the cyclosporine is CsA and the concentration of the cyclosporine, when contacted with the cell, is about 6 &#x3bc;M. In some embodiments, the cyclosporine is CsH and the concentration of the cyclosporine, when contacted with the cell, is about 8 &#x3bc;M.</p><p id="p-0302" num="0261">In some embodiments, the cell is further contacted with an activator of prostaglandin E receptor signaling. The cell may be contacted with the poloxamer and with the activator of prostaglandin E receptor signaling simultaneously. Alternatively, the cell may be contacted with the poloxamer before being contacted with the activator of prostaglandin E receptor signaling. In some embodiments, the cell is contacted with the activator of prostaglandin E receptor signaling before being contacted with the poloxamer.</p><p id="p-0303" num="0262">In some embodiments, the activator of prostaglandin E receptor signaling is a small molecule, such as a compound described in WO 2007/112084 or WO 2010/108028, the disclosures of each of which are incorporated herein by reference as they pertain to prostaglandin E receptor signaling activators.</p><p id="p-0304" num="0263">In some embodiments, the activator of prostaglandin E receptor signaling is a small molecule, such as a small organic molecule, a prostaglandin, a Wnt pathway agonist, a cAMP/PI3K/AKT pathway agonist, a Ca<sup>2+</sup> second messenger pathway agonist, a nitric oxide (NO)/angiotensin signaling agonist, or another compound known to stimulate the prostaglandin signaling pathway, such as a compound selected from Mebeverine, Flurandrenolide, Atenolol, Pindolol, Gaboxadol, Kynurenic Acid, Hydralazine, Thiabendazole, Bicuculline, Vesamicol, Peruvoside, Imipramine, Chlorpropamide, 1,5-Pentamethylenetetrazole, 4-Aminopyridine, Diazoxide, Benfotiamine, 12-Methoxydodecenoic acid, N-Formyl-Met-Leu-Phe, Gallamine, IAA 94, Chlorotrianisene, and or a derivative of any of these compounds.</p><p id="p-0305" num="0264">In some embodiments, the activator of prostaglandin E receptor signaling is a naturally-occurring or synthetic chemical molecule or polypeptide that binds to and/or interacts with a prostaglandin E receptor, typically to activate or increase one or more of the downstream signaling pathways associated with a prostaglandin E receptor.</p><p id="p-0306" num="0265">In some embodiments, the activator of prostaglandin E receptor signaling is selected from the group consisting of: prostaglandin (PG) A2 (PGA2), PGB2, PGD2, PGE1 (Alprostadil), PGE2, PGF2, PGI2 (Epoprostenol), PGH2, PGJ2, and derivatives and analogs thereof.</p><p id="p-0307" num="0266">In some embodiments, the activator of prostaglandin E receptor signaling is 15d-PGJ2, deltaI2-PGJ2, 2-hydroxyheptadecatrienoic acid (HHT), Thromboxane (TXA2 and TXB2), PG12 analogs, e.g., Iloprost and Treprostinil, PGF2 analogs, e.g., Travoprost, Carboprost tromethamine, Tafluprost, Latanoprost, Bimatoprost, Unoprostone isopropyl, Cloprostenol, Oestrophan, and Superphan, PGE1 analogs, e.g., 11-deoxy PGE1, Misoprostol, and Butaprost, and Corey alcohol-A ([3aa,4a,5,6aa]-(&#x2212;)-[Hexahydro-4-(hydroxymethyl)-2-oxo-2H-cyclopenta/b/furan-5-yl][1,1&#x2032;-biphenyl]-4-carboxylate), Corey alcohol-B (2H-Cyclopenta[b]furan-2-on,5-(benzoyloxy)hexahydro-4-(hydroxymethyl)[3aR-(3aa,4a,5,6aa)]), and Corey diol ((3aR,4S,5R,6aS)-hexahydro-5-hydroxy-4-(hydroxymethyl)-2H-cyclopenta[b]furan-2-one).</p><p id="p-0308" num="0267">In some embodiments, the activator of prostaglandin E receptor signaling is a prostaglandin E receptor ligand, such as prostaglandin E2 (PGE2), or an analogs or derivative thereof. Prostaglandins refer generally to hormone-like molecules that are derived from fatty acids containing 20 carbon atoms, including a 5-carbon ring, as described herein and known in the art. Illustrative examples of PGE2 &#x201c;analogs&#x201d; or &#x201c;derivatives&#x201d; include, but are not limited to, 16,16-dimethyl PGE2, 16-16 dimethyl PGE2 p-(p-acetamidobenzamido) phenyl ester, I I-deoxy-16,16-dimethyl PGE2, 9-deoxy-9-methylene-16, 16-dimethyl PGE2, 9-deoxy-9-methylene PGE2, 9-keto Fluprostenol, 5-trans PGE2, 17-phenyl-omega-trinor PGE2, PGE2 serinol amide, PGE2 methyl ester, 16-phenyl tetranor PGE2, 15(S)-15-methyl PGE2, 15 (R)-15-methyl PGE2, 8-iso-15-keto PGE2, 8-iso PGE2 isopropyl ester, 20-hydroxy PGE2, nocloprost, sulprostone, butaprost, 15-keto PGE2, and 19 (R) hydroxy PGE2.</p><p id="p-0309" num="0268">In some embodiments, the activator of prostaglandin E receptor signaling is a prostaglandin analog or derivative having a similar structure to PGE2 that is substituted with halogen at the 9-position (see, e.g., WO 2001/12596, herein incorporated by reference in its entirety), as well as 2-decarboxy-2-phosphinico prostaglandin derivatives, such as those described in US 2006/0247214, herein incorporated by reference in its entirety).</p><p id="p-0310" num="0269">In some embodiments, the activator of prostaglandin E receptor signaling is a non-PGE2-based ligand. In some embodiments, the activator of prostaglandin E receptor signaling is CAY10399, ONO_8815Ly, ONO-AE1-259, or CP-533,536. Additional examples of non-PGE2-based EP2 agonists include the carbazoles and fluorenes disclosed in WO 2007/071456, herein incorporated by reference for its disclosure of such agents. Illustrative examples of non-PGE2-based EP<sub>3 </sub>agonist include, but are not limited to, AE5-599, MB28767, GR 63799X, ONO-NT012, and ONO-AE-248. Illustrative examples of non-PGE2-based EP4 agonist include, but are not limited to, ONO-4819, APS-999 Na, AH23848, and ONO-AE 1-329. Additional examples of non-PGE2-based EP4 agonists can be found in WO 2000/038663; U.S. Pat. Nos. 6,747,037; and 6,610,719, each of which are incorporated by reference for their disclosure of such agonists</p><p id="p-0311" num="0270">In some embodiments, the activator of prostaglandin E receptor signaling is a Wnt agonist. Illustrative examples of Wnt agonists include, but are not limited to, Wnt polypeptides and glycogen synthase kinase 3 (GSK3) inhibitors. Illustrative examples of Wnt polypeptides suitable for use as compounds that stimulate the prostaglandin EP receptor signaling pathway include, but are not limited to, Wnt1, Wnt2, Wnt2b/13, Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b, Wnt7c, Wnt8, Wnt8a, Wnt8b, Wnt8c, Wnt1 Oa, Wnt1 Ob, Wnt11, Wnt14, Wnt15, or biologically active fragments thereof. GSK3 inhibitors suitable for use as agents that stimulate the prostaglandin EP receptor signaling pathway bind to and decrease the activity of GSK3a, or GSK3. Illustrative examples of GSK3 inhibitors include, but are not limited to, BIO (6-bromoindirubin-3&#x2032;-oxime), LiCl or other GSK-3 inhibitors, as exemplified in U.S. Pat. Nos. 6,057,117 and 6,608,063, as well as US 2004/0092535 and US 2004/0209878, and ATP-competitive, selective GSK-3 inhibitors CHIR-911 and CHIR-837 (also referred to as CT-99021 and CT-98023 respectively) (Chiron Corporation (Emeryville, Calif.)).</p><p id="p-0312" num="0271">In some embodiments, the activator of prostaglandin E receptor signaling is an agent that increases signaling through the cAMP/P13K/AKT second messenger pathway, such as an agent selected from the group consisting of dibutyryl cAMP (DBcAMP), phorbol ester, forskolin, sclareline, 8-bromo-cAMP, cholera toxin (CTx), aminophylline, 2,4 dinitrophenol (DNP), norepinephrine, epinephrine, isoproterenol, isobutylmethylxanthine (IBMX), caffeine, theophylline (dimethylxanthine), dopamine, rolipram, iloprost, pituitary adenylate cyclase activating polypeptide (PACAP), and vasoactive intestinal polypeptide (VIP), and derivatives of these agents.</p><p id="p-0313" num="0272">In some embodiments, the activator of prostaglandin E receptor signaling is an agent that increases signaling through the Ca<sup>2+</sup> second messenger pathway, such as an agent selected from the group consisting of Bapta-AM, Fendiline, Nicardipine, and derivatives of these agents.</p><p id="p-0314" num="0273">In some embodiments, the activator of prostaglandin E receptor signaling is an agent that increases signaling through the NO/Angiotensin signaling, such as an agent selected from the group consisting of L-Arg, Sodium Nitroprusside, Sodium Vanadate, Bradykinin, and derivatives thereof.</p><p id="p-0315" num="0274">In some embodiments, the cell is further contacted with a polycationic polymer. The cell may be contacted with the poloxamer and with the polycationic polymer simultaneously. Alternatively, the cell may be contacted with the poloxamer before being contacted with the polycationic polymer. In some embodiments, the cell is contacted with the polycationic polymer before being contacted with the poloxamer.</p><p id="p-0316" num="0275">In some embodiments, the polycationic polymer is polybrene, protamine sulfate, polyethylenimine, or a polyethylene glycol/poly-L-lysine block copolymer.</p><p id="p-0317" num="0276">In some embodiments, the cell is further contacted with an expansion agent during the transduction procedure. The cell may be, for example, a hematopoietic stem cell and the expansion agent may be a hematopoietic stem cell expansion agent, such as a hematopoietic stem cell expansion agent known in the art or described herein.</p><p id="p-0318" num="0277">In some embodiments, during the transduction procedure, the cell is further contacted with an agent that inhibits mTor signalling. The agent that inhibits mTor signaling may be, for example, rapamycin, among other suppressors of mTor signaling.</p><p id="p-0319" num="0278">In some embodiments, the cell is incubated with the viral vector (e.g., in combination with the one or more agents described above) for a period of from about 6 hours to about 48 hours (e.g., about 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 25 hours, 26 hours, 27 hours, 28 hours, 29 hours, 30 hours, 31 hours, 32 hours, 33 hours, 34 hours, 35 hours, 36 hours, 37 hours, 38 hours, 39 hours, 40 hours, 41 hours, 42 hours, 43 hours, 44 hours, 45 hours, 46 hours, 47 hours, or 48 hours). In some embodiments, the cell is incubated with the viral vector (e.g., in combination with the one or more agents described above) for a period of from about 12 hours to about 24 hours (e.g., about 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, or 24 hours). In some embodiments, the cell is incubated with the viral vector (e.g., in combination with the one or more agents described above) for a period of from about 16 hours to about 22 hours (e.g., about 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, or 22 hours). In some embodiments, the cell is incubated with the viral vector (e.g., in combination with the one or more agents described above) for a period of from about 17 hours to about 19 hours (e.g., about 17 hours, 18 hours, or 19 hours). In some embodiments, the cell is incubated with the viral vector (e.g., in combination with the one or more agents described above) for a period of about 18 hours.</p><p id="p-0320" num="0279">In some embodiments, the cell is spun (e.g., by centrifugation, i.e., &#x201c;centrifuged&#x201d;) while being contacted with the viral vector (e.g., in combination with the one or more agents described above). This process, referred to herein as &#x201c;spinoculation,&#x201d; may occur with a centripetal force of, e.g., from about 200&#xd7;g to about 2,000&#xd7;g. In some embodiments, the cell is spun at a centripetal force of from about 300&#xd7;g to about 1,200&#xd7;g while being contacted with the viral vector (e.g., in combination with the one or more agents described above). For example, the cell may be spun at a centripetal force of about 300&#xd7;g, 400&#xd7;g, 500&#xd7;g, 600&#xd7;g, 700&#xd7;g, 800&#xd7;g, 900&#xd7;g, 1,000&#xd7;g, 1,100&#xd7;g, or 1,200&#xd7;g while being contacted with the viral vector (e.g., in combination with the one or more agents described above). In some embodiments, the cell is spun for from about 10 minutes to about 3 hours (e.g., about 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 60 minutes, 65 minutes, 70 minutes, 75 minutes, 80 minutes, 85 minutes, 90 minutes, 95 minutes, 100 minutes, 105 minutes, 110 minutes, 115 minutes, 120 minutes, 125 minutes, 130 minutes, 135 minutes, 140 minutes, 145 minutes, 150 minutes, 155 minutes, 160 minutes, 165 minutes, 170 minutes, 175 minutes, 180 minutes, or more). In some embodiments, the cell is spun at room temperature, such as at a temperature of about 25&#xb0; C.</p><p id="p-0321" num="0280">In an additional aspect, the disclosure features a method of expressing a transgene in a subject (e.g., a mammalian subject, such as a human) by administering to the subject a population of cells that have been modified in accordance with the method of any of the above aspects or embodiments of the disclosure, or progeny thereof.</p><p id="p-0322" num="0281">In a further aspect, the disclosure features a method of delivering a population of genetically modified cells to a subject (e.g., a mammalian subject, such as a human) by administering to the subject a population of cells that have been modified in accordance with the method of any of the above aspects or embodiments of the disclosure, or progeny thereof.</p><p id="p-0323" num="0282">In yet another aspect, the disclosure features a method of providing cell therapy to a subject in need thereof (e.g., a mammalian subject, such as a human) by administering to the subject a population of cells that have been modified in accordance with the method of any of the above aspects or embodiments of the disclosure, or progeny thereof.</p><p id="p-0324" num="0283">In some embodiments of the three preceding aspects of the disclosure, the cells are allogeneic with respect to the subject. In some embodiments, the cells are HLA-matched to the subject. In some embodiments, the cells are autologous with respect to the subject.</p><p id="p-0325" num="0284">In some embodiments, prior to contacting the cells with the one or more agents described above or herein, a population of precursor cells is isolated from the subject (e.g., in the case of an autologous cell population) or a donor (e.g., in the case of an allogeneic cell population). The precursor cells may then be expanded ex vivo, for example, by incubating the precursor cells with one or more cell expansion substances described herein or known in the art to promote cell proliferation, thereby yielding the population of cells being administered to the subject. For example, the expansion agent may be StemRegenin 1, also known in the art as compound SR1, represented by formula (110), below.</p><p id="p-0326" num="0000"><chemistry id="CHEM-US-00068" num="00068"><img id="EMI-C00068" he="49.11mm" wi="67.48mm" file="US20230002784A1-20230105-C00068.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0327" num="0000">SR1 and other expansion agents are described, for example, in U.S. Pat. Nos. 8,927,281 and 9,580,426, the disclosures of each of which are incorporated herein by reference in their entirety.</p><p id="p-0328" num="0285">Additional expansion agents that may be used in conjunction with the compositions and methods of the disclosure include compound UM-171, which is described in U.S. Pat. No. 9,409,906, the disclosure of which is incorporated herein by reference in its entirety. Expansion agents that may be used herein further include structural or stereoisomeric variants of compound UM-171, such as the compounds described in US 2017/0037047, the disclosure of which is incorporated herein by reference in its entirety. The structure of compound UM-171 is shown in formula (111), below.</p><p id="p-0329" num="0000"><chemistry id="CHEM-US-00069" num="00069"><img id="EMI-C00069" he="50.97mm" wi="72.81mm" file="US20230002784A1-20230105-C00069.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0330" num="0286">In some embodiments, the expansion agent is a bromide salt of compound (111), such as a compound represented by formula (112), below.</p><p id="p-0331" num="0000"><chemistry id="CHEM-US-00070" num="00070"><img id="EMI-C00070" he="53.68mm" wi="72.81mm" file="US20230002784A1-20230105-C00070.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0332" num="0287">Additional expansion agents that may be used in conjunction with the compositions and methods of the disclosure include histone deacetylase (HDAC) inhibitors, as described, for example, in WO 2000/023567, the disclosure of which is incorporated herein by reference. Exemplary agents that may be used to expand a population of precursor cells as described herein are trichostatin A, trapoxin, trapoxin A, chlamydocin, sodium butyrate, dimethyl sulfoxide, suberanilohydroxamic acid, m-carboxycinnamic acid bishydroxamide, HC-toxin, Cyl-2, WF-3161, depudecin, and radicicol, among others.</p><p id="p-0333" num="0288">In some embodiments, the precursor cells are CD34+ HSCs. Using HSC expansion agents described herein and known in the art, the precursor cells may be expanded without loss of HSC functional potential.</p><p id="p-0334" num="0289">In some embodiments, prior to isolation of the precursor cells from the subject (e.g., in the case of an autologous cell population) or donor (e.g., in the case of an allogeneic cell population), the subject or donor is administered one or more mobilization agents that stimulate the migration of pluripotent cells (e.g., CD34+ HSCs and HPCs) from a stem cell niche, such as the bone marrow, to peripheral circulation.</p><p id="p-0335" num="0290">Exemplary cell mobilization agents that may be used in conjunction with the compositions and methods of the disclosure are described herein and known in the art. For example, the mobilization agent may be a C&#x2014;X&#x2014;C motif chemokine receptor (CXCR) 2 (CXCR2) agonist. The CXCR2 agonist may be Gro-beta, or a truncated variant thereof. Gro-beta and variants thereof are described, for example, in U.S. Pat. Nos. 6,080,398; 6,447,766; and 6,399,053, the disclosures of each of which are incorporated herein by reference in their entirety. Additionally or alternatively, the mobilization agent may include a CXCR4 antagonist, such as plerixafor or a variant thereof. Plerixafor and structurally similar compounds are described, for example, in U.S. Pat. Nos. 6,987,102; 7,935,692; and 7,897,590, the disclosures of each of which are incorporated herein by reference. Additionally or alternatively, the mobilization agent may include granulocyte colony-stimulating factor (G-CSF). The use of G-CSF as an agent to induce mobilization of pluripotent cells (e.g., CD34+ HSCs and/or HPCs) from a stem cell niche to peripheral circulation is described, for example, in US 2010/0178271, the disclosure of which is incorporated herein by reference in its entirety.</p><p id="p-0336" num="0291">In some embodiments, prior to administering the population of cells to the subject, a population of endogenous pluripotent cells (e.g., a population of endogenous CD34+ HSCs or HPCs) is ablated in the subject by administration of one or more conditioning agents to the subject. In some embodiments, the method includes ablating a population of endogenous pluripotent cells (e.g., a population of endogenous CD34+ HSCs or HPCs) in the subject by administering to the subject one or more conditioning agents prior to administering to the subject the population of cells. The one or more conditioning agents may be myeloablative conditioning agents that deplete a wide variety of hematopoietic cells from the bone marrow of the subject. In some embodiments, the one or more conditioning agents are non-myeloablative conditioning agents that selectively target and ablate a specific population of endogenous pluripotent cells, such as a population of endogenous CD34+ HSCs or HPCs.</p><p id="p-0337" num="0292">In some embodiments, upon administration of the population of cells to the subject, the administered cells, or progeny thereof, differentiate into one or more cell types selected from megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeloblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen-presenting cells, macrophages, dendritic cells, natural killer cells, T-lymphocytes, and B-lymphocytes.</p><p id="p-0338" num="0293">In some embodiments, the subject has been diagnosed as having a deficiency of an endogenous protein encoded by the transgene. The subject may have been diagnosed, for example, as having a disease set forth in Table 2. In some embodiments, the subject has been diagnosed as having beta thalassemia.</p><p id="p-0339" num="0294">In some embodiments of any of the above aspects or embodiments of the disclosure, the transgene encodes a beta-globin protein. The transgene may contain, for example, a nucleic acid having at least 85% sequence identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 1. In some embodiments, the transgene contains a nucleic acid having at least 90% sequence identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 1. In some embodiments, the transgene contains a nucleic acid having at least 95% sequence identity (e.g., 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 1. In some embodiments, the transgene contains a nucleic acid having the nucleic acid sequence of SEQ ID NO: 1.</p><p id="p-0340" num="0295">In some embodiments, the beta-globin protein has an amino acid sequence that is at least 85% identical (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the beta-globin protein has an amino acid sequence that is at least 90% identical (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the beta-globin protein has an amino acid sequence that is at least 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, or 100% identical) to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the beta-globin protein the amino acid sequence of SEQ ID NO: 2.</p><p id="p-0341" num="0296">In some embodiments, the beta-globin protein has an amino acid sequence that differs from that of SEQ ID NO: 2 by way of one or more amino acid substitutions, insertions, and/or deletions. For example, the beta-globin protein may have an amino acid sequence that differs from that of SEQ ID NO: 2 by way of one or more conservative amino acid substitutions or nonconservative amino acid substitutions. The beta-globin protein may have an amino acid sequence that differs from that of SEQ ID NO: 2 by way, for example, of from 1 to 50 conservative amino acid substitutions, from 1 to 40 conservative amino acid substitutions, from 1 to 30 conservative amino acid substitutions, from 1 to 20 conservative amino acid substitutions, or from 1 to 10 conservative amino acid substitutions, optionally in combination with one or more nonconservative amino acid substitutions.</p><p id="p-0342" num="0297">In another aspect, the disclosure features a composition containing a mixture formed by modifying a eukaryotic cell in accordance with the method of any of the above aspects or embodiments of the disclosure.</p><p id="p-0343" num="0298">In a further aspect, the disclosure features a cell culture medium containing the composition of the preceding aspect.</p><p id="p-0344" num="0299">In yet another aspect, the disclosure features a population of eukaryotic cells that have been modified in accordance with the method of any of the above aspects or embodiments of the disclosure.</p><p id="p-0345" num="0300">In another aspect, the disclosure features a pharmaceutical composition containing the population of cells of the preceding aspect. The pharmaceutical composition may further contain one or more excipients, diluents, and/or carriers. In some embodiments, the pharmaceutical composition is formulated for administration, such as by way of intravenous infusion, to a subject, such as a mammalian subject (e.g., a human).</p><p id="p-0346" num="0301">In another aspect, the disclosure features a kit containing a composition containing a mixture formed by modifying a eukaryotic cell in accordance with the method of any of the above aspects or embodiments of the disclosure. Additionally or alternatively, the kit may contain a cell culture medium containing this composition. The kit may additionally contain a package insert that includes instructions for using the contents of the kit to transduce a target cell.</p><p id="p-0347" num="0302">In another aspect, the disclosure features a kit containing a population of eukaryotic cells that have been modified in accordance with the method of any of the above aspects or embodiments of the disclosure. Additionally or alternatively, the kit may contain a pharmaceutical composition containing a population of eukaryotic cells that have been modified in accordance with the method of any of the above aspects or embodiments of the disclosure. The kit may additionally contain a package insert instructing a user to administer the population of cells to a subject in accordance with any of the cell administration methods described above or herein.</p><heading id="h-0005" level="1">Definitions</heading><p id="p-0348" num="0303">As used herein, the terms &#x201c;ablate,&#x201d; &#x201c;ablating,&#x201d; &#x201c;ablation,&#x201d; and the like refer to the depletion of one or more cells in a population of cells in vivo or ex vivo. In some embodiments of the present disclosure, it may be desirable to ablate endogenous cells within a patient (e.g., a patient undergoing treatment for a disease described herein) before administering a therapeutic composition, such as a therapeutic population of cells, to the patient. This can be beneficial, for example, in order to provide newly-administered cells with an environment within which the cells may engraft. Ablation of a population of endogenous cells can be performed in a manner that selectively targets a specific cell type, for example, using antibody-drug conjugates that bind to an antigen expressed on the target cell and subsequently engender the killing of the target cell. Additionally or alternatively, ablation may be performed in a non-specific manner using cytotoxins that do not localize to a particular cell type, but are instead capable of exerting their cytotoxic effects on a variety of different cells. Examples of ablation include depletion of at least 5% of cells (e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or more) in a population of cells in vivo or in vitro. Quantifying cell counts within a sample of cells can be performed using a variety of cell-counting techniques, such as through the use of a counting chamber, a Coulter counter, flow cytometry, or other cell-counting methods known in the art.</p><p id="p-0349" num="0304">As used herein, the term &#x201c;about&#x201d; refers to a quantity that varies by as much as 30% (e.g., 25%, 20%, 25%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1%) relative to a reference quantity.</p><p id="p-0350" num="0305">As used herein in the context of a protein of interest, the term &#x201c;activity&#x201d; refers to the biological functionality that is associated with a wild-type form of the protein. For example, in the context of an enzyme, the term &#x201c;activity&#x201d; refers to the ability of the protein to effectuate substrate turnover in a manner that yields the product of a corresponding chemical reaction. Activity levels of enzymes can be detected and quantitated, for example, using substrate turnover assays known in the art. As another example, in the context of a membrane-bound receptor, the term &#x201c;activity&#x201d; may refer to signal transduction initiated by the receptor, e.g., upon binding to its cognate ligand. Activity levels of receptors involved in signal transduction pathways can be detected and quantitated, for example, by observing an increase in the outcome of receptor signaling, such as an increase in the transcription of one or more genes (which may be detected, e.g., using polymerase chain reaction techniques known in the art).</p><p id="p-0351" num="0306">As used herein, the terms &#x201c;administering,&#x201d; &#x201c;administration,&#x201d; and the like refer to directly giving a patient a therapeutic agent (e.g., a population of cells, such as a population of pluripotent cells (e.g., embryonic stem cells, induced pluripotent stem cells, or CD34+ cells)) by any effective route. Exemplary routes of administration are described herein and include systemic administration routes, such as intravenous injection, among others.</p><p id="p-0352" num="0307">As used herein, the term &#x201c;allogeneic&#x201d; refers to cells, tissues, nucleic acid molecules, or other substances obtained or derived from a different subject of the same species. For example, in the context of a population of cells (e.g., a population of pluripotent cells) expressing one or more proteins described herein, allogeneic cells include those that are (i) obtained from a subject that is not undergoing therapy and are then (ii) transduced or transfected with a vector that directs the expression of one or more desired proteins. The phrase &#x201c;directs expression&#x201d; refers to the inclusion of one or more polynucleotides encoding the one or more proteins to be expressed. The polynucleotide may contain additional sequence motifs that enhances expression of the protein of interest.</p><p id="p-0353" num="0308">As used herein, the term &#x201c;anneal&#x201d; refers to the formation of a stable duplex of nucleic acids by way of hybridization mediated by inter-strand hydrogen bonding, for example, according to Watson-Crick base pairing. The nucleic acids of the duplex may be, for example, at least 50% complementary to one another (e.g., about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary to one another. The &#x201c;stable duplex&#x201d; formed upon the annealing of one nucleic acid to another is a duplex structure that is not denatured by a stringent wash. Exemplary stringent wash conditions are known in the art and include temperatures of about 5&#xb0; C. less than the melting temperature of an individual strand of the duplex and low concentrations of monovalent salts, such as monovalent salt concentrations (e.g., NaCl concentrations) of less than 0.2 M (e.g., 0.2 M, 0.19 M, 0.18 M, 0.17 M, 0.16 M, 0.15 M, 0.14 M, 0.13 M, 0.12 M, 0.11 M, 0.1 M, 0.09 M, 0.08 M, 0.07 M, 0.06 M, 0.05 M, 0.04 M, 0.03 M, 0.02 M, 0.01 M, or less).</p><p id="p-0354" num="0309">As used herein, the term &#x201c;autologous&#x201d; refers to cells, tissues, nucleic acid molecules, or other substances obtained or derived from an individual's own cells, tissues, nucleic acid molecules, or the like. For example, in the context of a population of cells (e.g., a population of pluripotent cells) expressing one or more proteins described herein, autologous cells include those that are obtained from the patient undergoing therapy that are then transduced or transfected with a vector that directs the expression of one or more proteins of interest.</p><p id="p-0355" num="0310">As used herein, the term &#x201c;cell type&#x201d; refers to a group of cells sharing a phenotype that is statistically separable based on gene expression data. For example, cells of a common cell type may share similar structural and/or functional characteristics, such as similar gene activation patterns and antigen presentation profiles. Cells of a common cell type may include those that are isolated from a common tissue (e.g., epithelial tissue, neural tissue, connective tissue, or muscle tissue) and/or those that are isolated from a common organ, tissue system, blood vessel, or other structure and/or region in an organism.</p><p id="p-0356" num="0311">As used herein, the terms &#x201c;condition&#x201d; and &#x201c;conditioning&#x201d; refer to processes by which a subject is prepared for receipt of a transplant containing a population of cells (e.g., a population of pluripotent cells, such as CD34+ cells). Such procedures promote the engraftment of a cell transplant, for example, by selectively depleting endogenous cells (e.g., endogenous CD34+ cells, among others) thereby creating a vacancy which is in turn filled by the exogenous cell transplant. According to the methods described herein, a subject may be conditioned for cell transplant procedure by administration to the subject of one or more agents capable of ablating endogenous cells (e.g., CD34+ cells, among others), radiation therapy, or a combination thereof. Conditioning regimens useful in conjunction with the compositions and methods of the disclosure may be myeloablative or non-myeloablative. Other cell-ablating agents and methods well known in the art (e.g., antibody-drug conjugates) may also be used.</p><p id="p-0357" num="0312">As used herein, the terms &#x201c;conservative mutation,&#x201d; &#x201c;conservative substitution,&#x201d; &#x201c;conservative amino acid substitution,&#x201d; and the like refer to a substitution of one or more amino acids for one or more different amino acids that exhibit similar physicochemical properties, such as polarity, electrostatic charge, and steric volume. These properties are summarized for each of the twenty naturally-occurring amino acids in Table 1 below.</p><p id="p-0358" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="259pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Representative physicochemical properties of naturally occurring amino acids</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="28pt" align="left"/><colspec colname="3" colwidth="28pt" align="left"/><colspec colname="4" colwidth="35pt" align="left"/><colspec colname="5" colwidth="70pt" align="left"/><colspec colname="6" colwidth="42pt" align="left"/><tbody valign="top"><row><entry/><entry/><entry/><entry/><entry>Electrostatic</entry><entry/></row><row><entry/><entry/><entry/><entry>Side-</entry><entry>character at</entry></row><row><entry/><entry>3 Letter</entry><entry>1 Letter</entry><entry>chain</entry><entry>physiological pH</entry><entry>Steric</entry></row><row><entry>Amino Acid</entry><entry>Code</entry><entry>Code</entry><entry>Polarity</entry><entry>(7.4)</entry><entry>Volume<sup>&#x2020;</sup></entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row><row><entry>Alanine</entry><entry>Ala</entry><entry>A</entry><entry>nonpolar</entry><entry>neutral</entry><entry>small</entry></row><row><entry>Arginine</entry><entry>Arg</entry><entry>R</entry><entry>polar</entry><entry>cationic</entry><entry>large</entry></row><row><entry>Asparagine</entry><entry>Asn</entry><entry>N</entry><entry>polar</entry><entry>neutral</entry><entry>intermediate</entry></row><row><entry>Aspartic acid</entry><entry>Asp</entry><entry>D</entry><entry>polar</entry><entry>anionic</entry><entry>intermediate</entry></row><row><entry>Cysteine</entry><entry>Cys</entry><entry>C</entry><entry>nonpolar</entry><entry>neutral</entry><entry>intermediate</entry></row><row><entry>Glutamic acid</entry><entry>Glu</entry><entry>E</entry><entry>polar</entry><entry>anionic</entry><entry>intermediate</entry></row><row><entry>Glutamine</entry><entry>Gln</entry><entry>Q</entry><entry>polar</entry><entry>neutral</entry><entry>intermediate</entry></row><row><entry>Glycine</entry><entry>Gly</entry><entry>G</entry><entry>nonpolar</entry><entry>neutral</entry><entry>small</entry></row><row><entry>Histidine</entry><entry>His</entry><entry>H</entry><entry>polar</entry><entry>Both neutral and</entry><entry>large</entry></row><row><entry/><entry/><entry/><entry/><entry>cationic forms in</entry></row><row><entry/><entry/><entry/><entry/><entry>equilibrium at pH 7.4</entry></row><row><entry>Isoleucine</entry><entry>Ile</entry><entry>I</entry><entry>nonpolar</entry><entry>neutral</entry><entry>large</entry></row><row><entry>Leucine</entry><entry>Leu</entry><entry>L</entry><entry>nonpolar</entry><entry>neutral</entry><entry>large</entry></row><row><entry>Lysine</entry><entry>Lys</entry><entry>K</entry><entry>polar</entry><entry>cationic</entry><entry>large</entry></row><row><entry>Methionine</entry><entry>Met</entry><entry>M</entry><entry>nonpolar</entry><entry>neutral</entry><entry>large</entry></row><row><entry>Phenylalanine</entry><entry>Phe</entry><entry>F</entry><entry>nonpolar</entry><entry>neutral</entry><entry>large</entry></row><row><entry>Proline</entry><entry>Pro</entry><entry>P</entry><entry>non-</entry><entry>neutral</entry><entry>intermediate</entry></row><row><entry/><entry/><entry/><entry>polar</entry></row><row><entry>Serine</entry><entry>Ser</entry><entry>S</entry><entry>polar</entry><entry>neutral</entry><entry>small</entry></row><row><entry>Threonine</entry><entry>Thr</entry><entry>T</entry><entry>polar</entry><entry>neutral</entry><entry>intermediate</entry></row><row><entry>Tryptophan</entry><entry>Trp</entry><entry>W</entry><entry>nonpolar</entry><entry>neutral</entry><entry>bulky</entry></row><row><entry>Tyrosine</entry><entry>Tyr</entry><entry>Y</entry><entry>polar</entry><entry>neutral</entry><entry>large</entry></row><row><entry>Valine</entry><entry>Val</entry><entry>V</entry><entry>nonpolar</entry><entry>neutral</entry><entry>intermediate</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row><row><entry namest="1" nameend="6" align="left" id="FOO-00001"><sup>&#x2020;</sup>based on volume in A<sup>3</sup>: 50-100 is small, 100-150 is intermediate, 150-200 is large, and &#x3e;200 is bulky</entry></row></tbody></tgroup></table></tables></p><p id="p-0359" num="0313">From this table it is appreciated that the conservative amino acid families include (i) G, A, V, L and I; (ii) D and E; (iii) C, S and T; (iv) H, K and R; (v) N and Q; and (vi) F, Y and W. A conservative mutation or substitution is therefore one that substitutes one amino acid for a member of the same amino acid family (e.g., a substitution of Ser for Thr or Lys for Arg).</p><p id="p-0360" num="0314">As used herein, the terms &#x201c;embryonic stem cell&#x201d; and &#x201c;ES cell&#x201d; refer to an embryo-derived totipotent or pluripotent stem cell, derived from the inner cell mass of a blastocyst that can be maintained in an in vitro culture under suitable conditions. ES cells are capable of differentiating into cells of any of the three vertebrate germ layers, e.g., the endoderm, the ectoderm, or the mesoderm. ES cells are also characterized by their ability propagate indefinitely under suitable in vitro culture conditions. ES cells are described, for example, in Thomson et al., Science 282:1145 (1998), the disclosure of which is incorporated herein by reference as it pertains to the structure and functionality of embryonic stem cells.</p><p id="p-0361" num="0315">As used herein, the term &#x201c;endogenous&#x201d; describes a molecule (e.g., a polypeptide, nucleic acid, or cofactor) that is found naturally in a particular organism (e.g., a human) or in a particular location within an organism (e.g., an organ, a tissue, or a cell, such as a human cell).</p><p id="p-0362" num="0316">As used herein, the term &#x201c;expansion agent&#x201d; refers to a substance capable of promoting the proliferation of a given cell type ex vivo. Accordingly, a &#x201c;hematopoietic stem cell expansion agent&#x201d; or an &#x201c;HSC expansion agent&#x201d; refers to a substance capable of promoting the proliferation of a population of hematopoietic stem cells ex vivo. Hematopoietic stem cell expansion agents include those that effectuate the proliferation of a population of hematopoietic stem cells such that the cells retain hematopoietic stem cell functional potential. Exemplary hematopoietic stem cell expansion agents that may be used in conjunction with the compositions and methods of the disclosure include, without limitation, aryl hydrocarbon receptor antagonists, such as those described in U.S. Pat. Nos. 8,927,281 and 9,580,426, the disclosures of each of which are incorporated herein by reference in their entirety, and, in particular, compound SR1. Additional hematopoietic stem cell expansion agents that may be used in conjunction with the compositions and methods of the disclosure include compound UM-171 and other compounds described in U.S. Pat. No. 9,409,906, the disclosure of which is incorporated herein by reference in its entirety. Hematopoietic stem cell expansion agents further include structural and/or stereoisomeric variants of compound UM-171, such as the compounds described in US 2017/0037047, the disclosure of which is incorporated herein by reference in its entirety. Additional hematopoietic stem cell expansion agents suitable for use in the instant disclosure include histone deacetylase (HDAC) inhibitors, such as trichostatin A, trapoxin, trapoxin A, chlamydocin, sodium butyrate, dimethyl sulfoxide, suberanilohydroxamic acid, m-carboxycinnamic acid bishydroxamide, HC-toxin, Cyl-2, WF-3161, depudecin, and radicicol, among others described, for example, in WO 2000/023567, the disclosure of which is incorporated herein by reference.</p><p id="p-0363" num="0317">As used herein, the term &#x201c;express&#x201d; refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, 5&#x2032; cap formation, and/or 3&#x2032; end processing); (3) translation of an RNA into a polypeptide or protein; and (4) post-translational modification of a polypeptide or protein. In the context of a gene that encodes a protein product, the terms &#x201c;gene expression&#x201d; and the like are used interchangeably with the terms &#x201c;protein expression&#x201d; and the like. Expression of a gene or protein of interest in a subject can manifest, for example, by detecting: an increase in the quantity or concentration of mRNA encoding corresponding protein (as assessed, e.g., using RNA detection procedures described herein or known in the art, such as quantitative polymerase chain reaction (qPCR) and RNA seq techniques), an increase in the quantity or concentration of the corresponding protein (as assessed, e.g., using protein detection methods described herein or known in the art, such as enzyme-linked immunosorbent assays (ELISA), among others), and/or an increase in the activity of the corresponding protein (e.g., in the case of an enzyme, as assessed using an enzymatic activity assay described herein or known in the art) in a sample obtained from the subject. As used herein, a cell is considered to &#x201c;express&#x201d; a gene or protein of interest if one or more, or all, of the above events can be detected in the cell or in a medium in which the cell resides. For example, a gene or protein of interest is considered to be &#x201c;expressed&#x201d; by a cell or population of cells if one can detect (i) production of a corresponding RNA transcript, such as an mRNA template, by the cell or population of cells (e.g., using RNA detection procedures described herein); (ii) processing of the RNA transcript (e.g., splicing, editing, 5&#x2032; cap formation, and/or 3&#x2032; end processing, such as using RNA detection procedures described herein); (iii) translation of the RNA template into a protein product (e.g., using protein detection procedures described herein); and/or (iv) post-translational modification of the protein product (e.g., using protein detection procedures described herein).</p><p id="p-0364" num="0318">As used herein, the term &#x201c;functional potential&#x201d; as it pertains to a pluripotent cell, such as a hematopoietic stem cell, refers to the functional properties of stem cells which include: 1) multi-potency (which refers to the ability to differentiate into multiple different blood lineages including, but not limited to granulocytes (e.g., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g., reticulocytes, erythrocytes), thrombocytes (e.g., megakaryoblasts, platelet producing megakaryocytes, platelets), monocytes (e.g., monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g., NK cells, B-cells and T-cells); 2) self-renewal (which refers to the ability of stem cells to give rise to daughter cells that have equivalent potential as the mother cell, and further that this ability can repeatedly occur throughout the lifetime of an individual without exhaustion); and 3) the ability of stem cells or progeny thereof to be reintroduced into a transplant recipient whereupon they home to the stem cell niche and re-establish productive and sustained cell growth and differentiation.</p><p id="p-0365" num="0319">As used herein, the terms &#x201c;hematopoietic stem cells&#x201d; and &#x201c;HSCs&#x201d; refer to immature blood cells having the capacity to self-renew and to differentiate into mature blood cells of diverse lineages including but not limited to granulocytes (e.g., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g., reticulocytes, erythrocytes), thrombocytes (e.g., megakaryoblasts, platelet producing megakaryocytes, platelets), monocytes (e.g., monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g., NK cells, B-cells and T-cells). It is known in the art that such cells may or may not include CD34+ cells. CD34+ cells are immature cells that express the CD34 cell surface marker. In humans, CD34+ cells are believed to include a subpopulation of cells with the stem cell properties defined above, whereas in mice, HSCs are CD34-. In addition, HSCs also refer to long term repopulating HSC (LT-HSC) and short-term repopulating HSC (ST-HSC). LT-HSC and ST-HSC are differentiated, based on functional potential and on cell surface marker expression. For example, human HSC are a CD34+, CD38&#x2212;, CD45RA&#x2212;, CD90+, CD49F+, and lin&#x2212; (negative for mature lineage markers including CO2, CD3, CD4, CD7, CD8, CD10, CD11B, CD19, CD20, CD56, CD235A). In mice, bone marrow LT-HSC are CD34&#x2212;, SCA-1+, C-kit+, CD135&#x2212;, Slamf1/CD150+, CD48&#x2212;, and lin&#x2212; (negative for mature lineage markers including Ter119, CD11b, Gr1, CD3, CD4, CD8, B220, IL-7ra), whereas ST-HS Care CD34+, SCA-1+, C-kit+, CD135&#x2212;, Slamf1/CD150+, and lin&#x2212; (negative for mature lineage markers including Ter119, CD11b, Gr1, CD3, CD4, CD8, B220, IL-7ra). In addition, ST-HSC are less quiescent (i.e., more active) and more proliferative than L T-HSC under homeostatic conditions. However, LT-HSC have greater self-renewal potential (i.e., they survive throughout adulthood, and can be serially transplanted through successive recipients), whereas ST-HSC have limited self-renewal (i.e., they survive for only a limited period of time, and do not possess serial transplantation potential). Any of these HSCs can be used in any of the methods described herein. Optionally, ST-HSCs are useful because they are highly proliferative and thus, can more quickly give rise to differentiated progeny.</p><p id="p-0366" num="0320">As used herein, the term &#x201c;HLA-matched&#x201d; refers to a donor-recipient pair in which none of the HLA antigens are mismatched between the donor and recipient, such as a donor providing a hematopoietic stem cell graft to a recipient in need of hematopoietic stem cell transplant therapy. HLA-matched (i.e., where all of the 6 alleles are matched) donor-recipient pairs have a decreased risk of graft rejection, as endogenous T cells and NK cells are less likely to recognize the incoming graft as foreign, and are thus less likely to mount an immune response against the transplant.</p><p id="p-0367" num="0321">As used herein, the term &#x201c;HLA-mismatched&#x201d; refers to a donor-recipient pair in which at least one HLA antigen, in particular with respect to HLA-A, HLA-B, HLA-C, and HLA-DR, is mismatched between the donor and recipient, such as a donor providing a hematopoietic stem cell graft to a recipient in need of hematopoietic stem cell transplant therapy. In some embodiments, one haplotype is matched and the other is mismatched. HLA-mismatched donor-recipient pairs may have an increased risk of graft rejection relative to HLA-matched donor-recipient pairs, as endogenous T cells and NK cells are more likely to recognize the incoming graft as foreign in the case of an HLA-mismatched donor-recipient pair, and such T cells and NK cells are thus more likely to mount an immune response against the transplant.</p><p id="p-0368" num="0322">As used herein, the terms &#x201c;induced pluripotent stem cell,&#x201d; &#x201c;iPS cell,&#x201d; and &#x201c;iPSC&#x201d; refer to a pluripotent stem cell that can be derived directly from a differentiated somatic cell. Human iPS cells can be generated by introducing specific sets of reprogramming factors into a non-pluripotent cell that can include, for example, Oct3/4, Sox family transcription factors (e.g., Sox1, Sox2, Sox3, SoxI5), Myc family transcription factors (e.g., c-Myc, 1-Myc, n-Myc), Kruppel-like family (KLF) transcription factors (e.g., KLF1, KLF2, KLF4, KLF5), and/or related transcription factors, such as NANOG, LIN28, and/or Glis1. Human iPS cells can also be generated, for example, by the use of miRNAs, small molecules that mimic the actions of transcription factors, or lineage specifiers. Human iPS cells are characterized by their ability to differentiate into any cell of the three vertebrate germ layers, e.g., the endoderm, the ectoderm, or the mesoderm. Human iPS cells are also characterized by their ability propagate indefinitely under suitable in vitro culture conditions. Human iPS cells are described, for example, in Takahashi and Yamanaka, Cell 126:663 (2006), the disclosure of which is incorporated herein by reference as it pertains to the structure and functionality of iPS cells.</p><p id="p-0369" num="0323">As used herein, the terms &#x201c;interfering ribonucleic acid&#x201d; and &#x201c;interfering RNA&#x201d; refer to a RNA, such as a short interfering RNA (siRNA), micro RNA (miRNA), or short hairpin RNA (shRNA) that suppresses the expression of a target RNA transcript by way of (i) annealing to the target RNA transcript, thereby forming a nucleic acid duplex; and (ii) promoting the nuclease-mediated degradation of the RNA transcript and/or (iii) slowing, inhibiting, or preventing the translation of the RNA transcript, such as by sterically precluding the formation of a functional ribosome-RNA transcript complex or otherwise attenuating formation of a functional protein product from the target RNA transcript. Interfering RNAs as described herein may be provided to a patient in the form of, for example, a single- or double-stranded oligonucleotide, or in the form of a vector (e.g., a viral vector) containing a transgene encoding the interfering RNA. Exemplary interfering RNA platforms are described, for example, in Lam et al., Molecular Therapy&#x2014;Nucleic Acids 4:e252 (2015); Rao et al., Advanced Drug Delivery Reviews 61:746-769 (2009); and Borel et al., Molecular Therapy 22:692-701 (2014), the disclosures of each of which are incorporated herein by reference in their entirety.</p><p id="p-0370" num="0324">As used herein in the context of a viral transduction protocol, the term &#x201c;multiplicity of infection&#x201d; or &#x201c;MOI&#x201d; refers to the ratio of (i) virions added to a population of cells being targeted for transduction to (ii) the quantity of cells in the population. As an example, a transduction protocol in which a population of 1&#xd7;10<sup>6 </sup>cells being targeted for transduction is contacted with 1&#xd7;10<sup>7 </sup>virions (e.g., lentiviral virions, such as a lentiviral virion described herein) would be characterized by a multiplicity of infection of 10.</p><p id="p-0371" num="0325">As used herein in the context of hematopoietic stem and/or progenitor cells, the term &#x201c;mobilization&#x201d; refers to release of such cells from a stem cell niche where the cells typically reside (e.g., the bone marrow) into peripheral circulation. &#x201c;Mobilization agents&#x201d; are agents that are capable of inducing the release of hematopoietic stem and/or progenitor cells from a stem cell niche into peripheral circulation.</p><p id="p-0372" num="0326">As used herein, the term &#x201c;myeloablative&#x201d; or &#x201c;myeloablation&#x201d; refers to a conditioning regiment that substantially impairs or destroys the hematopoietic system, typically by exposure to a cytotoxic agent or radiation. Myeloablation encompasses complete myeloablation brought on by high doses of cytotoxic agent or total body irradiation that destroys the hematopoietic system.</p><p id="p-0373" num="0327">As used herein, the term &#x201c;non-myeloablative&#x201d; or &#x201c;myelosuppressive&#x201d; refers to a conditioning regiment that does not eliminate substantially all hematopoietic cells of host origin.</p><p id="p-0374" num="0328">As used herein, the term &#x201c;poloxamer&#x201d; refers to a non-ionic triblock copolymer composed of a central hydrophobic chain of polyoxypropylene flanked by two hydrophilic chains of polyoxyethylene.</p><p id="p-0375" num="0329">Poloxamers are also known by the trade name of &#x201c;Pluronics&#x201d; or &#x201c;Synperonics&#x201d; (BASF). The block copolymer can be represented by the following formula: HO(C<sub>2</sub>H<sub>4</sub>O)<sub>x</sub>(C<sub>3</sub>H<sub>6</sub>O)<sub>y</sub>(C<sub>2</sub>H<sub>4</sub>O)<sub>z</sub>H. The lengths of the polymer blocks can be customized. As a result, many different poloxamers exist. Poloxamers suitable for use in conjunction with the compositions and methods of the present disclosure include those having an average molecular weight of at least about 10,000 g/mol, at least about 11,400 g/mol, at least about 12,600 g/mol, at least about 13,000 g/mol, at least about 14,600 g/mol, or at least about 15,000 g/mol. Since the synthesis of block copolymers is associated with a natural degree of variation from one batch to another, the numerical values recited above (and those used herein to characterize a given poloxamer) may not be precisely achievable upon synthesis, and the average value will differ to a certain extent. Thus, the term &#x201c;poloxamer&#x201d; as used herein can be used interchangeably with the term &#x201c;poloxamers&#x201d; (representing an entity of several poloxamers, also referred to as mixture of poloxamers) if not explicitly stated otherwise. The term &#x201c;average&#x201d; in relation to the number of monomer units or molecular weight of (a) poloxamer(s) as used herein is a consequence of the technical inability to produce poloxamers all having the identical composition and thus the identical molecular weight. Poloxamers produced according to state of the art methods will be present as a mixture of poloxamers each showing a variability as regards their molecular weight, but the mixture as a whole averaging the molecular weight specified herein. BASF and Sigma Aldrich are suitable sources of poloxamers for use in conjunction with the compositions and methods of the disclosure.</p><p id="p-0376" num="0330">As used herein, the term &#x201c;pluripotent cell&#x201d; refers to a cell that possesses the ability to develop into more than one differentiated cell type, such as a cell type of the hematopoietic lineage (e.g., granulocytes (e.g., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g., reticulocytes, erythrocytes), thrombocytes (e.g., megakaryoblasts, platelet producing megakaryocytes, platelets), monocytes (e.g., monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g., NK cells, B-cells and T-cells). Examples of pluripotent cells are ESCs, iPSCs, and CD34+ cells.</p><p id="p-0377" num="0331">As used herein, the term &#x201c;promoter&#x201d; refers to a recognition site on DNA that is bound by an RNA polymerase. The polymerase drives transcription of the transgene. Exemplary promoters suitable for use with the compositions and methods described herein are described, for example, in Sandelin et al., Nature Reviews Genetics 8:424 (2007), the disclosure of which is incorporated herein by reference as it pertains to nucleic acid regulatory elements. Additionally, the term &#x201c;promoter&#x201d; may refer to a synthetic promoter, which are regulatory DNA sequences that do not occur naturally in biological systems. Synthetic promoters contain parts of naturally occurring promoters combined with polynucleotide sequences that do not occur in nature and can be optimized to express recombinant DNA using a variety of transgenes, vectors, and target cell types.</p><p id="p-0378" num="0332">&#x201c;Percent (%) sequence complementarity&#x201d; with respect to a reference polynucleotide sequence is defined as the percentage of nucleic acids in a candidate sequence that are complementary to the nucleic acids in the reference polynucleotide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence complementarity. A given nucleotide is considered to be &#x201c;complementary&#x201d; to a reference nucleotide as described herein if the two nucleotides form canonical Watson-Crick base pairs. For the avoidance of doubt, Watson-Crick base pairs in the context of the present disclosure include adenine-thymine, adenine-uracil, and cytosine-guanine base pairs. A proper Watson-Crick base pair is referred to in this context as a &#x201c;match,&#x201d; while each unpaired nucleotide, and each incorrectly paired nucleotide, is referred to as a &#x201c;mismatch.&#x201d; Alignment for purposes of determining percent nucleic acid sequence complementarity can be achieved in various ways that are within the capabilities of one of skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, or Megalign software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal complementarity over the full length of the sequences being compared. As an illustration, the percent sequence complementarity of a given nucleic acid sequence, A, to a given nucleic acid sequence, B, (which can alternatively be phrased as a given nucleic acid sequence, A that has a certain percent complementarity to a given nucleic acid sequence, B) is calculated as follows:</p><p id="p-0379" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>100 multiplied by (the fraction X/Y)<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0380" num="0000">where X is the number of complementary base pairs in an alignment (e.g., as executed by computer software, such as BLAST) of A and B, and where Y is the total number of nucleic acids in B. It will be appreciated that where the length of nucleic acid sequence A is not equal to the length of nucleic acid sequence B, the percent sequence complementarity of A to B will not equal the percent sequence complementarity of B to A. As used herein, a query nucleic acid sequence is considered to be &#x201c;completely complementary&#x201d; to a reference nucleic acid sequence if the query nucleic acid sequence has 100% sequence complementarity to the reference nucleic acid sequence.</p><p id="p-0381" num="0333">&#x201c;Percent (%) sequence identity&#x201d; with respect to a reference polynucleotide or polypeptide sequence is defined as the percentage of nucleic acids or amino acids in a candidate sequence that are identical to the nucleic acids or amino acids in the reference polynucleotide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid or amino acid sequence identity can be achieved in various ways that are within the capabilities of one of skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, or Megalign software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For example, percent sequence identity values may be generated using the sequence comparison computer program BLAST. As an illustration, the percent sequence identity of a given nucleic acid or amino acid sequence, A, to, with, or against a given nucleic acid or amino acid sequence, B, (which can alternatively be phrased as a given nucleic acid or amino acid sequence, A that has a certain percent sequence identity to, with, or against a given nucleic acid or amino acid sequence, B) is calculated as follows:</p><p id="p-0382" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>100 multiplied by (the fraction X/Y)<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0383" num="0000">where X is the number of nucleotides or amino acids scored as identical matches by a sequence alignment program (e.g., BLAST) in that program's alignment of A and B, and where Y is the total number of nucleic acids in B. It will be appreciated that where the length of nucleic acid or amino acid sequence A is not equal to the length of nucleic acid or amino acid sequence B, the percent sequence identity of A to B will not equal the percent sequence identity of B to A.</p><p id="p-0384" num="0334">As used herein, the term &#x201c;pharmaceutically acceptable&#x201d; refers to those compounds, materials, compositions and/or dosage forms, which are suitable for contact with the tissues of a subject, such as a mammal (e.g., a human) without excessive toxicity, irritation, allergic response and other problem complications commensurate with a reasonable benefit/risk ratio.</p><p id="p-0385" num="0335">As used herein, the term &#x201c;regulatory sequence&#x201d; includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals) that control the transcription or translation of the antibody chain genes. Such regulatory sequences are described, for example, in Perdew et al., Regulation of Gene Expression (Humana Press, New York, N.Y., (2014)); incorporated herein by reference.</p><p id="p-0386" num="0336">As used herein, the terms &#x201c;stem cell&#x201d; and &#x201c;undifferentiated cell&#x201d; refer to a cell in an undifferentiated or partially differentiated state that has the developmental potential to differentiate into multiple cell types. A stem cell is capable of proliferation and giving rise to more such stem cells while maintaining its functional potential. Stem cells can divide asymmetrically, which is known as obligatory asymmetrical differentiation, with one daughter cell retaining the functional potential of the parent stem cell and the other daughter cell expressing some distinct other specific function, phenotype and/or developmental potential from the parent cell. The daughter cells themselves can be induced to proliferate and produce progeny that subsequently differentiate into one or more mature cell types, while also retaining one or more cells with parental developmental potential. A differentiated cell may derive from a multipotent cell, which itself is derived from a multipotent cell, and so on. Alternatively, some of the stem cells in a population can divide symmetrically into two stem cells. Accordingly, the term &#x201c;stem cell&#x201d; refers to any subset of cells that have the developmental potential, under particular circumstances, to differentiate to a more specialized or differentiated phenotype, and which retain the capacity, under certain circumstances, to proliferate without substantially differentiating. In some embodiments, the term stem cell refers generally to a naturally occurring parent cell whose descendants (progeny cells) specialize, often in different directions, by differentiation, e.g., by acquiring completely individual characters, as occurs in progressive diversification of embryonic cells and tissues. Some differentiated cells also have the capacity to give rise to cells of greater developmental potential. Such capacity may be natural or may be induced artificially upon treatment with various factors. Cells that begin as stem cells might proceed toward a differentiated phenotype, but then can be induced to &#x201c;reverse&#x201d; and re-express the stem cell phenotype, a term often referred to as &#x201c;dedifferentiation&#x201d; or &#x201c;reprogramming&#x201d; or &#x201c;retrodifferentiation&#x201d; by persons of ordinary skill in the art.</p><p id="p-0387" num="0337">As used herein, the term &#x201c;transgene&#x201d; refers to a recombinant nucleic acid (e.g., DNA or cDNA) encoding a gene product (e.g., a gene product described herein). The gene product may be an RNA, peptide, or protein. In addition to the coding region for the gene product, the transgene may include or be operably linked to one or more elements to facilitate or enhance expression, such as a promoter, enhancer(s), destabilizing domain(s), response element(s), reporter element(s), insulator element(s), polyadenylation signal(s), and/or other functional elements. Embodiments of the disclosure may utilize any known suitable promoter, enhancer(s), destabilizing domain(s), response element(s), reporter element(s), insulator element(s), polyadenylation signal(s), and/or other functional elements.</p><p id="p-0388" num="0338">As used herein, the terms &#x201c;subject&#x201d; and &#x201c;patient&#x201d; are used interchangeably and refer to an organism (e.g., a mammal, such as a human) that has been diagnosed as having, and/or is undergoing treatment for, a disease, such as a disease characterized by a gene or protein deficiency described herein.</p><p id="p-0389" num="0339">As used herein, the terms &#x201c;transduction&#x201d; and &#x201c;transduce&#x201d; refer to a method of introducing a viral vector construct or a part thereof into a cell and subsequent expression of a transgene encoded by the vector construct or part thereof in the cell.</p><p id="p-0390" num="0340">As used herein, the term &#x201c;transduction efficiency&#x201d; refers to the proportion of cells in a given population that are transduced with at least one copy of a vector (e.g., a viral vector, such as a lentiviral vector described herein). For example, if 1&#xd7;10<sup>6 </sup>cells are exposed to a virus (e.g., a lentivirus) and 0.5&#xd7;10<sup>6 </sup>cells are determined to have a least one copy of the viral vector in their genome following a transduction procedure, then the transduction efficiency for that procedure is 50%. Exemplary methods for determining transduction efficiency include polymerase chain reaction (PCR) procedures and flow cytometry.</p><p id="p-0391" num="0341">As used herein, &#x201c;treatment&#x201d; and &#x201c;treating&#x201d; refer to an approach for obtaining beneficial or desired results, e.g., clinical results. Beneficial or desired results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions; diminishment of extent of disease or condition; stabilized (i.e., not worsening) state of disease, disorder, or condition; preventing spread of disease or condition; delay or slowing the progress of the disease or condition; amelioration or palliation of the disease or condition; and remission (whether partial or total), whether detectable or undetectable. &#x201c;Ameliorating&#x201d; or &#x201c;palliating&#x201d; a disease or condition means that the extent and/or undesirable clinical manifestations of the disease, disorder, or condition are lessened and/or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment. &#x201c;Treatment&#x201d; can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder, as well as those prone to or at risk of developing the condition or disorder, as well as those in which the condition or disorder is to be prevented.</p><p id="p-0392" num="0342">As used herein, the term &#x201c;vector&#x201d; includes a nucleic acid vector, e.g., a DNA vector, such as a plasmid, a RNA vector, virus, or other suitable replicon (e.g., viral vector). A variety of vectors have been developed for the delivery of polynucleotides encoding exogenous proteins into a prokaryotic or eukaryotic cell. Examples of such expression vectors are disclosed in, e.g., WO 1994/011026; incorporated herein by reference as it pertains to vectors suitable for the expression of a gene of interest. Expression vectors suitable for use with the compositions and methods described herein contain a polynucleotide sequence as well as, e.g., additional sequence elements used for the expression of proteins and/or the integration of these polynucleotide sequences into the genome of a mammalian cell. Vectors that can be used for the expression of a protein or proteins described herein include plasmids that contain regulatory sequences, such as promoter and enhancer regions, which direct gene transcription. Additionally, useful vectors for expression of a protein or proteins described herein may contain polynucleotide sequences that enhance the rate of translation of the corresponding gene or genes, or improve the stability or nuclear export of the mRNA that results from gene transcription. Examples of such sequence elements are 5&#x2032; and 3&#x2032; untranslated regions, an IRES, and a polyadenylation signal site in order to direct efficient transcription of a gene or genes carried on an expression vector. Expression vectors suitable for use with the compositions and methods described herein may also contain a polynucleotide encoding a marker for selection of cells that contain such a vector. Examples of a suitable marker are genes that encode resistance to antibiotics, such as ampicillin, chloramphenicol, kanamycin, nourseothricin, or zeocin, among others.</p><p id="p-0393" num="0343">As used herein, the term &#x201c;vector copy number&#x201d; or &#x201c;VCN&#x201d; refers to the quantity of copies of a vector, or portion thereof (e.g., a portion that encodes a transgene of interest), in the genome of a cell. The average VCN may be determined for a population of cells or for individual cell colonies. Exemplary methods for measuring VCN include PCR procedures and flow cytometry.</p><p id="p-0394" num="0344">As used herein, the term &#x201c;beta-globin,&#x201d; along with the names of other genes or proteins recited in the present disclosure, include wild-type forms of the corresponding gene or protein, as well as variants (e.g., splice variants, truncations, concatemers, and fusion constructs, among others) thereof. In the context of beta-globin, examples of such variants are proteins having at least 70% sequence identity (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.9% identity, or more) to any of the amino acid sequences of a wild-type beta-globin protein (e.g., SEQ ID NO: 2), provided, for example, that the beta-globin variant retains the functionality of a wild-type beta-globin.</p><p id="p-0395" num="0345">As used herein, the term &#x201c;alkyl&#x201d; refers to monovalent, optionally branched alkyl groups, such as those having from 1 to 6 carbon atoms, or more. This term is exemplified by groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-hexyl and the like.</p><p id="p-0396" num="0346">As used herein, the term &#x201c;lower alkyl&#x201d; refers to alkyl groups having from 1 to 6 carbon atoms.</p><p id="p-0397" num="0347">As used herein, the term &#x201c;aryl&#x201d; refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl). Preferred aryl include phenyl, naphthyl, phenanthrenyl and the like.</p><p id="p-0398" num="0348">As used herein, the terms &#x201c;aralkyl&#x201d; and &#x201c;aryl alkyl&#x201d; are used interchangeably and refer to an alkyl group containing an aryl moiety. Similarly, the terms &#x201c;aryl lower alkyl&#x201d; and the like refer to lower alkyl groups containing an aryl moiety.</p><p id="p-0399" num="0349">As used herein, the term &#x201c;alkyl aryl&#x201d; refers to alkyl groups having an aryl substituent, including benzyl, phenethyl and the like.</p><p id="p-0400" num="0350">As used herein, the term &#x201c;heteroaryl&#x201d; refers to a monocyclic heteroaromatic, or a bicyclic or a tricyclic fused-ring heteroaromatic group. Particular examples of heteroaromatic groups include optionally substituted pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadia-zolyl, 1,2,5-oxadiazolyl, I,3,4-oxadiazolyl,I,3,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydrobenzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, imidazo[I,2-a]pyridyl, benzothiazolyl, benzoxa-zolyl, quinolizinyl, quinazolinyl, phthalazinyl, quinoxalinyl, cinnolinyl, napthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, pteridinyl, carbazolyl, xanthenyl, benzoquinolyl, and the like.</p><p id="p-0401" num="0351">As used herein, the term &#x201c;alkyl heteroaryl&#x201d; refers to alkyl groups having a heteroaryl substituent, including 2-furylmethyl, 2-thienylmethyl, 2-(1H-indol-3-yl)ethyl and the like.</p><p id="p-0402" num="0352">As used herein, the term &#x201c;lower alkenyl&#x201d; refers to alkenyl groups preferably having from 2 to 6 carbon atoms and having at least 1 or 2 sites of alkenyl unsaturation. Exemplary alkenyl groups are ethenyl (&#x2014;CH&#x2550;CH<sub>2</sub>), n-2-propenyl (allyl, &#x2014;CH<sub>2</sub>CH&#x2550;CH<sub>2</sub>) and the like.</p><p id="p-0403" num="0353">As used herein, the term &#x201c;alkenyl aryl&#x201d; refers to alkenyl groups having an aryl substituent, including 2-phenylvinyl and the like.</p><p id="p-0404" num="0354">As used herein, the term &#x201c;alkenyl heteroaryl&#x201d; refers to alkenyl groups having a heteroaryl substituent, including 2-(3-pyridinyl)vinyl and the like.</p><p id="p-0405" num="0355">As used herein, the term &#x201c;lower alkynyl&#x201d; refers to alkynyl groups preferably having from 2 to 6 carbon atoms and having at least 1-2 sites of alkynyl unsaturation, preferred alkynyl groups include ethynyl (&#x2014;C&#x2261;CH), propargyl (&#x2014;CH<sub>2</sub>C&#x2261;CH), and the like.</p><p id="p-0406" num="0356">As used herein, the term &#x201c;alkynyl aryl&#x201d; refers to alkynyl groups having an aryl substituent, including phenylethynyl and the like.</p><p id="p-0407" num="0357">As used herein, the term &#x201c;alkynyl heteroaryl&#x201d; refers to alkynyl groups having a heteroaryl substituent, including 2-thienylethynyl and the like.</p><p id="p-0408" num="0358">As used herein, the term &#x201c;cycloalkyl&#x201d; refers to a monocyclic cycloalkyl group having from 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.</p><p id="p-0409" num="0359">As used herein, the term &#x201c;lower cycloalkyl&#x201d; refers to a saturated carbocyclic group of from 3 to 8 carbon atoms having a single ring (e.g., cyclohexyl) or multiple condensed rings (e.g., norbornyl). Preferred cycloalkyl include cyclopentyl, cyclohexyl, norbornyl and the like.</p><p id="p-0410" num="0360">As used herein, the term &#x201c;heterocycloalkyl&#x201d; refers to a cycloalkyl group in which one or more ring carbon atoms are replaced with a heteroatom, such as a nitrogen atom, an oxygen atom, a sulfur atom, and the like. Exemplary heterocycloalkyl groups are pyrrolidinyl, piperidinyl, oxopiperidinyl, morpholinyl, piperazinyl, oxopiperazinyl, thiomorpholinyl, azepanyl, diazepanyl, oxazepanyl, thiazepanyl, dioxothiazepanyl, azokanyl, tetrahydrofuranyl, tetrahydropyranyl, and the like.</p><p id="p-0411" num="0361">As used herein, the term &#x201c;alkyl cycloalkyl&#x201d; refers to alkyl groups having a cycloalkyl substituent, including cyclohexylmethyl, cyclopentylpropyl, and the like.</p><p id="p-0412" num="0362">As used herein, the term &#x201c;alkyl heterocycloalkyl&#x201d; refers to C<sub>1</sub>-C<sub>6</sub>-alkyl groups having a heterocycloalkyl substituent, including 2-(1-pyrrolidinyl)ethyl, 4-morpholinylmethyl, (1-methyl-4-piperidinyl)methyl and the like.</p><p id="p-0413" num="0363">As used herein, the term &#x201c;carboxy&#x201d; refers to the group &#x2014;C(O)OH.</p><p id="p-0414" num="0364">As used herein, the term &#x201c;alkyl carboxy&#x201d; refers to C<sub>1</sub>-C<sub>5</sub>-alkyl groups having a carboxy substituent, including 2-carboxyethyl and the like.</p><p id="p-0415" num="0365">As used herein, the term &#x201c;acyl&#x201d; refers to the group &#x2014;C(O)R, wherein R may be, for example, C<sub>1</sub>-C<sub>6</sub>-alkyl, aryl, heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, or C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, among other substituents.</p><p id="p-0416" num="0366">As used herein, the term &#x201c;acyloxy&#x201d; refers to the group &#x2014;OC(O)R, wherein R may be, for example, C<sub>1</sub>-C<sub>6</sub>-alkyl, aryl, heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, or C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, among other substituents.</p><p id="p-0417" num="0367">As used herein, the term &#x201c;alkoxy&#x201d; refers to the group &#x2014;O&#x2014;R, wherein R is, for example, an optionally substituted alkyl group, such as an optionally substituted C<sub>1</sub>-C<sub>6</sub>-alkyl, aryl, heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, or C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, among other substituents. Exemplary alkoxy groups include by way of example, methoxy, ethoxy, phenoxy, and the like.</p><p id="p-0418" num="0368">As used herein, the term &#x201c;alkoxycarbonyl&#x201d; refers to the group &#x2014;C(O)OR, wherein R is, for example, hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, aryl, heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, or C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, among other possible substituents.</p><p id="p-0419" num="0369">As used herein, the term &#x201c;alkyl alkoxycarbonyl&#x201d; refers to alkyl groups having an alkoxycarbonyl substituent, including 2-(benzyloxycarbonyl)ethyl and the like.</p><p id="p-0420" num="0370">As used herein, the term &#x201c;aminocarbonyl&#x201d; refers to the group &#x2014;C(O)NRR&#x2032;, wherein each of R and R&#x2032; may independently be, for example, hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, aryl, heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, or C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, among other substituents.</p><p id="p-0421" num="0371">As used herein, the term &#x201c;alkyl aminocarbonyl&#x201d; refers to alkyl groups having an aminocarbonyl substituent, including 2-(dimethylaminocarbonyl)ethyl and the like.</p><p id="p-0422" num="0372">As used herein, the term &#x201c;acylamino&#x201d; refers to the group &#x2014;NRC(O)R&#x2032;, wherein each of R and R&#x2032; may independently be, for example, hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, aryl, heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, or C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, among other substituents.</p><p id="p-0423" num="0373">As used herein, the term &#x201c;alkyl acylamino&#x201d; refers to alkyl groups having an acylamino substituent, including 2-(propionylamino)ethyl and the like.</p><p id="p-0424" num="0374">As used herein, the term &#x201c;ureido&#x201d; refers to the group &#x2014;NRC(O)NR&#x2032;R&#x2033;, wherein each of R, R&#x2032;, and R&#x2033; may independently be, for example, hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, aryl, heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, cycloalkyl, or heterocycloalkyl, among other substituents. Exemplary ureido groups further include moieties in which R&#x2032; and R&#x2033;, together with the nitrogen atom to which they are attached, form a 3-8-membered heterocycloalkyl ring.</p><p id="p-0425" num="0375">As used herein, the term &#x201c;alkyl ureido&#x201d; refers to alkyl groups having an ureido substituent, including 2-(N&#x2032;-methylureido)ethyl and the like.</p><p id="p-0426" num="0376">As used herein, the term &#x201c;amino&#x201d; refers to the group &#x2014;NRR&#x2032;, wherein each of R and R&#x2032; may independently be, for example, hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, aryl, heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, cycloalkyl, or heterocycloalkyl, among other substituents. Exemplary amino groups further include moieties in which R and R&#x2032;, together with the nitrogen atom to which they are attached, can form a 3-8-membered heterocycloalkyl ring.</p><p id="p-0427" num="0377">As used herein, the term &#x201c;alkyl amino&#x201d; refers to alkyl groups having an amino substituent, including 2-(1-pyrrolidinyl)ethyl and the like.</p><p id="p-0428" num="0378">As used herein, the term &#x201c;ammonium&#x201d; refers to a positively charged group &#x2014;N<sup>+</sup>RR&#x2032;R&#x2033;, wherein each of R, R&#x2032;, and R&#x2033; may independently be, for example, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, cycloalkyl, or heterocycloalkyl, among other substituents. Exemplary ammonium groups further include moieties in which R and R&#x2032;, together with the nitrogen atom to which they are attached, form a 3-8-membered heterocycloalkyl ring.</p><p id="p-0429" num="0379">As used herein, the term &#x201c;halogen&#x201d; refers to fluoro, chloro, bromo and iodo atoms.</p><p id="p-0430" num="0380">As used herein, the term &#x201c;sulfonyloxy&#x201d; refers to a group &#x2014;OSO<sub>2</sub>&#x2014;R wherein R is selected from hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl substituted with halogens, e.g., an &#x2014;OSO<sub>2</sub>&#x2014;CF<sub>3 </sub>group, aryl, heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, and C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl.</p><p id="p-0431" num="0381">As used herein, the term &#x201c;alkyl sulfonyloxy&#x201d; refers to alkyl groups having a sulfonyloxy substituent, including 2-(methylsulfonyloxy)ethyl and the like.</p><p id="p-0432" num="0382">As used herein, the term &#x201c;sulfonyl&#x201d; refers to group &#x201c;&#x2014;SO<sub>2</sub>&#x2014;R&#x201d; wherein R is selected from hydrogen, aryl, heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl substituted with halogens, e.g., an &#x2014;SO<sub>2</sub>&#x2014;CF<sub>3 </sub>group, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl or C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl.</p><p id="p-0433" num="0383">As used herein, the term &#x201c;alkyl sulfonyl&#x201d; refers to alkyl groups having a sulfonyl substituent, including 2-(methylsulfonyl)ethyl and the like.</p><p id="p-0434" num="0384">As used herein, the term &#x201c;sulfinyl&#x201d; refers to a group &#x201c;&#x2014;S(O)&#x2014;R&#x201d; wherein R is selected from hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl substituted with halogens, e.g., a &#x2014;SO&#x2014;CF<sub>3 </sub>group, aryl, heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl or C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl.</p><p id="p-0435" num="0385">As used herein, the term &#x201c;alkyl sulfinyl&#x201d; refers to C<sub>1</sub>-C<sub>5</sub>-alkyl groups having a sulfinyl substituent, including 2-(methylsulfinyl)ethyl and the like.</p><p id="p-0436" num="0386">As used herein, the term &#x201c;sulfanyl&#x201d; refers to groups &#x2014;S&#x2014;R, wherein R is, for example, alkyl, aryl, heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, or C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, among other substituents. Exemplary sulfanyl groups are methylsulfanyl, ethylsulfanyl, and the like.</p><p id="p-0437" num="0387">As used herein, the term &#x201c;alkyl sulfanyl&#x201d; refers to alkyl groups having a sulfanyl substituent, including 2-(ethylsulfanyl)ethyl and the like.</p><p id="p-0438" num="0388">As used herein, the term &#x201c;sulfonylamino&#x201d; refers to a group &#x2014;NRSO<sub>2</sub>&#x2014;R&#x2032;, wherein each of R and R&#x2032; may independently be hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, aryl, heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, or C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, among other substituents.</p><p id="p-0439" num="0389">As used herein, the term &#x201c;alkyl sulfonylamino&#x201d; refers to alkyl groups having a sulfonylamino substituent, including 2-(ethylsulfonylamino)ethyl and the like.</p><p id="p-0440" num="0390">Unless otherwise constrained by the definition of the individual substituent, the above set out groups, like &#x201c;alkyl&#x201d;, &#x201c;alkenyl&#x201d;, &#x201c;alkynyl&#x201d;, &#x201c;aryl&#x201d; and &#x201c;heteroaryl&#x201d; etc. groups can optionally be substituted, for example, with one or more substituents, as valency permits, such as a substituent selected from alkyl (e.g., C<sub>1</sub>-C<sub>6</sub>-alkyl), alkenyl (e.g., C<sub>2</sub>-C<sub>6</sub>-alkenyl), alkynyl (e.g., C<sub>2</sub>-C<sub>6</sub>-alkynyl), cycloalkyl, heterocycloalkyl, alkyl aryl (e.g., C<sub>1</sub>-C<sub>6</sub>-alkyl aryl), alkyl heteroaryl (e.g., C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, alkyl cycloalkyl (e.g., C<sub>1</sub>-C<sub>6</sub>-alkyl cycloalkyl), alkyl heterocycloalkyl (e.g., C<sub>1</sub>-C<sub>6</sub>-alkyl heterocycloalkyl), amino, ammonium, acyl, acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, ureido, aryl, heteroaryl, sulfinyl, sulfonyl, alkoxy, sulfanyl, halogen, carboxy, trihalomethyl, cyano, hydroxy, mercapto, nitro, and the like. In some embodiments, the substitution is one in which neighboring substituents have undergone ring closure, such as situations in which vicinal functional substituents are involved, thus forming, e.g., lactams, lactones, cyclic anhydrides, acetals, thioacetals, and aminals, among others.</p><p id="p-0441" num="0391">As used herein, the term &#x201c;optionally fused&#x201d; refers to a cyclic chemical group that may be fused with a ring system, such as cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. Exemplary ring systems that may be fused to an optionally fused chemical group include, e.g., indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzoisoxazolyl, benzoisothiazolyl, indazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, phthalazinyl, quinoxalinyl, quinazolinyl, cinnolinyl, indolizinyl, naphthyridinyl, pteridinyl, indanyl, naphtyl, 1,2,3,4-tetrahydronaphthyl, indolinyl, isoindolinyl, 2,3,4,5-tetrahydrobenzo[b]oxepinyl, 6,7,8,9-tetrahydro-5H-benzocycloheptenyl, chromanyl, and the like.</p><p id="p-0442" num="0392">As used herein, the term &#x201c;pharmaceutically acceptable salt&#x201d; refers to a salt, such as a salt of a compound described herein, that retains the desired biological activity of the non-ionized parent compound from which the salt is formed. Examples of such salts include, but are not restricted to acid addition salts formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, fumaric acid, maleic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalene sulfonic acid, naphthalene disulfonic acid, and poly-galacturonic acid. The compounds can also be administered as pharmaceutically acceptable quaternary salts, such as quaternary ammonium salts of the formula &#x2014;NR,R&#x2032;,R&#x2033;+Z&#x2014;, wherein each of R, R&#x2032;, and R&#x2033; may independently be, for example, hydrogen, alkyl, benzyl, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, cycloalkyl, heterocycloalkyl, or the like, and Z is a counterion, such as chloride, bromide, iodide, &#x2014;O-alkyl, toluenesulfonate, methyl sulfonate, sulfonate, phosphate, carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, fumarate, citrate, tartrate, ascorbate, cinnamoate, mandeloate, and diphenylacetate), or the like.</p><p id="p-0443" num="0393">As used herein, for example, in the context of a protein kinase C (PKC) inhibitor, such as staurosporine, the term &#x201c;variant&#x201d; refers to an agent containing one or more modifications relative to a reference agent and that (i) retains a functional property of the reference agent (e.g., the ability to inhibit PKC activity) and/or (ii) is converted within a cell (e.g., a cell of a type described herein, such as a CD34+ cell) into the reference agent. In the context of small molecule PKC inhibitors, such as staurosporine, structural variants of a reference compound include those that differ from the reference compound by the inclusion and/or location of one or more substituents, as well as variants that are isomers of a reference compound, such as structural isomers (e.g., regioisomers) or stereoisomers (e.g., enantiomers or diastereomers), as well as prodrugs of a reference compound. In the context of an interfering RNA molecule, a variant may contain one or more nucleic acid substitutions relative to a parent interfering RNA molecule.</p><p id="p-0444" num="0394">The structural compositions described herein also include the tautomers, geometrical isomers (e.g., E/Z isomers and cis/trans isomers), enantiomers, diastereomers, and racemic forms, as well as pharmaceutically acceptable salts thereof. Such salts include, e.g., acid addition salts formed with pharmaceutically acceptable acids like hydrochloride, hydrobromide, sulfate or bisulfate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methanesulfonate, benzenesulfonate, and para-toluenesulfonate salts.</p><p id="p-0445" num="0395">As used herein, chemical structural formulas that do not depict the stereochemical configuration of a compound having one or more stereocenters will be interpreted as encompassing any one of the stereoisomers of the indicated compound, or a mixture of one or more such stereoisomers (e.g., any one of the enantiomers or diastereomers of the indicated compound, or a mixture of the enantiomers (e.g., a racemic mixture) or a mixture of the diastereomers). As used herein, chemical structural formulas that do specifically depict the stereochemical configuration of a compound having one or more stereocenters will be interpreted as referring to the substantially pure form of the particular stereoisomer shown. &#x201c;Substantially pure&#x201d; forms refer to compounds having a purity of greater than 85%, such as a purity of from 85% to 99%, 85% to 99.9%, 85% to 99.99%, or 85% to 100%, such as a purity of 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99%, 99.999%, or 100%, as assessed, for example, using chromatography and nuclear magnetic resonance techniques known in the art.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0006" level="1">BRIEF DESCRIPTION OF THE FIGURES</heading><p id="p-0446" num="0396"><figref idref="DRAWINGS">FIG. <b>1</b>A</figref> is a graph showing the effect of poloxamer P407, when incubated with CD34+ hematopoietic stem cells at various concentrations, on lentiviral transduction efficiency, as described in Example One, below. Briefly, CD34+ cells were transduced with a lentiviral vector containing a transgene encoding green fluorescent protein (GFP). Cells were either untreated (&#x201c;Untr&#x201d;) or incubated with: the lentivirus alone (&#x201c;Vector only&#x201d;), the lentivirus in combination with vehicle (&#x201c;Vector+Vehicle&#x201d;), or the lentivirus in combination with particular concentrations of P407, as indicated along the x axis. Values along the y axis represent fold increase in the quantity of transduced cells 12 days after exposure to each of the specified conditions relative to the quantity of transduced cells 12 days after treatment with lentiviral vector alone (&#x201c;Vector only&#x201d;). Quantities of transduced cells were determined by measuring expression of the encoded transgene, which was evaluated using flow cytometry to detect GFP-mediated fluorescence. Values along the y axis denote the mean&#xb1;standard error of the mean (SEM) for n=4 independent experiments.</p><p id="p-0447" num="0397"><figref idref="DRAWINGS">FIG. <b>1</b>B</figref> is a graph showing the effect of poloxamer P407, when incubated with CD34+ hematopoietic stem cells at various concentrations, on lentiviral vector copy number, as described in Example One, below. CD34+ cells were transduced with a lentiviral vector containing a transgene encoding GFP. Cells were either untreated (&#x201c;Untr&#x201d;) or incubated with the lentivirus alone (&#x201c;Vector only&#x201d;), the lentivirus in combination with vehicle (&#x201c;Vector+Vehicle&#x201d;), or the lentivirus in combination with particular concentrations of P407, as indicated along the x axis. Values along the y axis represent fold increase in vector copy number of cells 12 days after exposure to each of the specified conditions relative to vector copy number of cells 12 days after exposure to lentiviral vector alone (&#x201c;Vector only&#x201d;). Values along the y axis denote the mean&#xb1;standard error of the mean (SEM) for n=3 independent experiments.</p><p id="p-0448" num="0398"><figref idref="DRAWINGS">FIGS. <b>2</b>A-<b>2</b>C</figref> are graphs showing the effect of poloxamers P407 and P338 on lentiviral transduction of human hematopoietic stem cells, as described in Example Two, below. CD34+ hematopoietic stem cells from peripheral mobilized blood were either untreated (&#x201c;Untr&#x201d;) or incubated with a lentiviral vector containing a transgene encoding GFP. Among those cells incubated with a lentiviral vector, cells were either transduced with the vector alone (&#x201c;Vector only,&#x201d; multiplicity of infection 5-20) or in the presence of various concentrations of poloxamer P407 (final concentration 1 &#x3bc;g/mL-10 mg/mL) or poloxamer P338 (final concentration 10 &#x3bc;g/mL-4 mg/mL). <figref idref="DRAWINGS">FIG. <b>2</b>A</figref> is a plot summarizing the percentage of viable cells 18-24 hours post-transduction, as determined by flow cytometry detection of 7AAD-AnnexinV-cells. <figref idref="DRAWINGS">FIG. <b>2</b>B</figref> is a plot summarizing the fold change in percentage of transduced cells induced by the addition of P407 or P338, relative to cells treated with vector alone. The percentage of transduced cells was assessed by flow cytometry detection of transgene expression 12 days post-transduction. <figref idref="DRAWINGS">FIG. <b>2</b>C</figref> is a plot summarizing the fold change in mean transgene copy number (VCN) relative to cells treated with vector alone. VCN was determined by droplet digital PCR detection of integrated transgene sequences in genomic DNA harvested from cell cultures 12 days post-transduction. The data shown are mean&#xb1;SEM for n=3-9 (<figref idref="DRAWINGS">FIGS. <b>2</b>A and <b>2</b>B</figref>) and n=3-6 (<figref idref="DRAWINGS">FIG. <b>2</b>C</figref>) independent experiments with healthy human donor cells. Statistical analysis was conducted using a paired T-test of test conditions relative to vector and poloxamer vehicle treated cells, where &#x201c;ns&#x201d; indicates no statistical significance was (p&#x3c;0.05).</p><p id="p-0449" num="0399"><figref idref="DRAWINGS">FIGS. <b>3</b>A and <b>3</b>B</figref> are graphs showing the effect of poloxamer P407 or poloxamer P338 in combination with protamine sulfate on lentiviral transduction of human hematopoietic stem cells, as described in Example Three, below. CD34+ hematopoietic stem cells from peripheral mobilized blood were transduced with a lentiviral vector encoding GFP in the presence of poloxamer P407 (7 &#x3bc;g/mL) or poloxamer P338 (1 mg/mL), in combination with protamine sulfate (&#x201c;PS,&#x201d; 3.5 &#x3bc;g/mL). The plots summarize the fold change in the percentage of transduced cells as assessed by flow cytometry (<figref idref="DRAWINGS">FIG. <b>3</b>A</figref>) and mean transgene copy number (VCN, <figref idref="DRAWINGS">FIG. <b>3</b>B</figref>) induced by the addition of P407 or P338, in combination with protamine sulfate, relative to cells treated with vector alone. At 12 days post-transduction, percentage of transduced cells was assessed by flow cytometry detection of transgene expression, and VCN was determined by droplet digital PCR detection of integrated transgene sequences in genomic DNA. The data show mean&#xb1;range of n=5-8 independent experiments with healthy human donor cells. Statistical analysis was conducted using a T-test (p&#x3c;0.05).</p><p id="p-0450" num="0400"><figref idref="DRAWINGS">FIGS. <b>4</b>A and <b>4</b>B</figref> are graphs showing the effect of poloxamer P407 and protamine sulfate, in combination with either cyclosporine H or lithium carbonate, on lentiviral transduction of human hematopoietic stem cells, as described in Example Three, below. CD34+ stem cells freshly isolated from peripheral mobilized blood were transduced with a clinical therapeutic lentiviral vector in the presence of poloxamer P407 (7 &#x3bc;g/mL) in combination with protamine sulfate (&#x201c;PS,&#x201d; 3.5 &#x3bc;g/mL) and either cyclosporine H (&#x201c;CSH,&#x201d; 8 &#x3bc;M, dark grey) or lithium carbonate (Li<sub>2</sub>CO<sub>3</sub>, represented in the figures as &#x201c;LiCO,&#x201d; 2 mM, light grey). Plots summarize the percentage of transduced colonies determined by droplet digital PCR detection of integrated transgene sequences in genomic DNA isolated from Colony Forming Units (CFU, <figref idref="DRAWINGS">FIG. <b>4</b>A</figref>), and mean transgene copy number (VCN) per cell, detected 12 days post transduction, achieved when using a range of vector doses (moi, multiplicity of infection, <figref idref="DRAWINGS">FIG. <b>4</b>B</figref>). White bars show transduction efficiency and VCN achieved by addition of vector alone. Data show mean&#xb1;range of n=4 independent experiments with clinical scale isolation of healthy human donor CD34+ cells.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0007" level="1">DETAILED DESCRIPTION</heading><p id="p-0451" num="0401">The compositions and methods described herein can be used, for example, to modify eukaryotic cells, such as pluripotent cells, including hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). Using the compositions and methods of the disclosure, such cells may be engineered to express a gene of interest, and/or manipulated so as to proliferate ex vivo. In some embodiments of the disclosure, a population of pluripotent cells, such as a population of HSCs and/or HPCs, is contacted with a viral vector encoding a transgene. The transgene may encode a protein product or a regulatory ribonucleic acid (RNA) molecule that modulates the expression of a different gene. In some embodiments, the transgene encodes a protein that is deficient or non-functional in a patient (e.g., a mammalian patient, such as a human) suffering from a genetic disease for example, a genetic disease characterized by a loss-of-function mutation. The cell may be contacted with the virus in a manner that promotes transduction of the cell so as to express the desired transgene. In some embodiments, the cell is then administered to a patient suffering from a disease described above, thereby restoring gene expression in the individual.</p><p id="p-0452" num="0402">A variety of viral vectors can be used in conjunction with the compositions and methods of the disclosure. For examples, the viral vector may be a retrovirus, such as a lentivirus. Other viral vectors that may be used to achieve transduction of a target cell are described herein.</p><p id="p-0453" num="0403">To augment the extent of transduction and/or the rate at which the target cell is transduced, the cell may be contacted with a poloxamer, such as a poloxamer having a molar mass in excess of 10,000 g/mol, a molar mass of polyoxypropylene subunits greater than 2,000 g/mol, and/or an ethylene oxide content of greater than 40% by mass.</p><p id="p-0454" num="0404">The sections that follow describe the use of various viral vectors and agents that can be used to augment viral transduction of a target cell and an array of therapeutic uses of the transduced cells.</p><heading id="h-0008" level="2">Poloxamers</heading><p id="p-0455" num="0405">Poloxamers that may be used in conjunction with the compositions and methods of the disclosure include those having an average molar mass of polyoxypropylene subunits of greater than 2,050 g/mol (e.g., an average molar mass of polyoxypropylene subunits of about 2,055 g/mol, 2,060 g/mol, 2,075 g/mol, 2,080 g/mol, 2,085 g/mol, 2,090 g/mol, 2,095 g/mol, 2,100 g/mol, 2,200 g/mol, 2,300 g/mol, 2,400 g/mol, 2,500 g/mol, 2,600 g/mol, 2,700 g/mol, 2,800 g/mol, 2,900 g/mol, 3,000 g/mol, 3,100 g/mol, 3,200 g/mol, 3,300 g/mol, 3,400 g/mol, 3,500 g/mol, 3,600 g/mol, 3,700 g/mol, 3,800 g/mol, 3,900 g/mol, 4,000 g/mol, 4,100 g/mol, 4,200 g/mol, 4,300 g/mol, 4,400 g/mol, 4,500 g/mol, 4,600 g/mol, 4,700 g/mol, 4,800 g/mol, 4,900 g/mol, or 5,000 g/mol).</p><p id="p-0456" num="0406">In some embodiments, the poloxamer has an average molar mass of polyoxypropylene subunits of greater than 2,250 g/mol (e.g., an average molar mass of polyoxypropylene subunits of about 2,300 g/mol, 2,400 g/mol, 2,500 g/mol, 2,600 g/mol, 2,700 g/mol, 2,800 g/mol, 2,900 g/mol, 3,000 g/mol, 3,100 g/mol, 3,200 g/mol, 3,300 g/mol, 3,400 g/mol, 3,500 g/mol, 3,600 g/mol, 3,700 g/mol, 3,800 g/mol, 3,900 g/mol, 4,000 g/mol, 4,100 g/mol, 4,200 g/mol, 4,300 g/mol, 4,400 g/mol, 4,500 g/mol, 4,600 g/mol, 4,700 g/mol, 4,800 g/mol, 4,900 g/mol, or 5,000 g/mol).</p><p id="p-0457" num="0407">In some embodiments, the poloxamer has an average molar mass of polyoxypropylene subunits of greater than 2,750 g/mol (e.g., an average molar mass of polyoxypropylene subunits of about 2,800 g/mol, 2,900 g/mol, 3,000 g/mol, 3,100 g/mol, 3,200 g/mol, 3,300 g/mol, 3,400 g/mol, 3,500 g/mol, 3,600 g/mol, 3,700 g/mol, 3,800 g/mol, 3,900 g/mol, 4,000 g/mol, 4,100 g/mol, 4,200 g/mol, 4,300 g/mol, 4,400 g/mol, 4,500 g/mol, 4,600 g/mol, 4,700 g/mol, 4,800 g/mol, 4,900 g/mol, or 5,000 g/mol).</p><p id="p-0458" num="0408">In some embodiments, the poloxamer has an average molar mass of polyoxypropylene subunits of greater than 3,250 g/mol (e.g., an average molar mass of polyoxypropylene subunits of about 3,300 g/mol, 3,400 g/mol, 3,500 g/mol, 3,600 g/mol, 3,700 g/mol, 3,800 g/mol, 3,900 g/mol, 4,000 g/mol, 4,100 g/mol, 4,200 g/mol, 4,300 g/mol, 4,400 g/mol, 4,500 g/mol, 4,600 g/mol, 4,700 g/mol, 4,800 g/mol, 4,900 g/mol, or 5,000 g/mol).</p><p id="p-0459" num="0409">In some embodiments, the poloxamer has an average molar mass of polyoxypropylene subunits of greater than 3,625 g/mol (e.g., an average molar mass of polyoxypropylene subunits of about 3,700 g/mol, 3,800 g/mol, 3,900 g/mol, 4,000 g/mol, 4,100 g/mol, 4,200 g/mol, 4,300 g/mol, 4,400 g/mol, 4,500 g/mol, 4,600 g/mol, 4,700 g/mol, 4,800 g/mol, 4,900 g/mol, or 5,000 g/mol).</p><p id="p-0460" num="0410">In some embodiments, the poloxamer has an average molar mass of polyoxypropylene subunits of from about 2,050 g/mol to about 4,000 g/mol (e.g., about 2,050 g/mol, 2,055 g/mol, 2,060 g/mol, 2,065 g/mol, 2,070 g/mol, 2,075 g/mol, 2,080 g/mol, 2,085 g/mol, 2,090 g/mol, 2,095 g/mol, 2,100 g/mol, 2,105 g/mol, 2,110 g/mol, 2,115 g/mol, 2,120 g/mol, 2,125 g/mol, 2,130 g/mol, 2,135 g/mol, 2,140 g/mol, 2,145 g/mol, 2,150 g/mol, 2,155 g/mol, 2,160 g/mol, 2,165 g/mol, 2,170 g/mol, 2,175 g/mol, 2,180 g/mol, 2,185 g/mol, 2,190 g/mol, 2,195 g/mol, 2,200 g/mol, 2,205 g/mol, 2,210 g/mol, 2,215 g/mol, 2,220 g/mol, 2,225 g/mol, 2,230 g/mol, 2,235 g/mol, 2,240 g/mol, 2,245 g/mol, 2,250 g/mol, 2,255 g/mol, 2,260 g/mol, 2,265 g/mol, 2,270 g/mol, 2,275 g/mol, 2,280 g/mol, 2,285 g/mol, 2,290 g/mol, 2,295 g/mol, 2,300 g/mol, 2,305 g/mol, 2,310 g/mol, 2,315 g/mol, 2,320 g/mol, 2,325 g/mol, 2,330 g/mol, 2,335 g/mol, 2,340 g/mol, 2,345 g/mol, 2,350 g/mol, 2,355 g/mol, 2,360 g/mol, 2,365 g/mol, 2,370 g/mol, 2,375 g/mol, 2,380 g/mol, 2,385 g/mol, 2,390 g/mol, 2,395 g/mol, 2,400 g/mol, 2,405 g/mol, 2,410 g/mol, 2,415 g/mol, 2,420 g/mol, 2,425 g/mol, 2,430 g/mol, 2,435 g/mol, 2,440 g/mol, 2,445 g/mol, 2,450 g/mol, 2,455 g/mol, 2,460 g/mol, 2,465 g/mol, 2,470 g/mol, 2,475 g/mol, 2,480 g/mol, 2,485 g/mol, 2,490 g/mol, 2,495 g/mol, 2,500 g/mol, 2,505 g/mol, 2,510 g/mol, 2,515 g/mol, 2,520 g/mol, 2,525 g/mol, 2,530 g/mol, 2,535 g/mol, 2,540 g/mol, 2,545 g/mol, 2,550 g/mol, 2,555 g/mol, 2,560 g/mol, 2,565 g/mol, 2,570 g/mol, 2,575 g/mol, 2,580 g/mol, 2,585 g/mol, 2,590 g/mol, 2,595 g/mol, 2,600 g/mol, 2,605 g/mol, 2,610 g/mol, 2,615 g/mol, 2,620 g/mol, 2,625 g/mol, 2,630 g/mol, 2,635 g/mol, 2,640 g/mol, 2,645 g/mol, 2,650 g/mol, 2,655 g/mol, 2,660 g/mol, 2,665 g/mol, 2,670 g/mol, 2,675 g/mol, 2,680 g/mol, 2,685 g/mol, 2,690 g/mol, 2,695 g/mol, 2,700 g/mol, 2,705 g/mol, 2,710 g/mol, 2,715 g/mol, 2,720 g/mol, 2,725 g/mol, 2,730 g/mol, 2,735 g/mol, 2,740 g/mol, 2,745 g/mol, 2,750 g/mol, 2,755 g/mol, 2,760 g/mol, 2,765 g/mol, 2,770 g/mol, 2,775 g/mol, 2,780 g/mol, 2,785 g/mol, 2,790 g/mol, 2,795 g/mol, 2,800 g/mol, 2,805 g/mol, 2,810 g/mol, 2,815 g/mol, 2,820 g/mol, 2,825 g/mol, 2,830 g/mol, 2,835 g/mol, 2,840 g/mol, 2,845 g/mol, 2,850 g/mol, 2,855 g/mol, 2,860 g/mol, 2,865 g/mol, 2,870 g/mol, 2,875 g/mol, 2,880 g/mol, 2,885 g/mol, 2,890 g/mol, 2,895 g/mol, 2,900 g/mol, 2,905 g/mol, 2,910 g/mol, 2,915 g/mol, 2,920 g/mol, 2,925 g/mol, 2,930 g/mol, 2,935 g/mol, 2,940 g/mol, 2,945 g/mol, 2,950 g/mol, 2,955 g/mol, 2,960 g/mol, 2,965 g/mol, 2,970 g/mol, 2,975 g/mol, 2,980 g/mol, 2,985 g/mol, 2,990 g/mol, 2,995 g/mol, 3,000 g/mol, 3,005 g/mol, 3,010 g/mol, 3,015 g/mol, 3,020 g/mol, 3,025 g/mol, 3,030 g/mol, 3,035 g/mol, 3,040 g/mol, 3,045 g/mol, 3,050 g/mol, 3,055 g/mol, 3,060 g/mol, 3,065 g/mol, 3,070 g/mol, 3,075 g/mol, 3,080 g/mol, 3,085 g/mol, 3,090 g/mol, 3,095 g/mol, 3,100 g/mol, 3,105 g/mol, 3,110 g/mol, 3,115 g/mol, 3,120 g/mol, 3,125 g/mol, 3,130 g/mol, 3,135 g/mol, 3,140 g/mol, 3,145 g/mol, 3,150 g/mol, 3,155 g/mol, 3,160 g/mol, 3,165 g/mol, 3,170 g/mol, 3,175 g/mol, 3,180 g/mol, 3,185 g/mol, 3,190 g/mol, 3,195 g/mol, 3,200 g/mol, 3,205 g/mol, 3,210 g/mol, 3,215 g/mol, 3,220 g/mol, 3,225 g/mol, 3,230 g/mol, 3,235 g/mol, 3,240 g/mol, 3,245 g/mol, 3,250 g/mol, 3,255 g/mol, 3,260 g/mol, 3,265 g/mol, 3,270 g/mol, 3,275 g/mol, 3,280 g/mol, 3,285 g/mol, 3,290 g/mol, 3,295 g/mol, 3,300 g/mol, 3,305 g/mol, 3,310 g/mol, 3,315 g/mol, 3,320 g/mol, 3,325 g/mol, 3,330 g/mol, 3,335 g/mol, 3,340 g/mol, 3,345 g/mol, 3,350 g/mol, 3,355 g/mol, 3,360 g/mol, 3,365 g/mol, 3,370 g/mol, 3,375 g/mol, 3,380 g/mol, 3,385 g/mol, 3,390 g/mol, 3,395 g/mol, 3,400 g/mol, 3,405 g/mol, 3,410 g/mol, 3,415 g/mol, 3,420 g/mol, 3,425 g/mol, 3,430 g/mol, 3,435 g/mol, 3,440 g/mol, 3,445 g/mol, 3,450 g/mol, 3,455 g/mol, 3,460 g/mol, 3,465 g/mol, 3,470 g/mol, 3,475 g/mol, 3,480 g/mol, 3,485 g/mol, 3,490 g/mol, 3,495 g/mol, 3,500 g/mol, 3,505 g/mol, 3,510 g/mol, 3,515 g/mol, 3,520 g/mol, 3,525 g/mol, 3,530 g/mol, 3,535 g/mol, 3,540 g/mol, 3,545 g/mol, 3,550 g/mol, 3,555 g/mol, 3,560 g/mol, 3,565 g/mol, 3,570 g/mol, 3,575 g/mol, 3,580 g/mol, 3,585 g/mol, 3,590 g/mol, 3,595 g/mol, 3,600 g/mol, 3,605 g/mol, 3,610 g/mol, 3,615 g/mol, 3,620 g/mol, 3,625 g/mol, 3,630 g/mol, 3,635 g/mol, 3,640 g/mol, 3,645 g/mol, 3,650 g/mol, 3,655 g/mol, 3,660 g/mol, 3,665 g/mol, 3,670 g/mol, 3,675 g/mol, 3,680 g/mol, 3,685 g/mol, 3,690 g/mol, 3,695 g/mol, 3,700 g/mol, 3,705 g/mol, 3,710 g/mol, 3,715 g/mol, 3,720 g/mol, 3,725 g/mol, 3,730 g/mol, 3,735 g/mol, 3,740 g/mol, 3,745 g/mol, 3,750 g/mol, 3,755 g/mol, 3,760 g/mol, 3,765 g/mol, 3,770 g/mol, 3,775 g/mol, 3,780 g/mol, 3,785 g/mol, 3,790 g/mol, 3,795 g/mol, 3,800 g/mol, 3,805 g/mol, 3,810 g/mol, 3,815 g/mol, 3,820 g/mol, 3,825 g/mol, 3,830 g/mol, 3,835 g/mol, 3,840 g/mol, 3,845 g/mol, 3,850 g/mol, 3,855 g/mol, 3,860 g/mol, 3,865 g/mol, 3,870 g/mol, 3,875 g/mol, 3,880 g/mol, 3,885 g/mol, 3,890 g/mol, 3,895 g/mol, 3,900 g/mol, 3,905 g/mol, 3,910 g/mol, 3,915 g/mol, 3,920 g/mol, 3,925 g/mol, 3,930 g/mol, 3,935 g/mol, 3,940 g/mol, 3,945 g/mol, 3,950 g/mol, 3,955 g/mol, 3,960 g/mol, 3,965 g/mol, 3,970 g/mol, 3,975 g/mol, 3,980 g/mol, 3,985 g/mol, 3,990 g/mol, 3,995 g/mol, or 4,000 g/mol).</p><p id="p-0461" num="0411">In some embodiments, the poloxamer has an average molar mass of polyoxypropylene subunits of from about 2,750 g/mol to about 4,000 g/mol (e.g., about 2,750 g/mol, 2,755 g/mol, 2,760 g/mol, 2,765 g/mol, 2,770 g/mol, 2,775 g/mol, 2,780 g/mol, 2,785 g/mol, 2,790 g/mol, 2,795 g/mol, 2,800 g/mol, 2,805 g/mol, 2,810 g/mol, 2,815 g/mol, 2,820 g/mol, 2,825 g/mol, 2,830 g/mol, 2,835 g/mol, 2,840 g/mol, 2,845 g/mol, 2,850 g/mol, 2,855 g/mol, 2,860 g/mol, 2,865 g/mol, 2,870 g/mol, 2,875 g/mol, 2,880 g/mol, 2,885 g/mol, 2,890 g/mol, 2,895 g/mol, 2,900 g/mol, 2,905 g/mol, 2,910 g/mol, 2,915 g/mol, 2,920 g/mol, 2,925 g/mol, 2,930 g/mol, 2,935 g/mol, 2,940 g/mol, 2,945 g/mol, 2,950 g/mol, 2,955 g/mol, 2,960 g/mol, 2,965 g/mol, 2,970 g/mol, 2,975 g/mol, 2,980 g/mol, 2,985 g/mol, 2,990 g/mol, 2,995 g/mol, 3,000 g/mol, 3,005 g/mol, 3,010 g/mol, 3,015 g/mol, 3,020 g/mol, 3,025 g/mol, 3,030 g/mol, 3,035 g/mol, 3,040 g/mol, 3,045 g/mol, 3,050 g/mol, 3,055 g/mol, 3,060 g/mol, 3,065 g/mol, 3,070 g/mol, 3,075 g/mol, 3,080 g/mol, 3,085 g/mol, 3,090 g/mol, 3,095 g/mol, 3,100 g/mol, 3,105 g/mol, 3,110 g/mol, 3,115 g/mol, 3,120 g/mol, 3,125 g/mol, 3,130 g/mol, 3,135 g/mol, 3,140 g/mol, 3,145 g/mol, 3,150 g/mol, 3,155 g/mol, 3,160 g/mol, 3,165 g/mol, 3,170 g/mol, 3,175 g/mol, 3,180 g/mol, 3,185 g/mol, 3,190 g/mol, 3,195 g/mol, 3,200 g/mol, 3,205 g/mol, 3,210 g/mol, 3,215 g/mol, 3,220 g/mol, 3,225 g/mol, 3,230 g/mol, 3,235 g/mol, 3,240 g/mol, 3,245 g/mol, 3,250 g/mol, 3,255 g/mol, 3,260 g/mol, 3,265 g/mol, 3,270 g/mol, 3,275 g/mol, 3,280 g/mol, 3,285 g/mol, 3,290 g/mol, 3,295 g/mol, 3,300 g/mol, 3,305 g/mol, 3,310 g/mol, 3,315 g/mol, 3,320 g/mol, 3,325 g/mol, 3,330 g/mol, 3,335 g/mol, 3,340 g/mol, 3,345 g/mol, 3,350 g/mol, 3,355 g/mol, 3,360 g/mol, 3,365 g/mol, 3,370 g/mol, 3,375 g/mol, 3,380 g/mol, 3,385 g/mol, 3,390 g/mol, 3,395 g/mol, 3,400 g/mol, 3,405 g/mol, 3,410 g/mol, 3,415 g/mol, 3,420 g/mol, 3,425 g/mol, 3,430 g/mol, 3,435 g/mol, 3,440 g/mol, 3,445 g/mol, 3,450 g/mol, 3,455 g/mol, 3,460 g/mol, 3,465 g/mol, 3,470 g/mol, 3,475 g/mol, 3,480 g/mol, 3,485 g/mol, 3,490 g/mol, 3,495 g/mol, 3,500 g/mol, 3,505 g/mol, 3,510 g/mol, 3,515 g/mol, 3,520 g/mol, 3,525 g/mol, 3,530 g/mol, 3,535 g/mol, 3,540 g/mol, 3,545 g/mol, 3,550 g/mol, 3,555 g/mol, 3,560 g/mol, 3,565 g/mol, 3,570 g/mol, 3,575 g/mol, 3,580 g/mol, 3,585 g/mol, 3,590 g/mol, 3,595 g/mol, 3,600 g/mol, 3,605 g/mol, 3,610 g/mol, 3,615 g/mol, 3,620 g/mol, 3,625 g/mol, 3,630 g/mol, 3,635 g/mol, 3,640 g/mol, 3,645 g/mol, 3,650 g/mol, 3,655 g/mol, 3,660 g/mol, 3,665 g/mol, 3,670 g/mol, 3,675 g/mol, 3,680 g/mol, 3,685 g/mol, 3,690 g/mol, 3,695 g/mol, 3,700 g/mol, 3,705 g/mol, 3,710 g/mol, 3,715 g/mol, 3,720 g/mol, 3,725 g/mol, 3,730 g/mol, 3,735 g/mol, 3,740 g/mol, 3,745 g/mol, 3,750 g/mol, 3,755 g/mol, 3,760 g/mol, 3,765 g/mol, 3,770 g/mol, 3,775 g/mol, 3,780 g/mol, 3,785 g/mol, 3,790 g/mol, 3,795 g/mol, 3,800 g/mol, 3,805 g/mol, 3,810 g/mol, 3,815 g/mol, 3,820 g/mol, 3,825 g/mol, 3,830 g/mol, 3,835 g/mol, 3,840 g/mol, 3,845 g/mol, 3,850 g/mol, 3,855 g/mol, 3,860 g/mol, 3,865 g/mol, 3,870 g/mol, 3,875 g/mol, 3,880 g/mol, 3,885 g/mol, 3,890 g/mol, 3,895 g/mol, 3,900 g/mol, 3,905 g/mol, 3,910 g/mol, 3,915 g/mol, 3,920 g/mol, 3,925 g/mol, 3,930 g/mol, 3,935 g/mol, 3,940 g/mol, 3,945 g/mol, 3,950 g/mol, 3,955 g/mol, 3,960 g/mol, 3,965 g/mol, 3,970 g/mol, 3,975 g/mol, 3,980 g/mol, 3,985 g/mol, 3,990 g/mol, 3,995 g/mol, or 4,000 g/mol).</p><p id="p-0462" num="0412">In some embodiments, the poloxamer has an average molar mass of polyoxypropylene subunits of from about 3,250 g/mol to about 4,000 g/mol (e.g., about 3,250 g/mol, 3,255 g/mol, 3,260 g/mol, 3,265 g/mol, 3,270 g/mol, 3,275 g/mol, 3,280 g/mol, 3,285 g/mol, 3,290 g/mol, 3,295 g/mol, 3,300 g/mol, 3,305 g/mol, 3,310 g/mol, 3,315 g/mol, 3,320 g/mol, 3,325 g/mol, 3,330 g/mol, 3,335 g/mol, 3,340 g/mol, 3,345 g/mol, 3,350 g/mol, 3,355 g/mol, 3,360 g/mol, 3,365 g/mol, 3,370 g/mol, 3,375 g/mol, 3,380 g/mol, 3,385 g/mol, 3,390 g/mol, 3,395 g/mol, 3,400 g/mol, 3,405 g/mol, 3,410 g/mol, 3,415 g/mol, 3,420 g/mol, 3,425 g/mol, 3,430 g/mol, 3,435 g/mol, 3,440 g/mol, 3,445 g/mol, 3,450 g/mol, 3,455 g/mol, 3,460 g/mol, 3,465 g/mol, 3,470 g/mol, 3,475 g/mol, 3,480 g/mol, 3,485 g/mol, 3,490 g/mol, 3,495 g/mol, 3,500 g/mol, 3,505 g/mol, 3,510 g/mol, 3,515 g/mol, 3,520 g/mol, 3,525 g/mol, 3,530 g/mol, 3,535 g/mol, 3,540 g/mol, 3,545 g/mol, 3,550 g/mol, 3,555 g/mol, 3,560 g/mol, 3,565 g/mol, 3,570 g/mol, 3,575 g/mol, 3,580 g/mol, 3,585 g/mol, 3,590 g/mol, 3,595 g/mol, 3,600 g/mol, 3,605 g/mol, 3,610 g/mol, 3,615 g/mol, 3,620 g/mol, 3,625 g/mol, 3,630 g/mol, 3,635 g/mol, 3,640 g/mol, 3,645 g/mol, 3,650 g/mol, 3,655 g/mol, 3,660 g/mol, 3,665 g/mol, 3,670 g/mol, 3,675 g/mol, 3,680 g/mol, 3,685 g/mol, 3,690 g/mol, 3,695 g/mol, 3,700 g/mol, 3,705 g/mol, 3,710 g/mol, 3,715 g/mol, 3,720 g/mol, 3,725 g/mol, 3,730 g/mol, 3,735 g/mol, 3,740 g/mol, 3,745 g/mol, 3,750 g/mol, 3,755 g/mol, 3,760 g/mol, 3,765 g/mol, 3,770 g/mol, 3,775 g/mol, 3,780 g/mol, 3,785 g/mol, 3,790 g/mol, 3,795 g/mol, 3,800 g/mol, 3,805 g/mol, 3,810 g/mol, 3,815 g/mol, 3,820 g/mol, 3,825 g/mol, 3,830 g/mol, 3,835 g/mol, 3,840 g/mol, 3,845 g/mol, 3,850 g/mol, 3,855 g/mol, 3,860 g/mol, 3,865 g/mol, 3,870 g/mol, 3,875 g/mol, 3,880 g/mol, 3,885 g/mol, 3,890 g/mol, 3,895 g/mol, 3,900 g/mol, 3,905 g/mol, 3,910 g/mol, 3,915 g/mol, 3,920 g/mol, 3,925 g/mol, 3,930 g/mol, 3,935 g/mol, 3,940 g/mol, 3,945 g/mol, 3,950 g/mol, 3,955 g/mol, 3,960 g/mol, 3,965 g/mol, 3,970 g/mol, 3,975 g/mol, 3,980 g/mol, 3,985 g/mol, 3,990 g/mol, 3,995 g/mol, or 4,000 g/mol).</p><p id="p-0463" num="0413">In some embodiments, the poloxamer has an average molar mass of polyoxypropylene subunits of from about 3,625 g/mol to about 4,000 g/mol (e.g., about 3,625 g/mol, 3,630 g/mol, 3,635 g/mol, 3,640 g/mol, 3,645 g/mol, 3,650 g/mol, 3,655 g/mol, 3,660 g/mol, 3,665 g/mol, 3,670 g/mol, 3,675 g/mol, 3,680 g/mol, 3,685 g/mol, 3,690 g/mol, 3,695 g/mol, 3,700 g/mol, 3,705 g/mol, 3,710 g/mol, 3,715 g/mol, 3,720 g/mol, 3,725 g/mol, 3,730 g/mol, 3,735 g/mol, 3,740 g/mol, 3,745 g/mol, 3,750 g/mol, 3,755 g/mol, 3,760 g/mol, 3,765 g/mol, 3,770 g/mol, 3,775 g/mol, 3,780 g/mol, 3,785 g/mol, 3,790 g/mol, 3,795 g/mol, 3,800 g/mol, 3,805 g/mol, 3,810 g/mol, 3,815 g/mol, 3,820 g/mol, 3,825 g/mol, 3,830 g/mol, 3,835 g/mol, 3,840 g/mol, 3,845 g/mol, 3,850 g/mol, 3,855 g/mol, 3,860 g/mol, 3,865 g/mol, 3,870 g/mol, 3,875 g/mol, 3,880 g/mol, 3,885 g/mol, 3,890 g/mol, 3,895 g/mol, 3,900 g/mol, 3,905 g/mol, 3,910 g/mol, 3,915 g/mol, 3,920 g/mol, 3,925 g/mol, 3,930 g/mol, 3,935 g/mol, 3,940 g/mol, 3,945 g/mol, 3,950 g/mol, 3,955 g/mol, 3,960 g/mol, 3,965 g/mol, 3,970 g/mol, 3,975 g/mol, 3,980 g/mol, 3,985 g/mol, 3,990 g/mol, 3,995 g/mol, or 4,000 g/mol).</p><p id="p-0464" num="0414">In some embodiments, the poloxamer has an average ethylene oxide content of greater than 40% by mass (e.g., about 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, or more).</p><p id="p-0465" num="0415">In some embodiments, the poloxamer has an average ethylene oxide content of greater than 50% by mass (e.g., about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, or more).</p><p id="p-0466" num="0416">In some embodiments, the poloxamer has an average ethylene oxide content of greater than 60% by mass (e.g., about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, or more).</p><p id="p-0467" num="0417">In some embodiments, the poloxamer has an average ethylene oxide content of greater than 70% by mass (e.g., about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, or more).</p><p id="p-0468" num="0418">In some embodiments, the poloxamer has an average ethylene oxide content of from about 40% to about 90% (e.g., about 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%).</p><p id="p-0469" num="0419">In some embodiments, the poloxamer has an average ethylene oxide content of from about 50% to about 85% (e.g., about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, or 85%).</p><p id="p-0470" num="0420">In some embodiments, the poloxamer has an average ethylene oxide content of from about 60% to about 80% (e.g., about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%).</p><p id="p-0471" num="0421">In some embodiments, the poloxamer has an average molar mass of greater than 10,000 g/mol (e.g., about 10,100 g/mol, 10,200 g/mol, 10,300 g/mol, 10,400 g/mol, 10,500 g/mol, 10,600 g/mol, 10,700 g/mol, 10,800 g/mol, 10,900 g/mol, 11,000 g/mol, 11,100 g/mol, 11,200 g/mol, 11,300 g/mol, 11,400 g/mol, 11,500 g/mol, 11,600 g/mol, 11,700 g/mol, 11,800 g/mol, 11,900 g/mol, 12,000 g/mol, 12,100 g/mol, 12,200 g/mol, 12,300 g/mol, 12,400 g/mol, 12,500 g/mol, 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0472" num="0422">In some embodiments, the poloxamer has an average molar mass of greater than 11,000 g/mol (e.g., about 11,100 g/mol, 11,200 g/mol, 11,300 g/mol, 11,400 g/mol, 11,500 g/mol, 11,600 g/mol, 11,700 g/mol, 11,800 g/mol, 11,900 g/mol, 12,000 g/mol, 12,100 g/mol, 12,200 g/mol, 12,300 g/mol, 12,400 g/mol, 12,500 g/mol, 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0473" num="0423">In some embodiments, the poloxamer has an average molar mass of greater than 12,000 g/mol (e.g., about 12,100 g/mol, 12,200 g/mol, 12,300 g/mol, 12,400 g/mol, 12,500 g/mol, 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0474" num="0424">In some embodiments, the poloxamer has an average molar mass of greater than 12,500 g/mol (e.g., about 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0475" num="0425">In some embodiments, the poloxamer has an average molar mass of from about 10,000 g/mol to about 15,000 g/mol (e.g., about 10,000 g/mol, 10,100 g/mol, 10,200 g/mol, 10,300 g/mol, 10,400 g/mol, 10,500 g/mol, 10,600 g/mol, 10,700 g/mol, 10,800 g/mol, 10,900 g/mol, 11,000 g/mol, 11,100 g/mol, 11,200 g/mol, 11,300 g/mol, 11,400 g/mol, 11,500 g/mol, 11,600 g/mol, 11,700 g/mol, 11,800 g/mol, 11,900 g/mol, 12,000 g/mol, 12,100 g/mol, 12,200 g/mol, 12,300 g/mol, 12,400 g/mol, 12,500 g/mol, 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0476" num="0426">In some embodiments, the poloxamer has an average molar mass of from about 11,000 g/mol to about 15,000 g/mol (e.g., about 11,000 g/mol, 11,100 g/mol, 11,200 g/mol, 11,300 g/mol, 11,400 g/mol, 11,500 g/mol, 11,600 g/mol, 11,700 g/mol, 11,800 g/mol, 11,900 g/mol, 12,000 g/mol, 12,100 g/mol, 12,200 g/mol, 12,300 g/mol, 12,400 g/mol, 12,500 g/mol, 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0477" num="0427">In some embodiments, the poloxamer has an average molar mass of from about 11,500 g/mol to about 15,000 g/mol (e.g., about 11,500 g/mol, 11,600 g/mol, 11,700 g/mol, 11,800 g/mol, 11,900 g/mol, 12,000 g/mol, 12,100 g/mol, 12,200 g/mol, 12,300 g/mol, 12,400 g/mol, 12,500 g/mol, 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0478" num="0428">In some embodiments, the poloxamer has an average molar mass of from about 12,000 g/mol to about 15,000 g/mol (e.g., about 12,000 g/mol, 12,100 g/mol, 12,200 g/mol, 12,300 g/mol, 12,400 g/mol, 12,500 g/mol, 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0479" num="0429">In some embodiments, the poloxamer has an average molar mass of from about 12,500 g/mol to about 15,000 g/mol (e.g., about 12,500 g/mol, 12,600 g/mol, 12,700 g/mol, 12,800 g/mol, 12,900 g/mol, 13,000 g/mol, 13,100 g/mol, 13,200 g/mol, 13,300 g/mol, 13,400 g/mol, 13,500 g/mol, 13,600 g/mol, 13,700 g/mol, 13,800 g/mol, 13,900 g/mol, 14,000 g/mol, 14,100 g/mol, 14,200 g/mol, 14,300 g/mol, 14,400 g/mol, 14,500 g/mol, 14,600 g/mol, 14,700 g/mol, 14,800 g/mol, 14,900 g/mol, or 15,000 g/mol).</p><p id="p-0480" num="0430">Poloxamers P288, P335, P338, and P407</p><p id="p-0481" num="0431">Poloxamers that may be used in conjunction with the compositions and methods of the disclosure include &#x201c;poloxamer 288&#x201d; (also referred to in the art as &#x201c;P 288&#x201d; and poloxamer &#x201c;F98&#x201d;) having the approximate chemical formula HO(C<sub>2</sub>H<sub>4</sub>O)<sub>x</sub>(C<sub>3</sub>H<sub>6</sub>O)<sub>y</sub>(C<sub>2</sub>H<sub>4</sub>O)<sub>z</sub>H, wherein the sum of x and y is about 236.36, and z is about 44.83. The average molecular weight of P288 is about 13,000 g/mol.</p><p id="p-0482" num="0432">In some embodiments, the poloxamer is a variant of P288, such as a variant of the formula HO(C<sub>2</sub>H<sub>4</sub>O)<sub>x</sub>(C<sub>3</sub>H<sub>6</sub>O)<sub>y</sub>(C<sub>2</sub>H<sub>4</sub>O)<sub>z</sub>H, wherein the sum of x and y is from about 220 to about 250, and z is from about 40 to about 50. In some embodiments, the average molecular weight of the poloxamer is from about 12,000 g/mol to about 14,000 g/mol.</p><p id="p-0483" num="0433">Poloxamers that may be used in conjunction with the compositions and methods of the disclosure further include &#x201c;poloxamer 335&#x201d; (also referred to in the art as &#x201c;P 335&#x201d; and poloxamer &#x201c;P105&#x201d;), having the approximate chemical formula HO(C<sub>2</sub>H<sub>4</sub>O)<sub>x</sub>(C<sub>3</sub>H<sub>6</sub>O)<sub>y</sub>(C<sub>2</sub>H<sub>4</sub>O)<sub>z</sub>H, wherein the sum of x and y is about 73.86, and z is about 56.03. The average molecular weight of P335 is about 6,500 g/mol.</p><p id="p-0484" num="0434">In some embodiments, the poloxamer is a variant of P335, such as a variant of the formula HO(C<sub>2</sub>H<sub>4</sub>O)<sub>x</sub>(C<sub>3</sub>H<sub>6</sub>O)<sub>y</sub>(C<sub>2</sub>H<sub>4</sub>O)<sub>z</sub>H, wherein the sum of x and y is from about 60 to about 80, and z is from about 50 to about 60. In some embodiments, the average molecular weight of the poloxamer is from about 6,000 g/mol to about 7,000 g/mol.</p><p id="p-0485" num="0435">Poloxamers that may be used in conjunction with the compositions and methods of the disclosure further include &#x201c;poloxamer 338&#x201d; (also referred to in the art as &#x201c;P 338&#x201d; and poloxamer &#x201c;F108&#x201d;), having the approximate chemical formula HO(C<sub>2</sub>H<sub>4</sub>O)<sub>x</sub>(C<sub>3</sub>H<sub>6</sub>O)<sub>y</sub>(C<sub>2</sub>H<sub>4</sub>O)<sub>z</sub>H, wherein the sum of x and y is about 265.45, and z is about 50.34. The average molecular weight of P335 is about 14,600 g/mol.</p><p id="p-0486" num="0436">In some embodiments, the poloxamer is a variant of P338, such as a variant of the formula HO(C<sub>2</sub>H<sub>4</sub>O)<sub>x</sub>(C<sub>3</sub>H<sub>6</sub>O)<sub>y</sub>(C<sub>2</sub>H<sub>4</sub>O)<sub>z</sub>H, wherein the sum of x and y is from about 260 to about 270, and z is from about 45 to about 55. In some embodiments, the average molecular weight of the poloxamer is from about 14,000 g/mol to about 15,000 g/mol.</p><p id="p-0487" num="0437">Poloxamers that may be used in conjunction with the compositions and methods of the disclosure further include &#x201c;poloxamer 407&#x201d; (also referred to in the art as &#x201c;P 407&#x201d; and poloxamer &#x201c;F127&#x201d;), having the approximate chemical formula HO(C<sub>2</sub>H<sub>4</sub>O)<sub>x</sub>(C<sub>3</sub>H<sub>6</sub>O)<sub>y</sub>(C<sub>2</sub>H<sub>4</sub>O)<sub>z</sub>H, wherein the sum of x and y is about 200.45, and z is about 65.17. The average molecular weight of P335 is about 12,600 g/mol.</p><p id="p-0488" num="0438">In some embodiments, the poloxamer is a variant of P407, such as a variant of the formula HO(C<sub>2</sub>H<sub>4</sub>O)<sub>x</sub>(C<sub>3</sub>H<sub>6</sub>O)<sub>y</sub>(C<sub>2</sub>H<sub>4</sub>O)<sub>z</sub>H, wherein the sum of x and y is from about 190 to about 210, and z is from about 60 to about 70. In some embodiments, the average molecular weight of the poloxamer is from about 12,000 g/mol to about 13,000 g/mol.</p><p id="p-0489" num="0439">For clarity, the terms &#x201c;average molar mass&#x201d; and &#x201c;average molecular weight&#x201d; are used interchangeable herein to refer to the same quantity. The average molar mass, ethylene oxide content, and propylene oxide content of a poloxamer, as described herein, can be determined using methods disclosed in Alexandridis and Hatton, Colloids and Surfaces A: Physicochemical and Engineering Aspects 96:1-46 (1995), the disclosure of which is incorporated herein by reference in its entirety.</p><heading id="h-0009" level="2">PKC Modulating Agents</heading><p id="p-0490" num="0440">A variety of agents can be used to reduce PKC activity and/or expression. Without being limited by mechanism, such agents can augment viral transduction by stimulating Akt signal transduction and/or maintaining cofilin in a dephosphorylated state, thereby promoting actin depolymerization. This actin depolymerization event may serve to remove a physical barrier that hinders entry of a viral vector into the nucleus of a target cell.</p><heading id="h-0010" level="2">Staurosporine and Variants Thereof</heading><p id="p-0491" num="0441">In some embodiments, the substance that reduces activity and/or expression of PKC is a PKC inhibitor. The PKC inhibitor may be staurosporine or a variant thereof. For example, the PKC inhibitor may be a compound represented by formula (I)</p><p id="p-0492" num="0000"><chemistry id="CHEM-US-00071" num="00071"><img id="EMI-C00071" he="34.80mm" wi="66.55mm" file="US20230002784A1-20230105-C00071.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0493" num="0442">wherein R<sub>1 </sub>is H, OH, optionally substituted alkoxy, optionally substituted acyloxy, optionally substituted amino, optionally substituted alkylamino, optionally substituted amido, halogen, optionally substituted C<sub>1-6 </sub>alkyl, optionally substituted C<sub>2-6 </sub>alkenyl, optionally substituted C<sub>2-6 </sub>alkynyl, optionally substituted acyl, optionally substituted alkoxycarbonyl, oxo, thiocarbonyl, optionally substituted carboxy, or ureido;</p><p id="p-0494" num="0443">R<sub>2 </sub>is H, optionally substituted C<sub>1-6 </sub>alkyl, optionally substituted C<sub>2-6 </sub>alkenyl, optionally substituted C<sub>2-6 </sub>alkynyl, or optionally substituted acyl;</p><p id="p-0495" num="0444">R<sub>a </sub>and R<sub>b </sub>are each, independently, H, optionally substituted C<sub>1-6 </sub>alkyl, optionally substituted C<sub>2-6 </sub>alkenyl, or optionally substituted C<sub>2-6 </sub>alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl, or R<sub>a </sub>and R<sub>b</sub>, together with the atoms to which they are bound, are joined to form an optionally substituted and optionally fused heterocycloalkyl ring;</p><p id="p-0496" num="0445">R<sub>c </sub>is O, NR<sub>d</sub>, or S;</p><p id="p-0497" num="0446">R<sub>d </sub>is H, optionally substituted C<sub>1-6 </sub>alkyl, optionally substituted C<sub>2-6 </sub>alkenyl, or optionally substituted C<sub>2-6 </sub>alkynyl;</p><p id="p-0498" num="0447">each X is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0499" num="0448">each Y is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0500" num="0449"><img id="CUSTOM-CHARACTER-00002" he="2.12mm" wi="5.33mm" file="US20230002784A1-20230105-P00001.TIF" alt="custom-character" img-content="character" img-format="tif"/> represents a bond that is optionally present;</p><p id="p-0501" num="0450">n is an integer from 0-4; and</p><p id="p-0502" num="0451">m is an integer from 0-4;</p><p id="p-0503" num="0452">or a salt thereof.</p><p id="p-0504" num="0453">In some embodiments, the PKC inhibitor is a staurosporine variant described in WO 1991/009034, the disclosure of which is incorporated herein by reference in its entirety. Examples of such staurosporine variants are represented by formula (II)</p><p id="p-0505" num="0000"><chemistry id="CHEM-US-00072" num="00072"><img id="EMI-C00072" he="34.71mm" wi="66.97mm" file="US20230002784A1-20230105-C00072.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0506" num="0454">wherein R<sub>1 </sub>is H, OH, optionally substituted alkoxy, optionally substituted acyloxy, optionally substituted amino, optionally substituted alkylamino, optionally substituted amido, halogen, oxo, or thiocarbonyl;</p><p id="p-0507" num="0455">R<sub>2 </sub>is H, optionally substituted C<sub>1-6 </sub>alkyl, optionally substituted C<sub>2-6 </sub>alkenyl, optionally substituted C<sub>2-6 </sub>alkynyl, or optionally substituted acyl;</p><p id="p-0508" num="0456">R<sub>a </sub>and R<sub>b</sub>, together with the atoms to which they are bound, are joined to form an optionally substituted and optionally fused heterocycloalkyl ring;</p><p id="p-0509" num="0457">R<sub>c </sub>is O or S;</p><p id="p-0510" num="0458">each X is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0511" num="0459">each Y is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0512" num="0460">n is an integer from 0-4; and</p><p id="p-0513" num="0461">m is an integer from 0-4;</p><p id="p-0514" num="0462">or a salt thereof.</p><p id="p-0515" num="0463">Additional examples of such staurosporine variants are represented by formula (III)</p><p id="p-0516" num="0000"><chemistry id="CHEM-US-00073" num="00073"><img id="EMI-C00073" he="41.57mm" wi="67.39mm" file="US20230002784A1-20230105-C00073.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0517" num="0464">wherein R<sub>1 </sub>is H, OH, oxo, or thiocarbonyl;</p><p id="p-0518" num="0465">R<sub>2 </sub>is H, optionally substituted C<sub>1-6 </sub>alkyl, optionally substituted C<sub>2-6 </sub>alkenyl, optionally substituted C<sub>2-6 </sub>alkynyl, or optionally substituted acyl;</p><p id="p-0519" num="0466">Ring A is an optionally substituted and optionally fused heterocycloalkyl ring;</p><p id="p-0520" num="0467">R<sub>c </sub>is O or S;</p><p id="p-0521" num="0468">each X is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0522" num="0469">each Y is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0523" num="0470">n is an integer from 0-4; and</p><p id="p-0524" num="0471">m is an integer from 0-4;</p><p id="p-0525" num="0472">or a salt thereof.</p><p id="p-0526" num="0473">Further examples of such staurosporine variants are represented by formula (IV)</p><p id="p-0527" num="0000"><chemistry id="CHEM-US-00074" num="00074"><img id="EMI-C00074" he="43.35mm" wi="67.48mm" file="US20230002784A1-20230105-C00074.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0528" num="0474">wherein R<sub>1 </sub>is H, OH, or oxo;</p><p id="p-0529" num="0475">Ring B is an optionally substituted heteroaryl or heterocycloalkyl ring;</p><p id="p-0530" num="0476">R<sub>c </sub>is O or S;</p><p id="p-0531" num="0477">W is O, NH, or S;</p><p id="p-0532" num="0478">each X is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0533" num="0479">each Y is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0534" num="0480">n is an integer from 0-4; and</p><p id="p-0535" num="0481">m is an integer from 0-4;</p><p id="p-0536" num="0482">or a salt thereof.</p><p id="p-0537" num="0483">Additional examples of such staurosporine variants are represented by formula (V)</p><p id="p-0538" num="0000"><chemistry id="CHEM-US-00075" num="00075"><img id="EMI-C00075" he="43.86mm" wi="61.98mm" file="US20230002784A1-20230105-C00075.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0539" num="0484">wherein R<sub>1 </sub>is H, OH, or oxo;</p><p id="p-0540" num="0485">R<sub>c </sub>is O or S;</p><p id="p-0541" num="0486">W is O, NH, or S;</p><p id="p-0542" num="0487">each Z is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl; and</p><p id="p-0543" num="0488">p is 0 or 1;</p><p id="p-0544" num="0489">or a salt thereof.</p><p id="p-0545" num="0490">Additional examples of such staurosporine variants are represented by formula (VI)</p><p id="p-0546" num="0000"><chemistry id="CHEM-US-00076" num="00076"><img id="EMI-C00076" he="42.25mm" wi="62.40mm" file="US20230002784A1-20230105-C00076.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0547" num="0491">wherein R<sub>1 </sub>is H, OH, or oxo;</p><p id="p-0548" num="0492">each Z is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl; and</p><p id="p-0549" num="0493">s is an integer from 0-8;</p><p id="p-0550" num="0494">or a salt thereof.</p><p id="p-0551" num="0495">Further examples of such staurosporine variants are represented by formula (VII)</p><p id="p-0552" num="0000"><chemistry id="CHEM-US-00077" num="00077"><img id="EMI-C00077" he="49.28mm" wi="62.82mm" file="US20230002784A1-20230105-C00077.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0553" num="0496">wherein R<sub>1 </sub>is H, OH, or oxo;</p><p id="p-0554" num="0497">R<sub>2 </sub>is H, OH, optionally substituted alkoxy, or optionally substituted acyloxy; and</p><p id="p-0555" num="0498">R<sub>3 </sub>is H, OH, optionally substituted alkoxy, optionally substituted acyloxy, optionally substituted amino, or optionally substituted amido</p><p id="p-0556" num="0499">or a salt thereof.</p><p id="p-0557" num="0500">Additional examples of such staurosporine variants are represented by formula (VIII)</p><p id="p-0558" num="0000"><chemistry id="CHEM-US-00078" num="00078"><img id="EMI-C00078" he="49.28mm" wi="63.25mm" file="US20230002784A1-20230105-C00078.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0559" num="0501">wherein R<sub>1 </sub>is H, OH, or oxo;</p><p id="p-0560" num="0502">R<sub>2 </sub>is H, OH, optionally substituted alkoxy, or optionally substituted acyloxy; and</p><p id="p-0561" num="0503">R<sub>3 </sub>is H, OH, optionally substituted alkoxy, optionally substituted acyloxy, optionally substituted amino, or optionally substituted amido</p><p id="p-0562" num="0504">or a salt thereof.</p><p id="p-0563" num="0505">Further examples of such staurosporine variants are represented by formula (IX)</p><p id="p-0564" num="0000"><chemistry id="CHEM-US-00079" num="00079"><img id="EMI-C00079" he="50.72mm" wi="67.56mm" file="US20230002784A1-20230105-C00079.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0565" num="0506">wherein each X is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0566" num="0507">each Y is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0567" num="0508">n is an integer from 0-4; and</p><p id="p-0568" num="0509">m is an integer from 0-4;</p><p id="p-0569" num="0510">or a salt thereof.</p><p id="p-0570" num="0511">Additional examples of such staurosporine variants are represented by formula (1)</p><p id="p-0571" num="0000"><chemistry id="CHEM-US-00080" num="00080"><img id="EMI-C00080" he="50.72mm" wi="61.72mm" file="US20230002784A1-20230105-C00080.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0572" num="0512">or a salt thereof.</p><p id="p-0573" num="0513">In some embodiments, the PKC inhibitor is staurosporine, (2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one, represented by formula (2)</p><p id="p-0574" num="0000"><chemistry id="CHEM-US-00081" num="00081"><img id="EMI-C00081" he="50.72mm" wi="61.72mm" file="US20230002784A1-20230105-C00081.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0575" num="0514">or a salt thereof.</p><p id="p-0576" num="0515">Further examples of such staurosporine variants are represented by formula (X)</p><p id="p-0577" num="0000"><chemistry id="CHEM-US-00082" num="00082"><img id="EMI-C00082" he="39.62mm" wi="61.98mm" file="US20230002784A1-20230105-C00082.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0578" num="0516">wherein R<sub>1 </sub>is H, OH, or oxo;</p><p id="p-0579" num="0517">each Z is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl; and</p><p id="p-0580" num="0518">t is an integer from 0-6;</p><p id="p-0581" num="0519">or a salt thereof.</p><p id="p-0582" num="0520">Additional examples of such staurosporine variants are represented by formula (XI)</p><p id="p-0583" num="0000"><chemistry id="CHEM-US-00083" num="00083"><img id="EMI-C00083" he="46.23mm" wi="62.40mm" file="US20230002784A1-20230105-C00083.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0584" num="0521">wherein R<sub>1 </sub>is H, OH, or oxo; and</p><p id="p-0585" num="0522">R<sub>4 </sub>is H, OH, optionally substituted alkoxy, or optionally substituted acyloxy;</p><p id="p-0586" num="0523">or a salt thereof.</p><p id="p-0587" num="0524">Further examples of such staurosporine variants are represented by formula (XII)</p><p id="p-0588" num="0000"><chemistry id="CHEM-US-00084" num="00084"><img id="EMI-C00084" he="46.23mm" wi="62.82mm" file="US20230002784A1-20230105-C00084.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0589" num="0525">wherein R<sub>1 </sub>is H, OH, or oxo; and</p><p id="p-0590" num="0526">R<sub>4 </sub>is H, OH, optionally substituted alkoxy, or optionally substituted acyloxy;</p><p id="p-0591" num="0527">or a salt thereof.</p><p id="p-0592" num="0528">Additional examples of such staurosporine variants are represented by formula (XIII)</p><p id="p-0593" num="0000"><chemistry id="CHEM-US-00085" num="00085"><img id="EMI-C00085" he="46.23mm" wi="68.41mm" file="US20230002784A1-20230105-C00085.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0594" num="0529">wherein each X is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0595" num="0530">each Y is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</p><p id="p-0596" num="0531">n is an integer from 0-4; and</p><p id="p-0597" num="0532">m is an integer from 0-4;</p><p id="p-0598" num="0533">or a salt thereof.</p><p id="p-0599" num="0534">Additional examples of such staurosporine variants are represented by formula (3)</p><p id="p-0600" num="0000"><chemistry id="CHEM-US-00086" num="00086"><img id="EMI-C00086" he="46.23mm" wi="61.72mm" file="US20230002784A1-20230105-C00086.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0601" num="0535">or a salt thereof.</p><p id="p-0602" num="0536">Additional examples of such staurosporine variants are represented by formula (4)</p><p id="p-0603" num="0000"><chemistry id="CHEM-US-00087" num="00087"><img id="EMI-C00087" he="46.23mm" wi="61.72mm" file="US20230002784A1-20230105-C00087.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0604" num="0537">or a salt thereof.</p><p id="p-0605" num="0538">Additional examples of such staurosporine variants are:</p><p id="p-0606" num="0000"><chemistry id="CHEM-US-00088" num="00088"><img id="EMI-C00088" he="214.71mm" wi="62.06mm" file="US20230002784A1-20230105-C00088.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00089" num="00089"><img id="EMI-C00089" he="235.63mm" wi="62.65mm" file="US20230002784A1-20230105-C00089.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00090" num="00090"><img id="EMI-C00090" he="160.44mm" wi="66.04mm" file="US20230002784A1-20230105-C00090.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0607" num="0000">or a salt thereof.</p><p id="p-0608" num="0539">In some embodiments, the PKC inhibitor is a staurosporine variant described in WO 1993/007153, the disclosure of which is incorporated herein by reference in its entirety. Examples of such staurosporine variants are represented by formula (XIV)</p><p id="p-0609" num="0000"><chemistry id="CHEM-US-00091" num="00091"><img id="EMI-C00091" he="54.53mm" wi="63.25mm" file="US20230002784A1-20230105-C00091.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0610" num="0540">wherein R<sub>1 </sub>is H or optionally substituted C<sub>1-6 </sub>alkyl; and</p><p id="p-0611" num="0541">R<sub>2 </sub>is optionally substituted C<sub>1-6 </sub>alkyl;</p><p id="p-0612" num="0542">or a salt thereof.</p><p id="p-0613" num="0543">In some embodiments, the PKC inhibitor is a compound represented by formula (XV)</p><p id="p-0614" num="0000"><chemistry id="CHEM-US-00092" num="00092"><img id="EMI-C00092" he="54.53mm" wi="62.91mm" file="US20230002784A1-20230105-C00092.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0615" num="0544">wherein R<sub>1 </sub>is H or optionally substituted C<sub>1-6 </sub>alkyl; and</p><p id="p-0616" num="0545">R<sub>2 </sub>is optionally substituted C<sub>1-6 </sub>alkyl;</p><p id="p-0617" num="0546">or a salt thereof.</p><p id="p-0618" num="0547">In some embodiments, the PKC inhibitor is a compound selected from:</p><p id="p-0619" num="0000"><chemistry id="CHEM-US-00093" num="00093"><img id="EMI-C00093" he="139.62mm" wi="64.52mm" file="US20230002784A1-20230105-C00093.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0620" num="0000">or a salt thereof.</p><p id="p-0621" num="0548">In some embodiments, the PKC inhibitor is a staurosporine variant described in U.S. Pat. No. 5,093,330, the disclosure of which is incorporated herein by reference in its entirety. Examples of such staurosporine variants are represented by formula (XVI)</p><p id="p-0622" num="0000"><chemistry id="CHEM-US-00094" num="00094"><img id="EMI-C00094" he="52.07mm" wi="63.33mm" file="US20230002784A1-20230105-C00094.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0623" num="0549">wherein R is H, optionally substituted alkyl, optionally substituted acyl, optionally substituted sulfonyl, optionally substituted sulfinyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;</p><p id="p-0624" num="0550">or a salt or quaternized variant thereof.</p><p id="p-0625" num="0551">In some embodiments, the PKC inhibitor is a compound represented by formula (XVII)</p><p id="p-0626" num="0000"><chemistry id="CHEM-US-00095" num="00095"><img id="EMI-C00095" he="52.07mm" wi="63.75mm" file="US20230002784A1-20230105-C00095.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0627" num="0552">wherein R is H, optionally substituted alkyl, optionally substituted acyl, optionally substituted sulfonyl, optionally substituted sulfinyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;</p><p id="p-0628" num="0553">or a salt or quaternized variant thereof.</p><p id="p-0629" num="0554">In some embodiments the PKC inhibitor is a compound selected from:</p><p id="p-0630" num="0000"><chemistry id="CHEM-US-00096" num="00096"><img id="EMI-C00096" he="169.84mm" wi="62.65mm" file="US20230002784A1-20230105-C00096.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00097" num="00097"><img id="EMI-C00097" he="167.72mm" wi="62.65mm" file="US20230002784A1-20230105-C00097.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00098" num="00098"><img id="EMI-C00098" he="168.66mm" wi="66.55mm" file="US20230002784A1-20230105-C00098.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00099" num="00099"><img id="EMI-C00099" he="165.02mm" wi="62.65mm" file="US20230002784A1-20230105-C00099.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00100" num="00100"><img id="EMI-C00100" he="196.85mm" wi="64.94mm" file="US20230002784A1-20230105-C00100.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00101" num="00101"><img id="EMI-C00101" he="203.28mm" wi="64.01mm" file="US20230002784A1-20230105-C00101.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00102" num="00102"><img id="EMI-C00102" he="184.40mm" wi="64.18mm" file="US20230002784A1-20230105-C00102.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00103" num="00103"><img id="EMI-C00103" he="192.96mm" wi="64.35mm" file="US20230002784A1-20230105-C00103.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00104" num="00104"><img id="EMI-C00104" he="183.47mm" wi="65.45mm" file="US20230002784A1-20230105-C00104.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00105" num="00105"><img id="EMI-C00105" he="183.81mm" wi="66.63mm" file="US20230002784A1-20230105-C00105.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00106" num="00106"><img id="EMI-C00106" he="120.57mm" wi="69.00mm" file="US20230002784A1-20230105-C00106.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00107" num="00107"><img id="EMI-C00107" he="184.15mm" wi="65.45mm" file="US20230002784A1-20230105-C00107.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00108" num="00108"><img id="EMI-C00108" he="180.51mm" wi="69.00mm" file="US20230002784A1-20230105-C00108.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00109" num="00109"><img id="EMI-C00109" he="194.90mm" wi="68.92mm" file="US20230002784A1-20230105-C00109.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00110" num="00110"><img id="EMI-C00110" he="186.52mm" wi="69.34mm" file="US20230002784A1-20230105-C00110.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00111" num="00111"><img id="EMI-C00111" he="181.27mm" wi="69.34mm" file="US20230002784A1-20230105-C00111.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00112" num="00112"><img id="EMI-C00112" he="124.97mm" wi="72.05mm" file="US20230002784A1-20230105-C00112.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00113" num="00113"><img id="EMI-C00113" he="124.46mm" wi="69.26mm" file="US20230002784A1-20230105-C00113.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00114" num="00114"><img id="EMI-C00114" he="185.08mm" wi="66.55mm" file="US20230002784A1-20230105-C00114.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0631" num="0000">or a salt thereof.</p><p id="p-0632" num="0555">In some embodiments, the PKC inhibitor is a staurosporine variant described in U.S. Pat. No. 5,264,431, the disclosure of which is incorporated herein by reference in its entirety. Examples of such staurosporine variants are represented by formula (XVIII)</p><p id="p-0633" num="0000"><chemistry id="CHEM-US-00115" num="00115"><img id="EMI-C00115" he="52.66mm" wi="64.09mm" file="US20230002784A1-20230105-C00115.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0634" num="0556">wherein R is H, OH, C<sub>1-6 </sub>alkoxy, or oxo; and</p><p id="p-0635" num="0557">R<sub>2 </sub>is</p><p id="p-0636" num="0000"><chemistry id="CHEM-US-00116" num="00116"><img id="EMI-C00116" he="23.45mm" wi="41.91mm" file="US20230002784A1-20230105-C00116.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0637" num="0000">optionally wherein the configuration of the sugar moiety is derived from D-glucose, D-galactose, or D-mannose;</p><p id="p-0638" num="0558">R<sub>3 </sub>is H, OH, C<sub>1-6 </sub>alkanoyloxy, C<sub>1-6 </sub>alkoxy, benzyloxy, benzoyloxy or phenyloxy, each of which is optionally substituted in the phenyl moiety by halogen, hydroxyl, trifluoromethyl, C<sub>1-6 </sub>alkyl, or C<sub>1-6 </sub>alkoxy;</p><p id="p-0639" num="0559">R<sub>4 </sub>is OH, C<sub>1-6 </sub>alkanoyloxy, benzoyloxy, benzyloxy, amino, C<sub>1-6 </sub>alkylamino, di-C<sub>1-6 </sub>alkylamino, C<sub>1-6 </sub>alkoxycarbonylamino, C<sub>2-20 </sub>alkanoylamino, benzoylamino, benzyloxycarbonylamino, or phenyloxycarbonylamino, each of which is optionally substituted in the phenyl moiety by halogen, hydroxyl, trifluoromethyl, C<sub>1-6 </sub>alkyl, C<sub>1-6 </sub>alkoxy;</p><p id="p-0640" num="0560">R<sub>5 </sub>is H or C<sub>1-6 </sub>alkyl;</p><p id="p-0641" num="0561">R<sub>6 </sub>is hydroxyl which is free or esterified with an aliphatic C<sub>2-22 </sub>carboxylic acid, or is C<sub>1-6 </sub>alkoxycarbonyloxy, C<sub>1-6 </sub>alkylsulfonyloxy, amino which is free or acylated with an aliphatic C<sub>2-22 </sub>carboxylic acid, C<sub>1-6 </sub>alkoxycarbonylamino, azido, benzoyloxy, benzyloxycarbonyloxy, benzoylamino, benzyloxycarbonylamino, or phenylsulfonyloxy, each of which is optionally substituted in the phenyl moiety by halogen, hydroxyl, trifluoromethyl, C<sub>1-6 </sub>alkyl, or C<sub>1-6 </sub>alkoxy; and</p><p id="p-0642" num="0562">R<sub>7 </sub>is OH which is free or esterified with an aliphatic C<sub>2-22 </sub>carboxylic acid, C<sub>1-6 </sub>alkoxycarbonyloxy, C<sub>1-6 </sub>alkylsulfonyloxy, azido, amino which is free or acylated with an aliphatic C<sub>2-22 </sub>carboxylic acid, C<sub>1-6 </sub>alkylamino, di-C<sub>1-6 </sub>alkylamino, C<sub>1-6 </sub>alkoxycarbonylamino, carbamoylamino, benzoyloxy, benzyloxycarbonyloxy, phenylsulfonyloxy, benzoylamino, benzylamino or benzyloxycarbonylamino, each of which is optionally substituted in the phenyl moiety by halogen, hydroxyl, trifluoromethyl, C<sub>1-6 </sub>alkyl, C<sub>1-6 </sub>alkoxy, or C<sub>1-6 </sub>alkoxycarbonyl;</p><p id="p-0643" num="0563">or a salt thereof.</p><p id="p-0644" num="0564">In some embodiments, the PKC inhibitor is a compound represented by formula (XIX)</p><p id="p-0645" num="0000"><chemistry id="CHEM-US-00117" num="00117"><img id="EMI-C00117" he="52.66mm" wi="63.33mm" file="US20230002784A1-20230105-C00117.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0646" num="0565">wherein R is H, OH, C<sub>1-6 </sub>alkoxy, or oxo; and</p><p id="p-0647" num="0566">R<sub>2 </sub>is</p><p id="p-0648" num="0000"><chemistry id="CHEM-US-00118" num="00118"><img id="EMI-C00118" he="22.35mm" wi="37.85mm" file="US20230002784A1-20230105-C00118.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0649" num="0567">R<sub>3 </sub>is H, OH, C<sub>1-6 </sub>alkanoyloxy, C<sub>1-6 </sub>alkoxy, benzyloxy, benzoyloxy or phenyloxy, each of which is optionally substituted in the phenyl moiety by halogen, hydroxyl, trifluoromethyl, C<sub>1-6 </sub>alkyl, or C<sub>1-6 </sub>alkoxy;</p><p id="p-0650" num="0568">R<sub>4 </sub>is OH, C<sub>1-6 </sub>alkanoyloxy, benzoyloxy, benzyloxy, amino, C<sub>1-6 </sub>alkylamino, di-C<sub>1-6 </sub>alkylamino, C<sub>1-6 </sub>alkoxycarbonylamino, C<sub>2-20 </sub>alkanoylamino, benzoylamino, benzyloxycarbonylamino, or phenyloxycarbonylamino, each of which is optionally substituted in the phenyl moiety by halogen, hydroxyl, trifluoromethyl, C<sub>1-6 </sub>alkyl, C<sub>1-6 </sub>alkoxy;</p><p id="p-0651" num="0569">R<sub>5 </sub>is H or C<sub>1-6 </sub>alkyl;</p><p id="p-0652" num="0570">R<sub>6 </sub>is hydroxyl which is free or esterified with an aliphatic C<sub>2-22 </sub>carboxylic acid, or is C<sub>1-6 </sub>alkoxycarbonyloxy, C<sub>1-6 </sub>alkylsulfonyloxy, amino which is free or acylated with an aliphatic C<sub>2-22 </sub>carboxylic acid, C<sub>1-6 </sub>alkoxycarbonylamino, azido, benzoyloxy, benzyloxycarbonyloxy, benzoylamino, benzyloxycarbonylamino, or phenylsulfonyloxy, each of which is optionally substituted in the phenyl moiety by halogen, hydroxyl, trifluoromethyl, C<sub>1-6 </sub>alkyl, or C<sub>1-6 </sub>alkoxy; and</p><p id="p-0653" num="0571">R<sub>7 </sub>is OH which is free or esterified with an aliphatic C<sub>2-22 </sub>carboxylic acid, C<sub>1-6 </sub>alkoxycarbonyloxy, C<sub>1-6 </sub>alkylsulfonyloxy, azido, amino which is free or acylated with an aliphatic C<sub>2-22 </sub>carboxylic acid, C<sub>1-6 </sub>alkylamino, di-C<sub>1-6 </sub>alkylamino, C<sub>1-6 </sub>alkoxycarbonylamino, carbamoylamino, benzoyloxy, benzyloxycarbonyloxy, phenylsulfonyloxy, benzoylamino, benzylamino or benzyloxycarbonylamino, each of which is optionally substituted in the phenyl moiety by halogen, hydroxyl, trifluoromethyl, C<sub>1-6 </sub>alkyl, C<sub>1-6 </sub>alkoxy, or C<sub>1-6 </sub>alkoxycarbonyl;</p><p id="p-0654" num="0572">or a salt thereof.</p><p id="p-0655" num="0573">In some embodiments, the PKC inhibitor is a compound selected from N-(1-&#x3b1;-O-Benzyl-2-N-acetylmuramyl)staurosporine, N-(2-N-Acetyl-muramyl)staurosporine, N-(6-0-Mesyl-1-&#x3b1;-O-benzyl-2-N-acetylmuramyl)staurosporine, N-(6-Azido-1-&#x3b1;-O-benzyl-2-N-acetyl-6-deoxymuramyl)staurosporine, N-(6-Amino-1-&#x3b1;-O-benzyl-2-N-acetyl-6-deoxymuramyl)staurosporine, N-(6-Amino-6-deoxy-2-N-acetylmuramyl)staurosporine, N-(6-O-Mesyl-2-N-acetylmuramyl)staurosporine, N-(2-N-Acetyl-demethylmuramyl)staurosporine, N-(1-&#x3b1;-O-Benzyl-2-N-acetylhomomuramyl)staurosporine, N-(1-&#x3b1;-O-Benzyl-2&#x2014;N-acetyl-L-homomuramyl)staurosporine, the 1-&#x3b1;-anomer of N-(2-N-acetyl-L-homomuramyl)staurosporine, N-(1-&#x3b1;-O-Benzyl-4,6-O-diacetyl-2-N-acetylmuramyl)staurosporine, N-(1-&#x3b1;-O-Benzyl-4-O-acetyl-6-O-stearoyl-2-N-acetylmuramyl)staurosporin, N-(1-Deoxy-2-N-acetylmuramyl)staurosporine, the 1-&#x3b1;-anomer of N-(4-O-acetyl-6-O-stearoyl-2-N-acetylmuramyl)staurosporine, the 1-&#x3b1;-anomer of N-(4,6-O-diacetyl-2-N-acetylmuramyl)staurosporine, N-(1-&#x3b1;,4-O-diacetyl-6-O-stearoyl-2-N-acetylmuramyl)staurosporine, N-(1-&#x3b1;,4,6-O-Triacetyl-2-N-acetylmuramyl)staurosporine, N-(1-Deoxy-6-O-acetyl-2-N-acetylmuramyl)staurosporine, N-(1-Deoxy-6-O-mesyl-2-N-acetylmuramyl)staurosporine, N-(1-Deoxy-6-O-toluylsulfonyl-2-N-acetylmuramyl)staurosporine, N-(1-Deoxy-6-azido-2-N-acetylmuramyl)staurosporine, and N-(1-Deoxy-6-O-mesyl-2-N-acetylmuramyl)staurosporine, or a salt thereof.</p><p id="p-0656" num="0574">In some embodiments, the PKC inhibitor is a staurosporine variant described in U.S. Pat. No. 5,461,146, the disclosure of which is incorporated herein by reference in its entirety. Examples of such staurosporine variants are represented by formula (XX)</p><p id="p-0657" num="0000"><chemistry id="CHEM-US-00119" num="00119"><img id="EMI-C00119" he="46.06mm" wi="68.41mm" file="US20230002784A1-20230105-C00119.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0658" num="0575">wherein Z<sub>1 </sub>is H or OH;</p><p id="p-0659" num="0576">Z<sub>2 </sub>is H or OH;</p><p id="p-0660" num="0577">R<sub>1 </sub>is H, halogen, or optionally substituted alkyl;</p><p id="p-0661" num="0578">R<sub>2 </sub>is H or halogen;</p><p id="p-0662" num="0579">R is OH or optionally substituted alkoxy; and</p><p id="p-0663" num="0580">X is optionally substituted alkyl or optionally substituted acyl, optionally wherein X is CH<sub>2</sub>&#x2014;NH-serine, CO<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>NHCO<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, CONHC<sub>6</sub>H<sub>5</sub>, or CH<sub>2</sub>NHCO<sub>2</sub>CH<sub>3</sub>, wherein C<sub>6</sub>H<sub>5 </sub>denotes a phenyl moiety;</p><p id="p-0664" num="0581">or a salt thereof.</p><p id="p-0665" num="0582">In some embodiments, the PKC inhibitor is a staurosporine variant described in U.S. Pat. No. 5,756,494, the disclosure of which is incorporated herein by reference in its entirety. Examples of such staurosporine variants are represented by formula (XXI)</p><p id="p-0666" num="0000"><chemistry id="CHEM-US-00120" num="00120"><img id="EMI-C00120" he="46.06mm" wi="68.16mm" file="US20230002784A1-20230105-C00120.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0667" num="0583">wherein Z<sub>1 </sub>is H or OH;</p><p id="p-0668" num="0584">Z<sub>2 </sub>is H or OH;</p><p id="p-0669" num="0585">R<sub>1 </sub>is H, halogen, or optionally substituted alkyl;</p><p id="p-0670" num="0586">R<sub>2 </sub>is H or halogen;</p><p id="p-0671" num="0587">R is OH or optionally substituted alkoxy; and</p><p id="p-0672" num="0588">X is optionally substituted alkyl or optionally substituted acyl, optionally wherein X is CH<sub>2</sub>&#x2014;NH-serine, CO<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>NHCO<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, CONHC<sub>6</sub>H<sub>5</sub>, or CH<sub>2</sub>NHCO<sub>2</sub>CH<sub>3</sub>, wherein C<sub>6</sub>H<sub>5 </sub>denotes a phenyl moiety;</p><p id="p-0673" num="0589">or a salt thereof.</p><p id="p-0674" num="0590">In some embodiments, the PKC inhibitor is a staurosporine variant described in US 2005/0020570, the disclosure of which is incorporated herein by reference in its entirety. Examples of such staurosporine variants are represented by formula (XXII), (XXIII), (XXIV or (XXV)</p><p id="p-0675" num="0000"><chemistry id="CHEM-US-00121" num="00121"><img id="EMI-C00121" he="163.83mm" wi="71.20mm" file="US20230002784A1-20230105-C00121.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0676" num="0591">wherein each R<sub>1 </sub>is, independently, optionally substituted alkyl, hydrogen, halogen, hydroxy, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl, or N-mono- or N,N-di-substituted aminosulfonyl;</p><p id="p-0677" num="0592">each R<sub>2 </sub>is, independently, optionally substituted alkyl, hydrogen, halogen, hydroxy, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl, or N-mono- or N,N-di-substituted aminosulfonyl;</p><p id="p-0678" num="0593">each R<sub>5 </sub>is, independently, H, an aliphatic, carbocyclic, or carbocyclic-aliphatic radical with up to 29 carbon atoms in each case, or a heterocyclic or heterocyclic-aliphatic radical with up to 20 carbon atoms in each case, and in each case up to 9 heteroatoms, or acyl with up to 30 carbon atoms; and</p><p id="p-0679" num="0594">each X is, independently, O, OH and H, or a pair of hydrogen atoms;</p><p id="p-0680" num="0595">each Q is, independently, H, OH, halogen, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl or N-mono- or N,N-di-substituted aminosulfonyl;</p><p id="p-0681" num="0596">each Q&#x2032; is, independently, H, OH, halogen, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl or N-mono- or N,N-di-substituted aminosulfonyl;</p><p id="p-0682" num="0597">each n is, independently, an integer from 0-4; and</p><p id="p-0683" num="0598">each m is, independently, an integer from 0-4;</p><p id="p-0684" num="0599">or a salt thereof.</p><p id="p-0685" num="0600">In some embodiments, the PKC inhibitor is a compound represented by formula (XXVI) or (XXVII)</p><p id="p-0686" num="0000"><chemistry id="CHEM-US-00122" num="00122"><img id="EMI-C00122" he="154.69mm" wi="73.32mm" file="US20230002784A1-20230105-C00122.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0687" num="0601">wherein each R<sub>1 </sub>is, independently, optionally substituted alkyl, hydrogen, halogen, hydroxy, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl or N-mono- or N,N-di-substituted aminosulfonyl;</p><p id="p-0688" num="0602">each R<sub>2 </sub>is, independently, optionally substituted alkyl, hydrogen, halogen, hydroxy, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl or N-mono- or N,N-di-substituted aminosulfonyl;</p><p id="p-0689" num="0603">each R<sub>5 </sub>is, independently, H, an aliphatic, carbocyclic, or carbocyclic-aliphatic radical with up to 29 carbon atoms in each case, or a heterocyclic or heterocyclic-aliphatic radical with up to 20 carbon atoms in each case, and in each case up to 9 heteroatoms, or acyl with up to 30 carbon atoms;</p><p id="p-0690" num="0604">each R<sub>8 </sub>is, independently, acyl with up to 30 carbon atoms, an aliphatic, carbocyclic, or carbocyclic-aliphatic radical with up to 29 carbon atoms in each case, a heterocyclic or heterocyclic-aliphatic radical with up to 20 carbon atoms in each case, and in each case up to 9 heteroatoms;</p><p id="p-0691" num="0605">each R<sub>9 </sub>is, independently, optionally substituted acyl, optionally substituted alkyl, hydrogen, halogen, hydroxy, etherified or esterified hydroxy, amino, mono- or disubstituted amino, cyano, nitro, mercapto, substituted mercapto, carboxy, carbonyl, carbonyldioxy, esterified carboxy, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, sulfo, substituted sulfonyl, aminosulfonyl or N-mono- or N,N-di-substituted aminosulfonyl;</p><p id="p-0692" num="0606">each R<sub>10 </sub>is, independently, acyl with up to 30 carbon atoms, an aliphatic, carbocyclic, or carbocyclic-aliphatic radical with up to 29 carbon atoms in each case, a heterocyclic or heterocyclic-aliphatic radical with up to 20 carbon atoms in each case, and in each case up to 9 heteroatoms;</p><p id="p-0693" num="0607">each X is, independently, O, OH and H, or a pair of hydrogen atoms;</p><p id="p-0694" num="0608">each n is, independently, an integer from 0-4;</p><p id="p-0695" num="0609">each m is, independently, an integer from 0-4;</p><p id="p-0696" num="0610">each n&#x2032; is, independently, an integer from 0-4; and</p><p id="p-0697" num="0611">each m&#x2032; is, independently, an integer from 0-4;</p><p id="p-0698" num="0612">or a salt thereof.</p><p id="p-0699" num="0613">In some embodiments, the PKC inhibitor is a staurosporine variant described in U.S. Pat. No. 5,624,949, the disclosure of which is incorporated herein by reference in its entirety. Examples of such staurosporine variants are represented by formula (XXVIII)</p><p id="p-0700" num="0000"><chemistry id="CHEM-US-00123" num="00123"><img id="EMI-C00123" he="45.72mm" wi="69.43mm" file="US20230002784A1-20230105-C00123.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0701" num="0614">wherein R<sub>1 </sub>is H or optionally substituted C<sub>1-6 </sub>alkyl; and</p><p id="p-0702" num="0615">R<sub>2 </sub>is optionally substituted C<sub>1-6 </sub>alkyl;</p><p id="p-0703" num="0616">or a salt thereof.</p><p id="p-0704" num="0617">In some embodiments, the PKC inhibitor is a compound represented by formula (XXIX)</p><p id="p-0705" num="0000"><chemistry id="CHEM-US-00124" num="00124"><img id="EMI-C00124" he="45.64mm" wi="64.60mm" file="US20230002784A1-20230105-C00124.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0706" num="0618">wherein R<sub>1 </sub>is H or optionally substituted C<sub>1-6 </sub>alkyl; and</p><p id="p-0707" num="0619">R<sub>2 </sub>is optionally substituted C<sub>1-6 </sub>alkyl;</p><p id="p-0708" num="0620">or a salt thereof.</p><p id="p-0709" num="0621">In some embodiments, the PKC inhibitor is a compound represented by formula (XXX)</p><p id="p-0710" num="0000"><chemistry id="CHEM-US-00125" num="00125"><img id="EMI-C00125" he="47.33mm" wi="64.18mm" file="US20230002784A1-20230105-C00125.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0711" num="0622">wherein R<sub>1 </sub>is H or optionally substituted 01-6 alkyl; and</p><p id="p-0712" num="0623">R<sub>2 </sub>is optionally substituted C<sub>1-6 </sub>alkyl;</p><p id="p-0713" num="0624">or a salt thereof.</p><p id="p-0714" num="0625">In some embodiments, the PKC inhibitor is a compound represented by formula (XXXI)</p><p id="p-0715" num="0000"><chemistry id="CHEM-US-00126" num="00126"><img id="EMI-C00126" he="47.58mm" wi="64.60mm" file="US20230002784A1-20230105-C00126.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0716" num="0626">wherein R<sub>1 </sub>is H or optionally substituted C<sub>1-6 </sub>alkyl; and</p><p id="p-0717" num="0627">R<sub>2 </sub>is optionally substituted C<sub>1-6 </sub>alkyl;</p><p id="p-0718" num="0628">or a salt thereof.</p><p id="p-0719" num="0629">In some embodiments, the PKC inhibitor is a compound selected from:</p><p id="p-0720" num="0000"><chemistry id="CHEM-US-00127" num="00127"><img id="EMI-C00127" he="164.51mm" wi="62.65mm" file="US20230002784A1-20230105-C00127.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00128" num="00128"><img id="EMI-C00128" he="154.69mm" wi="62.65mm" file="US20230002784A1-20230105-C00128.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00129" num="00129"><img id="EMI-C00129" he="166.96mm" wi="64.94mm" file="US20230002784A1-20230105-C00129.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00130" num="00130"><img id="EMI-C00130" he="212.26mm" wi="66.04mm" file="US20230002784A1-20230105-C00130.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00131" num="00131"><img id="EMI-C00131" he="235.03mm" wi="67.56mm" file="US20230002784A1-20230105-C00131.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00132" num="00132"><img id="EMI-C00132" he="213.95mm" wi="62.65mm" file="US20230002784A1-20230105-C00132.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00133" num="00133"><img id="EMI-C00133" he="215.05mm" wi="72.05mm" file="US20230002784A1-20230105-C00133.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00134" num="00134"><img id="EMI-C00134" he="223.18mm" wi="67.90mm" file="US20230002784A1-20230105-C00134.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00135" num="00135"><img id="EMI-C00135" he="225.98mm" wi="73.24mm" file="US20230002784A1-20230105-C00135.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00136" num="00136"><img id="EMI-C00136" he="214.21mm" wi="66.80mm" file="US20230002784A1-20230105-C00136.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00137" num="00137"><img id="EMI-C00137" he="52.41mm" wi="63.25mm" file="US20230002784A1-20230105-C00137.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><heading id="h-0011" level="2">Interfering RNA</heading><p id="p-0721" num="0630">Exemplary PKC modulating agents that may be used in conjunction with the compositions and methods of the disclosure include interfering RNA molecules, such as short interfering RNA (siRNA), short hairpin RNA (shRNA), and/or micro RNA (miRNA), that diminish PKC gene expression. Methods for producing interfering RNA molecules are known in the art and are described in detail, for example, in WO 2004/044136 and U.S. Pat. No. 9,150,605, the disclosures of each of which are incorporated herein by reference in their entirety.</p><heading id="h-0012" level="2">Spinoculation</heading><p id="p-0722" num="0631">In some embodiments of the disclosure, a cell targeted for transduction may be spun e.g., by centrifugation, while being cultured with a viral vector (e.g., in combination with one or more additional agents described herein). This &#x201c;spinoculation&#x201d; process may occur with a centripetal force of, e.g., from about 200&#xd7;g to about 2,000&#xd7;g. The centripetal force may be, e.g., from about 300&#xd7;g to about 1,200&#xd7;g (e.g., about 300&#xd7;g, 400&#xd7;g, 500&#xd7;g, 600&#xd7;g, 700&#xd7;g, 800&#xd7;g, 900&#xd7;g, 1,000&#xd7;g, 1,100&#xd7;g, or 1,200&#xd7;g, or more). In some embodiments, the cell is spun for from about 10 minutes to about 3 hours (e.g., about 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 60 minutes, 65 minutes, 70 minutes, 75 minutes, 80 minutes, 85 minutes, 90 minutes, 95 minutes, 100 minutes, 105 minutes, 110 minutes, 115 minutes, 120 minutes, 125 minutes, 130 minutes, 135 minutes, 140 minutes, 145 minutes, 150 minutes, 155 minutes, 160 minutes, 165 minutes, 170 minutes, 175 minutes, 180 minutes, or more). In some embodiments, the cell is spun at room temperature, such as at a temperature of about 25&#xb0; C.</p><p id="p-0723" num="0632">Exemplary transduction protocols involving a spinoculation step are described, e.g., in Millington et al., PLoS One 4:e6461 (2009); Guo et al., Journal of Virology 85:9824-9833 (2011); O'Doherty et al., Journal of Virology 74:10074-10080 (2000); and Federico et al., Lentiviral Vectors and Exosomes as Gene and Protein Delivery Tools, Methods in Molecular Biology 1448, Chapter 4 (2016), the disclosures of each of which are incorporated herein by reference.</p><heading id="h-0013" level="2">Target Cells</heading><p id="p-0724" num="0633">Cells that may be used in conjunction with the compositions and methods described herein include cells that are capable of undergoing further differentiation. For example, one type of cell that can be used in conjunction with the compositions and methods described herein is a pluripotent cell. A pluripotent cell is a cell that possesses the ability to develop into more than one differentiated cell type. Examples of pluripotent cells are ESCs, iPSCs, and CD34+ cells. ESCs and iPSCs have the ability to differentiate into cells of the ectoderm, which gives rise to the skin and nervous system, endoderm, which forms the gastrointestinal and respiratory tracts, endocrine glands, liver, and pancreas, and mesoderm, which forms bone, cartilage, muscles, connective tissue, and most of the circulatory system.</p><p id="p-0725" num="0634">Cells that may be used in conjunction with the compositions and methods described herein include hematopoietic stem cells and hematopoietic progenitor cells. Hematopoietic stem cells (HSCs) are immature blood cells that have the capacity to self-renew and to differentiate into mature blood cells including diverse lineages including but not limited to granulocytes (e.g., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g., reticulocytes, erythrocytes), thrombocytes (e.g., megakaryoblasts, platelet producing megakaryocytes, platelets), monocytes (e.g., monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g., NK cells, B-cells and T-cells). Human HSCs are CD34+. In addition, HSCs also refer to long term repopulating HSC (LT-HSC) and short-term repopulating HSC (ST-HSC). Any of these HSCs can be used in conjunction with the compositions and methods described herein.</p><p id="p-0726" num="0635">HSCs and other pluripotent progenitors can be obtained from blood products. A blood product is a product obtained from the body or an organ of the body containing cells of hematopoietic origin. Such sources include unfractionated bone marrow, umbilical cord, placenta, peripheral blood, or mobilized peripheral blood. All of the aforementioned crude or unfractionated blood products can be enriched for cells having HSC or myeloid progenitor cell characteristics in a number of ways. For example, the more mature, differentiated cells can be selected against based on cell surface molecules they express. The blood product may be fractionated by positively selecting for CD34+ cells, which include a subpopulation of hematopoietic stem cells capable of self-renewal, multi-potency, and that can be re-introduced into a transplant recipient whereupon they home to the hematopoietic stem cell niche and reestablish productive and sustained hematopoiesis. Such selection is accomplished using, for example, commercially available magnetic anti-CD34 beads (Dynal, Lake Success, N.Y.). Myeloid progenitor cells can also be isolated based on the markers they express. Unfractionated blood products can be obtained directly from a donor or retrieved from cryopreservative storage. HSCs and myeloid progenitor cells can also be obtained from by differentiation of ES cells, iPS cells or other reprogrammed mature cells types.</p><p id="p-0727" num="0636">Cells that may be used in conjunction with the compositions and methods described herein include allogeneic cells and autologous cells. When allogeneic cells are used, the cells may optionally be HLA-matched to the subject receiving a cell treatment.</p><heading id="h-0014" level="2">Viral Vectors for Transgene Expression</heading><p id="p-0728" num="0637">Viral genomes provide a rich source of vectors that can be used for the efficient delivery of exogenous genes into a mammalian cell. Viral genomes are particularly useful vectors for gene delivery as the polynucleotides contained within such genomes are typically incorporated into the nuclear genome of a mammalian cell by generalized or specialized transduction. These processes occur as part of the natural viral replication cycle, and do not require added proteins or reagents in order to induce gene integration. Examples of viral vectors are a retrovirus (e.g., Retroviridae family viral vector), adenovirus (e.g., Ad5, Ad26, Ad34, Ad35, and Ad48), parvovirus (e.g., adeno-associated viruses), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e.g. measles and Sendai), positive strand RNA viruses, such as picornavirus and alphavirus, and double stranded DNA viruses including adenovirus, herpesvirus (e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g., vaccinia, modified vaccinia Ankara (MVA), fowlpox and canarypox). Other viruses include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, human papilloma virus, human foamy virus, and hepatitis virus, for example. Examples of retroviruses are: avian leukosis-sarcoma, avian C-type viruses, mammalian C-type, B-type viruses, D-type viruses, oncoretroviruses, HTLV-BLV group, lentivirus, alpharetrovirus, gammaretrovirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, Virology, Third Edition (Lippincott-Raven, Philadelphia, (1996))). Other examples are murine leukemia viruses, murine sarcoma viruses, mouse mammary tumor virus, bovine leukemia virus, feline leukemia virus, feline sarcoma virus, avian leukemia virus, human T-cell leukemia virus, baboon endogenous virus, Gibbon ape leukemia virus, Mason Pfizer monkey virus, simian immunodeficiency virus, simian sarcoma virus, Rous sarcoma virus and lentiviruses. Other examples of vectors are described, for example, in McVey et al., (U.S. Pat. No. 5,801,030), the teachings of which are incorporated herein by reference.</p><heading id="h-0015" level="2">Retroviral Vectors</heading><p id="p-0729" num="0638">The delivery vector used in the methods and compositions described herein may be a retroviral vector. One type of retroviral vector that may be used in the methods and compositions described herein is a lentiviral vector. Lentiviral vectors (LVs), a subset of retroviruses, transduce a wide range of dividing and non-dividing cell types with high efficiency, conferring stable, long-term expression of the transgene. An overview of optimization strategies for packaging and transducing LVs is provided in Delenda, The Journal of Gene Medicine 6: S125 (2004), the disclosure of which is incorporated herein by reference.</p><p id="p-0730" num="0639">The use of lentivirus-based gene transfer techniques relies on the in vitro production of recombinant lentiviral particles carrying a highly deleted viral genome in which the transgene of interest is accommodated. In particular, the recombinant lentivirus are recovered through the in trans coexpression in a permissive cell line of (1) the packaging constructs, i.e., a vector expressing the Gag-Pol precursors together with Rev (alternatively expressed in trans); (2) a vector expressing an envelope receptor, generally of an heterologous nature; and (3) the transfer vector, consisting in the viral cDNA deprived of all open reading frames, but maintaining the sequences required for replication, encapsidation, and expression, in which the sequences to be expressed are inserted.</p><p id="p-0731" num="0640">A LV used in the methods and compositions described herein may include one or more of a 5&#x2032;-Long terminal repeat (LTR), HIV signal sequence, HIV Psi signal 5&#x2032;-splice site (SD), delta-GAG element, Rev Responsive Element (RRE), 3&#x2032;-splice site (SA), elongation factor (EF) 1-alpha promoter and 3&#x2032;-self inactivating LTR (SIN-LTR). The lentiviral vector optionally includes a central polypurine tract (cPPT) and a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), as described in U.S. Pat. No. 6,136,597, the disclosure of which is incorporated herein by reference as it pertains to WPRE. The lentiviral vector may further include a pHR&#x2032; backbone, which may include for example as provided below.</p><p id="p-0732" num="0641">The Lentigen LV described in Lu et al., Journal of Gene Medicine 6:963 (2004) may be used to express the DNA molecules and/or transduce cells. A LV used in the methods and compositions described herein may a 5&#x2032;-Long terminal repeat (LTR), HIV signal sequence, HIV Psi signal 5&#x2032;-splice site (SD), delta-GAG element, Rev Responsive Element (RRE), 3&#x2032;-splice site (SA), elongation factor (EF) 1-alpha promoter and 3&#x2032;-self inactivating L TR (SIN-LTR). It will be readily apparent to one skilled in the art that optionally one or more of these regions is substituted with another region performing a similar function.</p><p id="p-0733" num="0642">Enhancer elements can be used to increase expression of modified DNA molecules or increase the lentiviral integration efficiency. The LV used in the methods and compositions described herein may include a nef sequence. The LV used in the methods and compositions described herein may include a cPPT sequence which enhances vector integration. The cPPT acts as a second origin of the (+)-strand DNA synthesis and introduces a partial strand overlap in the middle of its native HIV genome. The introduction of the cPPT sequence in the transfer vector backbone strongly increased the nuclear transport and the total amount of genome integrated into the DNA of target cells. The LV used in the methods and compositions described herein may include a Woodchuck Posttranscriptional Regulatory Element (WPRE). The WPRE acts at the transcriptional level, by promoting nuclear export of transcripts and/or by increasing the efficiency of polyadenylation of the nascent transcript, thus increasing the total amount of mRNA in the cells. The addition of the WPRE to LV results in a substantial improvement in the level of transgene expression from several different promoters, both in vitro and in vivo. The LV used in the methods and compositions described herein may include both a cPPT sequence and WPRE sequence. The vector may also include an IRES sequence that permits the expression of multiple polypeptides from a single promoter.</p><p id="p-0734" num="0643">In addition to IRES sequences, other elements which permit expression of multiple polypeptides are useful. The vector used in the methods and compositions described herein may include multiple promoters that permit expression more than one polypeptide. The vector used in the methods and compositions described herein may include a protein cleavage site that allows expression of more than one polypeptide. Examples of protein cleavage sites that allow expression of more than one polypeptide are described in Klump et al., Gene Ther.; 8:811 (2001), Osborn et al., Molecular Therapy 12:569 (2005), Szymczak and Vignali, Expert Opin Biol Ther. 5:627 (2005), and Szymczak et al., Nat Biotechnol. 22:589 (2004), the disclosures of which are incorporated herein by reference as they pertain to protein cleavage sites that allow expression of more than one polypeptide. It will be readily apparent to one skilled in the art that other elements that permit expression of multiple polypeptides identified in the future are useful and may be utilized in the vectors suitable for use with the compositions and methods described herein.</p><p id="p-0735" num="0644">The vector used in the methods and compositions described herein may, be a clinical grade vector.</p><heading id="h-0016" level="2">Methods of Treatment</heading><p id="p-0736" num="0645">Exemplary diseases that may be treated using the compositions and methods of the disclosure Transgenes that may be introduced into a target cell and ultimately delivered to a patient (e.g., by administration of the target cell to a patient) using the compositions and methods of the disclosure include those that encode therapeutic proteins. The recipient of the transgene (e.g., the recipient of a cell transduced to express the transgene) may be suffering from a disease characterized by deficiency in the encoded protein. For example, transgenes that can expressed in a target cell and delivered to a patient in accordance with the compositions and methods of the disclosure include transgenes encoding beta-globin, which are particularly useful for the treatment of patients having beta-thalassemia. Exemplary nucleic acid and amino acid sequences of human beta-globin cDNA and protein are shown below.</p><p id="p-0737" num="0000">Exemplary Wild-Type Human Beta-Globin cDNA Sequence:</p><p id="p-0738" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="35pt" align="left"/><colspec colname="1" colwidth="182pt" align="right"/><tbody valign="top"><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;1)</entry></row><row><entry/><entry>ATGGTGCATCTGACCCCGGAAGAAAAAAGCGCGGTG</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>ACCGCGCTGTGGGGCAAAGTGAACGTGGATGAAGT</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>GGGCGGCGAAGCGCTGGGCCGCCTGCTGGTGGTGT</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>ATCCGTGGACCCAGCGCTTTTTTGAAAGCTTTGGC</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>GATCTGAGCACCCCGGATGCGGTGATGGGCAACCC</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>GAAAGTGAAAGCGCATGGCAAAAAAGTGCTGGGCG</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>CGTTTAGCGATGGCCTGGCGCATCTGGATAACCTG</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>AAAGGCACCTTTGCGACCCTGAGCGAACTGCATTG</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>CGATAAACTGCATGTGGATCCGGAAAACTTTCGCC</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>TGCTGGGCAACGTGCTGGTGTGCGTGCTGGCGCAT</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>CATTTTGGCAAAGAATTTACCCCGCCGGTGCAGGC</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>GGCGTATCAGAAAGTGGTGGCGGGCGTGGCGAACG</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>CGCTGGCGCATAAATATCAT</entry></row></tbody></tgroup></table></tables></p><heading id="h-0017" level="2">Exemplary Wild-Type Human Beta-Globin Amino Acid Sequence:</heading><p id="p-0739" num="0646"></p><p id="p-0740" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="28pt" align="left"/><colspec colname="1" colwidth="189pt" align="right"/><tbody valign="top"><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;2)</entry></row><row><entry/><entry>MVHLTPEEKSAVTALWGKVNVDEVGGEALGRLLVVYPW</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>TQRFFESFGDLSTPDAVMGNPKVKAHGKKVLGAFSDGL</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>AHLDNLKGTFATLSELHCDKLHVDPENFRLLGNVLVCV</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>LAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH</entry></row></tbody></tgroup></table></tables></p><p id="p-0741" num="0647">Additional examples of transgenes that may be used in conjunction with the compositions and methods of the disclosure include hormones and growth and differentiation factors including, without limitation, insulin, glucagon, growth hormone (GH), parathyroid hormone (PTH), calcitonin, growth hormone releasing factor (GRF), thyroid stimulating hormone (TSH), adrenocorticotropic hormone (ACTH), prolactin, melatonin, vasopressin, &#x3b2;-endorphin, met-enkephalin, leu-enkephalin, prolactin-releasing factor, prolactin-inhibiting factor, corticotropin-releasing hormone, thyrotropin-releasing hormone (TRH), follicle stimulating hormone (FSH), luteinizing hormone (LH), chorionic gonadotropin (CG), vascular endothelial growth factor (VEGF), angiopoietins, angiostatin, endostatin, granulocyte colony stimulating factor (GCSF), erythropoietin (EPO), connective tissue growth factor (CTGF), basic fibroblast growth factor (bFGF), bFGF2, acidic fibroblast growth factor (aFGF), epidermal growth factor (EGF), transforming growth factor &#x3b1; (TGF&#x3b1;), platelet-derived growth factor (PDGF), insulin-like growth factors I and II (IGF-I and IGF-II), any one of the transforming growth factor &#x3b2; (TGF&#x3b2;) superfamily comprising TGF&#x3b2;, activins, inhibins, or any of the bone morphogenic proteins (BMP) BMPs 1 15, any one of the heregulin/neuregulin/ARIA/neu differentiation factor (NDF) family of growth factors, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophins NT-3, NT-4/5 and NT-6, ciliary neurotrophic factor (CNTF), glial cell line derived neurotrophic factor (GDNF), neurturin, persephin, agrin, any one of the family of semaphorins/collapsins, netrin-1 and netrin-2, hepatocyte growth factor (HGF), ephrins, noggin, sonic hedgehog and tyrosine hydroxylase.</p><p id="p-0742" num="0648">Further examples of transgenes that may be used in conjunction with the compositions and methods of the disclosure include those that encode proteins that regulate the immune system including, without limitation, cytokines and lymphokines such as thrombopoietin (TPO), interleukins (IL) IL-1&#x3b1;, IL-1&#x3b2;, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, and IL-17, monocyte chemoattractant protein (MCP-1), leukemia inhibitory factor (LIF), granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), monocyte colony stimulating factor (M-CSF), Fas ligand, tumor necrosis factors &#x3b1; and &#x3b2; (TNF&#x3b1; and TNF&#x3b2;), interferons (IFN) IFN-&#x3b1;, IFN-&#x3b2;, and IFN-&#x3b3;, stem cell factor, flk-2/flt3 ligand. Transgenes encoding protein products produced by the immune system are also encompassed by the present disclosure. These include, without limitations, immunoglobulins IgG, IgM, IgA, IgD and IgE, chimeric immunoglobulins, humanized antibodies, single chain antibodies, T cell receptors, chimeric T cell receptors, single chain T cell receptors, class I and class II MHC molecules, as well as engineered MHC molecules including single chain MHC molecules. Useful gene products also include complement regulatory proteins such as membrane cofactor protein (MCP), decay accelerating factor (DAF), CR1, CR2 and CD59.</p><p id="p-0743" num="0649">Additional examples of suitable transgenes include those that encode any one of the receptors for the hormones, growth factors, cytokines, lymphokines, regulatory proteins and immune system proteins. Examples of such receptors include flt-1, flk-1, TIE-2; the trk family of receptors such as TrkA, MuSK, Eph, PDGF receptor, EGF receptor, HER2, insulin receptor, IGF-1 receptor, the FGF family of receptors, the TGF&#x3b2; receptors, the interleukin receptors, the interferon receptors, serotonin receptors, &#x3b1;-adrenergic receptors, &#x3b2;-adrenergic receptors, the GDNF receptor, p75 neurotrophin receptor, among others. Further examples are transgenes encoding extracellular matrix proteins, such as integrins, counter-receptors for transmembrane-bound proteins, such as intercellular adhesion molecules (ICAM-1, ICAM-2, ICAM-3 and ICAM-4), vascular cell adhesion molecules (VCAM), and selectins E-selectin, P-selectin and L-selectin. The invention encompasses receptors for cholesterol regulation, including the LDL receptor, HDL receptor, VLDL receptor, and the scavenger receptor. Additional examples are transgenes encoding the apolipoprotein ligands for these receptors, including ApoAI, ApoAIV and ApoE.</p><p id="p-0744" num="0650">Additional transgenes include those encoding antimicrobial peptides such as defensins and maginins, transcription factors such as jun, fos, max, mad, serum response factor (SRF), AP-1, AP-2, myb, MRG1, CREM, Alx4, FREAC1, NF-&#x3ba;B, members of the leucine zipper family, C<sub>2</sub>H<sub>4 </sub>zinc finger proteins, including Zif268, EGR1, EGR2, C6 zinc finger proteins, including the glucocorticoid and estrogen receptors, POU domain proteins, exemplified by Pit 1, homeodomain proteins, including HOX-1, basic helix-loop-helix proteins, including myc, MyoD and myogenin, ETS-box containing proteins, TFE3, E2F, ATF1, ATF2, ATF3, ATF4, ZF5, NFAT, CREB, HNF-4, C/EBP, SP1, CCAAT-box binding proteins, interferon regulation factor 1 (IRF-1), Wilms' tumor protein, ETS-binding protein, STAT, GATA-box binding proteins, e.g., GATA-3, and the forkhead family of winged helix proteins.</p><p id="p-0745" num="0651">Other useful transgenes include those encoding carbamoyl synthetase I, ornithine transcarbamylase, arginosuccinate synthetase, arginosuccinate lyase, arginase, fumarylacetoacetate hydrolase, phenylalanine hydroxylase, alpha-1 antitrypsin, glucose-6-phosphatase, porphobilinogen deaminase, factor VII, factor VIII, factor IX, factor II, factor V, factor X, factor XII, factor XI, von Willebrand factor, superoxide dismutase, glutathione peroxidase and reductase, heme oxygenase, angiotensin converting enzyme, endothelin-1, atrial natriuretic peptide, pro-urokinase, urokinase, plasminogen activator, heparin cofactor II, activated protein C (Factor V Leiden), Protein C, antithrombin, cystathione beta-synthase, branched chain ketoacid decarboxylase, albumin, isovaleryl-CoA dehydrogenase, propionyl CoA carboxylase, methyl malonyl CoA mutase, glutaryl CoA dehydrogenase, insulin, beta-glucosidase, pyruvate carboxylase, hepatic phosphorylase, phosphorylase kinase, glycine decarboxylase (also referred to as P-protein), H-protein, T-protein, Menkes disease protein, tumor suppressors (e.g., p53), cystic fibrosis transmembrane regulator (CFTR), the product of Wilson's disease gene PWD, Cu/Zn superoxide dismutase, aromatic amino acid decarboxylase, tyrosine hydroxylase, acetylcholine synthetase, prohormone convertases, protease inhibitors, lactase, lipase, trypsin, gastrointestinal enzymes including chymotrypsin, and pepsin, adenosine deaminase, &#x3b1;1 anti-trypsin, tissue inhibitor of metalloproteinases (TIMP), GLUT-1, GLUT-2, trehalose phosphate synthase, hexokinases I, II and III, glucokinase, any one or more of the individual chains or types of collagen, elastin, fibronectin, thrombospondin, vitronectin and tenascin, and suicide genes such as thymidine kinase and cytosine deaminase. Other useful proteins include those involved in lysosomal storage disorders, including acid &#x3b2;-glucosidase, &#x3b1;-galactosidase a, &#x3b1;-1-iduronidase, iduronate sulfatase, lysosomal acid &#x3b1;-glucosidase, sphingomyelinase, hexosaminidase A, hexomimidases A and B, arylsulfatase A, acid lipase, acid ceramidase, galactosylceramidase, &#x3b1;-fucosidase, &#x3b1;-, &#x3b2;-mannosidosis, aspartylglucosaminidase, neuramidase, galactosylceramidase, heparan-N-sulfatase, N-acetyl-&#x3b1;-glucosaminidase, Acetyl-CoA: &#x3b1;-glucosaminide N-acetyltransferase, N-acetylglucosamine-6-sulfate sulfatase, N-acetylgalactosamine-6-sulfate sulfatase, arylsulfatase B, &#x3b2;-glucuoronidase and hexosaminidases A and B.</p><p id="p-0746" num="0652">Other useful transgenes include those encoding non-naturally occurring polypeptides, such as chimeric or hybrid polypeptides or polypeptides having a non-naturally occurring amino acid sequence containing insertions, deletions or amino acid substitutions. For example, single-chain engineered immunoglobulins could be useful in certain immunocompromised patients. Other useful proteins include truncated receptors which lack their transmembrane and cytoplasmic domain. These truncated receptors can be used to antagonize the function of their respective ligands by binding to them without concomitant signaling by the receptor. Other types of non-naturally occurring gene sequences include sense and antisense molecules and catalytic nucleic acids, such as ribozymes, which could be used to modulate expression of a gene.</p><p id="p-0747" num="0653">Exemplary transgenes that can be expressed in a target cell, which may then be administered to a patient for the treatment of a disease characterized by a deficiency or dysfunction of the encoded product, include those encoding a protein product listed in Table 2, below.</p><p id="p-0748" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="308pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 2</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Exemplary disorders associated with gene deficiency or dysfunction</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="105pt" align="left"/><colspec colname="2" colwidth="98pt" align="left"/><colspec colname="3" colwidth="105pt" align="left"/><tbody valign="top"><row><entry/><entry>Disease associated with</entry><entry>Exemplary amino acid</entry></row><row><entry>Protein</entry><entry>deficiency in protein</entry><entry>sequence of protein</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>acid &#x3b1;-glucosidase (GAA)</entry><entry>Pompe</entry><entry>NP_000143.2,</entry></row><row><entry/><entry/><entry>NP_001073271.1,</entry></row><row><entry/><entry/><entry>NP_001073272.1</entry></row><row><entry>Methyl CpG binding protein 2</entry><entry>Rett syndrome</entry><entry>NP_001104262.1,</entry></row><row><entry>(MECP2)</entry><entry/><entry>NP_004983.1</entry></row><row><entry>Aromatic L-amino acid</entry><entry>Parkinson's disease</entry><entry>NP_000781.1,</entry></row><row><entry>decarboxylase (AADC)</entry><entry/><entry>NP_001076440.1,</entry></row><row><entry/><entry/><entry>NP_001229815.1,</entry></row><row><entry/><entry/><entry>NP_001229816.1,</entry></row><row><entry/><entry/><entry>NP_001229817.1,</entry></row><row><entry/><entry/><entry>NP_001229818.1,</entry></row><row><entry/><entry/><entry>NP_001229819.1</entry></row><row><entry>Glial cell-derived neurotrophic</entry><entry>Parkinson's disease</entry><entry>NP_000505.1,</entry></row><row><entry>factor (GDNF)</entry><entry/><entry>NP_001177397.1,</entry></row><row><entry/><entry/><entry>NP_001177398.1,</entry></row><row><entry/><entry/><entry>NP_001265027.1,</entry></row><row><entry/><entry/><entry>NP_954701.1</entry></row><row><entry>Glutamate decarboxylase 1</entry><entry>Parkinson's disease</entry><entry>NP_000808.2, NP_038473.2</entry></row><row><entry>(GAD1)</entry></row><row><entry>Glutamate decarboxylase 2</entry><entry>Parkinson's disease</entry><entry>NP_000809.1,</entry></row><row><entry>(GAD2)</entry><entry/><entry>NP_001127838.1</entry></row><row><entry>Neurturin (NRTN)</entry><entry>Parkinson's disease</entry><entry>NP_004549.1</entry></row><row><entry>neuropeptide Y (NPY)</entry><entry>Parkinson's disease, epilepsy</entry><entry>NP_000896.1</entry></row><row><entry>Cystic fibrosis transmembrane</entry><entry>Cystic fibrosis</entry><entry>NP_000483.3</entry></row><row><entry>conductance regulator (CFTR)</entry></row><row><entry>Tumor necrosis factor receptor</entry><entry>Arthritis, Rheumatoid arthritis</entry><entry>SEQ ID NO. 1 of</entry></row><row><entry>fused to an antibody Fe</entry><entry/><entry>W02013025079</entry></row><row><entry>(TNFR:Fc)</entry></row><row><entry>Sarcoglycan &#x3b1;, &#x3b2;, &#x3b3;, &#x394;, &#x3b5;, or &#x3b6;</entry><entry>Muscular dystrophy</entry><entry>SGCA</entry></row><row><entry>(SGCA, SGCB, SGCG, SGCD,</entry><entry/><entry>NP_000014.1,</entry></row><row><entry>SGCE, or SGCZ)</entry><entry/><entry>NP_001129169.1</entry></row><row><entry/><entry/><entry>SGCB</entry></row><row><entry/><entry/><entry>NP_000223.1</entry></row><row><entry/><entry/><entry>SGCG</entry></row><row><entry/><entry/><entry>NP_000222.1</entry></row><row><entry/><entry/><entry>SGCD</entry></row><row><entry/><entry/><entry>NP_000328.2,</entry></row><row><entry/><entry/><entry>NP_001121681.1,</entry></row><row><entry/><entry/><entry>NP_758447.1</entry></row><row><entry/><entry/><entry>SGCE</entry></row><row><entry/><entry/><entry>NP_001092870.1,</entry></row><row><entry/><entry/><entry>NP_001092871.1,</entry></row><row><entry/><entry/><entry>NP_003910.1</entry></row><row><entry/><entry/><entry>SGCZ</entry></row><row><entry/><entry/><entry>NP_631906.2</entry></row><row><entry>&#x3b1;-1-antitrypsin (AAT)</entry><entry>Hereditary emphysema or &#x3b1;-1-</entry><entry>NP_000286.3,</entry></row><row><entry/><entry>antitrypsin deficiency</entry><entry>NP_001002235.1,</entry></row><row><entry/><entry/><entry>NP_001002236.1,</entry></row><row><entry/><entry/><entry>NP_001121172.1,</entry></row><row><entry/><entry/><entry>NP_001121173.1,</entry></row><row><entry/><entry/><entry>NP_001121174.1,</entry></row><row><entry/><entry/><entry>NP_001121175.1,</entry></row><row><entry/><entry/><entry>NP_001121176.1,</entry></row><row><entry/><entry/><entry>NP_001121177.1,</entry></row><row><entry/><entry/><entry>NP_001121178.1,</entry></row><row><entry/><entry/><entry>NP_001121179.1</entry></row><row><entry>Aspartoacylase (ASPA)</entry><entry>Canavan's disease</entry><entry>NP_000040.1,</entry></row><row><entry/><entry/><entry>NP_001121557.1</entry></row><row><entry>Nerve growth factor (NGF)</entry><entry>Alzheimer's disease</entry><entry>NP_002497.2</entry></row><row><entry>Granulocyte-macrophage</entry><entry>Prostate cancer</entry><entry>NP_000749.2</entry></row><row><entry>colonystimulating factory (GM-</entry></row><row><entry>CSF)</entry></row><row><entry>Cluster of Differentiation 86</entry><entry>Malignant melanoma</entry><entry>NP_001193853.1,</entry></row><row><entry>(CD86 or B7-2)</entry><entry/><entry>NP_001193854.1,</entry></row><row><entry/><entry/><entry>NP_008820.3,</entry></row><row><entry/><entry/><entry>NP_787058.4,</entry></row><row><entry/><entry/><entry>NP_795711.1</entry></row><row><entry>Interleukin 12 (IL-12)</entry><entry>Malignant melanoma</entry><entry>NP_000873.2, NP_002178.2</entry></row><row><entry>ATPase, Ca<sup>2+</sup> transporting,</entry><entry>Chronic heart failure</entry><entry>NP_001672.1,</entry></row><row><entry>cardiac muscle, slow twitch 2</entry><entry/><entry>NP_733765.1</entry></row><row><entry>(SERCA2)</entry></row><row><entry>Dystrophin or Minidystrophin</entry><entry>Muscular dystrophy</entry><entry>NP_000100.2, NP_003997.1,</entry></row><row><entry/><entry/><entry>NP_004000.1, NP_004001.1,</entry></row><row><entry/><entry/><entry>NP_004002.2, NP_004003.1,</entry></row><row><entry/><entry/><entry>NP_004004.1, NP_004005.1,</entry></row><row><entry/><entry/><entry>NP_004006.1, NP_004007.1,</entry></row><row><entry/><entry/><entry>NP_004008.1, NP_004009.1,</entry></row><row><entry/><entry/><entry>NP_004010.1, NP_004011.2,</entry></row><row><entry/><entry/><entry>NP_004012.1, NP_004013.1,</entry></row><row><entry/><entry/><entry>NP_004014.1</entry></row><row><entry>Ceroid lipofuscinosis neuronal 2</entry><entry>Late infantile neuronal</entry><entry>NP_000382.3</entry></row><row><entry>(CLN2)</entry><entry>ceroidlipofuscinosis or Batten's</entry></row><row><entry/><entry>disease</entry></row><row><entry>N-acetylglucosaminidase, &#x3b1;</entry><entry>Sanfilippo syndrome (MPSIIIB)</entry><entry>NP_000254.2</entry></row><row><entry>(NAGLU)</entry></row><row><entry>Iduronidase, &#x3b1; -1 (IDUA)</entry><entry>MPSI-Hurler</entry><entry>NP_000194.2</entry></row><row><entry>Iduronate 2-sulfatase (IDS)</entry><entry>MPSII-Hunter</entry><entry>NP_000193.1,</entry></row><row><entry/><entry/><entry>NP_001160022.1,</entry></row><row><entry/><entry/><entry>NP_006114.1</entry></row><row><entry>Glucuronidase, &#x3b2; (GUSB)</entry><entry>MPSVII-Sly</entry><entry>NP_000172.2, NP_001271219.1</entry></row><row><entry>Hexosaminidase A, &#x3b1;</entry><entry>Tay-Sachs</entry><entry>NP_000511.2</entry></row><row><entry>polypeptide (HEXA)</entry></row><row><entry>Retinal pigment epithelium-</entry><entry>Leber congenital amaurosis</entry><entry>NP_000320.1</entry></row><row><entry>specific protein 65 kDa (RPE65)</entry></row><row><entry>Factor IX (FIX)</entry><entry>Hemophilia B</entry><entry>NP_000124.1</entry></row><row><entry>Adenine nucleotide translocator</entry><entry>progressive external</entry><entry>NP_001142.2</entry></row><row><entry>(ANT-I)</entry><entry>ophthalmoplegia</entry></row><row><entry>ApaLI</entry><entry>mitochondrial heteroplasmy,</entry><entry>YP_007161330.1</entry></row><row><entry/><entry>myoclonic epilepsy with ragged</entry></row><row><entry/><entry>red fibers (MERRF) or</entry></row><row><entry/><entry>mitochondrial</entry></row><row><entry/><entry>encephalomyopathy,</entry></row><row><entry/><entry>lactic acidosis, and stroke-like</entry></row><row><entry/><entry>episodes (ME LAS)</entry></row><row><entry>NADH ubiquinone</entry><entry>Leber hereditary optic</entry><entry>YP_003024035.1</entry></row><row><entry>oxidoreductase subunit 4 (ND4)</entry></row><row><entry>very long-acyl-CoA</entry><entry>very long-chain acyl-CoA</entry><entry>NP_000009.1,</entry></row><row><entry>dehydrogenase (VLCAD)</entry><entry>dehydrogenase (VLCAD)</entry><entry>NP_001029031.1,</entry></row><row><entry/><entry>deficiency</entry><entry>NP_001257376.1,</entry></row><row><entry/><entry/><entry>NP_001257377.1</entry></row><row><entry>short-chain acyl-CoA</entry><entry>short-chain acyl-CoA</entry><entry>NP_000008.1</entry></row><row><entry>dehydrogenase (SCAD)</entry><entry>dehydrogenase (SCAD)</entry></row><row><entry/><entry>deficiency</entry></row><row><entry>medium-chain acyl-CoA</entry><entry>medium-chain acyl-CoA</entry><entry>NP_000007.1,</entry></row><row><entry>dehydrogenase (MCAD)</entry><entry>dehydrogenase (MCAD)</entry><entry>NP_001120800.1,</entry></row><row><entry/><entry>deficiency</entry><entry>NP_001272971.1,</entry></row><row><entry/><entry/><entry>NP_001272972.1,</entry></row><row><entry/><entry/><entry>NP_001272973.1</entry></row><row><entry>Myotubularin 1 (MTM1)</entry><entry>X-linked myotubular myopathy</entry><entry>NP_000243.1</entry></row><row><entry>Myophosphorylase (PYGM)</entry><entry>McArdle disease (glycogen</entry><entry>NP_001158188.1,</entry></row><row><entry/><entry>storage disease type V,</entry><entry>NP_005600.1</entry></row><row><entry/><entry>myophosphorylase deficiency)</entry></row><row><entry>Lipoprotein lipase (LPL)</entry><entry>LPL deficiency</entry><entry>NP_000228.1</entry></row><row><entry>sFLTOI (VEGF/PIGF (placental</entry><entry>Age-related macular</entry><entry>SEQ ID NO: 2, 8, 21, 23, or 25</entry></row><row><entry>growth factor) binding domain of</entry><entry>degeneration</entry><entry>of W02009105669</entry></row><row><entry>human VEGFRI/Flt-1 (hVEGFRI)</entry></row><row><entry>fused to the Fe portion of human</entry></row><row><entry>IgG(I) through a polyglycine</entry></row><row><entry>linker)</entry></row><row><entry>Glucocerebrosidase (GC)</entry><entry>Gaucher disease</entry><entry>NP_000148.2,</entry></row><row><entry/><entry/><entry>NP_001005741.1,</entry></row><row><entry/><entry/><entry>NP_001005742.1,</entry></row><row><entry/><entry/><entry>NP_001165282.1,</entry></row><row><entry/><entry/><entry>NP_001165283.1</entry></row><row><entry>Calsequestrin 2 (CASQ2)</entry><entry>Catecholaminergic polymorphic</entry><entry>NP_001223.2</entry></row><row><entry/><entry>ventricular tachycardia (CPVT)</entry></row><row><entry>UDP glucuronosyltransferase 1</entry><entry>Crigler-Najjar syndrome</entry><entry>NP_000454.1</entry></row><row><entry>family member A1 (UGT1A1)</entry></row><row><entry>Glucose 6-phosphatase</entry><entry>GSD-Ia</entry><entry>NP_000142.2,</entry></row><row><entry>(G6Pase)</entry><entry/><entry>NP_001257326.1</entry></row><row><entry>Omithine carbamoyltransferase</entry><entry>OTC deficiency</entry><entry>NP_000522.3</entry></row><row><entry>(OTC)</entry></row><row><entry>Cystathionine-&#x3b2;-synthase (CBS)</entry><entry>Homocystinuria</entry><entry>NP_000062.1,</entry></row><row><entry/><entry/><entry>NP_001171479.1,</entry></row><row><entry/><entry/><entry>NP_001171480.1</entry></row><row><entry>Factor VIII (F8)</entry><entry>Haemophilia A</entry><entry>NP_000123.1, NP_063916.1</entry></row><row><entry>Hemochromatosis (HFE)</entry><entry>Hemochromatosis</entry><entry>NP_000401.1, NP_620572.1,</entry></row><row><entry/><entry/><entry>NP_620573.1, NP_620575.1,</entry></row><row><entry/><entry/><entry>NP_620576.1, NP_620577.1,</entry></row><row><entry/><entry/><entry>NP_620578.1, NP_620579.1,</entry></row><row><entry/><entry/><entry>NP_620580.1</entry></row><row><entry>Low density lipoprotein receptor</entry><entry>Phenylketonuria (PKU)</entry><entry>NP_000518.1,</entry></row><row><entry>(LDLR)</entry><entry/><entry>NP_001182727.1,</entry></row><row><entry/><entry/><entry>NP_001182728.1,</entry></row><row><entry/><entry/><entry>NP_001182729.1,</entry></row><row><entry/><entry/><entry>NP_001182732.1</entry></row><row><entry>Galactosidase, &#x3b1; (AGA)</entry><entry>Fabry disease</entry><entry>NP_000160.1</entry></row><row><entry>Phenylalanine hydroxylase</entry><entry>Hypercholesterolaemia or</entry><entry>NP_000268.1</entry></row><row><entry>(PAH)</entry><entry>Phenylketonuria (PKU)</entry></row><row><entry>Propionyl CoA carboxylase,</entry><entry>Propionic acidaemias</entry><entry>NP_000273.2,</entry></row><row><entry>alpha polypeptide (PCCA)</entry><entry/><entry>NP_001121164.1,</entry></row><row><entry/><entry/><entry>NP_001171475.1</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0018" level="2">Selection of Donor Cells</heading><p id="p-0749" num="0654">In some embodiments, the subject undergoing treatment is the donor that provides cells (e.g., pluripotent cells, such as CD34+ HSCs or HPCs) which are subsequently modified to express one or more therapeutic proteins of the disclosure before being re-administered to the patient. In such cases, withdrawn cells (e.g., CD34+ HSCs or HPCs) may be re-infused into the subject following, for example, incorporation of a transgene encoding one or more therapeutic proteins of the disclosure, and/or disruption of an allelic variant harboring a deleterious mutation), such that the cells may subsequently home to hematopoietic tissue and establish productive hematopoiesis, thereby restoring expression of the transgene in the patient. In cases in which the subject undergoing treatment also serves as the cell donor, the transplanted cells (e.g., HSCs or HPCs) are less likely to undergo graft rejection. This stems from the fact that the infused cells are derived from the patient and express the same HLA class I and class II antigens as expressed by the patient. Alternatively, the subject and the donor may be distinct. In some embodiments, the subject and the donor are related, and may, for example, be HLA-matched. As described herein, HLA-matched donor-recipient pairs have a decreased risk of graft rejection, as endogenous T cells and NK cells within the transplant recipient are less likely to recognize the incoming hematopoietic stem or progenitor cell graft as foreign, and are thus less likely to mount an immune response against the transplant. Exemplary HLA-matched donor-recipient pairs are donors and recipients that are genetically related, such as familial donor-recipient pairs (e.g., sibling donor-recipient pairs). In some embodiments, the subject and the donor are HLA-mismatched, which occurs when at least one HLA antigen, in particular with respect to HLA-A, HLA-B and HLA-DR, is mismatched between the donor and recipient. To reduce the likelihood of graft rejection, for example, one haplotype may be matched between the donor and recipient, and the other may be mismatched.</p><heading id="h-0019" level="2">Pharmaceutical Compositions and Dosing</heading><p id="p-0750" num="0655">In cases in which a subject is administered a population of cells that together express one or more therapeutic proteins of the disclosure, the number of cells administered may depend, for example, on the expression level of the desired protein(s), the patient, pharmaceutical formulation methods, administration methods (e.g., administration time and administration route), the patient's age, body weight, sex, severity of the disease being treated, and whether or not the patient has been treated with agents to ablate endogenous pluripotent cells (e.g., endogenous CD34+ cells, hematopoietic stem or progenitor cells, or microglia, among others). The number of cells administered may be, for example, from 1&#xd7;10<sup>4 </sup>cells/kg to 1&#xd7;10<sup>14 </sup>cells/kg, or more. Cells may be administered in an undifferentiated state, or after partial or complete differentiation into a target cell type. The number of pluripotent cells may be administered in any suitable dosage form.</p><heading id="h-0020" level="1">EXAMPLES</heading><p id="p-0751" num="0656">The following examples are put forth so as to provide those of ordinary skill in the art with a description of how the compositions and methods described herein may be used, made, and evaluated, and are intended to be purely exemplary of the disclosure and are not intended to limit the scope of what the inventors regard as their disclosure.</p><heading id="h-0021" level="1">Example One. Poloxamers, when Used at Low Concentrations, Serve to Increase Viral Transduction Efficiency</heading><p id="p-0752" num="0657">This example describes a series of experiments designed to evaluate the effect of poloxamers, particularly poloxamer P407, on lentiviral transduction efficiency. Human CD34+ hematopoietic stem cells were mobilized into peripheral circulation and isolated from donor subjects. Cells were cultured in the presence of a lentiviral vector at a multiplicity of infection of 10. The lentiviral vector used in these experiments contained a transgene encoding green fluorescent protein (GFP), enabling the detection of transgene-expressing cells by monitoring fluorescence at about 510 nm.</p><p id="p-0753" num="0658">During the transduction procedure, cells were exposed to the GFP-encoding lentiviral vector either alone or in combination with poloxamer P407 at a concentration of 7 &#x3bc;g/ml, 10 &#x3bc;g/ml, or 100 &#x3bc;g/ml. For cells transduced in the presence of poloxamer, the cells were exposed to the lentivirus and P407 simultaneously. After 18 hours of incubation, cells were washed to remove the lentivirus (and the poloxamer, for co-cultured cells). The proportion of transgene-expressing cells and the vector copy number of each population of cells was then assessed 12 days after the transduction procedure. The results of these studies are reported in <figref idref="DRAWINGS">FIGS. <b>1</b>A and <b>1</b>B</figref>, respectively.</p><p id="p-0754" num="0659">To assess the quantity of transgene-expressing cells, each population of cells was monitored using flow cytometry to detect GFP+ cells. As shown in <figref idref="DRAWINGS">FIG. <b>1</b>A</figref>, surprisingly, lower concentrations of P407 appear to promote a general increase in the proportion of transgene-expressing cells. Vector copy number was evaluated using polymerase chain reaction techniques designed to measure the number of lentiviral genomes present in each cell. As shown in <figref idref="DRAWINGS">FIG. <b>1</b>B</figref>, cells transduced with 7 &#x3bc;g/ml of P407 appeared to exhibit elevated vector copy numbers relative to cells transduced with 10 &#x3bc;g/ml.</p><heading id="h-0022" level="1">Example Two. Effects of Poloxamers P407 and P338 on Lentiviral Transduction of Hematopoietic Stem Cells</heading><p id="p-0755" num="0660">This example describes a series of experiments designed to compare the effects of poloxamers P407 and P338 on lentiviral transduction efficiency. Human CD34+ hematopoietic stem cells were mobilized into peripheral circulation and isolated from donor subjects. Cells were cultured in the presence of a lentiviral vector at a multiplicity of infection of from 5 to 20. The lentiviral vector used in these experiments contained a transgene encoding GFP, enabling the detection of transgene-expressing cells by monitoring fluorescence at about 510 nm.</p><p id="p-0756" num="0661">During the transduction procedure, cells were exposed to the GFP-encoding lentiviral vector either alone or in combination with poloxamer P407 or poloxamer 338 at various concentrations. The proportion of transgene-expressing cells and the vector copy number of each population of cells was then assessed 12 days after the transduction procedure. The results of these studies are reported in <figref idref="DRAWINGS">FIGS. <b>2</b>A-<b>2</b>C</figref>.</p><p id="p-0757" num="0662">As shown in <figref idref="DRAWINGS">FIG. <b>2</b>A</figref>, both CD34+ stem cells were tolerant of both poloxamer P407 and poloxamer P338, as neither poloxamer exerted a detrimental effect on cell viability at the concentrations tested. Surprisingly, lower concentrations of P407, such as concentrations less than 10 &#x3bc;g/ml, were found to enhance lentiviral transduction to a greater extent than the same or higher concentrations of poloxamer P338, as shown in <figref idref="DRAWINGS">FIGS. <b>2</b>B and <b>2</b>C</figref>.</p><heading id="h-0023" level="1">Example Three. Poloxamers can be Used in Combination with Protamine Sulfate, Cyclosporine H, and/or Lithium Carbonate to Enhance Lentiviral Transduction</heading><p id="p-0758" num="0663">This example describes a series of experiments designed to evaluate the effects of poloxamers, such as poloxamer P407, in combination with protamine sulfate on lentiviral transduction efficiency. Briefly, human CD34+ hematopoietic stem cells were mobilized into peripheral circulation and isolated from donor subjects in accordance with the method described in Examples One and Two, above. Cells were then transduced with a lentiviral vector encoding GFP in the presence of poloxamer P407 (7 &#x3bc;g/mL) or poloxamer P338 (1 mg/mL), each in combination with protamine sulfate (3.5 &#x3bc;g/mL). At 12 days post-transduction, the percentage of transduced cells was assessed by flow cytometry detection of transgene expression, and VCN was determined by droplet digital PCR detection of integrated transgene sequences in genomic DNA. The results of these experiments are shown in <figref idref="DRAWINGS">FIGS. <b>3</b>A and <b>3</b>B</figref>.</p><p id="p-0759" num="0664">As <figref idref="DRAWINGS">FIGS. <b>3</b>A and <b>3</b>B</figref> show, poloxamer P407, in the presence of protamine sulfate, exhibited a surprisingly greater improvement in lentiviral transduction efficiency relative to poloxamer P338 in the presence of protamine sulfate.</p><p id="p-0760" num="0665">In addition to analyzing the effects of poloxamers in combination with protamine sulfate, a series of experiments was conducted in which poloxamer P407 was combined with protamine sulfate and either cyclosporine H or lithium carbonate (Li<sub>2</sub>CO<sub>3</sub>) in order to evaluate the effects of three-component combinations of agents on lentiviral transduction efficiency. In these experiments, CD34+ stem cells freshly isolated from peripheral mobilized blood were transduced with a clinical therapeutic lentiviral vector encoding a beta-globin transgene in the presence of poloxamer P407 (7 &#x3bc;g/mL) in combination with protamine sulfate (3.5 &#x3bc;g/mL) and either cyclosporine H (8 &#x3bc;M) or Li<sub>2</sub>CO<sub>3</sub>, (2 mM). The results of these experiments are shown in <figref idref="DRAWINGS">FIGS. <b>4</b>A and <b>4</b>B</figref>, as well as in Table 3, below.</p><p id="p-0761" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="294pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 3</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Effects of poloxamer P407, protamine sulfate, and either cyclosporine</entry></row><row><entry>H or Li<sub>2</sub>CO<sub>3 </sub>on lentiviral transduction efficiency</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><colspec colname="6" colwidth="35pt" align="center"/><colspec colname="7" colwidth="35pt" align="center"/><colspec colname="8" colwidth="14pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry/><entry>Range</entry><entry/><entry>Range</entry><entry/></row><row><entry/><entry/><entry>Mean</entry><entry>Mean</entry><entry>VCN per</entry><entry>Range %</entry><entry>VCN</entry></row><row><entry/><entry>Mean VCN</entry><entry>VCN</entry><entry>(range) %</entry><entry>cell in</entry><entry>trans-</entry><entry>per cell</entry></row><row><entry/><entry>(range) in</entry><entry>(range) in</entry><entry>Trans-</entry><entry>total CFU/</entry><entry>duction</entry><entry>in CFU</entry></row><row><entry>Transduction</entry><entry>eryth. LC</entry><entry>myel. LC</entry><entry>duction</entry><entry>only BFU</entry><entry>(MOI</entry><entry>(MOI</entry></row><row><entry>Conditions</entry><entry>(MOI 100)<sup>1</sup></entry><entry>(MOI 100)<sup>2</sup></entry><entry>(MOI 100)<sup>3</sup></entry><entry>(MOI 100)<sup>4</sup></entry><entry>10-20)</entry><entry>10-20)</entry><entry>n</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row><row><entry>Vector only</entry><entry>0.37</entry><entry>0.24</entry><entry>28.3</entry><entry>0.4-3.9/</entry><entry>13-28</entry><entry>0.15-0.36</entry><entry>5</entry></row><row><entry/><entry>(0.18-0.82)</entry><entry>(0.18-0.34)</entry><entry>(22-31)</entry><entry>0.8-6.7&#x2009;</entry></row><row><entry>P407 + PS +</entry><entry>3.4&#x2002;</entry><entry>1.81</entry><entry>76.9</entry><entry>2.1-3.4/</entry><entry>35-65</entry><entry>0.76-1.44</entry><entry>4</entry></row><row><entry>CSH</entry><entry>(3.02-4.05)</entry><entry>(1.38-2.32)</entry><entry>(65-94)</entry><entry>0.8-4.1&#x2009;</entry></row><row><entry>P407 + PS +</entry><entry>1.74</entry><entry>1.37</entry><entry>63&#x2009;&#x2002;</entry><entry>0.9-3.1/</entry><entry>33-64</entry><entry>0.56-0.90</entry><entry>4</entry></row><row><entry>Li<sub>2</sub>CO<sub>3</sub></entry><entry>(0.73-2.9)&#x2002;</entry><entry>(0.93-2.33)</entry><entry>(50-78)</entry><entry>1.2-2.6&#x2009;</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row><row><entry namest="1" nameend="8" align="left" id="FOO-00002"><sup>1, 2</sup>Mean VCN (and VCN range) detected in bulk liquid cultures for erythroid and myeloid differentiation</entry></row><row><entry namest="1" nameend="8" align="left" id="FOO-00003"><sup>3</sup>Range shows percentage of LV+ colonies detected of total colonies screened in CFU assays</entry></row><row><entry namest="1" nameend="8" align="left" id="FOO-00004"><sup>4</sup>Shows the lower and upper range of VCN/cell detected within all LV+ colonies detected within a CFU assay, followed by the range of VCN detected within LV+ BFU-E colonies within each CFU assay (n = 4-5 independent healthy donors)</entry></row></tbody></tgroup></table></tables></p><p id="p-0762" num="0666">As the results in <figref idref="DRAWINGS">FIGS. <b>4</b>A, <b>4</b>B</figref>, and Table 3 show, poloxamers, such as poloxamer P407, can be used to enhance lentiviral transduction efficiency in the presence of additional agents, such as protamine sulfate, cyclosporine H, and Li<sub>2</sub>CO<sub>3</sub>.</p><heading id="h-0024" level="1">OTHER EMBODIMENTS</heading><p id="p-0763" num="0667">Various modifications and variations of the described disclosure will be apparent to those skilled in the art without departing from the scope and spirit of the disclosure. Although the disclosure has been described in connection with specific embodiments, it should be understood that the disclosure as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the disclosure that are obvious to those skilled in the art are intended to be within the scope of the disclosure.</p><p id="p-0764" num="0668">Other embodiments are in the claims.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230002784A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><us-chemistry idref="CHEM-US-00001" cdx-file="US20230002784A1-20230105-C00001.CDX" mol-file="US20230002784A1-20230105-C00001.MOL"/><us-chemistry idref="CHEM-US-00002" cdx-file="US20230002784A1-20230105-C00002.CDX" mol-file="US20230002784A1-20230105-C00002.MOL"/><us-chemistry idref="CHEM-US-00003" cdx-file="US20230002784A1-20230105-C00003.CDX" mol-file="US20230002784A1-20230105-C00003.MOL"/><us-chemistry idref="CHEM-US-00004" cdx-file="US20230002784A1-20230105-C00004.CDX" mol-file="US20230002784A1-20230105-C00004.MOL"/><us-chemistry idref="CHEM-US-00005" cdx-file="US20230002784A1-20230105-C00005.CDX" mol-file="US20230002784A1-20230105-C00005.MOL"/><us-chemistry idref="CHEM-US-00006" cdx-file="US20230002784A1-20230105-C00006.CDX" mol-file="US20230002784A1-20230105-C00006.MOL"/><us-chemistry idref="CHEM-US-00007" cdx-file="US20230002784A1-20230105-C00007.CDX" mol-file="US20230002784A1-20230105-C00007.MOL"/><us-chemistry idref="CHEM-US-00008" cdx-file="US20230002784A1-20230105-C00008.CDX" mol-file="US20230002784A1-20230105-C00008.MOL"/><us-chemistry idref="CHEM-US-00009" cdx-file="US20230002784A1-20230105-C00009.CDX" mol-file="US20230002784A1-20230105-C00009.MOL"/><us-chemistry idref="CHEM-US-00010" cdx-file="US20230002784A1-20230105-C00010.CDX" mol-file="US20230002784A1-20230105-C00010.MOL"/><us-chemistry idref="CHEM-US-00011" cdx-file="US20230002784A1-20230105-C00011.CDX" mol-file="US20230002784A1-20230105-C00011.MOL"/><us-chemistry idref="CHEM-US-00012" cdx-file="US20230002784A1-20230105-C00012.CDX" mol-file="US20230002784A1-20230105-C00012.MOL"/><us-chemistry idref="CHEM-US-00013" cdx-file="US20230002784A1-20230105-C00013.CDX" mol-file="US20230002784A1-20230105-C00013.MOL"/><us-chemistry idref="CHEM-US-00014" cdx-file="US20230002784A1-20230105-C00014.CDX" mol-file="US20230002784A1-20230105-C00014.MOL"/><us-chemistry idref="CHEM-US-00015" cdx-file="US20230002784A1-20230105-C00015.CDX" mol-file="US20230002784A1-20230105-C00015.MOL"/><us-chemistry idref="CHEM-US-00016" cdx-file="US20230002784A1-20230105-C00016.CDX" mol-file="US20230002784A1-20230105-C00016.MOL"/><us-chemistry idref="CHEM-US-00017" cdx-file="US20230002784A1-20230105-C00017.CDX" mol-file="US20230002784A1-20230105-C00017.MOL"/><us-chemistry idref="CHEM-US-00018" cdx-file="US20230002784A1-20230105-C00018.CDX" mol-file="US20230002784A1-20230105-C00018.MOL"/><us-chemistry idref="CHEM-US-00019" cdx-file="US20230002784A1-20230105-C00019.CDX" mol-file="US20230002784A1-20230105-C00019.MOL"/><us-chemistry idref="CHEM-US-00020" cdx-file="US20230002784A1-20230105-C00020.CDX" mol-file="US20230002784A1-20230105-C00020.MOL"/><us-chemistry idref="CHEM-US-00021" cdx-file="US20230002784A1-20230105-C00021.CDX" mol-file="US20230002784A1-20230105-C00021.MOL"/><us-chemistry idref="CHEM-US-00022" cdx-file="US20230002784A1-20230105-C00022.CDX" mol-file="US20230002784A1-20230105-C00022.MOL"/><us-chemistry idref="CHEM-US-00023" cdx-file="US20230002784A1-20230105-C00023.CDX" mol-file="US20230002784A1-20230105-C00023.MOL"/><us-chemistry idref="CHEM-US-00024" cdx-file="US20230002784A1-20230105-C00024.CDX" mol-file="US20230002784A1-20230105-C00024.MOL"/><us-chemistry idref="CHEM-US-00025" cdx-file="US20230002784A1-20230105-C00025.CDX" mol-file="US20230002784A1-20230105-C00025.MOL"/><us-chemistry idref="CHEM-US-00026" cdx-file="US20230002784A1-20230105-C00026.CDX" mol-file="US20230002784A1-20230105-C00026.MOL"/><us-chemistry idref="CHEM-US-00027" cdx-file="US20230002784A1-20230105-C00027.CDX" mol-file="US20230002784A1-20230105-C00027.MOL"/><us-chemistry idref="CHEM-US-00028" cdx-file="US20230002784A1-20230105-C00028.CDX" mol-file="US20230002784A1-20230105-C00028.MOL"/><us-chemistry idref="CHEM-US-00029" cdx-file="US20230002784A1-20230105-C00029.CDX" mol-file="US20230002784A1-20230105-C00029.MOL"/><us-chemistry idref="CHEM-US-00030" cdx-file="US20230002784A1-20230105-C00030.CDX" mol-file="US20230002784A1-20230105-C00030.MOL"/><us-chemistry idref="CHEM-US-00031" cdx-file="US20230002784A1-20230105-C00031.CDX" mol-file="US20230002784A1-20230105-C00031.MOL"/><us-chemistry idref="CHEM-US-00032" cdx-file="US20230002784A1-20230105-C00032.CDX" mol-file="US20230002784A1-20230105-C00032.MOL"/><us-chemistry idref="CHEM-US-00033" cdx-file="US20230002784A1-20230105-C00033.CDX" mol-file="US20230002784A1-20230105-C00033.MOL"/><us-chemistry idref="CHEM-US-00034" cdx-file="US20230002784A1-20230105-C00034.CDX" mol-file="US20230002784A1-20230105-C00034.MOL"/><us-chemistry idref="CHEM-US-00035" cdx-file="US20230002784A1-20230105-C00035.CDX" mol-file="US20230002784A1-20230105-C00035.MOL"/><us-chemistry idref="CHEM-US-00036" cdx-file="US20230002784A1-20230105-C00036.CDX" mol-file="US20230002784A1-20230105-C00036.MOL"/><us-chemistry idref="CHEM-US-00037" cdx-file="US20230002784A1-20230105-C00037.CDX" mol-file="US20230002784A1-20230105-C00037.MOL"/><us-chemistry idref="CHEM-US-00038" cdx-file="US20230002784A1-20230105-C00038.CDX" mol-file="US20230002784A1-20230105-C00038.MOL"/><us-chemistry idref="CHEM-US-00039" cdx-file="US20230002784A1-20230105-C00039.CDX" mol-file="US20230002784A1-20230105-C00039.MOL"/><us-chemistry idref="CHEM-US-00040" cdx-file="US20230002784A1-20230105-C00040.CDX" mol-file="US20230002784A1-20230105-C00040.MOL"/><us-chemistry idref="CHEM-US-00041" cdx-file="US20230002784A1-20230105-C00041.CDX" mol-file="US20230002784A1-20230105-C00041.MOL"/><us-chemistry idref="CHEM-US-00042" cdx-file="US20230002784A1-20230105-C00042.CDX" mol-file="US20230002784A1-20230105-C00042.MOL"/><us-chemistry idref="CHEM-US-00043" cdx-file="US20230002784A1-20230105-C00043.CDX" mol-file="US20230002784A1-20230105-C00043.MOL"/><us-chemistry idref="CHEM-US-00044" cdx-file="US20230002784A1-20230105-C00044.CDX" mol-file="US20230002784A1-20230105-C00044.MOL"/><us-chemistry idref="CHEM-US-00045" cdx-file="US20230002784A1-20230105-C00045.CDX" mol-file="US20230002784A1-20230105-C00045.MOL"/><us-chemistry idref="CHEM-US-00046" cdx-file="US20230002784A1-20230105-C00046.CDX" mol-file="US20230002784A1-20230105-C00046.MOL"/><us-chemistry idref="CHEM-US-00047" cdx-file="US20230002784A1-20230105-C00047.CDX" mol-file="US20230002784A1-20230105-C00047.MOL"/><us-chemistry idref="CHEM-US-00048" cdx-file="US20230002784A1-20230105-C00048.CDX" mol-file="US20230002784A1-20230105-C00048.MOL"/><us-chemistry idref="CHEM-US-00049" cdx-file="US20230002784A1-20230105-C00049.CDX" mol-file="US20230002784A1-20230105-C00049.MOL"/><us-chemistry idref="CHEM-US-00050" cdx-file="US20230002784A1-20230105-C00050.CDX" mol-file="US20230002784A1-20230105-C00050.MOL"/><us-chemistry idref="CHEM-US-00051" cdx-file="US20230002784A1-20230105-C00051.CDX" mol-file="US20230002784A1-20230105-C00051.MOL"/><us-chemistry idref="CHEM-US-00052" cdx-file="US20230002784A1-20230105-C00052.CDX" mol-file="US20230002784A1-20230105-C00052.MOL"/><us-chemistry idref="CHEM-US-00053" cdx-file="US20230002784A1-20230105-C00053.CDX" mol-file="US20230002784A1-20230105-C00053.MOL"/><us-chemistry idref="CHEM-US-00054" cdx-file="US20230002784A1-20230105-C00054.CDX" mol-file="US20230002784A1-20230105-C00054.MOL"/><us-chemistry idref="CHEM-US-00055" cdx-file="US20230002784A1-20230105-C00055.CDX" mol-file="US20230002784A1-20230105-C00055.MOL"/><us-chemistry idref="CHEM-US-00056" cdx-file="US20230002784A1-20230105-C00056.CDX" mol-file="US20230002784A1-20230105-C00056.MOL"/><us-chemistry idref="CHEM-US-00057" cdx-file="US20230002784A1-20230105-C00057.CDX" mol-file="US20230002784A1-20230105-C00057.MOL"/><us-chemistry idref="CHEM-US-00058" cdx-file="US20230002784A1-20230105-C00058.CDX" mol-file="US20230002784A1-20230105-C00058.MOL"/><us-chemistry idref="CHEM-US-00059" cdx-file="US20230002784A1-20230105-C00059.CDX" mol-file="US20230002784A1-20230105-C00059.MOL"/><us-chemistry idref="CHEM-US-00060" cdx-file="US20230002784A1-20230105-C00060.CDX" mol-file="US20230002784A1-20230105-C00060.MOL"/><us-chemistry idref="CHEM-US-00061" cdx-file="US20230002784A1-20230105-C00061.CDX" mol-file="US20230002784A1-20230105-C00061.MOL"/><us-chemistry idref="CHEM-US-00062" cdx-file="US20230002784A1-20230105-C00062.CDX" mol-file="US20230002784A1-20230105-C00062.MOL"/><us-chemistry idref="CHEM-US-00063" cdx-file="US20230002784A1-20230105-C00063.CDX" mol-file="US20230002784A1-20230105-C00063.MOL"/><us-chemistry idref="CHEM-US-00064" cdx-file="US20230002784A1-20230105-C00064.CDX" mol-file="US20230002784A1-20230105-C00064.MOL"/><us-chemistry idref="CHEM-US-00065" cdx-file="US20230002784A1-20230105-C00065.CDX" mol-file="US20230002784A1-20230105-C00065.MOL"/><us-chemistry idref="CHEM-US-00066" cdx-file="US20230002784A1-20230105-C00066.CDX" mol-file="US20230002784A1-20230105-C00066.MOL"/><us-chemistry idref="CHEM-US-00067" cdx-file="US20230002784A1-20230105-C00067.CDX" mol-file="US20230002784A1-20230105-C00067.MOL"/><us-chemistry idref="CHEM-US-00068" cdx-file="US20230002784A1-20230105-C00068.CDX" mol-file="US20230002784A1-20230105-C00068.MOL"/><us-chemistry idref="CHEM-US-00069" cdx-file="US20230002784A1-20230105-C00069.CDX" mol-file="US20230002784A1-20230105-C00069.MOL"/><us-chemistry idref="CHEM-US-00070" cdx-file="US20230002784A1-20230105-C00070.CDX" mol-file="US20230002784A1-20230105-C00070.MOL"/><us-chemistry idref="CHEM-US-00071" cdx-file="US20230002784A1-20230105-C00071.CDX" mol-file="US20230002784A1-20230105-C00071.MOL"/><us-chemistry idref="CHEM-US-00072" cdx-file="US20230002784A1-20230105-C00072.CDX" mol-file="US20230002784A1-20230105-C00072.MOL"/><us-chemistry idref="CHEM-US-00073" cdx-file="US20230002784A1-20230105-C00073.CDX" mol-file="US20230002784A1-20230105-C00073.MOL"/><us-chemistry idref="CHEM-US-00074" cdx-file="US20230002784A1-20230105-C00074.CDX" mol-file="US20230002784A1-20230105-C00074.MOL"/><us-chemistry idref="CHEM-US-00075" cdx-file="US20230002784A1-20230105-C00075.CDX" mol-file="US20230002784A1-20230105-C00075.MOL"/><us-chemistry idref="CHEM-US-00076" cdx-file="US20230002784A1-20230105-C00076.CDX" mol-file="US20230002784A1-20230105-C00076.MOL"/><us-chemistry idref="CHEM-US-00077" cdx-file="US20230002784A1-20230105-C00077.CDX" mol-file="US20230002784A1-20230105-C00077.MOL"/><us-chemistry idref="CHEM-US-00078" cdx-file="US20230002784A1-20230105-C00078.CDX" mol-file="US20230002784A1-20230105-C00078.MOL"/><us-chemistry idref="CHEM-US-00079" cdx-file="US20230002784A1-20230105-C00079.CDX" mol-file="US20230002784A1-20230105-C00079.MOL"/><us-chemistry idref="CHEM-US-00080" cdx-file="US20230002784A1-20230105-C00080.CDX" mol-file="US20230002784A1-20230105-C00080.MOL"/><us-chemistry idref="CHEM-US-00081" cdx-file="US20230002784A1-20230105-C00081.CDX" mol-file="US20230002784A1-20230105-C00081.MOL"/><us-chemistry idref="CHEM-US-00082" cdx-file="US20230002784A1-20230105-C00082.CDX" mol-file="US20230002784A1-20230105-C00082.MOL"/><us-chemistry idref="CHEM-US-00083" cdx-file="US20230002784A1-20230105-C00083.CDX" mol-file="US20230002784A1-20230105-C00083.MOL"/><us-chemistry idref="CHEM-US-00084" cdx-file="US20230002784A1-20230105-C00084.CDX" mol-file="US20230002784A1-20230105-C00084.MOL"/><us-chemistry idref="CHEM-US-00085" cdx-file="US20230002784A1-20230105-C00085.CDX" mol-file="US20230002784A1-20230105-C00085.MOL"/><us-chemistry idref="CHEM-US-00086" cdx-file="US20230002784A1-20230105-C00086.CDX" mol-file="US20230002784A1-20230105-C00086.MOL"/><us-chemistry idref="CHEM-US-00087" cdx-file="US20230002784A1-20230105-C00087.CDX" mol-file="US20230002784A1-20230105-C00087.MOL"/><us-chemistry idref="CHEM-US-00088" cdx-file="US20230002784A1-20230105-C00088.CDX" mol-file="US20230002784A1-20230105-C00088.MOL"/><us-chemistry idref="CHEM-US-00089" cdx-file="US20230002784A1-20230105-C00089.CDX" mol-file="US20230002784A1-20230105-C00089.MOL"/><us-chemistry idref="CHEM-US-00090" cdx-file="US20230002784A1-20230105-C00090.CDX" mol-file="US20230002784A1-20230105-C00090.MOL"/><us-chemistry idref="CHEM-US-00091" cdx-file="US20230002784A1-20230105-C00091.CDX" mol-file="US20230002784A1-20230105-C00091.MOL"/><us-chemistry idref="CHEM-US-00092" cdx-file="US20230002784A1-20230105-C00092.CDX" mol-file="US20230002784A1-20230105-C00092.MOL"/><us-chemistry idref="CHEM-US-00093" cdx-file="US20230002784A1-20230105-C00093.CDX" mol-file="US20230002784A1-20230105-C00093.MOL"/><us-chemistry idref="CHEM-US-00094" cdx-file="US20230002784A1-20230105-C00094.CDX" mol-file="US20230002784A1-20230105-C00094.MOL"/><us-chemistry idref="CHEM-US-00095" cdx-file="US20230002784A1-20230105-C00095.CDX" mol-file="US20230002784A1-20230105-C00095.MOL"/><us-chemistry idref="CHEM-US-00096" cdx-file="US20230002784A1-20230105-C00096.CDX" mol-file="US20230002784A1-20230105-C00096.MOL"/><us-chemistry idref="CHEM-US-00097" cdx-file="US20230002784A1-20230105-C00097.CDX" mol-file="US20230002784A1-20230105-C00097.MOL"/><us-chemistry idref="CHEM-US-00098" cdx-file="US20230002784A1-20230105-C00098.CDX" mol-file="US20230002784A1-20230105-C00098.MOL"/><us-chemistry idref="CHEM-US-00099" cdx-file="US20230002784A1-20230105-C00099.CDX" mol-file="US20230002784A1-20230105-C00099.MOL"/><us-chemistry idref="CHEM-US-00100" cdx-file="US20230002784A1-20230105-C00100.CDX" mol-file="US20230002784A1-20230105-C00100.MOL"/><us-chemistry idref="CHEM-US-00101" cdx-file="US20230002784A1-20230105-C00101.CDX" mol-file="US20230002784A1-20230105-C00101.MOL"/><us-chemistry idref="CHEM-US-00102" cdx-file="US20230002784A1-20230105-C00102.CDX" mol-file="US20230002784A1-20230105-C00102.MOL"/><us-chemistry idref="CHEM-US-00103" cdx-file="US20230002784A1-20230105-C00103.CDX" mol-file="US20230002784A1-20230105-C00103.MOL"/><us-chemistry idref="CHEM-US-00104" cdx-file="US20230002784A1-20230105-C00104.CDX" mol-file="US20230002784A1-20230105-C00104.MOL"/><us-chemistry idref="CHEM-US-00105" cdx-file="US20230002784A1-20230105-C00105.CDX" mol-file="US20230002784A1-20230105-C00105.MOL"/><us-chemistry idref="CHEM-US-00106" cdx-file="US20230002784A1-20230105-C00106.CDX" mol-file="US20230002784A1-20230105-C00106.MOL"/><us-chemistry idref="CHEM-US-00107" cdx-file="US20230002784A1-20230105-C00107.CDX" mol-file="US20230002784A1-20230105-C00107.MOL"/><us-chemistry idref="CHEM-US-00108" cdx-file="US20230002784A1-20230105-C00108.CDX" mol-file="US20230002784A1-20230105-C00108.MOL"/><us-chemistry idref="CHEM-US-00109" cdx-file="US20230002784A1-20230105-C00109.CDX" mol-file="US20230002784A1-20230105-C00109.MOL"/><us-chemistry idref="CHEM-US-00110" cdx-file="US20230002784A1-20230105-C00110.CDX" mol-file="US20230002784A1-20230105-C00110.MOL"/><us-chemistry idref="CHEM-US-00111" cdx-file="US20230002784A1-20230105-C00111.CDX" mol-file="US20230002784A1-20230105-C00111.MOL"/><us-chemistry idref="CHEM-US-00112" cdx-file="US20230002784A1-20230105-C00112.CDX" mol-file="US20230002784A1-20230105-C00112.MOL"/><us-chemistry idref="CHEM-US-00113" cdx-file="US20230002784A1-20230105-C00113.CDX" mol-file="US20230002784A1-20230105-C00113.MOL"/><us-chemistry idref="CHEM-US-00114" cdx-file="US20230002784A1-20230105-C00114.CDX" mol-file="US20230002784A1-20230105-C00114.MOL"/><us-chemistry idref="CHEM-US-00115" cdx-file="US20230002784A1-20230105-C00115.CDX" mol-file="US20230002784A1-20230105-C00115.MOL"/><us-chemistry idref="CHEM-US-00116" cdx-file="US20230002784A1-20230105-C00116.CDX" mol-file="US20230002784A1-20230105-C00116.MOL"/><us-chemistry idref="CHEM-US-00117" cdx-file="US20230002784A1-20230105-C00117.CDX" mol-file="US20230002784A1-20230105-C00117.MOL"/><us-chemistry idref="CHEM-US-00118" cdx-file="US20230002784A1-20230105-C00118.CDX" mol-file="US20230002784A1-20230105-C00118.MOL"/><us-chemistry idref="CHEM-US-00119" cdx-file="US20230002784A1-20230105-C00119.CDX" mol-file="US20230002784A1-20230105-C00119.MOL"/><us-chemistry idref="CHEM-US-00120" cdx-file="US20230002784A1-20230105-C00120.CDX" mol-file="US20230002784A1-20230105-C00120.MOL"/><us-chemistry idref="CHEM-US-00121" cdx-file="US20230002784A1-20230105-C00121.CDX" mol-file="US20230002784A1-20230105-C00121.MOL"/><us-chemistry idref="CHEM-US-00122" cdx-file="US20230002784A1-20230105-C00122.CDX" mol-file="US20230002784A1-20230105-C00122.MOL"/><us-chemistry idref="CHEM-US-00123" cdx-file="US20230002784A1-20230105-C00123.CDX" mol-file="US20230002784A1-20230105-C00123.MOL"/><us-chemistry idref="CHEM-US-00124" cdx-file="US20230002784A1-20230105-C00124.CDX" mol-file="US20230002784A1-20230105-C00124.MOL"/><us-chemistry idref="CHEM-US-00125" cdx-file="US20230002784A1-20230105-C00125.CDX" mol-file="US20230002784A1-20230105-C00125.MOL"/><us-chemistry idref="CHEM-US-00126" cdx-file="US20230002784A1-20230105-C00126.CDX" mol-file="US20230002784A1-20230105-C00126.MOL"/><us-chemistry idref="CHEM-US-00127" cdx-file="US20230002784A1-20230105-C00127.CDX" mol-file="US20230002784A1-20230105-C00127.MOL"/><us-chemistry idref="CHEM-US-00128" cdx-file="US20230002784A1-20230105-C00128.CDX" mol-file="US20230002784A1-20230105-C00128.MOL"/><us-chemistry idref="CHEM-US-00129" cdx-file="US20230002784A1-20230105-C00129.CDX" mol-file="US20230002784A1-20230105-C00129.MOL"/><us-chemistry idref="CHEM-US-00130" cdx-file="US20230002784A1-20230105-C00130.CDX" mol-file="US20230002784A1-20230105-C00130.MOL"/><us-chemistry idref="CHEM-US-00131" cdx-file="US20230002784A1-20230105-C00131.CDX" mol-file="US20230002784A1-20230105-C00131.MOL"/><us-chemistry idref="CHEM-US-00132" cdx-file="US20230002784A1-20230105-C00132.CDX" mol-file="US20230002784A1-20230105-C00132.MOL"/><us-chemistry idref="CHEM-US-00133" cdx-file="US20230002784A1-20230105-C00133.CDX" mol-file="US20230002784A1-20230105-C00133.MOL"/><us-chemistry idref="CHEM-US-00134" cdx-file="US20230002784A1-20230105-C00134.CDX" mol-file="US20230002784A1-20230105-C00134.MOL"/><us-chemistry idref="CHEM-US-00135" cdx-file="US20230002784A1-20230105-C00135.CDX" mol-file="US20230002784A1-20230105-C00135.MOL"/><us-chemistry idref="CHEM-US-00136" cdx-file="US20230002784A1-20230105-C00136.CDX" mol-file="US20230002784A1-20230105-C00136.MOL"/><us-chemistry idref="CHEM-US-00137" cdx-file="US20230002784A1-20230105-C00137.CDX" mol-file="US20230002784A1-20230105-C00137.MOL"/><us-chemistry idref="CHEM-US-00138" cdx-file="US20230002784A1-20230105-C00138.CDX" mol-file="US20230002784A1-20230105-C00138.MOL"/><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A method of transducing a eukaryotic cell to express a transgene, the method comprising contacting the cell with (i) a viral vector encoding the transgene and (ii) a poloxamer, wherein the concentration of the poloxamer, when contacted with the cell, is less than 10 &#x3bc;g/ml.</claim-text></claim><claim id="CLM-002-3" num="002-3"><claim-text><b>2</b>-<b>3</b>. (canceled)</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the cell is:<claim-text>(a) a mammalian cell;</claim-text><claim-text>(b) a pluripotent cell;</claim-text><claim-text>(c) a CD34+ cell;</claim-text><claim-text>(d) an embryonic stem cell;</claim-text><claim-text>(e) an induced pluripotent stem cell; or</claim-text><claim-text>(f) a hematopoietic stem cell (HSC) or a hematopoietic progenitor cell (HPC).</claim-text></claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The method of <claim-ref idref="CLM-00004">claim 4</claim-ref>, wherein the mammalian cell is a human cell.</claim-text></claim><claim id="CLM-06-10" num="06-10"><claim-text><b>6</b>-<b>10</b>. (canceled)</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising contacting the cell with a substance that reduces activity and/or expression of protein kinase C (PKC).</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The method of <claim-ref idref="CLM-00011">claim 11</claim-ref>, wherein the substance that reduces activity and/or expression of PKC activates Akt signal transduction and/or is a PKC inhibitor or an agent that reduces translation of a ribonucleic acid (RNA) transcript encoding PKC.</claim-text></claim><claim id="CLM-13-15" num="13-15"><claim-text><b>13</b>-<b>15</b>. (canceled)</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. The method of <claim-ref idref="CLM-00012">claim 12</claim-ref>, wherein the agent comprises a nucleic acid, such as an interfering RNA or an antisense oligonucleotide.</claim-text></claim><claim id="CLM-17-22" num="17-22"><claim-text><b>17</b>-<b>22</b>. (canceled)</claim-text></claim><claim id="CLM-00023" num="00023"><claim-text><b>23</b>. The method of <claim-ref idref="CLM-00012">claim 12</claim-ref>, wherein the PKC inhibitor is a compound represented by formula (I)</claim-text><claim-text><chemistry id="CHEM-US-00138" num="00138"><img id="EMI-C00138" he="38.52mm" wi="65.36mm" file="US20230002784A1-20230105-C00138.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein R<sub>1 </sub>is H, OH, optionally substituted alkoxy, optionally substituted acyloxy, optionally substituted amino, optionally substituted alkylamino, optionally substituted amido, halogen, optionally substituted C<sub>1-6 </sub>alkyl, optionally substituted C<sub>2-6 </sub>alkenyl, optionally substituted C<sub>2-6 </sub>alkynyl, optionally substituted acyl, optionally substituted alkoxycarbonyl, oxo, thiocarbonyl, optionally substituted carboxy, or ureido;</claim-text><claim-text>R<sub>2 </sub>is H, optionally substituted C<sub>1-6 </sub>alkyl, optionally substituted C<sub>2-6 </sub>alkenyl, optionally substituted C<sub>2-6 </sub>alkynyl, or optionally substituted acyl;</claim-text><claim-text>R<sub>a </sub>and R<sub>b </sub>are each, independently, H, optionally substituted C<sub>1-6 </sub>alkyl, optionally substituted C<sub>2-6 </sub>alkenyl, or optionally substituted C<sub>2-6 </sub>alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl, or R<sub>a </sub>and R<sub>b</sub>, together with the atoms to which they are bound, are joined to form an optionally substituted and optionally fused heterocycloalkyl ring;</claim-text><claim-text>R<sub>c </sub>is O, NR<sub>d</sub>, or S;</claim-text><claim-text>R<sub>d </sub>is H, optionally substituted C<sub>1-6 </sub>alkyl, optionally substituted C<sub>2-6 </sub>alkenyl, or optionally substituted C<sub>2-6 </sub>alkynyl;</claim-text><claim-text>each X is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</claim-text><claim-text>each Y is, independently, halogen, optionally substituted haloalkyl, cyano, optionally substituted amino, hydroxyl, thiol, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted acyloxy, optionally substituted alkoxycarbonyl, optionally substituted carboxy, ureido, optionally substituted alkyl sulfonyl, optionally substituted aryl sulfonyl, optionally substituted heteroaryl sulfonyl, optionally substituted cycloalkyl sulfonyl, optionally substituted heterocycloalkyl sulfonyl, optionally substituted alkyl sulfanyl, optionally substituted aryl sulfanyl, optionally substituted heteroaryl sulfanyl, optionally substituted cycloalkyl sulfanyl, optionally substituted heterocycloalkyl sulfanyl, optionally substituted alkyl sulfinyl, optionally substituted aryl sulfinyl, optionally substituted heteroaryl sulfinyl, optionally substituted cycloalkyl sulfinyl, optionally substituted heterocycloalkyl sulfinyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted and optionally fused aryl, optionally substituted and optionally fused heteroaryl, optionally substituted and optionally fused cycloalkyl, or optionally substituted and optionally fused heterocycloalkyl;</claim-text><claim-text><img id="CUSTOM-CHARACTER-00003" he="2.12mm" wi="5.33mm" file="US20230002784A1-20230105-P00001.TIF" alt="custom-character" img-content="character" img-format="tif"/> represents a bond that is optionally present;</claim-text><claim-text>n is an integer from 0-4; and</claim-text><claim-text>m is an integer from 0-4;</claim-text><claim-text>or a salt thereof.</claim-text></claim-text></claim><claim id="CLM-24-58" num="24-58"><claim-text><b>24</b>-<b>58</b>. (canceled)</claim-text></claim><claim id="CLM-00059" num="00059"><claim-text><b>59</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the concentration of the poloxamer, when contacted with the cell, is from about 10 ng/ml to about 9 &#x3bc;g/ml.</claim-text></claim><claim id="CLM-60-64" num="60-64"><claim-text><b>60</b>-<b>64</b>. (canceled)</claim-text></claim><claim id="CLM-00065" num="00065"><claim-text><b>65</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the poloxamer:<claim-text>(a) has an average molar mass of polyoxypropylene subunits of greater than 2,050 g/mol, 2,250 g/mol, 2,750 g/mol, 3,250 g/mol, or 3,625 g/mol;</claim-text><claim-text>(b) has an average molar mass of polyoxypropylene subunits of from about 2,050 g/mol to about 4,000 g/mol;</claim-text><claim-text>(c) has an average ethylene oxide content of greater than 40%, 50%, 60%, or 70% by mass;</claim-text><claim-text>(d) has an average molar mass of greater than 10,000 g/mol, 11,000 g/mol, 12,000 g/mol, or 12,500 g/mol;</claim-text><claim-text>(e) has an average molar mass of from about 10,000 g/mol to about 15,000 g/mol; or</claim-text><claim-text>(f) is P407, P338, P288, or P188.</claim-text></claim-text></claim><claim id="CLM-66-88" num="66-88"><claim-text><b>66</b>-<b>88</b>. (canceled)</claim-text></claim><claim id="CLM-00089" num="00089"><claim-text><b>89</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the viral vector:<claim-text>(a) is selected from the group consisting of a Retroviridae family virus, an adeno-associated virus, an adenovirus, a parvovirus, a coronavirus, a rhabdovirus, a paramyxovirus, a picornavirus, an alphavirus, a herpes virus, and a poxvirus; or</claim-text><claim-text>(b) is a pseudotyped viral vector.</claim-text></claim-text></claim><claim id="CLM-00090" num="00090"><claim-text><b>90</b>. (canceled)</claim-text></claim><claim id="CLM-00091" num="00091"><claim-text><b>91</b>. The method of <claim-ref idref="CLM-00089">claim 89</claim-ref>, wherein:<claim-text>(a) the Retroviridae family viral vector is a lentiviral vector; or</claim-text><claim-text>(b) comprises a central polypurine tract, a woodchuck hepatitis virus post-transcriptional regulatory element, a 5&#x2032;-LTR, HIV signal sequence, HIV Psi signal 5&#x2032;-splice site, delta-GAG element, 3&#x2032;-splice site, and a 3&#x2032;-self inactivating LTR.</claim-text></claim-text></claim><claim id="CLM-92-96" num="92-96"><claim-text><b>92</b>-<b>96</b>. (canceled)</claim-text></claim><claim id="CLM-00097" num="00097"><claim-text><b>97</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein:<claim-text>(a) the contacting occurs ex vivo;</claim-text><claim-text>(b) the cell is further contacted with a cyclosporine, such as cyclosporine A or cyclosporine H;</claim-text><claim-text>(c) the cell is further contacted with an activator of prostaglandin E receptor signaling, such as prostaglandin E2;</claim-text><claim-text>(d) the cell is further contacted with a polycationic Polymer, such as polybrene, protamine sulfate, polyethylenimine, or a Polyethylene glycol/poly-L-lysine block copolymer; or</claim-text><claim-text>(e) the cell is spun by centrifugation while being contacted with the viral vector.</claim-text></claim-text></claim><claim id="CLM-98-107" num="98-107"><claim-text><b>98</b>-<b>107</b>. (canceled)</claim-text></claim><claim id="CLM-00108" num="00108"><claim-text><b>108</b>. A method of expressing a transgene in a subject, delivering a population of genetically modified cells to a subject, or providing cell therapy to a subject in need thereof, the method comprising administering to the subject a population of cells that have been modified in accordance with the method of <claim-ref idref="CLM-00001">claim 1</claim-ref> or progeny thereof.</claim-text></claim><claim id="CLM-109-110" num="109-110"><claim-text><b>109</b>-<b>110</b>. (canceled)</claim-text></claim><claim id="CLM-00111" num="00111"><claim-text><b>111</b>. The method of <claim-ref idref="CLM-00108">claim 108</claim-ref>, wherein the cells are allogeneic, HLA-matched, or autologous with respect to the subject.</claim-text></claim><claim id="CLM-112-113" num="112-113"><claim-text><b>112</b>-<b>113</b>. (canceled)</claim-text></claim><claim id="CLM-00114" num="00114"><claim-text><b>114</b>. The method of <claim-ref idref="CLM-00108">claim 108</claim-ref>, wherein:<claim-text>(a) prior to the contacting, a population of precursor cells is isolated from the subject or a donor, and wherein the precursor cells are expanded ex vivo to yield the population of cells being administered to the subject;</claim-text><claim-text>(b) prior to isolation of the precursor cells from the subject or donor, the subject or donor is administered one or more pluripotent cell mobilization agents;</claim-text><claim-text>(c) prior to administering the population of cells to the subject, a population of endogenous pluripotent cells is ablated in the subject by administration of one or more conditioning agents to the subject;</claim-text><claim-text>(d) the method further comprises ablating a population of endogenous pluripotent cells in the subject by administering to the subject one or more conditioning agents prior to administering to the subject the population of cells; and/or</claim-text><claim-text>(e) upon administration of the population of cells to the subject, the administered cells, or progeny thereof, differentiate into one or more cell types selected from megakaryocytes, thrombocytes, Platelets, erythrocytes, mast cells, myeloblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen-presenting cells, macrophages, dendritic cells, natural killer cells, T-lymphocytes, and B-lymphocytes.</claim-text></claim-text></claim><claim id="CLM-00115" num="00115"><claim-text><b>115</b>. The method of <claim-ref idref="CLM-00114">claim 114</claim-ref>, wherein the precursor cells are CD34+ HSCs, and wherein the precursor cells are expanded without loss of HSC functional potential, or wherein prior to administering the population of cells to the subject, a population of endogenous pluripotent cells is ablated in the subject by administration of one or more conditioning agents to the subject.</claim-text></claim><claim id="CLM-116-122" num="116-122"><claim-text><b>116</b>-<b>122</b>. (canceled)</claim-text></claim><claim id="CLM-00123" num="00123"><claim-text><b>123</b>. The method of <claim-ref idref="CLM-00108">claim 108</claim-ref>, wherein the subject has been diagnosed as having a deficiency of an endogenous protein encoded by the transgene.</claim-text></claim><claim id="CLM-00124" num="00124"><claim-text><b>124</b>. The method of <claim-ref idref="CLM-00123">claim 123</claim-ref>, wherein the subject has been diagnosed as having a disease set forth in Table 2.</claim-text></claim><claim id="CLM-00125" num="00125"><claim-text><b>125</b>. (canceled)</claim-text></claim><claim id="CLM-00126" num="00126"><claim-text><b>126</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the transgene encodes a beta-globin protein.</claim-text></claim><claim id="CLM-127-136" num="127-136"><claim-text><b>127</b>-<b>136</b>. (canceled)</claim-text></claim><claim id="CLM-00137" num="00137"><claim-text><b>137</b>. A population of eukaryotic cells that have been modified in accordance with the method of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-138-146" num="138-146"><claim-text><b>138</b>-<b>146</b>. (canceled)</claim-text></claim></claims></us-patent-application>